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Polysaccharide Storage Myopathy 
  
  Polysaccharide Storage Myopathy (PSSM) is a form of glycogen storage disease 
in horses, characterized by abnormal polysaccharide inclusions in skeletal muscle1. 
Clinical signs consistent with PSSM were first described in working draft horses after a 
period of rest in the 1900s 1-3. It was believed that clinical signs were a consequence of 
increased lactate accumulation in the muscle secondary to excessive accumulation of 
muscle glycogen during periods of rest. In 1992, PSSM was first described as a muscular 
glycogen storage disorder in Quarter Horses (QH) and related breeds2. The disease has 
now been described in many different breeds and countries. PSSM is a common 
diagnosed equine muscle disorder and can lead to poor performance, loss of athletic 
function and can be potentially life threatening2,4-8.  
 
Clinical Signs  
The severity of clinical signs can vary from decreased performance to severe 
signs of acute rhabdomyolysis. Quarter Horses and related breeds commonly develop 
muscle stiffness and pain, shifting lameness, sweating, reluctance to move, colic-like 
signs, camped-out stance, and in some cases myoglobinuria and recumbency1. In draft 
horses common clinical signs include muscle atrophy and progressive weakness, while 
gait abnormalities are commonly seen in Warmbloods 8,9.  
Signs are usually first noted at 2-3 years of age, when training begins. 
Subsequently, the disease is manifested when exercise is implemented after a period of 
rest. PSSM adult horses or young foals that are exposed to infectious diseases may have 
exacerbation of the signs and can develop rhabdomyolysis10. Post-anesthetic 
complications have also been reported11.  
 
Muscle Histopathology 
Interpretation of the amount and type of polysaccharide in muscle biopsy samples 
can be subjective and two different laboratories initially used two different criteria. The 
less restricted approach includes horses with amylase-sensitive glycogen and 
sarcoplasmic masses6. Since including horses with amylase-sensitive polysaccharide 
	  	  
3	  	  
increases sensitivity of the test but markedly decreases specificity, the suggested gold 
standard diagnosis of PSSM in muscle biopsy was the presence of periodic acid Schiff 
(PAS) positive inclusions of amylase-resistant polysaccharide in type 2A and type 2 B 
muscle fibers 2,12. Other histopathologic findings include centrofascicular atrophy and 
necrosis of type 2A and 2B muscle fibers. Electron microscopy shows increased 
filamentous material, large accumulation of beta glycogen between myofibrils and under 
the sarcolemma, mild to severe myofibrillar lysis and degenerate mitochondria containing 
electron dense inclusions 13,2 False negative PSSM cases can be found in young animals 
based on absence of amylase-resistant polysaccharide in muscle histopathology 14, since 
it can take up to 2 years for abnormal glycogen to start to accumulate. Although cardiac 
abnormalities are not a common feature in PSSM horses, evidence of abnormal 
polysaccharide has been identified in a few severely affected horses15-17.  
 
Prevalence 
Based on histopathology, PSSM has been described in many different breeds and 
is the most common muscular disorder in Draft Horses, QH and related breeds, and 
Warmbloods8,18,19. The overall prevalence of PSSM in horses with muscular disorders 
severe enough to prompt a muscle biopsy is 21.7% when only horses with PAS positive 
amylase-resistant polysaccharide inclusions in the muscle are considered. When a less 
stringent diagnostic criteria is used, and horses with abnormal amylase-sensitive 
polysaccharide in muscle fibers are considered, the prevalence increases from 21.7% to 
40.1%. The prevalence of PSSM among healthy QHs based on skeletal muscle biopsy 
was estimated to be between 6% and 12%20. Several QHs with abnormal polysaccharide 
lacked clinical signs of PSSM, likely due to management practices20, which in turn could 
lead to increase prevalence of the disease in the population by breeding affected 
asymptomatic horses. In North American Belgian Horses, a prevalence of 34% has been 
suggested based on amylase-resistant polysaccharide in muscle biopsies of 113 horses18, 
while in the UK the prevalence of PSSM in Draft Horses was reported to be 8% 7. 
Different from recurrent exertional rhabdomyolysis, no gender predisposition has been 
described in horses with PSSM1.   
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Biochemistry and metabolic findings related to the energy deficit 
 In humans, glycogen storage myopathies are commonly associated with inability 
to metabolize glycogen or its metabolites (glycogenolysis and glycolysis). This 
possibility was investigated in horses and no enzymatic defect similar to any glycogen 
disorder described in humans was found2,21,22. PSSM horses have 1.5 to 2 times normal 
glycogen concentrations in the muscle compared with controls, but have the ability to 
breakdown glycogen during exercise and produce lactate21. Muscle energy metabolism is 
closely regulated by the cytosolic ATP:ADP ratio. A decrease in this ratio stimulates 
oxidative metabolism, followed by myokinase reaction if ATP can’t be restored. The 
myokinase reaction combines 2 ADP and produces ATP and adenine monophosphate 
(AMP), which will activate AMP deaminase and consequently increase levels of muscle 
inosine monophosphate (IMP). Increased levels of IMP in the muscle usually occur 
during intense exercise or under metabolic stress. PSSM horses, during submaximal 
exercise (which relys mostly on aerobic metabolism), show disruption of cellular energy 
metabolism and considerable metabolic stress, characterized by increased IMP levels in 
single muscle fibers and increased serum CK activity23. This IMP elevation after 
submaximal (~ 20 minute) exercise is comparable with horses performing at maximal 
exercise. Even with as little as 11 minutes of walk and trot, horses with PSSM have 
adenine nucleotide degradation in some fibers that resembles horses performing at twice 
the speed for almost 5 times as long. During light submaximal exercise, healthy horses 
should not have any adenine depletion23,21. The mechanism for this energy deficit 
remains unknown.  
  
Discovery of the GYS1 mutation – Type 1 PSSM 
 
Candidate gene studies of various types appeared to exclude an association of 
PSSM with the muscle isoform of phosphofructokinase (PKFM); the AMP activated 
protein kinase (AMPK); the glucan (1,4-alpha); branching enzyme 1 gene - GBE1 
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(encodes a glycogen branching enzyme); amylo-alpha-1, 6-glucosidase; 4-alpha-
glucanotransferase gene – AGL (encodes a glycogen-debranching enzyme), 24.  
 
 
Discovery of the GYS1 mutation 
Genome-wide association analysis was performed in a population of 48 related 
PSSM and 48 unrelated Quarter Horses controls. Related cases were chosen to maximize 
the level of linkage disequilibrium (they did not share more genetic material than second 
cousins, to avoid false inflation of association due to sampling of closely related 
individuals). PSSM cases were selected based on muscle histopathology findings 
consistent with the presence of PAS-positive, amylase-resistant inclusions of 
polysaccharide in gluteal or semimembranous muscle fibers and the presence of 
excessive glycogen levels in the muscle and/or a clinical history of exertional 
rhabdomyolysis. Controls were selected based on normal muscle biopsy, normal muscle 
glycogen concentrations and no history of exertional rhabdomyolysis. Controls were not 
related to the case cohort and were not more related than third cousins25. 
One hundred and five microsatellite (MS) markers, distributed on all 31 equine 
autosomes, were used. Two markers, in two different chromosomes, had significant 
difference in allele distribution between cases and controls, based on Pearson’s X2 tests 
of independence. The marker on chromosome 10 had the lowest p-value and its allele 
distribution showed that 23 out of 48 affected horses had an allele virtually absent in 
controls. Eight additional ECA10 MS were genotyped and defined a 10-Mb region highly 
associated with PSSM. To narrow this candidate region and to account for possible 
association due to relatedness between cases and controls, an additional 52 PSSM cases 
(determined not to share common ancestor with initial case-cohort within 5 generations) 
and 44 controls were genotyped. Two markers within this follow up population were 
significantly associated with PSSM in the combined case and control populations and 
represented a 3-Mb region in chromosome 10. This region is homologous to human 
chromosome 19, where the only gene related to carbohydrate metabolism is the glycogen 
synthase 1 gene (GYS1). Genomic DNA or cDNA were isolated from a PSSM and a 
control horse and the GYS1 gene was amplified and sequenced. A single nucleotide 
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polymorphism was identified in the PSSM horse (G to A base pair substitution that 
changes the amino acid arginine to histidine on codon 309 – Arg309His). To further 
determine if this was the PSSM causative mutation, 6 additional cases and 6 controls 
were genotyped for the Arg309His mutation by restriction fragment length polymorphism 
assay. Briefly, the GYS1 exon 6 and the flanking intronic region are amplified and a 
restriction enzyme cuts the GYS1 H allele at the site of the mutation and at an intronic site 
present in both the R (wild-type) and A (mutant) alleles. None of the controls had the 
Arg309His mutation, while 4 cases were heterozygous and 2 were homozygous for the 
mutation. The non-mutated arginine 309 is highly conserved in the GYS1 and GYS2 
forms of glycogen synthase in several different species, indicating that the region has an 
important function25.  
An additional 99 PSSM QHs, used in the GWAS analysis were genotyped for the 
GYS1 mutation. While most of the horses were heterozygous (n=72) or homozygous 
(n=5) for the mutation, 22 PSSM horses were homozygous for the wild-type allele R, 
suggesting that a second form of PSSM (non-GYS1) was present or that the GYS1 was not 
the causative mutation. Sequencing from 480 bp upstream of the predicted promoter 
region through exon 1, the entire coding sequence and the 3’UTR showed no additional 
sequence difference between cases and controls. Also, association analysis using the 
same ECA10 MS markers excluded this chromosomal locus and GYS1 as the cause of 
PSSM in QH homozygous for the GYS1 wild-type allele. The vast majority of control 
horses were homozygous for the R allele, although a few horses were heterozygous for 
the H allele, which might be due to false negatives based on muscle histopathology25, or 
due to incomplete penetrance of the H allele.  
The GYS1 gene encodes the muscle glycogen synthase isoform; the limiting step 
in glycogen synthesis. The Arg309His mutation results in enhanced activity and/or poor 
regulation of the enzyme, leading to increased muscle glycogen concentrations. PSSM 
horses have 1.5 to 2 times more muscle glycogen compared to healthy controls26. The 
activity of the glycogen synthase enzyme is not highly regulated by GYS1 expression in 
mammals. Protein kinases (by phosphorylation), protein phosphatase-1 and allosteric 
stimulation by glucose-6-phosphate are important regulators of the enzyme activity27 . 
Glycogen synthase assays on muscle homogenates revealed increased activity of the 
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enzyme in PSSM comparing with control muscle, in the presence or absence of the 
allosteric activator glucose 6-phosphate (G6P) 25.  
 
Haplotype analysis in several different breeds that carry the GYS1 mutation, 
revealed that all chromosomes with the mutated GYS1 A allele had a single 351kb 
conserved haplotype, suggesting that the A allele is identical by descent in all horse 
breeds and the mutation arose in a single horse before the formation of the modern horse 
breeds.  
 
In summary, the GYS1 mutation causes type 1 polysaccharide storage myopathy 
and is a dominant gain-of-function mutation present in the coding sequence of exon 6, 
which results in poor regulation and increased activity of the skeletal muscle glycogen 
synthase isoform, the limiting step on glycogen synthesis. The mutation may result in the 
enzyme being in a continuously active state, which in turn could be responsible for the 
accumulation of excessive glycogen and abnormal amylase-resistant polysaccharide in 
horses with type 1 PSSM 28.  
 
Variable phenotypic expression in type 1 PSSM horses 
Environmental factors largely influence clinical phenotype of horses with PSSM. 
Controlled regular exercise, increased turn-out time, and a diet low in non-structural 
carbohydrates and high in fat concentration, have been successful in decreasing muscle 
stiffness in all PSSM horses and eliminating episodes of rhabdomyolysis in 75% of the 
cases1,29,30. 
The amount and type of fat that should be provided to PSSM horses have been 
evaluated. Providing fat with an odd number of carbon atoms (triheptanoin; short-chain 
fatty acid) has been used in humans with metabolic myopathies, to restore citric acid 
cycle intermediates (CAC) by providing a different source of energy (succinyl-COA)30. 
Surprisingly, in PSSM horses, this diet caused detrimental effects by possible stimulation 
of insulin secretion (that leads to increase glycogen synthesis and inhibition of lipolysis 
suggested by decreased availability of NEFA).  Feeding long-chain fatty acids (corn oil) 
significantly decreased exercise intolerance and rhabdomyolysis in PSSM horses, by 
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providing energy for aerobic exercise108 30. This energy was provided by increasing the 
availability of fat for skeletal muscle oxidation, and possibly increasing glycogenolytic, 
glycolytic and oxidative flux30.     
Even when those environmental factors are controlled, phenotypic variation in the 
severity of the disease is observed. Evidence that PSSM1 is an incomplete penetrant 
dominant trait has been shown in Draft horses15, Quarter Horses25 and Warmbloods31. 
Not all horses heterozygous for the GYS1 mutation show clinical signs of the disease.  
An additive effect of the mutated allele was demonstrated in Belgian and 
Percheron horses, where type 1 PSSM cases with 2 copies of the mutated allele had 
increased amounts of amylase-resistant polysaccharide in type 2A muscle fibers 
compared with heterozygotes, followed by control horses (homozygous normal allele). 
The changes in muscle histopathology were positively correlated with increased activity 
of resting serum aspartate transaminase (AST). Homozygous draft horses had higher 
serum muscle enzyme activities (CK and AST) at rest, followed by heterozygotes and 
controls, but post exercise, serum muscle enzymes were not depend on allele copy 
number. Post-­‐exercise,	   homozygous	   draft	   horses	   had	   higher	   creatine	   kinase	   (CK)	  activity	  than	  heterozygotes	  and	  controls,	  but	  no	  significant	  difference	   in	  serum	  CK	  activity	   was	   observed	   between	   heterozygotes	   and	   control	   horses.	   AST	   was	   not	  significantly	   different	   after	   exercise	   between	   homozygotes,	   heterozygotes	   and	  controls. The severity of muscle histopathology appears to depend on underlying 
genotype 15.       
The presence of modifying genes can also cause phenotypic variation. An 
identified family of Quarter Horses with a severe form of PSSM, characterized by signs 
of recurrent episodes of rhabdomyolysis and sudden death, was less likely to respond to 
recommended changes to diet and training32. The severity of the signs in this family 
could not be explained by homozygosity for the GYS1 mutation, since most of the horses 
had just one copy of the mutated allele. The presence of a mutation in the ryanodine 
receptor 1	   - skeletal muscle calcium release channel (RYR1) gene in this family, which 
causes malignant hyperthermia, in conjunction with the GYS1 mutation, led to a more 
severe PSSM phenotype32. This is likely due to more marked muscle damage secondary 
to excessive calcium release from the sarcoplamsic reticulum in muscle cells (caused by 
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the RYR1 mutation) in conjunction with muscle energy deficit during exercise in horses 
with the GYS1 mutation 32.  
 
Prevalence of the GYS1 mutation 
In a study of 750 horses diagnosed with PSSM based on muscle biopsy, 350 
horses from 15 different breeds were either homozygous or heterozygous for the GYS1 
mutation. Therefore, 394 PSSM horses were not carriers of the GYS1 mutation25.  In a 
second study of 901 horses from 36 different breeds diagnosed with PSSM by muscle 
biopsy, the GYS1 mutation was found in 50% of the cases and in 17 different breeds 9. 
The mutated H allele had a frequency of 0.35, the wild-type R allele had a frequency of 
0.65 and the majority of the horses were heterozygous for the mutation9.  
The highest prevalence was found in Belgian and Percheron horses (80% of 
PSSM cases that had amylase resistant polysaccharide in the muscle biopsy), with an 
11% incidence of homozygous draft horses. In QH and related breeds, the mutation is 
responsible for approximately half of PSSM cases diagnosed by muscle biopsy9. 
Warmblood horses with PSSM based on muscle biopsy had a lower prevalence of the 
GYS1 mutation at 18% and none of the Thoroughbred, Arabians and Standardbred horses 
diagnosed with PSSM by muscle biopsy were heterozygous or homozygous for the 
mutation9. In a study in the UK, 65% of horses with PSSM diagnosed by muscle biopsy 
were heterozygous for the GYS1 mutation33.  
So far, the mutation has been found in more than 20 breeds of horses from North 
America and Europe9,33, including Quarter Horses, Paint Horses, Appaloosa and Draft 
Horses (Belgian, Haflinger, Percheron, Shire, Suffolk Punch, American Cream Draft), 
Warmbloods (Hanoverian), Morgan, Mustang, Tennessee Walking horse, Rocky 
Mountain horse breeds, Cob Normand draught horses, mixed breeds and others 9,25,34. 
The frequency of the mutant allele was the highest in the North American Percheron and 
Belgian Draft breeds followed by the South German Coldbloods, QHs and related breeds. 
The mutation was found in low frequencies in Shires and Morgans35.  The presence of the 
GYS1 mutation was also evaluated in 403 horses from 13 different European draft horse 
breeds from Belgium, France, Spain, Germany, Sweden and the Netherlands. While the 
true prevalence of the disease could not be assessed in the study since the horses were not 
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randomly selected, the mutation was found in all 13 breeds (Ardenner, Belgian draft 
horse, Breton horse, Comtois, Trait du Nord, Hispano-Breton, Netherlands draft horse 
and German coldbloods) and all 6 countries. Sixty two per cent of the horses (250 of 403 
horses) were heterozygous for the GYS1 mutation and several horses within 8 of the 13 
breeds were homozygous for the mutation 36.   
A family of Warmblood horses in Switzerland, with a high prevalence of 
exertional rhabdomyolysis (ER), was evaluated for the presence of abnormal 
polysaccharide accumulation on muscle histopathology and the presence of the GYS1 
mutation. The sire and 71 of his descendants were investigated. Horses were in training 
for at least 1 year. Signs of ER were observed in 39% of the horses and the GYS1 
mutation was present in 51% of the 71 descendants, indicating that not all horses that are 
heterozygous for the type 1 PSSM genotype manifest signs of the disease. In this family, 
41% (15/37) of GYS1 positive horses did not have signs of ER. Risk factors associated 
with the manifestation of clinical signs include the presence of the GYS1 mutation (7.1-
times increased odds ratio for being affected by ER in comparison with wild-type horses) 
and gender. In contrast with previous studies1,19,33, females were more likely to develop 
signs of ER in the horses with a history of ER and horses with the GYS1 mutation. One 
possible explanation for the increased risk observed in GYS1 positive mares, is the 
possible presence of a concomitant muscle disorder, such as RER. Age and management 
factors (turn out time, frequency of use an amount of concentrate feed) had no effect on 
ER development in the GYS1 positive horses, but the specific amount of starch in the 
concentrate feed could not be evaluated 37.    
These findings confirm that the GYS1 mutation is not the only cause of PSSM and 
a second, non-GYS1 glycogenosis is present. PSSM horses that are not heterozygous for 
the GYS1 mutation are referred to as having type 2 PSSM.    
 With the association of PSSM with clinical disease, the large number of breeds 
that possess the GYS1 mutation and the high prevalence of the mutation in some breeds is 
surprising. However, previous studies have demonstrated that clinical signs of PSSM can 
be ameliorated with consistent daily exercise and limited starch intake29, conditions that 
were typical for horses from the time of domestication until their decline as a utilitarian 
animal after World War II. Under these historical management conditions, the ability to 
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rapidly restore muscle glycogen after exercise without supplemental feeding would create 
a more efficient work animal. Therefore, McCoy et al 38 hypothesized that the GYS1 
mutation represents a thrifty genotype that was driven to high frequency by artificial 
selection25.  
McCoy and colleagues investigated a 1.97 Mb region around the GYS1 mutation 
for evidence of positive selection in Quarter Horses and Belgian horses. Seventy-two 
horses from 5 different domestic breeds, 1 domestic ass and 2 Przewalski’s horses were 
Sanger sequenced around the GYS1 mutation (1606bp upstream and 1751bp downstream; 
3 homozygous horses, 49 heterozygous and 26 wild-type) and 9 novel intronic SNPs 
were identified. Phasing of this data revealed that all chromosomes that had the mutated 
A allele were found on a single haplotype across the 9 novel SNPs and the GYS1 
mutation. Chromosomes containing the wild-type G allele occurred as 8 distinguishible 
haplotypes. In addition 279 horses, from 8 breeds (including 51 horses from the initial 
Sanger sequencing) were genotyped for 51 SNPs in a 1.97–Mb region around the GYS1 
mutation. The markers include the GYS1 mutation itself, 41 SNPs previously discovered 
in the region by Sanger sequencing at the Broad Institute and 5 of the 9 SNPs discovered 
in the original 72 horses.  Samples included 166 PSSM1 cases and 113 controls (179 
chromosomes with the A allele and 379 with the G allele). The genotypes were phased, 
imputation was performed for missing data and haplotype frequency was estimated. A 
highly conserved haplotype of 350Kb and 20 SNPs surrounding the GYS1 mutation was 
observed in chromosomes containing the mutated A allele (80% of the chromosomes 
containing the A allele had a single haplotype). The chromosomes containing the G allele 
contained 9 haplotypes. Relative extended haplotype homozygosity (REHH) for the A 
haplotype was increased for Belgians horses in comparison with the G haplotypes even 
when comparing with simulated data under neutral drift, suggesting that the high 
frequency of the mutated allele in this population is unlikely due to a bottleneck process 
alone. Identifying genomic regions with unexpectedly high local haplotype homozygosity 
relative to neutral expectation represents a powerful strategy to ascertain candidate genes 
responding to natural or artificial selection. EHH is defined as the probability that two 
randomly chosen chromosomes carrying the same allele at a focal SNP are identical by 
descent over a given distance surrounding it. Different chromosomal regions can have 
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different recombination rates, which affects linkage disequilibrium (LD) (LD is stronger 
in regions where recombination is not common than in regions that exhibit elevated rates 
of recombination). So a greater measure of LD could originate from low recombination 
rates in a particular region, rather than recent positive selection. To take this issue into 
consideration, REHH measures LD surrounding a haplotype of interest to minimize the 
regional recombination effects. Excess muscle glycogen might have been advantageous 
under conditions of scare feed and strenuous exercise, which differs dramatically from 
modern management conditions that lead to precipitation of clinical signs. 39.      
 
 
Hypothesized link between GYS1, glycogen accumulation and rhabdomyolysis 
PSSM horses, during submaximal aerobic exercise, show disruption of cellular 
energy metabolism and considerable metabolic stress, characterized by increased IMP 
levels in single muscle fibers23. While a gain of function in glycogen synthase (GS) 
explains the muscle biopsy phenotype in type 1 PSSM, the link between excessive 
muscle glycogen, abnormal polysaccharide and rhabdomyolysis during sub-maximal 
exercise is less clear. PSSM1 horses can metabolize glycogen and have a normal flux of 
metabolites through glycolysis during maximal exercise21,  yet these horses demonstrate 
exercise intolerance, painful muscle cramping, and rhabdomyolysis during sub-maximal 
(aerobic) exercise.  
Carbohydrates and fatty acids are the two major donors for aerobic 
phosphorylation. During the first 30 minutes of submaximal exercise most of the energy 
is provided by muscle glycogen40. Circulating FFA concentrations increase within 15 
minutes of low-intensity exercise and uptake of short-chain and medium chain FFA 
across muscle membranes occurs down a concentration gradient by diffusion. Long-chain 
fats are translocated across the muscle membrane by active transport (fatty acid 
transporters). Transport of FFA from the cytoplasm into mitochondria for beta-oxidation 
is facilitated by an acylcarnitine transport system. A continuous supply of pyruvate from 
glucose or glycogen is essential for metabolism of FFA. Glycogen provides pyruvate 
which replenishes intermediates in the citric acid cycle allowing acetyl coenzyme A 
(CoA) derived from beta-oxidation of FFA to enter the first step of the citric acid cycle40.  
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The energy deficit observed during submaximal exercise in PSSM horses might 
be secondary to the constant activation of the GS enzyme (due to the gain of function 
mutation in GYS1 gene and exacerbation by insulin release when consuming grain), 
which might be interpreted by the cell as an indication that glycogen breakdown and 
lipolysis are not necessary. Normally, the cell would sense an energy deficit and AMP 
kinase activation would stimulate oxidative metabolism of fatty acid and carbohydrate by 
activation of pyruvate dehydrogenase.  If pyruvate dehydrogenase is not fully activated 
adequate acetyl CoA for oxidative metabolism is not produced. If PSSM horses are on a 
grain diet, they have low plasma FFA concentrations40, possibly due to suppression of 
lipolysis by high insulin. So fatty acid oxidation, also fails in supplying acetyl CoA. Also, 
PSSM horses on a grain diet have high muscle citrate concentrations which might inhibit 
generatation of sufficient acetyl CoA for muscle energy from carbohydrate or fat 
metabolism during submaximal exercise 108 30. High citrate concentrations activate acetyl 
CoA carboxylase that converts acetyl CoA to malonyl CoA which directs acetyl CoA 
away from the citric acid cycle and causes inhibition of carnitine palmytoyl transferase 
(CPT1), the key enzyme necessary to transport long-chain fatty acids into the 
mitochondria for β-oxidation40. 
Current recommendations to control rhabdomyolysis in PSSM horses include 
regular exercise, increased turnout time, and a diet with low non-structural carbohydrates 
and high fat concentration. The provision of long-chain fatty acids in the diet of PSSM 
horses significantly decreases exercise intolerance and rhabdomyolysis with exercise1 29. 
Fat supplementation increases plasma FFA concentrations and the availability of fat for 
oxidation in skeletal muscle. It has been shown that the contribution of FFAs to energy 
production during low-intensity exercise is largely dependent on supply40. Daily exercise 
may lower plasma insulin and increase plasma FFA concentrations, and training over 
time may enhance uptake of fatty acids into skeletal muscle and improve muscle 
oxidative capacity40. 
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Research questions to be addressed for PSSM1 
This section of the thesis will address the energy deficit responsible for 
rhabdomyolysis in type 1 PSSM horses.  
 
 
Hypothesis and Specific Aims: PSSM1 
 
Skeletal muscle energy deficit in type 1 PSSM 
 
Rationale: While a gain of function in glycogen synthase (GS) explains the muscle 
biopsy phenotype in type 1 PSSM, the link between GS, increased muscle glycogen 
content and clinical signs is unknown. PSSM1 horses can metabolize glycogen and have 
a normal flux of metabolites through glycolysis during maximal exercise21,  yet these 
horses demonstrate exercise intolerance, painful muscle cramping, and rhabdomyolysis 
during sub-maximal (aerobic) exercise 12,17,21,23, demonstrated by high IMP 
concentrations secondary to a decrease in the cytoplasmic ATP/ADP ratio and triggering 
of the myokinase reaction in an attempt to restore cellular ATP levels41. There are a 
number of cellular mechanisms that couple cellular energy balance and flux of substrates 
into aerobic metabolism with the intensity, duration and frequency of exercise42. One of 
the critical mechanisms may be cellular glycogen concentration and/or glycogen synthase 
activity.  
 
Central Hypothesis: Skeletal muscle energy deficit and rhabdomyolysis in type 1 PSSM 
horses is due to the effects of altered regulation of gene expression in energy producing 
metabolic pathways induced by excessive glycogen levels and\or improperly regulated 
GS activity. 
 
Secondary hypothesis: Rhabdomyolysis in PSSM1 horses can be managed in large part 
by consistent controlled daily exercise1,29,43, which increases the muscle’s capacity to 
oxidize fat 23,29,44. Extensive research in other species has demonstrated that exercise 
triggers nutrient sensing molecules such as AMP kinase, which in turn leads to altered 
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expression of several downstream targets42. This leads to the secondary hypothesis that 
the clinical improvement in PSSM1 horses resulting from consistent daily exercise is due 
to restoration of expression patterns of genes in major metabolic regulatory pathways. 
 
Aim 1: Investigate the genes and gene pathways that are altered in PSSM1 horses during 
subclinical rhabdomyolysis, and the altered expression patterns after training by 
quantifying gene expression using next generation sequencing of the skeletal muscle 
transcriptome (RNA-seq) in PSSM1 cases and controls. 
 
RNA-seq 
 Whole genome next generation RNA sequencing is a high throughput sequencing 
technology of cDNA.  It has several advantages over technologies for transcriptome 
analysis, such as microarray. It achieves base-pair level resolution, a higher dynamic 
range of expression levels, it does not rely on probe design and previous genome 
knowledge and therefore is not limited to detecting known transcripts and isoforms and 
permits de novo transcriptome assembly when a high quality reference genome or no 
reference genome is available. A few concerns have to be taken into consideration when 
performing RNA-seq, including how uniformly sequences from an entire transcript will 
be represented, how much sequence is required to detect and measure the transcripts with 
low abundance and appropriate downstream analysis since expression levels rely on 
proper mapping of sequencing reads to corresponding reference genome or on their 
efficient de novo assembly 45-48. Pathway analysis is then performed to gain insights into 
the underlying biology of differentially expressed genes at the function level. Common 
diseases often arise from the joint action of multiple SNPs/genes within a pathway. 
Although each single SNP may confer only a small disease risk, their joint actions are 
likely to have a significant role in the development of disease49.   
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Type 2 PSSM 
 
Clinical signs 
Both, type 1 and type 2 PSSM horses have similar clinical presentation, with no 
significant difference in the incidence of exertional rhabdomyolysis, muscle fasciculation 
or muscle atrophy12.  Horses with type 2 PSSM tend to present more often with an 
undiagnosed gait abnormality compared to GYS1 positive horses 12.  
 
Prevalence 
 In a study of QHs and related breeds, type 2 PSSM cases tend to be younger than 
type 1, with 32% being younger than 1 year old (against 6% of PSSM1 horses)12.  27% of 
QH diagnosed with PSSM based on muscle biopsy do not have the GYS1 mutation9 and a 
large proportion of Warmbloods with PSSM are not carriers of the GYS1 mutated 
allele9,12.  
 
Biopsy findings 
Muscle biopsy findings in type 1 and 2 PSSM horses differ mainly in the 
appearance and location of abnormal polysaccharide. Abnormal polysaccharide in type 1 
PSSM horses is often amylase resistant, course granular in appearance and commonly 
located in the cytoplasm. In type 2 PSSM horses the abnormal polysaccharide is often 
amylase-sensitive, fine granular and homogenous in appearance and commonly located 
just below the sarcolemma12. No significant difference in muscle atrophy, myonecrosis, 
central located nuclei and the amount of abnormal polysaccharide was observed between 
type 1 and 2 horses. On electron microscopy, GYS1 positive and negative PSSM horses 
contained large amounts of β glycogen particles in the cytoplasm and subsarcolemmal. 
The abnormal granular amylase-resistant polysaccharide in GYS1 positive horses had 
distinctive polyglucosan bodies, consisting of filamentous material surrounded by β 
glycogen particles. Immunohistochemistry showed strong staining for desmin in regions 
containing the granular abnormal polysaccharide in type 1 PSSM horses, while minimal 
staining was observed in controls and type 2 PSSM horses. Myoglobin was co-localized 
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with course granular polysaccharide in type 1 PSSM horses. Polyglucosan is a less highly 
branched β glycogen structure and contains several protein structures including 
myoglobin, desmin and ubiquitin 50 12. The abnormal β glycogen particles observed in 
type 2 PSSM horses were not membrane bound, and in association with the absence of 
polyglucosan, is consistent with other reported glycogenoses in humans where the ratio 
of branched-to-unbranched glycogen is not affected12. 
 
Preliminary GWAS analysis  
Genome wide association analysis (GWAS) involves the study of several genetic 
markers in the genome and their association with a trait. The goal of population 
association studies is to identify polymorphisms that vary systematically between cases 
and controls. In GWAS analysis no assumptions are made and association analyses are 
performed in the entire genome. GWAS analysis relies on the concept of LD, which is 
the non-random association between markers and the causal allele. There is a low chance 
of recombination between two loci that are close together within a chromosome segment, 
making it possible to find markers that are associated with disease in case-control GWAS 
analysis. In this type of study, population structure can generate false positive genotype-
phenotype association and should be accounted for during the analysis, using mixed 
model approaches. Correction for multiple testing should also be performed, to decrease 
the chance of rejecting the null hypothesis (no association between marker and 
phenotype) by chance51-54.  
 
To identify regions of the genome associated with the PSSM2 phenotype, a cohort 
of 228 horses (104 PSSM2 cases and 124 controls) was genotyped for 54,602 SNP 
markers with the Illumina Equine SNP50 Beadchip and genome wide association 
analysis was performed. GWAS consisted of both basic association tests and structured 
association analysis to account for population structure within the sample cohort. Basic 
(unstructured) association included allelic association (chi-square) and additive, 
genotypic, recessive and dominant logistic regression models. Dominant logistic 
regression identified six SNPs on equine chromosome 18 (ECA18) (p=9.44 x 10-7 to 
2.84 x 10-6) and a single SNP on ECA3 (2.99 x 10-6) that were associated with PSSM2. 
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Association with these SNPs persisted after correction for multiple testing using 10,000 
label-swapping permutations (Figure 1). To account for population structure present in 
the sample cohort (data not shown), structured associations were performed using mixed 
model, and combined mixed model and principal components analysis. Logistic 
regression with 3 principal components and a mixed model with a relationship matrix 
derived from whole genome SNP data confirmed initial GWAS results for the ECA18 
SNPs (1.29 x10-6 to 7.41 x 10-6) (Figure 2). The ECA3 SNP was not genome-wide 
significant after correction for population structure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure	   1: Manhattan plot PSSM2 GWAS. Chromosomes are plotted across the horizontal 
axis, and –log p-value for individual SNPs plotted on the vertical axis.	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The six ECA18 SNPs span an interval of ~350 kb (349,806 base pairs). This 
interval of ECA18 contains two protein-coding genes, both expressed in equine skeletal 
muscle, activin A receptor, type IIA (ACVR2A) and origin recognition complex, subunit 4 
like (ORC4L). PCR was attempted to amplify 5’ and 3’ untranslated regions (UTR), 
coding (exonic) regions and exon/intron boundaries (splice sites) from each gene to 
enable Sanger sequencing and detection of simple mutations (nonsynonymous 
substitutions, missense mutations and small insertions or deletions). Complete 
sequencing of these regions in ORCL4 did not identify simple mutations associated with 
PSSM2. Sequencing of most ACVR2a exons and intron/exon boundaries has not 
identified simple mutations within these sequences. Due to poor annotation and assembly 
of the reference equine genome (Twilight)55, amplification and sequencing of the 5” 
UTR/ promoter region and the first exon of ACVR2a was unsuccessful. Attempts to 
design primers and “walk” through the region with Sanger sequencing of genomic DNA 
in PSSM2 cases and controls and BAC clones (bacterial artificial chromosome clones)56 
have also been unsuccessful and suggest that large structural variants may be present in 
this region.  
 
Figure	  2.	  Ensembl.	  Equine	  chromosome	  18:	  30,442,277-­‐31,038,477.	  Red	  arrows	  represent	  significant	  SNPs	  on	  GWAS	  analysis.	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In addition, 3 other SNPs on chromosome 18, outside ACVR2, had significant p-
values on the GWAS analysis. The region is approximately 68 Kb and is composed of 
several repetitive elements and contains no known genes. A novel protein coding 
‘mRNA’ is present in this region (ENSECAG00000024833) and is also composed of 
several repetitive elements.   
 
Limitations to the initial GWAS 
The equine SNP50 chip has been successfully used in several association studies, 
but its performance can be limited by the lower SNP density and limited coverage in 
some regions of the genome. The markers originated from 7 equine breeds and have an 
inter-SNP space of 43 kb 57 . A newly develop equine SNP array has a total of 670,000 
markers and approximately 8 SNPs per 50 kb window. The markers were sequenced from 
166 horses representing 32 breeds and were further genotyped in 348 horses representing 
10 major breed groups to assess SNP performance. The 670k markers were chosen based 
on a list of 2 million markers, from which haplotype information is available.  
To increase the power and marker density of the initial GWAS performed to 
identify markers associated with PSSM2, cases and controls could be genotyped using 
the new 670,000 array. A second, more cost effective alternative to increase SNP density 
and therefore the power of the analysis is to predict genotypes by the use of imputation.     
 
Research questions to be addressed for PSSM2 
This section of the thesis study will address the genetic basis of type 2 PSSM by 
evaluating variants that could be associated with the disease.  
 
 
Hypothesis and Specific Aims PSSM2 
 
 
 Identification of the genes and alleles underlying PSSM2 
 
	  	  
21	  	  
Rationale: Although the prevalence of the GYS1 mutation is high in Draft Horses, 
approximately 25% of PSSM cases in Quarter Horses (QH) and 80% of PSSM cases in 
Warmbloods are not attributable to this mutation9. Histopathology and ultrastructural 
studies have demonstrated phenotypic differences between the GYS1 (PSSM1) and non-
GYS1 (PSSM2) forms of PSSM12. Similar to PSSM1, there is evidence that PSSM2 is an inheritable	   disorder	   based on visual analysis of pedigree (Molly McCue, personal 
communication).  The central hypothesis is that a gene or genes of moderate to major 
effect underlie type 2 PSSM in Quarter Horses. Preliminary work has identified a 
chromosomal region on equine chromosome 18 (ECA18) associated with PSSM2 in 
QHs, although the underlying mutation has not been identified. Thus the focus of Aim 2 
is to thoroughly interrogate this region on ECA18, to identify any alleles segregating with 
PSSM2.  
 
Aim 2: To thoroughly interrogate the genomic region on ECA18 associated with 
PSSM2, high throughput next-generation sequencing technology for genetic variants in 
PSSM2 cases and controls by target enrichment via long-PCR and next-generation 
sequencing of genomic DNA was used. This approach allowed me: 1) to overcome 
limitations in SNP-based fine structure mapping and Sanger sequencing of candidate 
genes imposed by haplotype structure and incomplete genome annotation in the horse; 2) 
to identify structural variants that may be missed with traditional Sanger sequencing 
technologies (i.e. large insertions, deletions, and/or inversions). Segregation of variants 
with disease status will be confirmed within the cohort used for our preliminary studies 
prior to validation in an independent population; 3) to interrogate the region on ECA18 
where the novel protein coding ‘mRNA’ is present (ENSECAG00000024833), next 
generation whole genome sequence was performed on 3 type 2 PSSM horses and 3 
controls using Illumina HiSeq, 100 bp paired end and 12x coverage.   
 
The strength of association on ECA18 in PSSM2 Quarter Horses is moderate. 
Further, other work in our lab has demonstrated that Quarter Horses have very short 
haplotype lengths and has suggested that the 54k array maybe inadequate for association 
mapping in the Quarter Horse57. The inadequate marker density on the 54k array may 
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result in failure to identify causal loci, since SNP markers on the array may not be in 
strong LD with the causative alleles. To overcome the inadequate marker density in Aim 
3, genotype imputation will be used to effectively increase marker density and the GWAS 
will be repeated to determine if there are additional loci associated with PSSM2.  
 
 
Genotype Imputation and GWAS 
The goal of genotype imputation is to predict the genotypes at the SNPs that are 
not directly genotyped in the study sample. A reference panel of haplotypes at a dense set 
of SNPs is used to impute into a study sample of individuals that have been genotyped at 
a subset of the SNPs. Genotype imputation can be carried out across the whole genome as 
part of a genome-wide association (GWA) study, increasing its power58.  According to 
McCoy the size of the imputed population did not impact imputation success when 
assessing genotype imputation accuracy from the 54,000 (SNP50) to 65,000 (SNP60) 
equine genotyping array. Imputation success increased with larger reference population 
sizes and when imputed and reference populations were breed-matched. Linkage 
disequilibrium also influenced genotype accuracy. Breeds with longer LD 
(Thoroughbred) had higher imputation success than did those with shorter LD (QH)59.  
Since the 54,000 markers from the SNP50 are present in the new 670k equine 
SNP array and the haplotype information from the 1.8 million markers is available, 
imputing from 50k to 670K or 1.8 million markers is feasible. Imputing less dense 
genotype arrays is a cost-effective and powerful way to include genetic markers into 
association studies without the need to re-genotype the samples.  
 
By identifying the genetic mutation that causes PSSM2, the sensitivity and 
specificity of diagnosing the disease improves, since there is controversy on PSSM 
diagnosis based on muscle biopsy evaluation. Also, we will be able to better understand 
the physiology of the disease and develop new therapeutic options and management 
recommendations. 
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Chapter 2 
 
Normal equine skeletal muscle gene expression profiles prior to and after a standardized 
submaximal exercise trial 
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Summary 
 
The objectives of this chapter are to identify the genes and transcripts expressed 
in normal equine skeletal muscle; and to determine the effects of a 3 week-period 
submaximal exercise training, and a bout of submaximal exercise on skeletal muscle gene 
expression. Middle gluteal muscle biopsies were collected from 6 normal horses prior to 
trial (t1) and before (t2) and after exercise (t3) following a 3-week controlled exercise 
protocol. RNA was extracted from muscle and RNASeq was performed (50 bp, single 
end reads).  
 
90-95% of the reads mapped uniquely to the equine reference genome using 
Bowtie and Tophat. Approximately ~8,800 skeletal muscle transcripts with an FPKM 
greater than 2 were identified by Cufflinks. Read counts were generated by HTSeq and 
were used by EdgeR to measure gene expression profile differences between time points. 
This analysis revealed 528 genes differentially expressed with FDR lower than 0.05 
between time point 1 (t1) and time point 2 (t2), and 108 genes differentially expressed 
between t2 and t3.  
    
The top differentially expressed genes were imported into DAVID to extract 
information and group clusters according to their biological function. Several genes were 
identified as being important for the MAPK signaling pathway between t2 and t3 (effect 
of exercise on gene expression).  Pathway analysis by GSEA (gene set enrichment 
analysis), which uses all genes in the dataset and their expression level revealed 
enrichment in pathways involved in glycolysis, mitochondrial biogenesis, muscle 
contraction and development and aerobic respiration.  
 
Better annotation of the equine reference genome and manual annotation of the 
pathways identified by GSEA will provide more insights into the changes in gene 
expression that occur in normal equine muscle in response to submaximal exercise 
training. Also, de novo assembly of the reads will make the discovery of new transcripts 
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and isoforms possible and will provide a more complete picture of the equine muscle 
transcriptome.  
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Introduction 
 
 Descriptions of the skeletal muscle transcriptome and the effect of exercise on 
muscle gene expression have been extensively reported in humans60 but only a few 
studies have evaluated equine muscle transcriptome and gene expression profile changes 
in response to an exercise trial. All muscle gene expression studies in horses so far have 
been performed in the Thoroughbred (TB) 61 62.  In one study, gene expression measured 
in the triceps brachii muscle by RNASeq before and after 30 minutes of trotting in six 
retired TB horses showed changes in genes previously reported to affect racing 
performance (H1F1; ADRB2; PPARD; VEGF; TNC; BDNF) and exercise training 
(ACTR3B; FBXO32; PER3; C1orf51; GATM) 61. By using digital gene expression (DGE) 
in the gluteal muscle of seven, 2 year-old TB horses before and after 10 months of 
training, overrepresentation of mitochondrial genes and genes involved in muscle 
contraction and aerobic respiration, as well as high expression of creatine kinase (CKM), 
mitochondrial creatine kinase (CKMT2) and ACTA1 were observed62. Only 25% (5,068 
unique genes) of annotated equine genes could be evaluated using the DGE technique. 
Overall, metabolic changes in response to exercise are related to increased oxidative 
enzyme activity and oxidative fibers, and an increase in volume density of mitochondria. 
Horses performing at submaximal aerobic exercise intensities benefit from enhanced 
delivery of oxidative substrates to muscle fibers as well as improved oxidative 
metabolism of glycogen and FFA40.  
None of the studies described above have evaluated the effect of controlled 
regular submaximal exercise in horses in gluteal muscle biopsies using RNASeq. By 
using RNASeq, genes expressed in equine muscle and their changes in expression values 
with exercise can be globally evaluated. RNA-seq has a higher sensitivity and lower 
technical variation, in comparison to microarray. The Illumina sequencing data are highly 
replicable and the information in a single lane appears comparable to that in a single 
array in enabling identification of differentially expressed genes, while allowing for 
detection of low-expressed genes, alternative splice variants, and novel transcripts 63.   
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The objectives of this chapter are to identify the genes and transcripts expressed 
in normal equine skeletal muscle; and to determine the effects of a 3 week-period 
submaximal exercise training, and a bout of submaximal exercise on skeletal muscle gene 
expression.  
 
 
Material and Methods 
 
Study Design 
Horses. Sample sizes needed to detect gene expression differences were estimated by n > 
(σ2 log f)/ (z2 1-α), (σ2, variance in gene expression was estimated from data in other 
species64, fold change = 2; and α=0.05). The sample size was determined to identify the 
changes between groups in chapter 3. Based on this calculation, a minimum of 5 biologic 
replicates are necessary to detect differences in gene expression, consistent with standard 
recommendations65. Six healthy control QHs; 4 mares and 2 geldings ranging in age from 
1.5 to 14 years were utilized for the study. Horses had normal muscle histology, normal 
amount of glycogen in the muscle, normal serum CK activities and no history of 
rhabdomyolysis. Prior to training, horses were unfit, and had a minimum of 90 days rest 
in a small paddock with no forced exercise. 
 
Collection of biopsy samples and training protocol. Baseline percutaneous gluteal muscle 
biopsy samples were collected for all horses prior the start of treadmill exercise20 (time 
point t1). Biopsy samples consisted of at least 0.25 g of tissue from either the left and 
right gluteal muscle; samples were immediately frozen in liquid nitrogen and stored at -
80˚C pending further analysis. Horses had up to a two-week period of acclimatization to 
treadmill training (Figure 3). After the acclimatization horses completed a 3-week 
training period. Daily exercise consisted of 4 minutes of walk, and then alternating 
intervals of 2 min walk (1.9 m/s) and 2 min trot (3.0 – 3.8 m/s) for 20 min. At the end of 
the training period (day 21), muscle biopsy samples were collected before (time point t2) 
and after submaximal exercise (time point t3).  
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RNA extraction and sequencing  
Total RNA was isolated from muscle tissue using Trizol reagent, quantified by 
Nanodrop spectrophotometry, and examined for integrity of RNA bands on an Agilent 
Bionalyzer. Library construction was performed using the Illumina HiSeq genome 
analyzer at the University of Minnesota Genomics Center (UMGC), using the TruSeq 
RNA V2 LT Illumina kit. First, the procedure purifies messenger RNA from total RNA, 
using polyA selection. The mRNA was then chemically fragmented and converted into 
single-stranded cDNA using random hexamer priming. Next, the second strand was 
generated to create double-stranded cDNA for the TruSeq library construction workflow, 
where adapters are ligated to ends of the fragments. Each library was sequenced (50 bp 
single end reads) at a rate of 40 million reads per sample. Individual libraries were 
sequenced in more than one lane so possible batch effects could be identified later66.  
 
Quality Control and Mapping 
Fastq files originating from sequencing were converted to fastq Sanger format. 
Prior to mapping, quality control of the reads was performed using FastQC program. QC 
reports were generated for every library and analyzed for per base sequence and per 
sequence quality score, per base and per sequence GC content, per base N content, 
sequence length distribution, duplication levels and overrepresented sequences and Kmer 
content. Reads with a quality score lower than 20 were trimmed. The reads were then 
mapped to the equine reference genome (EqCab2) using Bowtie2 and the splice-aware 
aligner Tophat267. First, Tophat uses Bowtie to align reads to the reference and breaks 
sequences that Bowtie cannot align on its own into shorter segments. Bowtie does not 
allow large gaps between read alignments to the reference genome, so it does not align 
reads that contain introns. The short segments created by Tophat67,68 are then aligned to 
the reference genome. When segments created from the same reads aligned to the 
genome far from each other, Tophat infers that the reads span a splice junction and builds 
an index of splice sites in the transcriptome. A gene model annotation file (GTF; gene 
transfer format) from ensemble was provided for the analysis. A GTF file is a tab-
delimited file describing genomic features and their location. The reads from the same 
individual (library) were mapped by lane and the generated BAM files were then merged 
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for follow-up analysis. A BAM file is a binary version of a SAM file, which is a tab-
delimited text file that contains sequence alignment data. 
 
Transcript assembly and normalized gene count  
Transcript assembly and abundance estimation was then performed by Cufflinks 
69(version 0.0.6) with the previously supplied GTF file. Cufflinks is a reference-based 
transcriptome assembler. It assembles individual transcripts from RNA-Seq reads that 
were aligned to the reference genome. Each sample (library) was assembled individually. 
After assembly, Cufflinks calculates gene expression abundance by normalizing the 
counts into RPKM levels (reads per kilobase per million). RPKM=109*C/NL; where 
C=number of mapped reads that fall into the gene’s exons; N=total number of mapped 
reads in the experiment; and L=sum of the exons in base pairs. The program outputs a list 
of all the genes expressed in muscle and their respective RPKM values70.  
 
Non-normalized (raw) gene count  
A non-normalized gene count (raw count) was also performed, as this is the 
required input for differentially expression analyses based on negative binomial 
distribution (edgeR). The BAM files originated from mapping with Tophat were sorted 
and indexed by Samtools.  HTSeq-count (a python package) was used to count the reads 
that mapped to each one of the equine genes present in the GTF file.  Given a file with 
aligned sequencing reads and a list of genomic features, HTSeq counts how many reads 
map to each feature. In this case, the read counts are the total number of reads aligned to 
each gene.  HTSeq has three overlap resolution modes that dictate how aligned reads that 
overlap more than one genomic feature are treated (union, intersection-strict, intersection-
nonempty - figure 4). A union counting mode was used to count the reads. The output is 
a tab-delimited table of read counts for each gene listed in the genomic annotation set. 
 
Differentially expression analysis - Edge R 
Gene differential expression analysis was performed on edgeR (Bioconductor R 
package71) based on negative binomial distribution since there is more variation in RNA-
seq data that can be accounted for by the Poisson model. In RNA-seq data, the variance 
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grows faster than the mean, which is known as overdispersion, so the mean and the 
variance are modeled separately. EdgeR works on a table of read counts where rows 
correspond to genes and columns to independent libraries containing the non-normalized 
count produced by HTSeq. This design matrix was created into an object (DGE list) in R. 
Adjustment for sequencing depth is always done automatically by EdgeR, since different 
libraries can have different sequencing depths and it can affect read counts.  
 
Another important issue is dealing with the total RNA output in a flow cell. Genes 
that have a very high expression level can consume most of the library size and cause the 
remaining genes to be under sampled, which can make them look down regulated unless 
this effect is controlled for in the analysis. The calcNormFactor function normalizes for 
RNA composition using a trimmed mean of M-values (TMM) between each pair of 
samples. This creates the effective library size, which is the dataset used for downstream 
analysis. EdgeR considers that GC content and gene length have little effect on 
differential expression analysis since they do not change from sample to sample (the 
same genes will have the same length and GC content regardless of the sample). Then 
dispersion was estimated and a linear model fitted (GLM) to ask the questions of interest 
(figure 5). 
  
 
Pathway Analysis 
 
David 
This approach focuses on examining a preset list of genes (which have the largest 
difference between groups), to evaluate their biological function. Following identification 
of genes differentially expressed, biologic themes, disease-gene relationships and 
metabolic pathways within the gene lists was identified with tools available from the 
DAVID bioinformatics resource (NIAID, http://david.abcc.ncifcrf.gov/). DAVID consists 
of an integrated biological knowledgebase and analytic tools aiming at systematically 
extracting biological meaning from large gene lists. This is more of an exploratory 
procedure than a pure statistical solution. The goal of the analysis is to map a large 
number of interesting genes in a list to the associated biological annotation, and then 
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statistically highlight the most over-represented (enriched) biological annotation out of 
thousands of linked terms and contents.  
 
First a gene list is provided for the analysis (differently expressed genes). In the 
gene name batch viewer, a gene history report is provided and information about each 
gene can be accessed. The genes from the gene list are then clustered into groups 
according to their biological function. An enrichment score is provided and represents 
how important this gene group is in the gene list (the higher the level the greater the 
importance). Next, the functional annotation chart tool identifies the most relevant (over-
expressed) biological terms with a given gene list (40 annotation categories are used). In 
this output, enriched functional annotations are divided into different categories which 
includes term (e.g.. transcription factor activity), number of genes in each category, 
percentage of genes involved is this category from the total gene list and a p-value 
(modified Fisher exact p-value. Fisher Exact test is adopted to measure the gene-
enrichment in annotation terms. It ranges from 0 to 1. A p-value of zero represents 
perfect enrichment). Other tools are also available to visualize the same data in different 
formats (pathway map viewer, tabular format and others). Clusters with FDR < 0.05 were 
considered significant.  
 
Gene Set Enrichment Analysis – GSEA 
 
 Traditional strategies for gene expression analysis have focused on identifying 
individual genes (single gene analysis) that exhibit differences between two states of 
interest. Although useful, they fail to detect biological processes, such as metabolic 
pathways and responses, that are distributed across an entire network of genes and subtle 
at the level of individual genes72. Cellular processes often affect sets of genes acting 
together. An increase of 20% in all genes encoding members of a metabolic pathway may 
dramatically alter the flux through the pathway and may be more important than a 20-fold 
increase in a single gene72.  
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Gene Set Enrichment Analysis (GSEA) is a computational method that 
determines whether an a priori defined set of genes shows statistically significant, 
concordant differences between two biological states (cases and controls for example). 
Gene sets are defined based on prior biological knowledge about the physiology of the 
disease of interest. The priori defined set of genes is chosen by the user, based on what is 
known about the pathological process of interest. It is a tool to interpret gene expression 
profile results, extracting meaning from their expression level and gaining insights into 
biological mechanisms72. Instead of a single gene analysis, GSEA calculates expression 
data at the level of gene sets. The goal of the program is to determine whether members 
of a gene set tend to occur at the top or bottom of the expression dataset, in which case 
the gene set is correlated with the phenotype of interest. Given an a priori defined set of 
genes S (e.g., genes encoding products in a metabolic pathway, located in the same 
cytogenetic band, or sharing the same GO category), the goal of GSEA is to determine 
whether the members of S are randomly distributed throughout L or primarily found at 
the top or bottom. We expect that sets related to the phenotypic distinction will tend to 
show the latter distribution. GSEA applies Kolmogorov-Smirnof test to find 
asymmetrical distributions for defined blocks of genes in datasets whole distribution. 
The program requires an expression dataset (created by the user). The first 
column contains information about genes (HUGO gene names in case of RNA-Seq data), 
the second column a description of the genes that is ignored by the program, followed by 
sample names (third column onwards). The rows are filled with expression value for each 
feature (gene) in each sample. Each column contains expression values for 1 sample. A 
phenotype label set (associates each sample to a phenotype) and gene sets that are 
exported from MSigDb or created by the user are also required. The expression data used 
in the present study was the read count number generated from HTSeq.  
First GSEA calculates a rank for each one of the genes present in expression 
dataset that are also present in the gene set list from a specific predefined pathway (list of 
genes expressed in a specific condition and their expression values). The genes are 
ranked based on their correlation with the phenotype and a ranked list is created (list L). 
Then an enrichment score (ES) is calculated and reflects the degree to which a set S (gene 
list from a specific pathway) is overrepresented at the extremes (top or bottom) of the 
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entire ranked list L. The score is calculated by walking down the list L, increasing a 
running-sum statistic when we encounter a gene in S and decreasing it when we 
encounter genes not in S. The magnitude of the increment depends on the correlation of 
the gene with the phenotype. The enrichment score is the maximum deviation from zero 
encountered in the random walk; it corresponds to a weighted Kolmogorov–Smirnov-like 
statistic. Next GSEA estimates the significance level of the ES by using an empirical 
phenotype-based permutation test procedure that preserves the complex correlation 
structure of the gene expression data. Estimated significance level to account for multiple 
hypothesis testing is also performed since an entire database of gene sets is evaluated. A 
normalized enrichment score (NES) is also performed to account for the size of the set, 
which allows comparisons between pathways. The proportion of false positives is then 
calculated using false discovery rate (FDR) corresponding to each NES. The FDR is the 
estimated probability that a set with a given NES represents a false positive finding; it is 
computed by comparing the tails of the observed and null distributions for the NES. The 
top portion of the plot shows the running ES for the gene set as the analysis walks down 
the ranked list. The score at the peak of the plot (the score furthest from 0.0) is the ES for 
the gene set. Gene sets with a distinct peak at the beginning or end of the ranked list are 
generally the most interesting. 
The leading edge subset of a gene set is the subset of members that contribute 
most to the ES. Leading-edge subset are the genes in the gene set S that appear in the 
ranked list L at, or before, the point where the running sum reaches its maximum 
deviation from zero. The leading-edge subset can be interpreted as the core of a gene set 
that accounts for the enrichment signal.  
The Molecular Signature Database (MSigDB) is a catalog of 1,325 gene sets, 
which are annotated gene sets for use with GSEA software. From this web site, the user 
can search for genes by keywords, browse gene sets by name or collection, examine a 
gene set and its annotation and download a gene set for analysis. For this study, gene sets 
for pathway analysis from the MSigDB database were selected based on general key 
words known to be important for training and exercise effect and include aerobic 
respiration and mitochondrial function, muscle contraction and structure, fat oxidation, 
glycogen and glycolysis 62.  
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A workflow representing the RNASeq analysis is represented in Figure 6. 
Results 
  
RNA and sequencing quality controls 
Total RNA integrity following isolation using an Agilent Technologies 2100 
Bioanalyzer revealed an RNA Integrity Number (RIN) value greater than eight for all 
samples. An average base calling Q score (a PHRED score) was above the quality cutoff 
of 30 (ie < 1/1000 probability that the base call is incorrect) in all lanes. All samples met 
the sequencing criteria of 40 million reads/sample.  
 
Mapping summary statistics 
Approximately 90-95 % of the total reads per library mapped to the equine 
reference genome and approximately 8,800 transcripts were identified in equine muscle 
with FPKM greater ≥ 2. Approximately 8% of the reads on each library did not align 
uniquely to the reference.  
 
List of genes expressed in normal equine muscle and FPKM values - Cufflinks 
 
Time point 1 (t1) - pretrial 
For time point 1 8949 transcripts with FPKM values greater than 2 and 9782 
transcripts with FPKM values greater than 1.5 were identified using Cufflinks. The top 
100 assembled transcripts and their FPKM values for each horse are shown on table1.  
 
Time point 2 (t2) – pre-exercise 
For time point 2 9074 transcripts with FPKM values greater than 2 and 9966 
transcripts with FPKM values greater than 1.5. The top 100 assembled transcripts and 
their FPKM values for each horse are shown on table 2.  
 
Time point 3 (t3) – post-exercise 
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For time point 3 8839 transcripts with FPKM values greater than 2 and 9676 
transcripts with FPKM values greater than 1.5 were identified using Cufflinks. The top 
100 assembled transcripts and their FPKM values for each horse are shown on table 3.  
Differential expression analysis – Effect of exercise and training  
 
 Differential expression analysis performed between healthy horses in all 3 time 
points revealed 528 genes differently expressed with FDR lower than 0.05 between time 
point 1 (t1) and time point 2 (t2) (table 4) and 108 between t2 and t3 (table 5). ID 
conversion from ensemble gene names to HUGO gene names was performed on DAVID 
and BIOMART. Hundreds of genes were not annotated in the equine reference genome 
and were therefore manually annotated using blast. Not all genes could be manually 
annotated. From those comparisons, the ones of major interest are between t1 and t2 
(effect of training on gene expression) and t2 and t3 (effect of exercise on gene 
expression). 
 
 
Biologic clustering of differentially expressed genes 
 
The top differentially expressed genes between time points 1 and 2 (training 
effect), and time points 2 and 3 (exercise effect), were clustered by DAVID based on 
their biological function. Inflammation and immune reaction biologic pathways were 
overrepresented in genes that were differentially expressed between time point 1 and 2 
(effect of training).  After exercise (between time point 2 and 3), overrepresented biologic 
processes included several pathways involved in up-regulated gene transcription in 
general as well as MAPK pathways (table 6).  
 
 
Gene Set Enrichment Analysis 
 
 Table 7 summarizes all the key words and pathways from the MSigDB database 
used for GSEA analysis. The two curated pathways involved in glycogen metabolism and 
breakdown identified in the database (keyword glycogen) were tested for enrichment 
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between t1 and t2 and t2 and t3. No significant enrichment was observed between those 
time points. Two pathways were identified using the keyword glycolysis. When testing 
for enrichment score, time point 2 showed enrichment of glycolytic pathways in 
comparison to t1 and t3. Fatty acid oxidation search revealed 2 pathways of interest, but 
no significant enrichment was observed between normal horses at different time points. 
Using the keyword aerobic respiration identified one pathway. No difference apart from 
suggestive of enrichment on t3 in comparison to t2 was observed (pathway: cellular 
respiration). Evaluation of pathways involved in mitochondrial biogenesis revealed 
enrichment in t2 in comparison with t1. Enrichment in the muscle contraction and 
development pathways was also observed in t2 in comparison to t1 (after training) and t3 
in comparison with t2 (after exercise) (table 8).   
  
 
Discussion 
  
More than 8000 transcripts were identified in equine muscle. Genes involved in 
respiratory oxidation and glycolysis were enriched after sub-maximal exercise training, 
as were pathways involved in mitochondrial biogenesis and muscle contraction.  
 
High RNA integrity, high mapping quality scores and a high sequence depth 
made it possible to map reads to the genome at a high mapping percentage. The reads 
created by the library process were short which can make it difficult to map it with 
certainty to the genome, but only 8% of the reads per library did not map uniquely. 
Although most of the reads mapped uniquely, TopHat is able to more accurately discover 
splice junctions with longer (75 bp or longer) and paired end reads.  
 
 Approximately 8,000 genes were expressed in equine muscle with an FPKM > 2. 
Analysis of the genes differentially expressed between time points using DAVID 
identified dozens of biologic annotations that were enriched within the differentially 
expressed (DE) gene set. The vast majority of the biologic functions that were 
overrepresented in the DE gene set after 3 weeks of training were involved in 
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inflammation and immune reaction pathways.  The biologic processes that were 
identified as enriched after exercise included several pathways that indicated up-regulated 
gene transcription in general as well as a few pathways that can be tied to response to 
exercise such as the MAPK pathway. While using edge R evaluates the statistical 
significance of genes by itself, there are advantages to analysis set of genes together 
according with their biological function. GSEA considers all of the genes in an 
experiment, not only those above an arbitrary cutoff in terms of significance and 
evaluates their significance as a set. Evaluation of GSEA of the genes differently 
expressed between t1 and t2 and t2 and t3 revealed enrichment on respiratory oxidation, 
glycolysis, mitochondrial biogenesis and muscle contracture and development. No 
enrichment in fatty acid oxidation was observed between time points.  
 
The study where gene expression profiles were measured in blood and the triceps 
brachii muscle in 6 retired thoroughbred horses before and after exercise found 1,285 
genes differentially expressed genes (62 up and 80 down regulated in blood and 878 up 
and 285 down regulated in muscle).  The samples were collected before and right after 30 
minutes of trotting and expression was measured by RNASeq. According to the author, 
six genes previously associated with racing performance (H1F1; ADRB2; PPARD; 
VEGF; TNC; BDNF) and five genes previously associated with exercise training 
(ACTR3B; FBXO32; PER3; C1orf51; GATM)61 were found to be upregulated after 
exercise. In the dataset presented in this chapter only genes FBXO32 (F-Box Protein 32), 
C1orf51 (CIART; circadian associated repressor of transcription) and BDNF (brain-
derived neurotrophic factor) were found to have a significant difference in expression 
(FDR <0.05) between time points 1 and 2 (effect of training). Those 3 genes had a higher 
expression at t2 in comparison to t1 (up regulation in response to training). The fact that 
the other genes were not differentially expressed on our dataset could possibly be 
explained by the different type of exercise that the horses performed in both studies, the 
different muscle group that was sampled and the different age and breed of the horses. It 
is also possible that the genes reported in the present study are not truly associated with 
performance in thoroughbred horses.  
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In one of the published studies, digital gene expression (DGE, Illumina) profiling 
was used in seven two-year-old untrained Thoroughbred race horses to characterize genes 
expressed in equine skeletal muscle and to identify the subset of genes that were 
differentially expressed following a ten month period of exercise training. The horses 
were raised on the same farm for the previous 2 - 3 months, and destined for flat racing. 
All horses undertook a regular exercise regime with the same trainer for 10 months (light 
canter once a day six times a week and higher intensity exercise no more than once a 
week which consisted of warm-up (walk and trot) followed by gallop with velocities 
reaching maximal intensity for 800-1,000 m. Gluteus medius muscle biopsies at 2 time 
points (at rest: untrained and trained) were performed. Using DAVID an 
overrepresentation of mitochondrial genes, and genes involved in muscle contraction and 
aerobic respiration was observed62. Creatine kinase (CKM) was the most abundant 
expressed gene in equine muscle, as well as CKMT2 and ACTA1 (skeletal muscle actin, 
alpha 1). 92 transcripts were differentially expressed (FDR=0.05) after 10 months of 
training.  Genes with higher post-training basal mRNA levels included those involved in 
the mitochondria, ubiquitination and circadian rhythm regulation, whereas genes with 
significantly reduced mRNA were mainly associated with cytoskeletal structure and the 
control of growth and development. Also, following exercise training an increase in 
genes involved in oxidative phosphorylation was observed. Functional analysis of all 
expressed genes using FatiScan revealed an asymmetric distribution of 482 Gene 
Ontology (GO) groups and 18 KEGG pathways. Functional groups displaying highly 
significant (P < 0.0001) increased expression included mitochondrion, oxidative 
phosphorylation and fatty acid metabolism while functional groups with decreased 
expression were mainly associated with structural genes and included the sarcoplasm, 
laminin complex and cytoskeleton. Several findings in this study were similar to what we 
describe in this chapter, including changes in respiratory oxidation, mitochondrion and 
muscle structure. The differences between studies again are likely due to the intensity of 
the exercise performed and the duration of the trial. Also, one of the limitations of DGE 
technique is the number of genes that could be evaluated for expression since it relies on 
an NlaIII restriction site. Seventy eight percent (n= 19,271) of currently annotated equine 
genes are quantifiable using DGE, but only the 20% of reads that unambiguously 
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matched Ensembl genes were used for further analysis, which represented 5,068 unique 
genes (~25% of annotated equine genes).  
 
One of the limitations of the study presented in this chapter is the fact that 
hundreds of transcripts that were found as being expressed did not have gene IDs and had 
only ensemble IDs. Several of those IDs were converted using Biomart and DAVID, but 
a large number had to be manually annotated. Also, to perform GSEA the equine 
transcript names have to be converted to HUGO gene names, which can be a challenge 
since a greater number of isoforms are present in the human database and the conversion 
is not always straightforward. A reference genome with better annotation and the use of a 
more consistent gene nomenclature between species would greatly improve this issue. 
Further, TopHat and Cufflinks are reference-based aligner and assembly tools, so the 
transcripts and isoforms identified are highly dependent on proper assembly and 
annotation of the reference genome; therefore it is quite possible that genes or novel 
transcripts/isoforms were missed by these tools. De novo assembly of the reads would 
also enable a more complete description of the equine muscle transcriptome.  In model 
species, like mice and in humans with well-annotated genomes, missing data due to poor 
annotation is less of a problem; however it still poses a significant challenge in species 
where the reference is not as well annotated like the horse. De novo assembly of the raw 
reads does not rely on a reference genome, allowing the issue of poor annotation to be 
partially overcome and allowing for identification of novel transcripts and isoforms.  
 
It has been shown that gene expression in muscle can increase hours after 
exercise. Several myogenic and metabolic genes, for example, have a peak in gene 
expression 4 to 8 hours post-exercise73. Our samples were collected immediately after 
exercise, so it is possible that some genes would have a higher level of expression if the 
biopsies were performed in different time points. Although this might be a limitation of 
the study, muscle biopsy immediately after exercise enables the identification of 
differentially expressed early response genes that are rapidly induced by exercise.  
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In conclusion ~8000 transcripts were found to be expressed in equine muscle. 
Once de novo assembly of the reads is performed, the number of transcripts and isoforms 
will likely increase significantly. When comparison of the gene expression profile was 
made between time points, genes involved in respiratory oxidation and glycolysis were 
found to be enriched after sub-maximal exercise training, as well as pathways involved in 
mitochondrial biogenesis and muscle contraction. Further annotation of available 
pathways and better annotation of the reference genome would probably allow the 
discovery of other important pathways.  
 
 
 
 
 
 
 
 
  
 
 
 
 
Baseline	  biopsy	   Trained	  biopsies	  
 3 week training period 	  Acclimatization 
Prior to trial Day 1 Day 7 Day 14 Day 21 
Figure 3. Sample collection protocol. Horses were acclimatized to the treadmill for 1 
to 2 weeks. Horses trained 5 days/week for 3 weeks during the training period. On day 
21 biopsies were taken before and after exercise 	  
Time point 
t1 
Time point 
t2 
Time point  
t3 
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Figure 4. The three overlap modes of HTSEq. 
*image from genomic-ranges bioconductor package: 
http://www.bioconductor.org/packages/release/bioc/html/GenomicRanges.html 
 	  
Figure 5. Comparisons performed between time points.  A. Training effect within group. B. 
Exercise effect within group.  
 
Time point 
t1 
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t2 
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Figure 6. Workflow of RNASeq data analysis.  	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Ensembl Transcript ID Ensembl Gene ID Gene 
FPKM 
1 
FPKM 
2 
FPKM 
3 
FPKM 
4 
FPKM 
5 
FPKM 
6 Average 
ENSECAT00000029843 ENSECAG00000027698 
Novel 
Mt 
tRNA 236985 389984 396414 458878 154167 213565 308332.1667 
ENSECAT00000005510 ENSECAG00000005606 SLN 152687 136560 187663 158261 184796 158028 162999.1667 
ENSECAT00000029864 ENSECAG00000027702 
 
43612.5 81824.3 71112.4 81895.3 44225.2 57060.2 63288.31667 
ENSECAT00000029837 ENSECAG00000027692 
MT-
CO2 35241.1 47652.7 38674.8 40270.5 29445.9 38704.7 38331.61667 
ENSECAT00000021003 ENSECAG00000019728 
TNN
C2 36028.6 32120 40642.5 38206.4 38579.3 38574.6 37358.56667 
ENSECAT00000027340 ENSECAG00000025328 
 
65971.8 28645.4 26957.3 20200.3 41367.2 33012.8 36025.8 
ENSECAT00000029850 ENSECAG00000027674 
 
28218.4 44570.4 33396.4 37085.9 15294 20134 29783.18333 
ENSECAT00000029222 ENSECAG00000027056 
 
50681.5 22346.8 18171.3 13389 30865.4 22114.2 26261.36667 
ENSECAT00000029835 ENSECAG00000027695 ND3 21292.7 29873.3 21886.9 19042.2 23030.8 28224.3 23891.7 
ENSECAT00000029790 ENSECAG00000027624 
 
45819.9 17638.6 16592.7 11694.1 24379.7 20419.9 22757.48333 
ENSECAT00000018609 ENSECAG00000017437 
MYL
PF 22008.1 18659.7 27409.5 23190.9 21287.7 23351.8 22651.28333 
ENSECAT00000016196 ENSECAG00000015494 
TNNI
2 19698 15720 20625.6 17139.3 18968.9 17977.6 18354.9 
ENSECAT00000029690 ENSECAG00000027524 
 
32276.2 12912.9 13029.9 10991.7 19016.7 14265.1 17082.08333 
ENSECAT00000000176 ENSECAG00000000207 
ACT
A1 19100.6 17923.6 20563.3 10675.3 14933.4 17738.7 16822.48333 
ENSECAT00000029856 ENSECAG00000027684 
MT-
ND1 13858.9 23330 13794.5 14944.2 16453.5 17989.3 16728.4 
ENSECAT00000029845 ENSECAG00000027669 
MT-
CYB 13552.4 19576.2 14954.2 18096.7 15841.7 16799 16470.03333 
ENSECAT00000029858 ENSECAG00000027675 
MT-
ND4 13656.5 20283.9 15220.9 18935.2 13336 14558 15998.41667 
ENSECAT00000029841 ENSECAG00000027677 ND6 14383.8 0 22344.5 24612.3 14773 17916.7 15671.71667 
ENSECAT00000029834 ENSECAG00000027681 ND2 12514.8 23046.1 11943.6 14064.4 13997.3 17868.6 15572.46667 
ENSECAT00000023921 ENSECAG00000022433 CKM 15460.7 18654.9 19482 15284.8 22748.7 0 15271.85 
ENSECAT00000006002 ENSECAG00000005145 
MYL
1 14153.2 10335.4 20236.9 11255.2 14871.7 15834.6 14447.83333 
ENSECAT00000029852 ENSECAG00000027682 
 
13336.4 20838.3 13002.3 3422.51 14419.7 20444.7 14243.985 
ENSECAT00000025982 ENSECAG00000023971 
TNNT
3 14672.3 12203.3 16775.7 13372.8 12507 13807.6 13889.78333 
ENSECAT00000004791 ENSECAG00000003121 
ALD
OA 0 16700.4 18686.8 17484.4 23513.3 0 12730.81667 
ENSECAT00000017356 ENSECAG00000016536 
 
33757.9 580.021 38334.3 925.578 493.022 469.943 12426.794 
ENSECAT00000029847 ENSECAG00000027680 
 
10562.6 13990.2 14424.8 15006.6 6749.67 13373.5 12351.22833 
ENSECAT00000029836 ENSECAG00000027670 
 
9325.68 12684.2 14003.6 13089.9 6451.36 12074.9 11271.60667 
ENSECAT00000022265 ENSECAG00000020981 
 
9500.11 8173.69 8530.74 9254.03 8943.97 8996.02 8899.76 
ENSECAT00000023721 ENSECAG00000022051 
G3PD
H 10113.4 7092.29 8730.72 7174.73 9221.53 10202.5 8755.861667 
ENSECAT00000029862 ENSECAG00000027694 
MT-
ND5 8411.54 0 10893.2 12288.2 9321.68 11098.4 8668.836667 
ENSECAT00000018976 ENSECAG00000017982 MB 9477.82 9502.3 8891.69 6621.11 7996.64 7851 8390.093333 
ENSECAT00000019534 ENSECAG00000018348 TPT1 7950.77 6504.03 8073.62 6994.7 7511.26 8940.54 7662.486667 
ENSECAT00000015761 ENSECAG00000014949 TPM1 5770.12 4944.28 7287.16 7059.05 6043.99 7374.24 6413.14 
ENSECAT00000029848 ENSECAG00000027667 
 
5308.86 6198.24 7158.24 8457.57 5177.37 6164.33 6410.768333 
ENSECAT00000029839 ENSECAG00000027668 
 
4840.31 6230.39 6624.17 6254.98 2797.55 5478.13 5370.921667 
ENSECAT00000000003 ENSECAG00000000008 
RPLP
2 4518.02 4626.21 5297.79 5865.1 4631.94 5575.37 5085.738333 
ENSECAT00000029015 ENSECAG00000026987 
NDU
FA4 5217.28 4949.5 4493.55 4713.51 4831.66 4692.72 4816.37 
Table 1.  Output from Cufflinks. Genes expressed in normal equine muscle at time point1. The top 
100 genes with the highest FPKM are shown on the table	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ENSECAT00000029844 ENSECAG00000027687 
 
3635.76 5043.67 4661.4 5202.53 3313.01 5688.85 4590.87 
ENSECAT00000021682 ENSECAG00000020400 ENO3 5123.24 3632.03 4850.18 3930.21 5088.74 4788.87 4568.878333 
ENSECAT00000008746 ENSECAG00000008542 
 
4991.39 3516.15 4262.49 3472.44 5566.78 5288.59 4516.306667 
ENSECAT00000018208 ENSECAG00000017292 
ATP5
I 4426.93 3724.07 3778.84 4048.75 3443.96 3605.79 3838.056667 
ENSECAT00000029854 ENSECAG00000027690 
 
3118.09 3386.23 5163.36 3686.67 1542.64 3608.01 3417.5 
ENSECAT00000022404 ENSECAG00000020669 
LDH
A 3882.95 2891.62 4069.56 2775.7 3247.17 3507.72 3395.786667 
ENSECAT00000007368 ENSECAG00000007378 
C14or
f2 3552.85 3337.8 3142.78 2987.58 2955.83 3387.32 3227.36 
ENSECAT00000007630 ENSECAG00000007612 
PPP1
R1A 3355.14 2492.49 3123.89 3495.03 3502.35 3131.45 3183.391667 
ENSECAT00000005912 ENSECAG00000005539 
PGA
M2 3226.54 2463.18 3609.59 2879.31 3223.38 3446.05 3141.341667 
ENSECAT00000029543 ENSECAG00000027377 
5_8S_
rRNA 7778.62 1468.5 2834.59 1448.31 780.624 4222.12 3088.794 
ENSECAT00000014627 ENSECAG00000013777 YBX3 2950.36 2658.99 2733.07 3441.27 3575.22 3029.79 3064.783333 
ENSECAT00000009354 ENSECAG00000009190 
TMS
B4 3097.35 3293.83 3145.07 2615.06 2352.6 3382.75 2981.11 
ENSECAT00000026040 ENSECAG00000024000 
PYG
M 2596.77 2795.47 2855.93 3360.38 3107.5 2700.24 2902.715 
ENSECAT00000029842 ENSECAG00000027673 
 
2251.55 3807.48 3164.9 3706.63 1725.37 2109.57 2794.25 
ENSECAT00000029838 ENSECAG00000027678 
 
1678.91 3630.75 2716.75 3305.35 1547.15 2872.04 2625.158333 
ENSECAT00000017584 ENSECAG00000016730 
 
1101.81 4829.49 1036.45 1387.83 3129.95 3359.25 2474.13 
ENSECAT00000016514 ENSECAG00000015581 TPI1 2500.07 1914.21 2797.6 2390.13 2496.21 2479.27 2429.581667 
ENSECAT00000017694 ENSECAG00000016739 
MYO
Z1 2442.56 2141.76 2304.88 2404.77 2262.22 2292.65 2308.14 
ENSECAT00000028889 ENSECAG00000026905 
RPL3
7 2048.21 1648.43 2155.98 1743.77 2403.85 2353.26 2058.916667 
ENSECAT00000022182 ENSECAG00000020407 
MYB
PC2 2150.03 1773.7 1592.04 2246.28 2180.92 2021.29 1994.043333 
ENSECAT00000018307 ENSECAG00000017154 
 
1787.3 1496.59 2143.25 1811.12 2266.08 2129.42 1938.96 
ENSECAT00000027968 ENSECAG00000025956 
 
1843 1450.34 1882.57 2404.68 1693.75 1609.2 1813.923333 
ENSECAT00000014200 ENSECAG00000012593 
ATP2
A1 1784.7 1648.53 1738.31 1993.75 1799.28 1911.22 1812.631667 
ENSECAT00000017254 ENSECAG00000016459 
 
1696.51 1457.57 1826.22 1718.31 2102.87 1994.04 1799.253333 
ENSECAT00000025638 ENSECAG00000023911 
NDU
FB1 2183.35 1827.5 1772.72 1759.18 1400.04 1849.71 1798.75 
ENSECAT00000011975 ENSECAG00000011578 
COX6
A2 1910.57 1726.88 1613.29 1617.13 1935.5 1879.19 1780.426667 
ENSECAT00000026923 ENSECAG00000024946 
 
1832.86 1355.29 1790.5 2018.99 1919.87 1722.79 1773.383333 
ENSECAT00000029866 ENSECAG00000027700 
 
1575.12 2224.32 1942.8 2005.7 1209.28 1639.48 1766.116667 
ENSECAT00000014809 ENSECAG00000014226 
 
3467.14 1458.49 1264.84 966.922 1924.2 1508.12 1764.952 
ENSECAT00000010069 ENSECAG00000009780 
UQC
RB 1775.3 1643.81 1822.96 1813.17 1359.08 1861.63 1712.658333 
ENSECAT00000008703 ENSECAG00000007644 PKM 1832.31 1339.65 1801.36 1547.5 1874.17 1665.69 1676.78 
ENSECAT00000021693 ENSECAG00000020452 
TNN
C1 2082.55 1701.9 858.016 1206.18 2019.93 2094.87 1660.574333 
ENSECAT00000029859 ENSECAG00000027685 
 
1371.74 1810.98 1687.1 2322.9 881.79 1863.96 1656.411667 
ENSECAT00000021383 ENSECAG00000019807 
CASQ
1 1604.72 1301.99 2276.03 1402.55 1520.16 1753.81 1643.21 
ENSECAT00000029502 ENSECAG00000027336 
 
4036.96 745.35 1196.74 630.506 569.469 2537.39 1619.4025 
ENSECAT00000003503 ENSECAG00000003667 
 
1652.15 1522.94 1570.88 1249.09 1710.46 2005.79 1618.551667 
ENSECAT00000014439 ENSECAG00000013832 DES 1795.21 1759.38 1531.32 1496.13 1540.27 1557.64 1613.325 
ENSECAT00000011798 ENSECAG00000011458 
COX7
A1 1557.78 1653.88 1502.78 1692.57 1684.67 1587.94 1613.27 
ENSECAT00000000951 ENSECAG00000001140 
ANA
PC11 1763.84 1254.93 1634.58 1373.74 1963.93 1655.73 1607.791667 
ENSECAT00000014463 ENSECAG00000012593 
ATP2
A1 1591.59 1403.86 1698.58 1859.63 1510.39 1549.32 1602.228333 
ENSECAT00000022345 ENSECAG00000020944 
SLC2
5A4 1756.73 1681.61 1437.9 1723.52 1454.59 1491.85 1591.033333 
ENSECAT00000000826 ENSECAG00000001012 
LINC
00116 1707.27 1179.83 1386.87 1440.12 1948.43 1697.24 1559.96 
ENSECAT00000006049 ENSECAG00000006065 
 
1720.92 1240.77 1518.55 1075.22 1932.78 1846.45 1555.781667 
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ENSECAT00000021149 ENSECAG00000018961 
ACT
N3 1259.61 1293.53 1635.18 1500.85 1537.41 1650.92 1479.583333 
ENSECAT00000023205 ENSECAG00000021705 
RPL3
0 1448.25 1156.41 1441.98 1323.94 1702.51 1621.11 1449.033333 
ENSECAT00000016617 ENSECAG00000015659 
KLHL
41 1533.97 1436.63 1344.06 1407.93 1742.12 1189.97 1442.446667 
ENSECAT00000014868 ENSECAG00000014009 TPM2 1613.77 1327.67 2099.69 1048.5 1156.18 1394.52 1440.055 
ENSECAT00000017586 ENSECAG00000016758 
 
1359.14 1071.36 1457.03 1475.9 1632.77 1631.09 1437.881667 
ENSECAT00000008496 ENSECAG00000008413 
 
1292.87 1348.47 1479.68 1715.94 1261.41 1516.64 1435.835 
ENSECAT00000027169 ENSECAG00000025162 
 
1482.46 1297.1 1370.39 1339.78 1468.11 1600.28 1426.353333 
ENSECAT00000028024 ENSECAG00000026012 
eca-
mir-
133a 1531.1 755.126 2028.28 860.676 1859.15 1459.45 1415.630333 
ENSECAT00000019668 ENSECAG00000018554 
 
1244.42 1112.39 1438.84 1355.16 1636.79 1627.17 1402.461667 
ENSECAT00000019116 ENSECAG00000017896 
PDLI
M3 1318.58 1425.27 1332.59 1327.6 1529.72 1215.14 1358.15 
ENSECAT00000001627 ENSECAG00000001815 
PYUR
F 1347.94 1115.36 1244.67 1292.57 1424.44 1570.91 1332.648333 
ENSECAT00000010020 ENSECAG00000009744 IRF7 1.37589 1.83482 1.88653 1.44641 1.43087 1.12187 1.516065 
ENSECAT00000000605 ENSECAG00000000684 
KDM
8 1.39021 1.53663 1.40723 1.42856 2.02973 1.2963 1.514776667 
ENSECAT00000011525 ENSECAG00000011164 
ZNF1
69 1.45355 1.18167 1.60412 1.50786 1.94483 1.39561 1.514606667 
ENSECAT00000013923 ENSECAG00000013399 
ROM
1 1.71618 1.33174 1.3661 1.68564 1.40195 1.58213 1.513956667 
ENSECAT00000021470 ENSECAG00000020088 
NOST
RIN 1.60529 1.52978 1.58723 1.0348 1.86109 1.46114 1.513221667 
ENSECAT00000025030 ENSECAG00000023009 LCP1 
0.52515
8 1.39128 4.22088 
0.77441
8 1.17403 
0.99186
3 1.512938167 
ENSECAT00000013257 ENSECAG00000012336 
ARH
GAP2
6 2.95591 
0.88774
5 
0.89620
2 0.33255 2.25517 1.74955 1.5128545 
 
          
Ensembl Transcript ID Ensembl Gene ID  Gene FPKM 1 FPKM 2 FPKM 3 FPKM 4 FPKM 5 FPKM 6 AVERAGE 
ENSECAT00000029843 ENSECAG00000027698 
 
838375 2584520 2382880 391636 759214 170391 1187836 
ENSECAT00000005510 ENSECAG00000005606 
 
339332 434425 462343 147187 174541 181643 289911.8333 
ENSECAT00000029864 ENSECAG00000027702 
 
187761 251515 281823 37491.1 98573.2 55033.9 152032.8667 
ENSECAT00000029690 ENSECAG00000027524 
 
97574.7 181213 73636.5 46006.1 17070 16332 71972.05 
ENSECAT00000027340 ENSECAG00000025328 
 
88852.3 165904 63447.7 64706.1 22608.5 21871.7 71231.71667 
ENSECAT00000005564 ENSECAG00000005658 
 
63235.5 60620.7 82299.1 60738.3 102381 49312.3 69764.48333 
ENSECAT00000029850 ENSECAG00000027674 
 
48493.7 91734.2 105821 30058 43268.7 11391.2 55127.8 
ENSECAT00000029222 ENSECAG00000027056 
 
77781 140335 46583.9 31294.8 12591.7 10986.9 53262.21667 
ENSECAT00000029836 ENSECAG00000027670 
 
56608.7 79613.7 93799.1 22159.1 21384.1 9175.59 47123.38167 
ENSECAT00000021003 ENSECAG00000019728 TNNC2 37092.1 51086.4 49778.3 32872.4 45924.7 44399.7 43525.6 
ENSECAT00000017356 ENSECAG00000016536 
 
24663.8 63983.1 35196.9 72728.7 30340.7 21234.4 41357.93333 
ENSECAT00000029275 ENSECAG00000027109 
 
43422.3 83706 28455.5 29575.4 12013.9 10305.8 34579.81667 
ENSECAT00000029277 ENSECAG00000027111 
 
43422.3 83706 28455.5 29575.4 12013.9 10305.8 34579.81667 
ENSECAT00000029790 ENSECAG00000027624 
 
46396.1 86359.3 27328.6 21666.4 8487.53 7940.21 33029.69 
ENSECAT00000018609 ENSECAG00000017437 MYLPF 24310.5 33778.8 36700.9 27848.2 28519.7 30170.6 30221.45 
ENSECAT00000029847 ENSECAG00000027680 
 
32786.4 51894.1 54893.1 11315.5 15048.2 7194.05 28855.225 
ENSECAT00000029852 ENSECAG00000027682 
 
55951.9 27342.6 12793.3 21707.2 28439.3 14739 26828.88333 
ENSECAT00000029837 ENSECAG00000027692 MT-CO2 26542.5 43167.5 40631 30205.8 0 20418.9 26827.61667 
ENSECAT00000029490 ENSECAG00000027324 
 
32532.6 58656.2 23056.9 22633.1 7549.44 6302.63 25121.81167 
ENSECAT00000029560 ENSECAG00000027394 RN28S 32532.6 58656.2 23056.9 22633.1 7549.44 6302.63 25121.81167 
ENSECAT00000016196 ENSECAG00000015494 TNNI2 21022.5 28266.9 27607.5 19418.6 25958.1 24726.9 24500.08333 
Table 2. Output from Cufflinks. Genes expressed in normal equine muscle at time point2. The top 100 
genes with the highest FPKM are shown on the table 	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ENSECAT00000029271 ENSECAG00000027105 
 
31713.9 59955.7 25209.8 16653.7 6549.68 5827.87 24318.44167 
ENSECAT00000006002 ENSECAG00000005145 MYL1 20963.1 24028.8 25349.5 20933.7 20058.1 24341.9 22612.51667 
ENSECAT00000029848 ENSECAG00000027667 
 
34304.4 23010.5 41438.9 18471 10387.2 6783.66 22399.27667 
ENSECAT00000025982 ENSECAG00000023971 TNNT3 19219.1 24862.5 26223.7 17351.5 22461.8 22531.4 22108.33333 
ENSECAT00000029835 ENSECAG00000027695 ND3 15836.3 25164.2 19625.6 13241.7 30426.7 16099.1 20065.6 
ENSECAT00000029839 ENSECAG00000027668 
 
27782 36903.7 37072.5 7074.26 6910.41 3457.76 19866.77167 
ENSECAT00000029856 ENSECAG00000027684 MT-ND1 11253.7 13458.8 15011.7 10501.8 22557.5 11514.6 14049.68333 
ENSECAT00000029713 ENSECAG00000027547 
 
18513.5 32371.3 12237.7 12250.7 4581.73 3628.7 13930.605 
ENSECAT00000029842 ENSECAG00000027673 
 
18701.7 25361.8 23599.4 3660.38 6317.37 2184.67 13304.22 
ENSECAT00000029845 ENSECAG00000027669 MT-CYB 11141.1 12651.9 16875.4 8460.15 16180.6 11157.1 12744.375 
ENSECAT00000029854 ENSECAG00000027690 
 
14399.9 24995.9 24285.1 2031.91 5712.95 2654.33 12346.68167 
ENSECAT00000023721 ENSECAG00000022051 G3PDH 12502.5 12059.7 13563 6239.65 10848.8 12775.4 11331.50833 
ENSECAT00000029834 ENSECAG00000027681 ND2 9374.94 9628.37 11890.3 8526.48 17778 8753.16 10991.875 
ENSECAT00000022265 ENSECAG00000020981 
 
9333.95 14929.2 12454.7 8410.32 10292.3 8478.57 10649.84 
ENSECAT00000029858 ENSECAG00000027675 MT-ND4 9170.18 11075 14595.9 6268.17 14649.4 7665.08 10570.62167 
ENSECAT00000001085 ENSECAG00000001272 
 
9910.92 8544.74 10065 15013.7 8494.81 9917.25 10324.40333 
ENSECAT00000004791 ENSECAG00000003121 ALDOA 18573 20465.4 0 19734.4 0 0 9795.466667 
ENSECAT00000029844 ENSECAG00000027687 
 
18652.2 13781.7 13864.6 5169.46 4431.57 2627.2 9754.455 
ENSECAT00000018976 ENSECAG00000017982 MB 8423.02 9643.88 8889.38 10062.3 13537.2 6891.6 9574.563333 
ENSECAT00000015761 ENSECAG00000014949 TPM1 8869.17 10898 12555.9 7809.85 7755.86 9472.92 9560.283333 
ENSECAT00000006031 ENSECAG00000006099 
 
9489.52 8198.66 9674.25 9850.77 8191.69 9545.89 9158.463333 
ENSECAT00000023921 ENSECAG00000022433 CKM 18235.7 19063.9 0 15710.2 0 0 8834.966667 
ENSECAT00000029841 ENSECAG00000027677 ND6 13166.9 15693.6 0 9553.97 0 12315.6 8455.011667 
ENSECAT00000000176 ENSECAG00000000207 ACTA1 25623 22254.8 0 0 0 0 7979.633333 
ENSECAT00000029218 ENSECAG00000027052 RN18S 8980.4 15648.5 9803.14 5197.37 3424.9 3509.25 7760.593333 
ENSECAT00000029223 ENSECAG00000027057 RN18S 8980.4 15648.5 9803.14 5197.37 3424.9 3509.25 7760.593333 
ENSECAT00000029516 ENSECAG00000027350 RN18S 8980.4 15648.5 9803.14 5197.37 3424.9 3509.25 7760.593333 
ENSECAT00000029666 ENSECAG00000027500 RN18S 8980.4 15648.5 9803.14 5197.37 3424.9 3509.25 7760.593333 
ENSECAT00000029394 ENSECAG00000027228 RN18S 8980.4 15643.1 9803.14 5194.77 3424.9 3505.84 7758.691667 
ENSECAT00000029403 ENSECAG00000027237 RN18S 8980.4 15643.1 9803.14 5194.77 3424.9 3505.84 7758.691667 
ENSECAT00000019534 ENSECAG00000018348 TPT1 6688.92 8722.31 6632.82 7850.17 7674.2 7492.99 7510.235 
ENSECAT00000021682 ENSECAG00000020400 ENO3 6337.94 6956.83 7156.21 6798.12 5959.61 7209.16 6736.311667 
ENSECAT00000024587 ENSECAG00000022693 SEPT7 54.9845 41.0978 53.5194 65.9318 57.7179 62.0795 6084.190129 
ENSECAT00000009054 ENSECAG00000008909 
 
49.9136 51.1791 60.9323 52.7987 55.8032 54.3081 6083.847857 
ENSECAT00000006999 ENSECAG00000005768 SEPT11 38.7124 21.5874 21.6766 44.7997 34.7171 37.6061 6065.2999 
ENSECAT00000018834 ENSECAG00000017553 SEPT2 19.1952 12.5367 17.372 20.0084 20.9431 23.7179 6051.824757 
ENSECAT00000015542 ENSECAG00000014530 SEPT10 13.0859 10.7813 13.1585 15.5888 12.6646 13.3536 6047.947529 
ENSECAT00000000444 ENSECAG00000000500 
 
17.0234 29.8501 35.821 19.2781 27.9404 19.4122 6045.760743 
ENSECAT00000021867 ENSECAG00000020246 SEPT9 5.85063 11.3399 9.11733 4.46602 8.85578 7.14005 6043.252816 
ENSECAT00000021975 ENSECAG00000020248 SEPT4 5.51205 5.83304 4.99521 4.75862 5.44671 5.73801 6040.469091 
ENSECAT00000024167 ENSECAG00000022349 SEPT8 2.40531 1.73687 2.7068 2.1427 2.75949 2.46312 6038.459184 
ENSECAT00000025351 ENSECAG00000023315 SEPT6 1.16857 4.32898 2.65724 1.25225 1.97661 1.10774 6037.927341 
ENSECAT00000022015 ENSECAG00000020718 SEPT5 2.32862 1.59444 2.31954 2.12618 1.81738 1.34341 6037.647081 
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ENSECAT00000018782 ENSECAG00000017362 SEPT14 0 0 0 0 
0.047197
6 
0.032297
4 6037.297071 
ENSECAT00000009959 ENSECAG00000009390 SEPT1 0.454846 5.76598 3.37626 0.679292 0.764812 0.348911 6037.055729 
ENSECAT00000020118 ENSECAG00000018692 SEPT12 0 0 0 0 0 
0.031281
5 6037.004469 
ENSECAT00000025376 ENSECAG00000023601 SEPT3 
0.021057
8 0.178791 
0.025009
4 0 
0.012597
6 0 6035.748208 
ENSECAT00000019881 ENSECAG00000018637 MARC1 17.8993 13.7024 15.7386 19.4781 20.4976 23.6037 6024.988529 
ENSECAT00000027025 ENSECAG00000025028 MARCH2 10.9743 14.9544 16.4024 12.3967 14.1696 12.742 6020.948486 
ENSECAT00000016745 ENSECAG00000015805 MARCH7 11.4633 8.20702 8.91466 13.2954 12.472 12.582 6019.562054 
ENSECAT00000029139 ENSECAG00000012069 MARCH6 12.6045 3.77882 6.83812 11.5967 12.1766 12.9958 6018.42722 
ENSECAT00000012487 ENSECAG00000012069 MARCH6 10.5893 6.66165 7.54756 10.119 9.0641 11.3188 6017.757201 
ENSECAT00000027143 ENSECAG00000025138 MARCH9 2.4495 3.11961 3.25463 3.16198 2.52569 4.11733 6012.946963 
ENSECAT00000002899 ENSECAG00000002745 MARCH8 2.23935 1.5674 2.27351 2.22577 1.85582 2.39958 6011.937347 
ENSECAT00000007639 ENSECAG00000007518 MARCH3 1.58155 3.11764 1.7662 1.2742 1.75069 1.70283 6011.027587 
ENSECAT00000026799 ENSECAG00000024858 
MARCH1
1 0 0 0 0 0 0 6010.571429 
ENSECAT00000000932 ENSECAG00000000705 
MARCH1
0 0 0 0 0 
0.008407
13 
0.017978
8 6010.432341 
ENSECAT00000000881 ENSECAG00000000705 
MARCH1
0 0 0 0 0 0 0 6010.428571 
ENSECAT00000007391 ENSECAG00000007360 MARCH4 0 0 0 0 0.01565 0 6009.573664 
ENSECAT00000015677 ENSECAG00000015012 MARCH1 0 
0.096762
7 0.21318 0 
0.091800
4 0.104694 6009.215205 
ENSECAT00000029866 ENSECAG00000027700 
 
7826.09 8982.69 8055.42 2478.92 3681.25 2411.53 5572.65 
ENSECAT00000029015 ENSECAG00000026987 NDUFA4 4336.62 6750.73 5957.95 5074.56 6504.6 4649.46 5545.653333 
ENSECAT00000017402 ENSECAG00000016604 
 
0 182.771 46.0192 15931.6 10378.7 5076.76 5269.308367 
ENSECAT00000022404 ENSECAG00000020669 LDHA 4591.98 5009.55 5302.53 5937.67 4961.99 5137.04 5156.793333 
ENSECAT00000009354 ENSECAG00000009190 TMSB4 3689.48 7454.31 5949.19 4560.83 4940.03 2652.46 4874.383333 
ENSECAT00000029859 ENSECAG00000027685 
 
6782.61 7752.19 7745.59 1692.92 2696.46 1980.2 4774.995 
ENSECAT00000005912 ENSECAG00000005539 PGAM2 3919.87 5744.4 5140.57 4186.8 4436.95 4796.95 4704.256667 
ENSECAT00000018208 ENSECAG00000017292 ATP5I 3228.02 5588.58 5359.48 3824.02 5032.25 3750.76 4463.851667 
ENSECAT00000029862 ENSECAG00000027694 MT-ND5 7839.19 5537.98 0 5062.02 0 7395.5 4305.781667 
ENSECAT00000008746 ENSECAG00000008542 
 
3528.17 4639.34 3942.44 2257.44 4614.13 4886.17 3977.948333 
ENSECAT00000029838 ENSECAG00000027678 
 
5575.01 5147.49 5705.5 1346.74 2703.56 1607.78 3681.013333 
ENSECAT00000029857 ENSECAG00000027683 
 
8142.99 4970.7 4456.28 1902.04 1449.37 691.552 3602.155333 
ENSECAT00000007630 ENSECAG00000007612 PPP1R1A 2919.15 3926.06 4137.52 3065.22 3693.46 3778.35 3586.626667 
ENSECAT00000007368 ENSECAG00000007378 C14orf2 2817.74 4291.24 3583.35 3083.27 4191.33 2969.21 3489.356667 
ENSECAT00000016514 ENSECAG00000015581 TPI1 3077.65 3682.05 3764.76 3076.15 3050.9 3763.22 3402.455 
ENSECAT00000006892 ENSECAG00000006913 
 
4044.55 3724.2 3148.91 1789.22 3844.29 3537.53 3348.116667 
ENSECAT00000000003 ENSECAG00000000008 RPLP2 2661.11 4407.01 4221.01 2797.78 3138.25 2805.75 3338.485 
ENSECAT00000029543 ENSECAG00000027377 
5_8S_rR
NA 3437.48 7343.98 5622.85 1970.37 459.119 1136.82 3328.4365 
ENSECAT00000003503 ENSECAG00000003667 
 
3310.46 4433.62 3440.24 1768.71 2705.04 2275.75 2988.97 
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Ensembl Transcript ID Ensembl Gene ID Gene 
FPKM 
1 
FPKM 
2 
FPKM 
3 
FPKM 
4 
FPKM 
5 
FPKM 
6 AVERAGE 
ENSECAT00000029843 ENSECAG00000027698 484483 
1.19E+0
6 
1.19E+0
6 
2.76E+0
6 685890 558458 1143296.833 
ENSECAT00000005510 ENSECAG00000005606 149819 388856 396154 412155 372891 144997 310812 
ENSECAT00000029864 ENSECAG00000027702 67393.8 248770 182347 375107 168342 83376.2 187556 
ENSECAT00000027340 ENSECAG00000025328 26021.5 56152.2 75271.5 119930 73128.4 222558 95510.26667 
ENSECAT00000029690 ENSECAG00000027524 17620.6 60212.5 87213.6 137605 77341 170419 91735.28333 
ENSECAT00000005564 ENSECAG00000005658 51501.7 90352.2 68741.4 122128 65889.9 46974.1 74264.55 
ENSECAT00000029222 ENSECAG00000027056 18527.1 38467.2 61753.5 90563.9 53165.9 180552 73838.26667 
ENSECAT00000029850 ENSECAG00000027674 27284.4 58062.9 69562.7 122228 30313.4 37265.3 57452.78333 
ENSECAT00000029790 ENSECAG00000027624 12581.9 24295 41284.7 59975.1 36475.2 164710 56553.65 
ENSECAT00000029275 ENSECAG00000027109 13642.7 23316 34937.1 52830.4 28471.4 134352 47924.93333 
ENSECAT00000029277 ENSECAG00000027111 13642.7 23316 34937.1 52830.4 28471.4 134352 47924.93333 
ENSECAT00000029836 ENSECAG00000027670 19050.5 78075.8 50804.9 77879.6 25732 27420.4 46493.86667 
ENSECAT00000021003 
ENSECAG00000019
728 TNNC2 44578.3 45989.8 44163.2 48421.8 43858.5 42999.3 45001.81667 
ENSECAT00000017356 ENSECAG00000016536 51590.6 33350.1 64409 35523.5 26157.5 17835.9 38144.43333 
ENSECAT00000029852 ENSECAG00000027682 11543.2 68293.8 45642.6 57332.3 35300.3 4632.83 37124.17167 
ENSECAT00000029490 ENSECAG00000027324 8613.57 18183.1 27215.9 46383 23304.7 79233.3 33822.26167 
ENSECAT00000029560 
ENSECAG00000027
394 RN28S 8613.57 18183.1 27215.9 46383 23304.7 79233.3 33822.26167 
ENSECAT00000018609 
ENSECAG00000017
437 MYLPF 29316.8 29799.2 28938.9 32208.6 29116.8 28690.5 29678.46667 
ENSECAT00000029271 ENSECAG00000027105 6139.69 19299.2 27350.5 44556.3 22618.8 57946 29651.74833 
ENSECAT00000029837 
ENSECAG00000027
692 
MT-
CO2 39135.6 36206.1 29585.5 0 20725.7 41016.4 27778.21667 
ENSECAT00000029847 ENSECAG00000027680 14040 49745.3 31316 40646 13878.8 16114.2 27623.38333 
ENSECAT00000029848 ENSECAG00000027667 9115.57 47961.9 41161.7 30942.1 18720.7 9002.48 26150.74167 
ENSECAT00000016196 
ENSECAG00000015
494 TNNI2 23760 25148.6 27436 28398.9 24307.2 25069 25686.61667 
ENSECAT00000029543 
ENSECAG00000027
377 
5_8S_r
RNA 2346.56 2508.21 5488.6 12724.2 6021.67 110750 23306.54 
ENSECAT00000025982 
ENSECAG00000023
971 TNNT3 21860.2 21703.1 22496.9 24166.3 22035 19553.5 21969.16667 
ENSECAT00000029835 
ENSECAG00000027
695 ND3 22496.4 24590.8 17083.6 30261.2 16015.5 19652.4 21683.31667 
ENSECAT00000006002 
ENSECAG00000005
145 MYL1 21064.4 22664.1 22284.6 21560.8 22537.2 19643.2 21625.71667 
ENSECAT00000029839 ENSECAG00000027668 7621.23 33356.2 24638.6 31135.7 10971.5 9670.34 19565.595 
ENSECAT00000029713 ENSECAG00000027547 4986.81 10220.7 15229.7 25243.5 13238.8 44927.9 18974.56833 
ENSECAT00000029842 ENSECAG00000027673 2510.7 19745.7 23005.4 37858.3 15113.6 3922.64 17026.05667 
ENSECAT00000029394 
ENSECAG00000027
228 RN18S 4027 5938.88 9669.82 22597 9853.43 49508.5 16932.43833 
ENSECAT00000029403 
ENSECAG00000027
237 RN18S 4027 5938.88 9669.82 22597 9853.43 49508.5 16932.43833 
ENSECAT00000029218 
ENSECAG00000027
052 RN18S 4027 5938.88 9669.82 22589.4 9847.1 49500.9 16928.85 
ENSECAT00000029223 
ENSECAG00000027
057 RN18S 4027 5938.88 9669.82 22589.4 9847.1 49500.9 16928.85 
ENSECAT00000029516 
ENSECAG00000027
350 RN18S 4027 5938.88 9669.82 22589.4 9847.1 49500.9 16928.85 
ENSECAT00000029666 
ENSECAG00000027
500 RN18S 4027 5938.88 9669.82 22589.4 9847.1 49500.9 16928.85 
ENSECAT00000029856 
ENSECAG00000027
684 
MT-
ND1 13474 16486.3 11874 22553.6 11559.1 13919.1 14977.68333 
Table 3. Output from Cufflinks. Genes expressed in normal equine muscle at time point3. The top 
100 genes with the highest FPKM are shown on the table 
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ENSECAT00000029845 
ENSECAG00000027
669 
MT-
CYB 12942.9 15218.2 10720.4 16691.6 11257.4 14058.3 13481.46667 
ENSECAT00000023721 
ENSECAG00000022
051 G3PDH 10421.6 13110 14510.7 11706.6 14393.2 9646.08 12298.03 
ENSECAT00000022265 ENSECAG00000020981 9929.63 14381.1 12795.5 15055.6 9640.69 10936.6 12123.18667 
ENSECAT00000029834 
ENSECAG00000027
681 ND2 10347.1 13004.1 9611.16 17724.4 9073.07 9877.05 11606.14667 
ENSECAT00000029854 ENSECAG00000027690 5141.18 18001.3 15004.5 19974.9 5665.63 4102.58 11315.015 
ENSECAT00000029844 ENSECAG00000027687 3072.66 19610.7 13785.3 18093.2 9179.66 3799.21 11256.78833 
ENSECAT00000029502 ENSECAG00000027336 1038 2003.51 4226.28 11632.3 7498.27 40138.5 11089.47667 
ENSECAT00000029858 
ENSECAG00000027
675 
MT-
ND4 10769.8 10984.4 8872.32 14944.8 7936.34 12585.9 11015.59333 
ENSECAT00000018976 
ENSECAG00000017
982 MB 11026.4 12744.5 10051.8 13908.3 7258.14 10632.2 10936.89 
ENSECAT00000029841 
ENSECAG00000027
677 ND6 17227.1 0 12754.3 0 13215.1 18356 10258.75 
ENSECAT00000001085 ENSECAG00000001272 7366.57 10027.3 11141.5 8840.88 11399.9 6727.31 9250.576667 
ENSECAT00000015761 
ENSECAG00000014
949 TPM1 9499.11 9532.86 9579.74 7735.95 9610.75 9286.08 9207.415 
ENSECAT00000006031 ENSECAG00000006099 7089.84 9600.44 10700.2 8497.72 10914.6 6486.45 8881.541667 
ENSECAT00000000176 
ENSECAG00000000
207 ACTA1 24936.5 0 0 0 0 23299 8039.25 
ENSECAT00000019534 
ENSECAG00000018
348 TPT1 8002.37 8805.87 8648.49 8576.98 6493.41 6101.21 7771.388333 
ENSECAT00000029866 ENSECAG00000027700 2458.13 10503.1 8607.71 11362.9 6216.15 2642.93 6965.153333 
ENSECAT00000021682 
ENSECAG00000020
400 ENO3 5969.48 6950.12 7925.55 6259.53 7771.94 5793.83 6778.408333 
ENSECAT00000029015 
ENSECAG00000026
987 
NDUFA
4 5665.89 5877.76 5798.27 7133.28 4902.44 6645.94 6003.93 
ENSECAT00000004791 
ENSECAG00000003
121 
ALDO
A 18507.4 0 0 0 0 15451.5 5659.816667 
ENSECAT00000023921 
ENSECAG00000022
433 CKM 18843.2 0 0 0 0 14876.9 5620.016667 
ENSECAT00000029859 ENSECAG00000027685 1604.61 6757.26 6795.56 9614.77 5493.34 2642.93 5484.745 
ENSECAT00000029862 
ENSECAG00000027
694 
MT-
ND5 8064.74 0 6615.01 0 7873 7305.18 4976.321667 
ENSECAT00000018208 
ENSECAG00000017
292 ATP5I 4106.01 5099.31 4820.16 6864.73 3580.44 5287.8 4959.741667 
ENSECAT00000022404 
ENSECAG00000020
669 LDHA 5004.9 4494.05 6191.25 5078.77 5128.04 3437.07 4889.013333 
ENSECAT00000005912 
ENSECAG00000005
539 PGAM2 4828.72 5027.05 5429.44 4878.34 4671.81 4350.73 4864.348333 
ENSECAT00000029838 ENSECAG00000027678 1469.99 6345.43 4767.33 8107.75 5192.83 2094.17 4662.916667 
ENSECAT00000008746 ENSECAG00000008542 3827.77 5221.32 4999.68 4978.09 4769.86 3774.3 4595.17 
ENSECAT00000029857 ENSECAG00000027683 1606.44 8811.08 6021.01 5028.8 2742.87 1581.6 4298.633333 
ENSECAT00000009354 
ENSECAG00000009
190 TMSB4 3483.61 4617.26 4306.75 5757.83 3419.36 4081.2 4277.668333 
ENSECAT00000007368 
ENSECAG00000007
378 C14orf2 3453.1 4567.29 3528.54 5211.28 3051.33 3944.15 3959.281667 
ENSECAT00000006892 ENSECAG00000006913 3449.83 5331.92 3724.33 3784.53 3914.98 3117.98 3887.261667 
ENSECAT00000007630 
ENSECAG00000007
612 
PPP1R1
A 3409.73 3833.75 4108.74 4023.77 3408.41 3646.98 3738.563333 
ENSECAT00000000003 
ENSECAG00000000
008 RPLP2 3511.08 4401.8 3412.37 3742.9 2823.15 3741.92 3605.536667 
ENSECAT00000003503 ENSECAG00000003667 1853.76 4577.13 4751.8 5090.46 3619.87 1410.46 3550.58 
ENSECAT00000014809 ENSECAG00000014226 1199.61 1263.2 1920.05 3225.47 1692.49 11055.6 3392.736667 
ENSECAT00000016514 
ENSECAG00000015
581 TPI1 3082.17 3442.82 3464.6 3363.21 3535.1 2981.08 3311.496667 
ENSECAT00000026040 
ENSECAG00000024
000 PYGM 2942.44 2801.71 3086.27 2594.79 3486.38 2467.25 2896.473333 
ENSECAT00000027884 
ENSECAG00000025
872 
eca-mir-
1842 418.45 3510.34 3479.8 3916.37 4857.94 411.244 2765.690667 
ENSECAT00000027983 
ENSECAG00000025
971 
eca-mir-
1842 418.45 3510.34 3479.8 3916.37 4857.94 411.244 2765.690667 
ENSECAT00000014627 
ENSECAG00000013
777 YBX3 2512.71 2869.46 2824.62 2774.47 2649.77 2384.85 2669.313333 
ENSECAT00000014868 
ENSECAG00000014
009 TPM2 2314.92 2768.98 2752.09 3058.89 2088.54 2627.69 2601.851667 
ENSECAT00000029865 ENSECAG00000027693 535.54 4054.34 2715.11 4245.86 2792.92 820.517 2527.381167 
ENSECAT00000029860 ENSECAG00000027696 1195.49 3866.09 3644.3 3423.86 2211.99 813.393 2525.853833 
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ENSECAT00000006049 ENSECAG00000006065 2036.8 2840.85 2698.95 2693.07 2677.09 1854.73 2466.915 
ENSECAT00000008314 
ENSECAG00000007
867 MYL2 1961.32 3439.48 3045.52 1916.25 1960.29 2473.93 2466.131667 
ENSECAT00000029375 ENSECAG00000027209 128.997 486.793 803.989 2525.18 1615.27 9177.74 2456.328167 
ENSECAT00000000951 
ENSECAG00000001
140 
ANAPC
11 1763.06 2915.71 2523.73 2978.52 2748.74 1670.97 2433.455 
ENSECAT00000021693 
ENSECAG00000020
452 TNNC1 1856.72 3667.07 2753.19 1781.48 2156.69 2222.16 2406.218333 
ENSECAT00000017584 ENSECAG00000016730 1523.8 3105.32 1476.92 4037.41 2554.51 1651.1 2391.51 
ENSECAT00000008703 
ENSECAG00000007
644 PKM 2078.99 2375.55 2821.86 2156.33 2820.02 1978.61 2371.893333 
ENSECAT00000026923 ENSECAG00000024946 2547.59 2425.11 2763.42 1872.21 2015.19 2302.17 2320.948333 
ENSECAT00000017694 
ENSECAG00000016
739 MYOZ1 2307.38 2461.26 2435.34 2365.87 2259.64 1998.45 2304.656667 
ENSECAT00000025638 
ENSECAG00000023
911 
NDUFB
1 1852.69 2356.35 2589.29 2982.56 1361.02 2037.25 2196.526667 
ENSECAT00000011975 
ENSECAG00000011
578 
COX6A
2 1833.36 2216.77 2056.24 2495.75 1730.61 2254.07 2097.8 
ENSECAT00000021383 
ENSECAG00000019
807 CASQ1 2096.59 2005.16 2309.92 1921.36 2328.48 1708.43 2061.656667 
ENSECAT00000022182 
ENSECAG00000020
407 
MYBP
C2 1655.65 2078.37 2589.56 1557.47 2652 1751.67 2047.453333 
ENSECAT00000028889 
ENSECAG00000026
905 RPL37 1684.26 2117.46 2145.75 2276.18 2011.62 1791.43 2004.45 
ENSECAT00000011798 
ENSECAG00000011
458 
COX7A
1 1738.64 2149.15 1530.75 2747.35 1435.26 2384.41 1997.593333 
ENSECAT00000028024 
ENSECAG00000026
012 
eca-mir-
133a 1131.2 1926.33 2372.89 2269.03 3056.34 1026.2 1963.665 
ENSECAT00000027968 ENSECAG00000025956 1108.29 2427.26 2327.86 2082.62 2401.86 1331.05 1946.49 
ENSECAT00000000826 
ENSECAG00000001
012 
LINC00
116 1856.86 2169.66 2111.11 1766.19 1963.07 1707.59 1929.08 
ENSECAT00000029840 ENSECAG00000027699 1602.07 1748.13 1070.22 2124.09 668.533 3954.64 1861.2805 
ENSECAT00000027169 ENSECAG00000025162 1730.1 2011.13 1808.91 2054.79 1496.36 1886.29 1831.263333 
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Comparison Ensembl GENE ID GENE Name logFC PValue FDR 
Case t1 X Case t2 ENSECAG00000011484 EPS8L2 -4.78128379 1.23738E-52 1.4272E-48 
Case t1 X Case t2 ENSECAG00000007809 OR2T27 -3.143150421 5.35865E-30 3.09033E-26 
Case t1 X Case t2 ENSECAG00000016846 ENSECAG00000016846 -2.598850406 2.99273E-22 1.15061E-18 
Case t1 X Case t2 ENSECAG00000020221 KNDC1 -3.2791048 6.42218E-22 1.85184E-18 
Case t1 X Case t2 ENSECAG00000026913 ENSECAG00000026913 -2.10756729 1.96691E-18 4.53727E-15 
Case t1 X Case t2 ENSECAG00000024589 ENSECAG00000024589 -2.311686808 3.89025E-17 7.47837E-14 
Case t1 X Case t2 ENSECAG00000013836 PKLR 2.298607192 4.91875E-16 8.1047E-13 
Case t1 X Case t2 ENSECAG00000019552 SLCO1C1 2.33545454 3.87642E-15 5.58883E-12 
Case t1 X Case t2 ENSECAG00000013781 KIAA1211 -1.697206356 3.77175E-14 4.83371E-11 
Case t1 X Case t2 ENSECAG00000006267 NR1D1 -1.346418978 7.26095E-11 7.61343E-08 
Case t1 X Case t2 ENSECAG00000019557 LDLR -1.388341109 6.80243E-11 7.61343E-08 
Case t1 X Case t2 ENSECAG00000014500 ART5 1.271377618 2.75373E-10 2.64679E-07 
Case t1 X Case t2 ENSECAG00000021096 NRXN2 -1.564598167 4.40512E-10 3.90836E-07 
Case t1 X Case t2 ENSECAG00000024790 ENSECAG00000024790 1.322693497 2.19685E-09 1.80989E-06 
Case t1 X Case t2 ENSECAG00000020485 PCOLCE2 1.296580385 2.54646E-09 1.95806E-06 
Case t1 X Case t2 ENSECAG00000027324 RNA28S1 1.36718335 4.25282E-09 3.06575E-06 
Case t1 X Case t2 ENSECAG00000023949 CCL2 1.515983122 1.90284E-08 1.29102E-05 
Case t1 X Case t2 ENSECAG00000016634 RPS2 -1.170961299 9.40957E-08 6.02944E-05 
Case t1 X Case t2 ENSECAG00000008710 FCER1A 1.588999592 1.08387E-07 6.57966E-05 
Case t1 X Case t2 ENSECAG00000007161 CYP2F1 1.294710352 1.40488E-07 8.10194E-05 
Case t1 X Case t2 ENSECAG00000002962 ADIPOQ 1.238907368 1.63498E-07 8.97993E-05 
Case t1 X Case t2 ENSECAG00000014226 ENSECAG00000014226 1.062158811 2.28842E-07 0.000119976 
Case t1 X Case t2 ENSECAG00000016225 TMEM144 1.665037785 2.63014E-07 0.000126209 
Case t1 X Case t2 ENSECAG00000025328 RNA45S5 1.056872193 2.67001E-07 0.000126209 
Case t1 X Case t2 ENSECAG00000027524 ENSECAG00000027524 1.058301003 2.73558E-07 0.000126209 
Case t1 X Case t2 ENSECAG00000013022 ACTC1 1.097707766 3.73807E-07 0.000165827 
Case t1 X Case t2 ENSECAG00000021019 CPXM1 1.102435473 4.71363E-07 0.000201359 
Case t1 X Case t2 ENSECAG00000020878 MNDA 1.104024877 4.97943E-07 0.000205117 
Case t1 X Case t2 ENSECAG00000013687 SMG1 -1.110581229 1.55494E-06 0.000618435 
Case t1 X Case t2 ENSECAG00000027056 ENSECAG00000027056 0.982814572 1.89724E-06 0.000729427 
Case t1 X Case t2 ENSECAG00000016560 CRABP2 1.00124932 2.22157E-06 0.000826569 
Case t1 X Case t2 ENSECAG00000019220 PROX1 -1.1209383 3.81444E-06 0.001374867 
Case t1 X Case t2 ENSECAG00000020059 FGF4 1.222608401 3.99579E-06 0.001396591 
Case t1 X Case t2 ENSECAG00000016782 MYO1F -0.960312958 4.84248E-06 0.001595806 
Case t1 X Case t2 ENSECAG00000017431 MYOZ2 0.916496424 4.74411E-06 0.001595806 
Case t1 X Case t2 ENSECAG00000027624 ENSECAG00000027624 0.956400782 5.02439E-06 0.001609758 
Case t1 X Case t2 ENSECAG00000008916 ANKRD2 0.942918425 5.80386E-06 0.001805296 
Case t1 X Case t2 ENSECAG00000021324 NR6A1 -1.022308695 5.94774E-06 0.001805296 
Case t1 X Case t2 ENSECAG00000016582 SSPO -1.118591246 7.19798E-06 0.002128757 
Table 4. Comparisons performed between time point t1 and t2. Training effect within group.  The list 
shows the top 100 genes differentially expressed with FDR<0.05 
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Case t1 X Case t2 ENSECAG00000017807 NAV2 -0.916963886 8.5914E-06 0.002416907 
Case t1 X Case t2 ENSECAG00000024660 DPF3 -0.943473031 8.5434E-06 0.002416907 
Case t1 X Case t2 ENSECAG00000027699 ENSECAG00000027699 0.869780299 1.27308E-05 0.003496134 
Case t1 X Case t2 ENSECAG00000026887 TSPAN8 0.871818503 1.39415E-05 0.003739571 
Case t1 X Case t2 ENSECAG00000013517 LCOR -0.902060461 1.5827E-05 0.004148821 
Case t1 X Case t2 ENSECAG00000009126 NOS1 -0.849016463 2.32812E-05 0.005967233 
Case t1 X Case t2 ENSECAG00000013728 MFSD2A 1.092417355 2.42829E-05 0.006088682 
Case t1 X Case t2 ENSECAG00000015909 MYBPHL 0.965982026 2.52362E-05 0.006193059 
Case t1 X Case t2 ENSECAG00000013913 PCK2 1.011936261 3.0714E-05 0.007115326 
Case t1 X Case t2 ENSECAG00000018927 ANGPTL4 1.315852475 3.00746E-05 0.007115326 
Case t1 X Case t2 ENSECAG00000018973 ENTHD1 0.882669224 3.0845E-05 0.007115326 
Case t1 X Case t2 ENSECAG00000011254 SMG1 -0.881040155 3.25071E-05 0.007332647 
Case t1 X Case t2 ENSECAG00000019769 PPARGC1B -0.845040345 3.30586E-05 0.007332647 
Case t1 X Case t2 ENSECAG00000008881 LYVE1 1.081690146 4.2435E-05 0.009063802 
Case t1 X Case t2 ENSECAG00000023163 ENSECAG00000023163 -0.823719561 4.24087E-05 0.009063802 
Case t1 X Case t2 ENSECAG00000009390 SEPT1 0.935311453 4.85474E-05 0.009823606 
Case t1 X Case t2 ENSECAG00000023118 MCC -0.839393141 4.82161E-05 0.009823606 
Case t1 X Case t2 ENSECAG00000024143 MYO7A -0.976939527 4.7703E-05 0.009823606 
Case t1 X Case t2 ENSECAG00000001101 SESN1 0.791257883 5.67922E-05 0.01092791 
Case t1 X Case t2 ENSECAG00000010266 NFAT5 -0.831615204 5.68471E-05 0.01092791 
Case t1 X Case t2 ENSECAG00000019083 SORL1 -0.930650876 5.52259E-05 0.01092791 
Case t1 X Case t2 ENSECAG00000000171 NPAS2 -0.988864073 6.25025E-05 0.011818092 
Case t1 X Case t2 ENSECAG00000022544 KMT2C -0.803892872 6.43492E-05 0.011971036 
Case t1 X Case t2 ENSECAG00000019111 CD163 0.874990518 7.04406E-05 0.012499409 
Case t1 X Case t2 ENSECAG00000023280 FADS1 -0.910205273 6.8483E-05 0.012499409 
Case t1 X Case t2 ENSECAG00000024267 TFRC -0.788703171 6.993E-05 0.012499409 
Case t1 X Case t2 ENSECAG00000007663 GIMAP5 0.924855529 7.46506E-05 0.013045752 
Case t1 X Case t2 ENSECAG00000018324 SLC43A2 0.794473572 7.76775E-05 0.013372127 
Case t1 X Case t2 ENSECAG00000007047 ASPN 0.891294062 7.94172E-05 0.013470556 
Case t1 X Case t2 ENSECAG00000007582 GIMAP7 0.915221414 8.58579E-05 0.014146927 
Case t1 X Case t2 ENSECAG00000023076 GPCPD1 0.777738691 8.55911E-05 0.014146927 
Case t1 X Case t2 ENSECAG00000006043 PHC3 -0.826927649 8.81954E-05 0.014327404 
Case t1 X Case t2 ENSECAG00000000040 IKZF2 -0.842827447 9.06308E-05 0.014518552 
Case t1 X Case t2 ENSECAG00000017294 SNTB1 -0.771538188 9.34903E-05 0.014771462 
Case t1 X Case t2 ENSECAG00000009759 TNRC6B -0.783049732 0.000100611 0.015681693 
Case t1 X Case t2 ENSECAG00000017238 MTC1 0.893145088 0.000104608 0.016087346 
Case t1 X Case t2 ENSECAG00000023387 FRRS1 -0.771461128 0.000108041 0.016396608 
Case t1 X Case t2 ENSECAG00000020410 FREM2 -0.840703902 0.000113946 0.017068175 
Case t1 X Case t2 ENSECAG00000015076 INO80D -0.841658102 0.00012068 0.017845165 
Case t1 X Case t2 ENSECAG00000008221 S100A4 0.777938675 0.000147727 0.021298474 
Case t1 X Case t2 ENSECAG00000016173 TK1 0.898468848 0.000147266 0.021298474 
Case t1 X Case t2 ENSECAG00000004773 TET2  -0.814472475 0.000154296 0.021971001 
Case t1 X Case t2 ENSECAG00000024549 KIAA2018 -0.761033967 0.000161431 0.022706626 
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Case t1 X Case t2 ENSECAG00000017015 MYH11 -0.766792538 0.000165872 0.023050243 
Case t1 X Case t2 ENSECAG00000005666 ZBED6 -0.755511021 0.000173707 0.023851587 
Case t1 X Case t2 ENSECAG00000002206 SPRY3 -0.938833481 0.000191771 0.026022189 
Case t1 X Case t2 ENSECAG00000012155 GAN -0.814082401 0.000197192 0.026446642 
Case t1 X Case t2 ENSECAG00000023650 ABAT -0.872861552 0.000204686 0.027136222 
Case t1 X Case t2 ENSECAG00000009535 FCER1G 0.801428029 0.000213226 0.027947086 
Case t1 X Case t2 ENSECAG00000013723 SLC7A8 -0.744908856 0.000215895 0.027979051 
Case t1 X Case t2 ENSECAG00000021790 LNPEP -0.75209736 0.000222891 0.028564707 
Case t1 X Case t2 ENSECAG00000017042 ENSECAG00000017042 0.854906711 0.000226468 0.028704213 
Case t1 X Case t2 ENSECAG00000020053 SLC4A4 -0.792815614 0.000230056 0.028831319 
Case t1 X Case t2 ENSECAG00000023632 RGS10 0.741984139 0.00023247 0.028831319 
Case t1 X Case t2 ENSECAG00000018191 GUCY1A2 -0.818695963 0.000244669 0.030021411 
Case t1 X Case t2 ENSECAG00000017946 KMT2D -0.73014834 0.000258841 0.031425966 
Case t1 X Case t2 ENSECAG00000000762 DDI2 -0.754614254 0.000272737 0.032230268 
Case t1 X Case t2 ENSECAG00000016683 SMYD1 -0.718670775 0.000273848 0.032230268 
Case t1 X Case t2 ENSECAG00000017427 OTOR 0.974489221 0.000270382 0.032230268 
Case t1 X Case t2 ENSECAG00000000237 DGKH -0.819461561 0.0002859 0.033308769 
Case t1 X Case t2 ENSECAG00000007668 ENSECAG00000007668 0.925416797 0.000289727 0.033417098 
Comparison Ensembl GENE ID GENE  logFC PValue FDR 
Case t2 X Case t3 ENSECAG00000014260 FOS 7.598763208 1.1264E-170 1.2992E-166 
Case t2 X Case t3 ENSECAG00000014338 EGR1 7.033589317 7.7632E-161 4.477E-157 
Case t2 X Case t3 ENSECAG00000018002 FOSB 8.638430603 2.0631E-146 7.932E-143 
Case t2 X Case t3 ENSECAG00000003816 JUNB 4.473073737 4.89699E-81 1.41205E-77 
Case t2 X Case t3 ENSECAG00000017203 BTG2 4.275525933 2.09277E-72 4.8276E-69 
Case t2 X Case t3 ENSECAG00000014232 NR4A2 4.130895224 5.90984E-57 1.13607E-53 
Case t2 X Case t3 ENSECAG00000010560 MGSA 4.774409938 1.12126E-56 1.84752E-53 
Case t2 X Case t3 ENSECAG00000011486 ATF3 3.418073922 1.55216E-51 2.23783E-48 
Case t2 X Case t3 ENSECAG00000010818 EGR2 3.999060604 4.51143E-50 5.78165E-47 
Case t2 X Case t3 ENSECAG00000009012 IER2 3.304921184 6.50951E-49 7.50807E-46 
Case t2 X Case t3 ENSECAG00000009958 DUSP1 3.09207054 4.50384E-46 4.72248E-43 
Case t2 X Case t3 ENSECAG00000004180 HSPA6 3.755188486 4.94437E-45 4.75237E-42 
Case t2 X Case t3 ENSECAG00000024993 CYR61 3.087759541 1.82075E-43 1.61542E-40 
Case t2 X Case t3 ENSECAG00000010613 KLF4 2.830283968 1.69338E-37 1.39511E-34 
Case t2 X Case t3 ENSECAG00000001249 SOCS3 3.838014794 1.60919E-34 1.23736E-31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Comparisons performed between time point t2 and t3. Exercise effect within group.  The 
list shows the top 100 genes differentially expressed with FDR<0.05  	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Case t2 X Case t3 
 
ENSECAG00000024055 
 
JUN 
 
2.576022754 
 
3.60964E-33 
 
2.6021E-30 
Case t2 X Case t3 ENSECAG00000013836 PKLR -5.039210367 6.11038E-33 4.14571E-30 
Case t2 X Case t3 ENSECAG00000019552 
SLCO1
C1 -5.987065861 3.30454E-32 2.11748E-29 
Case t2 X Case t3 ENSECAG00000020971 RND1 3.001285982 6.22398E-32 3.77829E-29 
Case t2 X Case t3 ENSECAG00000016611 KLF2 2.367888106 9.14709E-28 5.27513E-25 
Case t2 X Case t3 ENSECAG00000007242 DUSP2 4.011343384 3.77467E-27 2.07319E-24 
Case t2 X Case t3 ENSECAG00000011488 
MIP-
2BETA 3.905463879 4.3806E-27 2.29663E-24 
Case t2 X Case t3 ENSECAG00000020059 FGF4 -4.04051323 2.29056E-25 1.14867E-22 
Case t2 X Case t3 ENSECAG00000005487 IGLC7 4.043096642 6.73026E-24 3.23445E-21 
Case t2 X Case t3 ENSECAG00000017436 TREM1 2.788982413 3.46108E-22 1.5968E-19 
Case t2 X Case t3 ENSECAG00000011496 
NFKBI
Z 2.123171438 5.58381E-22 2.47706E-19 
Case t2 X Case t3 ENSECAG00000011895 ILT11B 2.629998058 3.49189E-20 1.49168E-17 
Case t2 X Case t3 ENSECAG00000013457 CSF3R 2.168765643 1.38393E-18 5.70079E-16 
Case t2 X Case t3 ENSECAG00000013081 MMP9 2.386807876 2.43589E-18 9.68813E-16 
Case t2 X Case t3 ENSECAG00000004066 
APOLD
1 2.118307517 4.09667E-18 1.57503E-15 
Case t2 X Case t3 ENSECAG00000013781 
KIAA12
11 -2.520995413 6.05905E-18 2.25436E-15 
Case t2 X Case t3 ENSECAG00000013730 ID1 1.818135687 1.84767E-17 6.65969E-15 
Case t2 X Case t3 ENSECAG00000023949 CCL2 2.009780927 2.03138E-17 7.09998E-15 
Case t2 X Case t3 ENSECAG00000020122 SELL 2.095629557 1.59054E-16 5.39566E-14 
Case t2 X Case t3 ENSECAG00000001471 GPR34 2.451200089 2.2118E-16 7.28884E-14 
Case t2 X Case t3 ENSECAG00000004312 IL1RN 2.20639216 6.33413E-16 2.02938E-13 
Case t2 X Case t3 ENSECAG00000025128 PIWIL2 -2.795650277 8.42879E-16 2.62751E-13 
Case t2 X Case t3 ENSECAG00000023741 EGR3 1.829703695 3.47678E-15 1.0553E-12 
Case t2 X Case t3 ENSECAG00000026998 
LRRC1
0B -2.702773129 8.86041E-15 2.62041E-12 
Case t2 X Case t3 ENSECAG00000007258 IGHG1 2.507466372 1.56053E-14 4.49979E-12 
Case t2 X Case t3 ENSECAG00000003072 C8orf4 1.640009076 3.07419E-14 8.64822E-12 
Case t2 X Case t3 ENSECAG00000009625 IGHA1 2.271488141 5.32225E-14 1.46159E-11 
Case t2 X Case t3 ENSECAG00000003774 IGHG1  2.157271251 6.11847E-14 1.64117E-11 
Case t2 X Case t3 ENSECAG00000012179 RGS2 1.630506187 1.11621E-13 2.92599E-11 
Case t2 X Case t3 ENSECAG00000010277 
PPP1R1
5A 1.503818816 1.71201E-13 4.38808E-11 
Case t2 X Case t3 ENSECAG00000008555 LTB 2.003356512 2.7128E-13 6.80205E-11 
Case t2 X Case t3 ENSECAG00000019922 
ADAM
DEC1 2.355693585 4.53342E-13 1.11252E-10 
Case t2 X Case t3 ENSECAG00000013692 IGL  2.639383224 5.58415E-13 1.34182E-10 
Case t2 X Case t3 ENSECAG00000022059 MYC 1.555354914 6.40528E-13 1.50772E-10 
Case t2 X Case t3 ENSECAG00000012527 
ENSEC
AG0000
0012527 -2.532313598 1.00159E-12 2.31047E-10 
Case t2 X Case t3 ENSECAG00000026913 
ENSEC
AG0000 -2.617271225 1.27844E-12 2.89127E-10 
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0026913 
Case t2 X Case t3 ENSECAG00000023399 
GADD4
5G 1.493241798 1.93254E-12 4.28653E-10 
Case t2 X Case t3 ENSECAG00000010847 
PGLYR
P1 2.151552793 3.15514E-12 6.8663E-10 
Case t2 X Case t3 ENSECAG00000000436 FCN1 1.798933702 5.87134E-12 1.25407E-09 
Case t2 X Case t3 ENSECAG00000015010 CYP4F3 1.828240309 6.89398E-12 1.44573E-09 
Case t2 X Case t3 ENSECAG00000000400 
AMICA
1 1.667306579 7.61419E-12 1.56825E-09 
Case t2 X Case t3 ENSECAG00000016610 CTGF 1.434782053 1.38568E-11 2.80394E-09 
Case t2 X Case t3 ENSECAG00000016661 NR4A1 1.344950583 2.18034E-11 4.33586E-09 
Case t2 X Case t3 ENSECAG00000023992 S100P 1.597944532 3.43324E-11 6.71169E-09 
Case t2 X Case t3 ENSECAG00000018649 UCP2 1.503545561 4.06927E-11 7.82249E-09 
Case t2 X Case t3 ENSECAG00000006561 TRBC2 1.474580243 4.90167E-11 9.26817E-09 
Case t2 X Case t3 ENSECAG00000006674 RRAD 1.346281032 5.29021E-11 9.8415E-09 
Case t2 X Case t3 ENSECAG00000000548 IGHM 1.636314299 5.48074E-11 1.00341E-08 
Case t2 X Case t3 ENSECAG00000015657 TNNT1 1.4281332 1.20509E-10 2.17179E-08 
Case t2 X Case t3 ENSECAG00000004763 XIRP1 1.293548826 1.94338E-10 3.44845E-08 
Case t2 X Case t3 ENSECAG00000009742 
S100A1
2 2.019360365 2.1197E-10 3.70434E-08 
Case t2 X Case t3 ENSECAG00000010089 DUSP6 1.288609136 3.23354E-10 5.56652E-08 
Case t2 X Case t3 ENSECAG00000007960 LIMD2 1.60180998 4.69878E-10 7.96997E-08 
Case t2 X Case t3 ENSECAG00000019932 
LGALS
9C 1.413355658 5.05261E-10 8.44592E-08 
Case t2 X Case t3 ENSECAG00000000419 TRAC 1.489322423 5.28441E-10 8.63161E-08 
Case t2 X Case t3 ENSECAG00000020452 TNNC1 1.369704764 5.31337E-10 8.63161E-08 
Case t2 X Case t3 ENSECAG00000010020 HBB 2.119562201 6.78278E-10 1.08656E-07 
Case t2 X Case t3 ENSECAG00000014875 
PTPRC
AP 1.4345552 7.53092E-10 1.18988E-07 
Case t2 X Case t3 ENSECAG00000016339 
ADAM
TS1 1.250351605 8.17222E-10 1.27376E-07 
Case t2 X Case t3 ENSECAG00000024788 
CORO1
A 1.349284846 1.16008E-09 1.78404E-07 
Case t2 X Case t3 ENSECAG00000007867 MYL2 1.316652752 1.4061E-09 2.13394E-07 
Case t2 X Case t3 ENSECAG00000017410 MYL3 1.309558654 2.60811E-09 3.90675E-07 
Case t2 X Case t3 ENSECAG00000018395 
TYROB
P 1.309718806 5.23159E-09 7.73605E-07 
Case t2 X Case t3 ENSECAG00000020463 HSPB1 1.187957489 5.31064E-09 7.75354E-07 
Case t2 X Case t3 ENSECAG00000015834 DMD  -1.201494777 5.69262E-09 8.20733E-07 
Case t2 X Case t3 ENSECAG00000014552 
ENSEC
AG0000
0014552 -1.223198618 6.2907E-09 8.95765E-07 
Case t2 X Case t3 ENSECAG00000017799 
MYO1
G 1.308878054 6.98058E-09 9.81879E-07 
Case t2 X Case t3 ENSECAG00000009192 SRGN 1.203957895 7.67809E-09 1.06698E-06 
Case t2 X Case t3 ENSECAG00000009474 
ENSEC
AG0000
0009474 1.97331704 8.21324E-09 1.12776E-06 
Case t2 X Case t3 ENSECAG00000000763 CSRNP 1.311913009 8.31742E-09 1.12862E-06 
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1 
Case t2 X Case t3 ENSECAG00000024888 CCL5 1.28672592 9.00109E-09 1.20719E-06 
Case t2 X Case t3 ENSECAG00000016776 TNNI1 1.257187544 9.85638E-09 1.30671E-06 
Case t2 X Case t3 ENSECAG00000009363 IRG1 1.854095132 1.0617E-08 1.39155E-06 
Case t2 X Case t3 ENSECAG00000011254 SMG1 -1.260155461 1.43074E-08 1.85417E-06 
Case t2 X Case t3 ENSECAG00000012148 NMES1 1.690723335 1.50469E-08 1.92834E-06 
Case t2 X Case t3 ENSECAG00000002668 RHOB 1.148074246 1.77873E-08 2.2545E-06 
Case t2 X Case t3 ENSECAG00000012572 
ENSEC
AG0000
0012572 -1.183876651 1.93002E-08 2.41966E-06 
Case t2 X Case t3 ENSECAG00000020638 NEB -1.122713663 2.39429E-08 2.96943E-06 
Case t2 X Case t3 ENSECAG00000023322 ID3 1.158760487 2.48422E-08 3.04819E-06 
Case t2 X Case t3 ENSECAG00000019124 LILRA5 1.516827666 2.63168E-08 3.19514E-06 
Case t2 X Case t3 ENSECAG00000001159 FOXS1 1.260488919 2.75603E-08 3.31126E-06 
Case t2 X Case t3 ENSECAG00000001784 CD14 1.168974284 3.75389E-08 4.46364E-06 
Case t2 X Case t3 ENSECAG00000016508 HK3 1.29768793 3.88245E-08 4.56941E-06 
Case t2 X Case t3 ENSECAG00000018028 TLR2 1.357514574 4.04357E-08 4.71096E-06 
Case t2 X Case t3 ENSECAG00000010918 SELP 1.305331929 5.07243E-08 5.85055E-06 
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Case t1 X Case t2 
      
Category Term Count PValue List Total 
Fold 
Enrichment FDR 
GOTERM_BP_FAT GO:0001775~cell activation 39 5.28202E-16 371 4.954985584 9.76996E-13 
GOTERM_BP_FAT GO:0045321~leukocyte activation 34 1.96577E-14 371 5.12298679 3.46723E-11 
GOTERM_BP_FAT GO:0006955~immune response 57 1.69367E-13 371 3.012211415 2.98972E-10 
SP_PIR_KEYWORDS signal 139 2.08901E-12 463 1.776816747 2.95892E-09 
GOTERM_BP_FAT GO:0002684~positive regulation of immune system process 31 2.53556E-12 371 4.749462049 4.47435E-09 
UP_SEQ_FEATURE signal peptide 139 2.85648E-12 462 1.769368631 4.73535E-09 
GOTERM_BP_FAT GO:0046649~lymphocyte activation 28 5.73119E-12 371 5.130558453 1.01136E-08 
GOTERM_BP_FAT GO:0050865~regulation of cell activation 25 7.09486E-11 371 5.209087409 1.252E-07 
SP_PIR_KEYWORDS disulfide bond 124 1.03979E-10 463 1.761795582 1.47279E-07 
GOTERM_BP_FAT GO:0006952~defense response 48 1.47226E-10 371 2.845940438 2.59805E-07 
       Case t2 X Case t3 
      
Category Term Count PValue List Total 
Fold 
Enrichment FDR 
GOTERM_BP_FAT GO:0010033~response to organic substance 15 2.20271E-05 73 3.855375905 0.03462474 
GOTERM_MF_FAT GO:0005539~glycosaminoglycan binding 7 5.79067E-05 64 10.14296875 0.07149988 
GOTERM_BP_FAT GO:0009617~response to bacterium 8 7.26185E-05 73 7.681453616 0.11410755 
GOTERM_MF_FAT GO:0030247~polysaccharide binding 7 9.82979E-05 64 9.220880682 0.12134468 
GOTERM_MF_FAT GO:0001871~pattern binding 7 9.82979E-05 64 9.220880682 0.12134468 
GOTERM_BP_FAT 
GO:0006357~regulation of transcription from RNA 
polymerase II promoter 14 0.00010476 73 3.568653313 0.16458541 
INTERPRO IPR004827:Basic-leucine zipper (bZIP) transcription factor 5 0.00012671 82 19.16589968 0.16021563 
GOTERM_MF_FAT GO:0008201~heparin binding 6 0.00013908 64 11.81705097 0.17165338 
GOTERM_BP_FAT GO:0032570~response to progesterone stimulus 4 0.00015443 73 37.0630137 0.24251377 
Table 6. DAVID clusters based on biological function for all of the comparisons. The top 10 clusters are represented 
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GOTERM_BP_FAT GO:0009991~response to extracellular stimulus 8 0.00016431 73 6.738729763 0.25802142 
KEEG_PATHWAY hsa04010:MAPK signaling pathway 9 2.29E-04 34 5.041308658 0.22493160 
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KEYWORD: glycolysis 
      COMPARISON T1 to T2  
      PATHWAYS SIZE ES NES NOM p-val FDR q-val 
 KEGG_GLYCOLYSIS_GLUCONEOGENESIS 35 -0.69490904 -1.9657172 0 0.001615509 ENRICHED T2 
REACTOME_GLYCOLYSIS 21 -0.6476651 -1.9034623 0.002020202 0.004038773 ENRICHED T2 
       KEYWORD: glycolysis 
      COMPARISON T2 to T3  
      PATHWAYS SIZE ES NES NOM p-val FDR q-val 
 KEGG_GLYCOLYSIS_GLUCONEOGENESIS 35 0.49987125 1.6620822 0.02008032 0.045878693 ENRICHED T2 
REACTOME_GLYCOLYSIS 21 0.4757577 1.5183991 0.033663366 0.07309489 ENRICHED T2 
              
KEYWORD: aerobic respiration 
      COMPARISON T1 to T2  
      PATHWAYS SIZE 
     REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_
TRANSPORT 101 
    
NO ENRICHMENT 
MITOCHONDRIAL_RESPIRATORY_CHAIN 21 
    
NO ENRICHMENT 
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT 54 
    
NO ENRICHMENT 
CELLULAR_RESPIRATION 18 
    
NO ENRICHMENT 
              
KEYWORD: aerobic respiration             
COMPARISON T2 to T3              
PATHWAYS SIZE ES NES NOM p-val FDR q-val 
 
Table	  7. Summary of pathways used by GSEA and their keywords  	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REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_
TRANSPORT 101 -0.5509119 -1.4273653 0.23837209 0.8328028 NO ENRICHMENT 
MITOCHONDRIAL_RESPIRATORY_CHAIN 21 -0.59782785 -1.3658537 0.22762646 0.48945075 NO ENRICHMENT 
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT 54 -0.6259762 -1.2918968 0.27237353 0.37738857 NO ENRICHMENT 
CELLULAR_RESPIRATION 18 -0.5079385 -1.262809 0.26029962 0.3018512 
Suggestive 
ENRICHED T3 
              
KEYWORD: mitochondria biogenesis 
      COMPARISON T1 to T2  
      PATHWAYS SIZE ES NES NOM p-val FDR q-val 
 
MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS 39 -0.45377496 -1.4908727 0.08102767 0.2633632 
Suggestive 
ENRICHED T2 
       KEYWORD: mitochondria biogenesis 
      COMPARISON T2 to T3  
      PATHWAYS SIZE 
     MITOCHONDRION_ORGANIZATION_AND_BIOGENESIS 39 
    
NO ENRICHMENT 
              
KEYWORD: fatty acid oxidation 
      COMPARISON T1 to T2    
      PATHWAYS SIZE 
     FATTY_ACID_OXIDATION 15 
    
NO ENRICHMENT 
REACTOME_ACTIVATED_AMPK_STIMULATES_FATTY_ACI
D_OXIDATION_IN_MUSCLE 16 
    
NO ENRICHMENT 
              
KEYWORD: fatty acid oxidation             
COMPARISON T2 to T3  
      PATHWAYS SIZE           
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FATTY_ACID_OXIDATION 15 
    
NO ENRICHMENT 
REACTOME_ACTIVATED_AMPK_STIMULATES_FATTY_ACI
D_OXIDATION_IN_MUSCLE 16         NO ENRICHMENT 
              
KEYWORD: striated muscle contraction 
      COMPARISON T1 to T2 
      PATHWAYS SIZE ES NES NOM p-val FDR q-val 
 REACTOME_STRIATED_MUSCLE_CONTRACTION 27 -0.43546376 -1.3614424 0.14078675 0.14367816 ENRICHED T2 
STRIATED_MUSCLE_DEVELOPMENT 31 -0.432036 -1.4706602 0.08523908 0.09508197 NO ENRICHMENT 
       KEYWORD: striated muscle contraction 
      COMPARISON T2 to T3  
      PATHWAYS SIZE ES NES NOM p-val FDR q-val 
 REACTOME_STRIATED_MUSCLE_CONTRACTION 27 -0.57616717 -1.7092016 0.038617887 0.047540985 ENRICHED T3 
STRIATED_MUSCLE_DEVELOPMENT 31 -0.432036 -1.4706602 0.08523908 0.09508197 ENRICHED T3 
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Glycolysis 
KEGG_GLYCOLYSIS_GLUCONEOGENESIS COMPARISON T2 to T3    
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
PKLR pyruvate kinase, liver and RBC 0.13907583 Yes 
HK3 hexokinase 3 (white cell) 0.25844055 Yes 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 0.339179 Yes 
PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) 0.38016167 Yes 
ALDOC aldolase C, fructose-bisphosphate 0.4313096 Yes 
PGK1 phosphoglycerate kinase 1 0.48479673 Yes 
PGAM4 phosphoglycerate mutase family member 4 0.49987125 Yes 
PGM2 phosphoglucomutase 2 0.46578398 No 
AKR1A1 aldo-keto reductase family 1, member A1 (aldehyde reductase) 0.45068592 No 
ALDH3A2 aldehyde dehydrogenase 3 family, member A2 0.2655334 No 
PFKP phosphofructokinase, platelet 0.23819382 No 
ENO1 enolase 1, (alpha) 0.19206505 No 
DLD dihydrolipoamide dehydrogenase 0.18905637 No 
LDHA lactate dehydrogenase A 0.18235655 No 
TPI1 triosephosphate isomerase 1 0.1792393 No 
ACSS2 acyl-CoA synthetase short-chain family member 2 0.16712666 No 
ACSS1 acyl-CoA synthetase short-chain family member 1 0.15924266 No 
Table 8. Summary of pathways used by GSEA and their keywords. ES: enrichment score. Core enrichment YES: Genes that contributed for 
the pathway to be significant  
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PGM1 phosphoglucomutase 1 0.13391243 No 
ALDH9A1 aldehyde dehydrogenase 9 family, member A1 0.10494192 No 
DLAT dihydrolipoamide S-acetyltransferase (E2 component of pyruvate 
dehydrogenase complex) 
0.10598044 No 
GPI glucose phosphate isomerase 0.114747964 No 
BPGM 2,3-bisphosphoglycerate mutase 0.09878541 No 
GALM galactose mutarotase (aldose 1-epimerase) 0.06806623 No 
ALDH7A1 aldehyde dehydrogenase 7 family, member A1 0.07998766 No 
HK1 hexokinase 1 0.0900982 No 
PDHB pyruvate dehydrogenase (lipoamide) beta 0.058411337 No 
PFKM phosphofructokinase, muscle 0.077250674 No 
ALDOA aldolase A, fructose-bisphosphate 0.09232678 No 
ENO3 enolase 3 (beta, muscle) 0.10141759 No 
PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1 0.05898392 No 
PGAM2 phosphoglycerate mutase 2 (muscle) 0.08422355 No 
FBP2 fructose-1,6-bisphosphatase 2 0.09376936 No 
PFKL phosphofructokinase, liver 0.07848208 No 
LDHB lactate dehydrogenase B 0.0472478 No 
ALDH1A3 aldehyde dehydrogenase 1 family, member A3 0.09059825 No 
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Glycolysis 
REACTOME_GLYCOLYSIS COMPARISON T2 to T3   
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
PKLR pyruvate kinase, liver and RBC 0.2103427 Yes 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 0.33489734 Yes 
ALDOC aldolase C, fructose-bisphosphate 0.39475855 Yes 
PGK1 phosphoglycerate kinase 1 0.4757577 Yes 
PFKP phosphofructokinase, platelet 0.14583541 No 
ENO1 enolase 1, (alpha) 0.10057233 No 
PPP2R5D protein phosphatase 2, regulatory subunit B (B56), delta isoform 0.09365212 No 
TPI1 triosephosphate isomerase 1 0.08818508 No 
PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 0.059443966 No 
GPI glucose phosphate isomerase 0.00244271 No 
PPP2CA protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform 0.005339099 No 
PFKM phosphofructokinase, muscle -0.08463839 No 
ALDOA aldolase A, fructose-bisphosphate -0.059717953 No 
PFKFB1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 -0.034038655 No 
ENO3 enolase 3 (beta, muscle) -0.010541584 No 
PPP2R1A protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), 
alpha isoform 
-0.007139669 No 
PPP2R1B protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta 
isoform 
0.013511842 No 
PGAM2 phosphoglycerate mutase 2 (muscle) 0.029780176 No 
PFKL phosphofructokinase, liver 0.012962782 No 
PFKFB2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 0.040970795 No 
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PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 0.028644124 No 
 
Glycolysis 
KEGG_GLYCOLYSIS_GLUCONEOGENESIS COMPARISON T1 to T2 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
ALDH7A1 aldehyde dehydrogenase 7 family, member A1 -0.26898795 No 
PFKL phosphofructokinase, liver -0.30118245 No 
ALDH3A2 aldehyde dehydrogenase 3 family, member A2 -0.34663817 No 
ALDH1A3 aldehyde dehydrogenase 1 family, member A3 -0.37494412 No 
DLD dihydrolipoamide dehydrogenase -0.40559292 No 
DLAT dihydrolipoamide S-acetyltransferase (E2 component of pyruvate 
dehydrogenase complex) 
-0.4231037 No 
PKLR pyruvate kinase, liver and RBC -0.46189758 No 
ALDH9A1 aldehyde dehydrogenase 9 family, member A1 -0.5486637 No 
ACSS2 acyl-CoA synthetase short-chain family member 2 -0.60186356 No 
HK1 hexokinase 1 -0.6437047 No 
PFKM phosphofructokinase, muscle -0.62816906 No 
PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1 -0.66450095 No 
FBP2 fructose-1,6-bisphosphatase 2 -0.6490245 No 
PDHB pyruvate dehydrogenase (lipoamide) beta -0.6346623 No 
ALDOA aldolase A, fructose-bisphosphate -0.62239015 No 
BPGM 2,3-bisphosphoglycerate mutase -0.61045015 No 
LDHB lactate dehydrogenase B -0.66791993 Yes 
PGM2 phosphoglucomutase 2 -0.64124805 Yes 
PGM1 phosphoglucomutase 1 -0.6219788 Yes 
AKR1A1 aldo-keto reductase family 1, member A1 (aldehyde reductase) -0.5988273 Yes 
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ACSS1 acyl-CoA synthetase short-chain family member 1 -0.57401395 Yes 
GAPDH glyceraldehyde-3-phosphate dehydrogenase -0.55068946 Yes 
ENO1 enolase 1, (alpha) -0.537385 Yes 
HK3 hexokinase 3 (white cell) -0.51060873 Yes 
GALM galactose mutarotase (aldose 1-epimerase) -0.48674762 Yes 
PFKP phosphofructokinase, platelet -0.48884705 Yes 
PGAM4 phosphoglycerate mutase family member 4 -0.45501506 Yes 
TPI1 triosephosphate isomerase 1 -0.40542296 Yes 
PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) -0.3517684 Yes 
PGK1 phosphoglycerate kinase 1 -0.29785973 Yes 
ENO3 enolase 3 (beta, muscle) -0.24386156 Yes 
PGAM2 phosphoglycerate mutase 2 (muscle) -0.18923523 Yes 
ALDOC aldolase C, fructose-bisphosphate -0.13250725 Yes 
GPI glucose phosphate isomerase -0.0704595 Yes 
LDHA lactate dehydrogenase A 0.001490959 Yes 
 
 
Glycolysis    
REACTOME_GLYCOLYSIS COMPARISON T1 to T2 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 0.11386655 No 
PFKFB1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 0.045146883 No 
PPP2R1B protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), beta 
isoform 
-0.12074023 No 
PFKL phosphofructokinase, liver -0.15947343 No 
PFKFB2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 -0.16874024 No 
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PKLR pyruvate kinase, liver and RBC -0.32761362 No 
PPP2R5D protein phosphatase 2, regulatory subunit B (B56), delta isoform -0.4235623 No 
PPP2R1A protein phosphatase 2 (formerly 2A), regulatory subunit A (PR 65), 
alpha isoform 
-0.49327064 No 
PFKM phosphofructokinase, muscle -0.48771518 No 
ALDOA aldolase A, fructose-bisphosphate -0.5300232 No 
GAPDH glyceraldehyde-3-phosphate dehydrogenase -0.60436356 Yes 
PPP2CA protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform -0.5705522 Yes 
ENO1 enolase 1, (alpha) -0.53083056 Yes 
PFKP phosphofructokinase, platelet -0.52939093 Yes 
PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 -0.46900293 Yes 
TPI1 triosephosphate isomerase 1 -0.4099281 Yes 
PGK1 phosphoglycerate kinase 1 -0.33125743 Yes 
ENO3 enolase 3 (beta, muscle) -0.2522874 Yes 
PGAM2 phosphoglycerate mutase 2 (muscle) -0.17203477 Yes 
ALDOC aldolase C, fructose-bisphosphate -0.08814424 Yes 
GPI glucose phosphate isomerase 0.003153408 Yes 
 
Aerobic respiration 
CELLULAR_RESPIRATION T2 to T3 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
PPARGC1A peroxisome proliferative activated receptor, gamma, coactivator 1, 
alpha 
-0.047863778 No 
NNT nicotinamide nucleotide transhydrogenase -0.34880745 No 
NDUFS4 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kDa (NADH-
coenzyme Q reductase) 
-0.47965235 Yes 
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SURF1 surfeit 1 -0.476851 Yes 
NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa (NADH-
coenzyme Q reductase) 
-0.4457616 Yes 
UQCRH ubiquinol-cytochrome c reductase hinge protein -0.4151305 Yes 
SDHC succinate dehydrogenase complex, subunit C, integral membrane 
protein, 15kDa 
-0.43732613 Yes 
PDHB pyruvate dehydrogenase (lipoamide) beta -0.40865698 Yes 
UQCRB ubiquinol-cytochrome c reductase binding protein -0.36510032 Yes 
UQCRC2 ubiquinol-cytochrome c reductase core protein II -0.32538426 Yes 
CYCS cytochrome c, somatic -0.29229105 Yes 
SLC25A14 solute carrier family 25 (mitochondrial carrier, brain), member 14 -0.28898168 Yes 
SDHA succinate dehydrogenase complex, subunit A, flavoprotein (Fp) -0.23563294 Yes 
ME3 malic enzyme 3, NADP(+)-dependent, mitochondrial -0.19035383 Yes 
ACO2 aconitase 2, mitochondrial -0.13451342 Yes 
SDHB succinate dehydrogenase complex, subunit B, iron sulfur (Ip) -0.05881529 Yes 
UQCRC1 ubiquinol-cytochrome c reductase core protein I 0.015974713 Yes 
OXA1L oxidase (cytochrome c) assembly 1-like 0.08993779 Yes 
 
 
Mitochondria biogenesis 
MITOCHONDRION ORGANIZATION AND BIOGENESIS T1 to T2 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
BCL2L1 BCL2-like 1 -0.03421537 No 
POLRMT polymerase (RNA) mitochondrial (DNA directed) -0.019665433 No 
COX18 COX18 cytochrome c oxidase assembly homolog (S. cerevisiae) -0.10877428 No 
BCL2 B-cell CLL/lymphoma 2 -0.12678462 No 
	  	  
69	  	  
MSTO1 misato homolog 1 (Drosophila) -0.2200554 No 
MFN2 mitofusin 2 -0.2226482 No 
FIS1 fission 1 (mitochondrial outer membrane) homolog (S. cerevisiae) -0.22191599 No 
OPA1 optic atrophy 1 (autosomal dominant) -0.24119109 No 
BID BH3 interacting domain death agonist -0.2729822 No 
STARD3 START domain containing 3 -0.28719562 No 
SLC25A15 solute carrier family 25 (mitochondrial carrier; ornithine transporter) 
member 15 
-0.2996277 No 
BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 -0.31462362 No 
TIMM50 translocase of inner mitochondrial membrane 50 homolog (S. 
cerevisiae) 
-0.3731208 No 
TFB2M transcription factor B2, mitochondrial -0.3718092 No 
SLC25A4 solute carrier family 25 (mitochondrial carrier; adenine nucleotide 
translocator), member 4 
-0.39457473 No 
TRNT1 tRNA nucleotidyl transferase, CCA-adding, 1 -0.39393988 No 
MIPEP mitochondrial intermediate peptidase -0.4365217 Yes 
NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa (NADH-
coenzyme Q reductase) 
-0.42774674 Yes 
TIMM17B translocase of inner mitochondrial membrane 17 homolog B (yeast) -0.41404352 Yes 
HSP90AA1 heat shock protein 90kDa alpha (cytosolic), class A member 1 -0.4044121 Yes 
TIMM17A translocase of inner mitochondrial membrane 17 homolog A (yeast) -0.40928012 Yes 
TIMM44 translocase of inner mitochondrial membrane 44 homolog (yeast) -0.40298837 Yes 
MPV17 MpV17 mitochondrial inner membrane protein -0.391342 Yes 
NDUFS7 NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa (NADH-
coenzyme Q reductase) 
-0.37916794 Yes 
TFAM transcription factor A, mitochondrial -0.39670292 Yes 
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TOMM22 translocase of outer mitochondrial membrane 22 homolog (yeast) -0.3812983 Yes 
MTX2 metaxin 2 -0.38879213 Yes 
MRPL12 mitochondrial ribosomal protein L12 -0.39989534 Yes 
SLC25A1 solute carrier family 25 (mitochondrial carrier; citrate transporter), 
member 1 
-0.37414286 Yes 
IFI6 interferon, alpha-inducible protein 6 -0.3401471 Yes 
TAZ tafazzin (cardiomyopathy, dilated 3A (X-linked); endocardial 
fibroelastosis 2; Barth syndrome) 
-0.30889738 Yes 
DNM1L dynamin 1-like -0.27195662 Yes 
BAK1 BCL2-antagonist/killer 1 -0.26316497 Yes 
NDUFS5 NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15kDa (NADH-
coenzyme Q reductase) 
-0.23313986 Yes 
TSPO translocator protein (18kDa) -0.21255793 Yes 
NDUFS4 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kDa (NADH-
coenzyme Q reductase) 
-0.19862464 Yes 
GPX1 glutathione peroxidase 1 -0.1414416 Yes 
TOMM34 translocase of outer mitochondrial membrane 34 -0.07798036 Yes 
BAX BCL2-associated X protein 0.004474507 Yes 
 
 
Muscle structure/ contraction 
STRIATED MUSCLE DEVELOPMENT COMPARISON T2 to T3 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
TGFB1 transforming growth factor, beta 1 (Camurati-Engelmann disease) 0.020540724 No 
MKL2 MKL/myocardin-like 2 0.035044942 No 
TTN titin 0.03964372 No 
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MYH11 myosin, heavy chain 11, smooth muscle -0.001456962 No 
MBNL1 muscleblind-like (Drosophila) -0.057826404 No 
HDAC9 histone deacetylase 9 -0.107838936 No 
SVIL supervillin -0.17907901 No 
MYF5 myogenic factor 5 -0.25892287 No 
NRD1 nardilysin (N-arginine dibasic convertase) -0.31160536 No 
NOTCH1 Notch homolog 1, translocation-associated (Drosophila) -0.3057011 No 
MYL6 myosin, light chain 6, alkali, smooth muscle and non-muscle -0.31764394 No 
BOC Boc homolog (mouse) -0.30960748 No 
CHRNA1 cholinergic receptor, nicotinic, alpha 1 (muscle) -0.30100578 No 
MYOZ1 myozenin 1 -0.35903817 No 
MYL6B myosin, light chain 6B, alkali, smooth muscle and non-muscle -0.40682152 Yes 
IFRD1 interferon-related developmental regulator 1 -0.38805324 Yes 
CACNA1H calcium channel, voltage-dependent, alpha 1H subunit -0.37127852 Yes 
ACTA1 actin, alpha 1, skeletal muscle -0.40591496 Yes 
IGFBP3 insulin-like growth factor binding protein 3 -0.402336 Yes 
CACNB2 calcium channel, voltage-dependent, beta 2 subunit -0.39274564 Yes 
HDAC5 histone deacetylase 5 -0.37332374 Yes 
SIRT2 sirtuin (silent mating type information regulation 2 homolog) 2 (S. 
cerevisiae) 
-0.37655866 Yes 
HDAC4 histone deacetylase 4 -0.35423258 Yes 
MAPK12 mitogen-activated protein kinase 12 -0.32556358 Yes 
TAZ tafazzin (cardiomyopathy, dilated 3A (X-linked); endocardial 
fibroelastosis 2; Barth syndrome) 
-0.31428343 Yes 
BMP4 bone morphogenetic protein 4 -0.27068335 Yes 
MYF6 myogenic factor 6 (herculin) -0.22545144 Yes 
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TBX3 T-box 3 (ulnar mammary syndrome) -0.18836586 Yes 
MYOD1 myogenic differentiation 1 -0.1326932 Yes 
MYEF2 myelin expression factor 2 -0.07235352 Yes 
CSRP3 cysteine and glycine-rich protein 3 (cardiac LIM protein) 0.00832884 Yes 
 
Muscle structure/ contraction 
REACTOME STRIATED MUSCLE CONTRACTION COMPARISON T2 to T3 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
TNNT2 troponin T type 2 (cardiac) 0.06958364 No 
DMD dystrophin (muscular dystrophy, Duchenne and Becker types) 0.046786375 No 
VIM vimentin 0.067855164 No 
NEB nebulin 0.093322285 No 
MYL4 myosin, light chain 4, alkali; atrial, embryonic -0.09171164 No 
MYL1 myosin, light chain 1, alkali; skeletal, fast -0.14351046 No 
TPM4 tropomyosin 4 -0.14367516 No 
TPM1 tropomyosin 1 (alpha) -0.15416498 No 
TMOD1 tropomodulin 1 -0.18672857 No 
TPM2 tropomyosin 2 (beta) -0.34792015 No 
ACTN2 actinin, alpha 2 -0.36552334 No 
MYH8 myosin, heavy chain 8, skeletal muscle, perinatal -0.41172448 No 
TNNC2 troponin C type 2 (fast) -0.4413656 No 
DES desmin -0.42408025 No 
MYBPC2 myosin binding protein C, fast type -0.45877194 No 
TNNI2 troponin I type 2 (skeletal, fast) -0.44600224 No 
TCAP titin-cap (telethonin) -0.47418872 No 
MYBPC1 myosin binding protein C, slow type -0.48536965 No 
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TPM3 tropomyosin 3 -0.5268663 Yes 
TNNC1 troponin C type 1 (slow) -0.4928308 Yes 
MYH3 myosin, heavy chain 3, skeletal muscle, embryonic -0.42703176 Yes 
MYL2 myosin, light chain 2, regulatory, cardiac, slow -0.36065263 Yes 
TNNT1 troponin T type 1 (skeletal, slow) -0.29308853 Yes 
TNNI3 troponin I type 3 (cardiac) -0.22549802 Yes 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow -0.15566489 Yes 
TNNI1 troponin I type 1 (skeletal, slow) -0.078808434 Yes 
MYH6 myosin, heavy chain 6, cardiac muscle, alpha (cardiomyopathy, 
hypertrophic 1) 
0.008589001 Yes 
 
 
Muscle structure/ contraction 
REACTOME COMPARISON T1 to T2 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
MYL4 myosin, light chain 4, alkali; atrial, embryonic 0.038398545 No 
TNNI3 troponin I type 3 (cardiac) 0.010624884 No 
MYH3 myosin, heavy chain 3, skeletal muscle, embryonic 0.04085993 No 
ACTN2 actinin, alpha 2 0.06784227 No 
DES desmin 0.079609826 No 
MYBPC1 myosin binding protein C, slow type 0.07167236 No 
DMD dystrophin (muscular dystrophy, Duchenne and Becker types) 0.08182785 No 
TNNT2 troponin T type 2 (cardiac) 0.032254517 No 
MYH6 myosin, heavy chain 6, cardiac muscle, alpha (cardiomyopathy, 
hypertrophic 1) 
0.035329115 No 
NEB nebulin 0.02225417 No 
MYH8 myosin, heavy chain 8, skeletal muscle, perinatal 0.024042623 No 
TCAP titin-cap (telethonin) -0.15751894 No 
	  	  
74	  	  
MYBPC2 myosin binding protein C, fast type -0.26426032 No 
TNNC1 troponin C type 1 (slow) -0.27327535 No 
TNNI1 troponin I type 1 (skeletal, slow) -0.26841295 No 
TNNC2 troponin C type 2 (fast) -0.2917354 No 
TMOD1 tropomodulin 1 -0.3492236 No 
TNNT1 troponin T type 1 (skeletal, slow) -0.39830953 Yes 
TPM3 tropomyosin 3 -0.3812591 Yes 
TNNI2 troponin I type 2 (skeletal, fast) -0.37670282 Yes 
MYL3 myosin, light chain 3, alkali; ventricular, skeletal, slow -0.33295575 Yes 
TPM4 tropomyosin 4 -0.31633145 Yes 
MYL2 myosin, light chain 2, regulatory, cardiac, slow -0.26498863 Yes 
TPM1 tropomyosin 1 (alpha) -0.24811675 Yes 
VIM Vimentin -0.18421523 Yes 
MYL1 myosin, light chain 1, alkali; skeletal, fast -0.09504266 Yes 
TPM2 tropomyosin 2 (beta) 0.005170855 Yes 
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Chapter 3 
 
Gene Expression Profile in Type 1 Polysaccharide Storage Myopathy 
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Summary 
  
 Polysaccharide Storage Myopathy (PSSM) is a form of glycogen storage disease 
in horses, characterized by abnormal polysaccharide inclusions in skeletal muscle. 
PSSM1 is caused by a dominant gain of function mutation in the GYS1 gene. While a 
gain of function in glycogen synthase explains the excessive muscle glycogen in PSSM1 
horses (1.5 to 2 times the normal amount), the link between excessive muscle glycogen, 
abnormal polysaccharide and rhabdomyolysis during sub-maximal exercise is less clear. 
PSSM1 horses can metabolize glycogen and have a normal flux of metabolites through 
glycolysis during maximal exercise, yet these horses demonstrate exercise intolerance, 
painful muscle cramping, and rhabdomyolysis during sub-maximal exercise.  
 
 To evaluate the changes in muscle that lead to this energy deficit, muscle gene 
expression profiles before and after a controlled exercise trial were evaluated in PSSM1 
cases and controls by RNASeq. Gene counts were determined by HTSeq, and EdgeR was 
used to calculate changes in gene expression between cases and controls at different time 
points (prior to the trial, and before and after exercise at the end of the trial). 201 genes 
were differentially expressed between cases and controls at time point one (pre-trial), 301 
genes were differently expressed between cases and controls at time point 2 (pre-
exercise, end of trial), and 803 genes were differentially expressed between cases and 
controls at time point 3 (post-exercise at the end of the trial). Pathway analysis performed 
by gene set enrichment analysis (GSEA) revealed enrichment in pathways involving 
mitochondria biogenesis, oxidative phosphorylation, fatty acid metabolism, glycogen and 
glucose metabolism. DAVID was used to cluster the top differentially expressed genes 
based on their functional annotation on each one of the comparisons performed. Clusters 
involved in inflammation were overrepresented.  
 
Manual curation of pathways based on what is known about PSSM1 will enable a 
better annotation of the gene sets and is the next step to better understand the changes 
identified by the current analyses and the pathophysiology of this disease.  
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Introduction 
 
Polysaccharide Storage Myopathy (PSSM) is a muscle glycogen storage disease 
in horses characterized by accumulation of excess and abnormal skeletal muscle 
glycogen and clinical myopathy2. A dominant mutation in the GYS1 gene has been 
described as a causative mutation in one form of PSSM (PSSM1)12,25. This mutation 
occurs in the coding sequence of exon 6 and results in amino acid substitution from 
arginine to histidine leading to a gain-of-function in the skeletal muscle isoform of 
glycogen synthase25. It has been hypothesized that this amino acid substitution leads to 
poor regulation and increased activity of glycogen synthase, which is the rate limiting 
step on glycogen synthesis. The mutation may result in the enzyme being in a 
continuously active state, which in turn could be responsible for the accumulation of 
excessive glycogen and abnormal amylase-resistant, less branched polysaccharide in 
horses with type 1 PSSM25. 
 
PSSM horses have 1.5 to 2 times higher glycogen concentration in the muscle 
compared with controls, but have the ability to breakdown glycogen during exercise and 
produce lactate21. However, during submaximal exercise (which relies mostly on aerobic 
metabolism), PSSM horses show disruption of cellular energy metabolism and 
considerable metabolic stress, characterized by increased IMP levels in single muscle 
fibers and increased serum CK activity23. Muscle energy metabolism is closely regulated 
by the cytosolic ATP:ADP ratio. A decrease in this ratio stimulates oxidative metabolism, 
followed by myokinase reaction if ATP can’t be restored. The myokinase reaction 
combines 2 ADP and produces ATP and adenine monophosphate (AMP), which will 
activate AMP deaminase and consequently increase levels of muscle inosine 
monophosphate (IMP). Increased levels of IMP in the muscle usually occur during 
intense exercise or under metabolic stress 23. This IMP elevation after submaximal (~ 20 
minute) exercise is comparable with horses performing at maximal exercise. Even with as 
little as 11 minutes of walk and trot, horses with PSSM have adenine nucleotide 
degradation in some fibers that resembles horses performing at twice the speed for almost 
5 times as long. During light submaximal exercise, healthy horses should not have any 
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adenine depletion23,21. IMP accumulation in PSSM horses suggests that they have a 
skeletal muscle energy deficit with submaximal exercise. The mechanism underlying this 
energy deficit remains unknown.  
 
Skeletal muscle of transgenic mice over-expressing GYS1, with resultant 
accumulation of excess glycogen, shows altered expression of > 700 genes; 98 which are 
directly involved in cellular energy metabolism, and 44 for which expression varies in 
either direct or inverse proportion to cellular glycogen content 74.  
. From the genes whose expression varies with glycogen concentrations, 3 
(besides GYS1) are involved in cellular metabolism, including hydroxysteroid (17-beta) 
dehydrogenase 7 (HSD17b7), UDP-glucose pyrophosphorylase 2 (Ugp2) and carbonic 
anhydrase 14 (Car14). Alteration in Ugp2 expression is perhaps not surprising, as this 
gene encodes an enzyme important for mammalian glycogen metabolism. This enzyme 
transfers a glucose moiety from glucose-1-phosphate to MgUTP and forms UDP-glucose 
and MgPPi. The UDP-glucose is a direct precursor of glycogen in muscle and liver. 
Eleven of the genes with varied expression are involved in muscle and contractile 
proteins, including Atp1β1 (ATPase, Na+/K+ Transport, Beta-1 Polypeptide), ATP2α2 
(ATPase, Ca++ transporting, cardiac muscle, slow twitch 2), myosin light and heavy 
chain family genes and others; and 14 other genes are involved in cell signaling 74. 
 
An equine homemade oligonucleotide microarray has been created to evaluate 
gene expression profile in 7 PSSM1 and 6 control Norman Cob horses. PSSM horses had 
amylase-resistant polysaccharide in the muscle and were either homozygous or 
heterozygous for the GYS1 mutation. The array included a total of 384 transcripts (50 
probes of the mitochondrial genome and 334 probes of the nuclear genome) and 129 
genes were found to be differently expressed between cases and controls. Thirteen genes 
involved in inflammatory pathways were up regulated in cases and six genes involved in 
mitochondrial function were down regulated. The top 10 up and down regulated genes 
(total of 20 genes) were also evaluated by quantitative RT-PCR. The expression levels of 
at least 4 of those genes were not in agreement between both methods. It is important to 
point out that this study was performed in a different breed of horse than the present 
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study and the number of oligo probes present in the array was very low and represents 
just a small portion of the transcriptome. Also a few of the microarray expression 
findings did not correlate with the quantitative RT-PCR expression results, raising 
questions	  about the quality of the probes75.  
 
While a gain of function in glycogen synthase (GS) likely explains the muscle 
biopsy phenotype in type 1 PSSM, the link between excessive muscle glycogen, 
abnormal polysaccharide and rhabdomyolysis during sub-maximal exercise is less clear. 
PSSM1 horses can metabolize glycogen and have a normal flux of metabolites through 
glycolysis during maximal exercise21,  yet these horses demonstrate exercise intolerance, 
painful muscle cramping, and rhabdomyolysis during sub-maximal (aerobic) exercise.  
 
Carbohydrates and fatty acids are the two major substrates for aerobic 
metabolism. During the first 30 minutes of submaximal exercise most of the energy is 
provided by muscle glycogen40. Circulating FFA concentrations increase within 15 
minutes of low-intensity exercise and uptake of short-chain and medium chain FFA 
across muscle membranes occurs down a concentration gradient by diffusion. Long-chain 
FFA are translocated across the muscle membrane by active transport (fatty acid 
transporters). Transport of FFA from the cytoplasm into mitochondria for β-oxidation is 
facilitated by an acylcarnitine transport system. A continuous supply of pyruvate from 
glucose or glycogen is essential for metabolism of FFA. Glycogen provides pyruvate 
which replenishes intermediates in the citric acid cycle (particularly oxaloacetate) 
allowing acetyl coenzyme A (CoA) derived from β-oxidation of FFA to enter the first 
step of the citric acid cycle40.  
 
The energy deficit observed during submaximal exercise in PSSM horses might 
be secondary to the constant activation of the GS enzyme or excessive glycogen stores, 
due to the gain of function mutation in GYS1 gene.  This scenario could be exacerbated 
by insulin release when consuming grain, which might be interpreted by the cell as an 
indication that glycogen breakdown and lipolysis are not necessary. Normally, the cell 
would sense an energy deficit and AMP kinase activation would stimulate oxidative 
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metabolism of fatty acid and carbohydrate by activation of pyruvate dehydrogenase.  If 
pyruvate dehydrogenase is not fully activated adequate acetyl CoA for oxidative 
metabolism is not produced. If PSSM horses are on a grain diet, they have low plasma 
FFA concentrations, possibly due to suppression of lipolysis by high insulin. So fatty acid 
oxidation, also fails in supplying acetyl CoA. Also, PSSM horses on a grain diet have 
high muscle citrate concentrations making them potentially unable to generate sufficient 
acetyl CoA for muscle energy from carbohydrate or fat metabolism during submaximal 
exercise30 108.  High citrate concentrations activate acetyl CoA carboxylase that converts 
acetyl CoA to malonyl CoA, which directs acetyl CoA away from the citric acid cycle 
and causes inhibition of carnitine palmytoyl transferase (CPT1), the key enzyme 
necessary to transport long-chain fatty acids into the mitochondria for β-oxidation40. 
Thus, the muscle cell’s mechanism to senses an energy deficit might not be working 
properly due to constant up regulation of the glycogen synthase enzyme and/or excessive 
muscle glycogen and this process could be accentuated if horses are on a grain diet.   
 
Current recommendations to control rhabdomyolysis in PSSM horses include 
regular exercise, increased turnout time, and a diet with low non-structural carbohydrates 
and high fat concentration. The provision of long-chain fatty acids in the diet of PSSM 
horses significantly decreases exercise intolerance and rhabdomyolysis with exercise1 29. 
Fat supplementation increases plasma FFA concentrations and the availability of fat for 
oxidation in skeletal muscle. It has been shown that the contribution of FFAs to energy 
production during low-intensity exercise is largely dependent on supply. Daily exercise 
may lower plasma insulin and increase plasma FFA concentrations, and training over 
time may enhance uptake of fatty acids into skeletal muscle and improve muscle 
oxidative capacity40. 
 
 Whole genome next generation RNA sequencing is a high throughput sequencing 
technology of cDNA.  It has several advantages over technologies for transcriptome 
analysis, such as microarray. It achieves base-pair level resolution and has a higher 
dynamic range of expression levels. Also, sequencing does not rely on probe design and 
previous genome knowledge and therefore is not limited to detecting known transcripts 
	  	  
81	  	  
and isoforms and permits de novo transcriptome assembly when a high quality reference 
genome or no reference genome is available. A few concerns have to be taken into 
consideration when performing RNA-seq, including how uniformly sequences from an 
entire transcript will be represented, how much sequence is required to detect and 
measure the transcripts with low abundance and appropriate downstream analysis since 
expression levels rely on proper mapping of sequencing reads to the corresponding 
reference genome or on their efficiency of de novo assembly 45-47,76. Pathway analysis is 
then performed to gain insights into the underlying biology of differentially expressed 
genes at the function level49.   
 
The purpose of this study was to investigate whether dyregulation of gene 
expression in key metabolic pathways could be responsible for the energy deficit and 
rhabdomyolysis that occurs with exercise in type 1 PSSM horses. The expression of 
genes and gene pathways that are potentially altered in PSSM1 horses during subclinical 
rhabdomyolysis, and the altered expression patterns after training, were determined by 
quantifying and comparing gene expression using next generation sequencing of the 
skeletal muscle transcriptome (RNA-seq) in PSSM1 cases and controls. 
 
 
Material and Methods 
 
Study Design 
Horses. Sample sizes needed to detect gene expression differences in cases and controls 
were estimated by n > (σ2 log f)/ (z2 1-α), (σ2, variance in gene expression was estimated 
from data in other species64, fold change = 2; and α=0.05). Based on this calculation, a 
minimum of 5 biologic replicates in each group is necessary to detect differences in gene 
expression, consistent with standard recommendations65. Eight PSSM1 and 6 healthy 
control QHs; 9 mares and 5 geldings ranging in age from 1.5 to 14 years (mean 6.3 +/- 
3.9 years) were utilized for the study. Prior to training, horses were unfit, and had a 
minimum of 90 days rest in a small paddock with no forced exercise. Results of muscle 
biochemistry for PSSM1 horses have been reported previously30. 
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Collection of biopsy samples and training protocol. Prior to the trial, a high-starch diet 
that predisposes PSSM1 horses to moderate rhabdomyolysis29 was introduced and this 
diet was consumed for the duration of the study. Baseline percutaneous gluteal muscle 
biopsy samples were collected for all horses prior to the start of treadmill exercise (time 
point t1)20. Biopsy samples consisted of at least 0.25 g of tissue from either the left or 
right gluteal muscle; samples were immediately frozen in liquid nitrogen and stored at -
80˚C pending further analysis. Horses had up to a two-week period of acclimatization to 
treadmill training (Figure 7). After the acclimatization horses completed a 3-week 
training period. Daily exercise for control horses consisted of 4 minutes of walk, and then 
alternating intervals of 2 min walk (1.9 m/s) and 2 min trot (3.0 – 3.8 m/s) for 20 min.  
Because individual PSSM1 horses have variable exercise tolerance, individual 
“exercise targets” of up to 20 min per day were established for each horse during the 2-
week acclimatization period. The goal of exercise targets for PSSM1 horses was to 
perform enough exercise to detect subclinical rhabdomyolysis (based on serum CK) 
without causing overt signs of muscle stiffness32. Similar to control horses, exercise 
consisted of 4 min walk (1.9 m/s) + repeated 2 min intervals of walk + trot (~3 m/s). At 
the end of the training period (day 21), muscle biopsy samples were collected before 
(time point t2) and after submaximal exercise (time point t3). To evaluate for subclinical 
rhabdomyolysis, CK activity was assessed 4 hours after every exercise bout in PSSM1 
cases and twice weekly in controls.  
 
RNA extraction and sequencing  
Total RNA was isolated from muscle tissue using Trizol reagent, quantified by 
Nanodrop spectrophotometry, and examined for integrity of RNA bands on an Agilent 
Bionalyzer. Library construction was performed using the Illumina HiSeq genome 
analyzer at the University of Minnesota Genomics Center (UMGC), using the TruSeq 
RNA V2 LT Illumina kit. First, the procedure purifies mRNA from total RNA, using 
polyA selection. The mRNA was then chemically fragmented and converted into single-
stranded cDNA using random hexamer priming. Next, the second strand was generated to 
create double-stranded cDNA that was ready for the TruSeq library construction 
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workflow, where adapters were ligated to end of the fragments. Each library was 
sequenced (50 bp single end reads) at a rate of 40 million reads per sample. Individual 
libraries were sequenced in more than one lane so possible batch effects could be later 
identified66. 
 
Quality Control and Mapping 
Fastq files created from sequencing were converted to fastq Sanger format. Prior 
to mapping, quality control of the reads was performed using FastQC program. QC 
reports were generated for every library and analyzed for per base sequence and per 
sequence quality score, per base and per sequence GC content, per base N content, 
sequence length distribution, duplication levels and overrepresented sequences and Kmer 
content. Reads with a quality score lower than 20 were trimmed. The reads were then 
mapped to the equine reference genome (EqCab2) using Bowtie2 and the splice-aware 
aligner Tophat267. First, Tophat uses Bowtie to align reads to the reference and breaks 
sequences that Bowtie cannot align on its own into shorter segments. Bowtie does not 
allow large gaps between read alignments to the reference genome, so it does not align 
reads that contain introns. The short segments created by Tophat67,77 are then aligned to 
the reference genome. When segments created from the same reads aligned to the 
genome far from each other, Tophat infers that the reads spans a splice junction and 
builds an index of splice sites in the transcriptome. A gene model annotation file (GTF; 
gene transfer format) from ensemble was provided for the analysis. A GTF file is a tab-
delimited file describing genomic features and their location. The reads from the same 
individual (library) were mapped by lane and the generated BAM files were then merged 
for follow-up analysis. A BAM file is a binary version of a SAM file, which is a tab-
delimited text file that contains sequence alignment data. 
 
Non-normalized (raw) gene count  
A non-normalized gene count (raw count) was performed, as this is the required 
input for differential expression analysis based on negative binomial distribution (edgeR). 
The BAM files originating from mapping with Tophat were sorted and indexed by 
Samtools.  HTSeq-count (a python package) was used to count the reads that mapped to 
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each one of the equine genes present in the GTF file.  Given a file with aligned 
sequencing reads and a list of genomic features, HTSeq counts how many reads map to 
each feature. In this case, the read counts are the total number of reads aligned to each 
gene.  HTSeq has three overlap resolution modes that dictate how aligned reads that 
overlap more than one genomic feature are treated (union, intersection-strict, intersection-
nonempty). A union-counting mode was used to count the reads. The output is a tab-
delimited table of read counts for each gene listed in the genomic annotation set. 
 
Differential expression analysis - Edge R 
Gene differential expression analysis was performed on edgeR (Bioconductor R 
package78) based on negative binomial distribution since there is more variation in RNA-
seq data that can be accounted for by the Poisson model. In RNA-seq data, the variance 
grows faster than the mean, which is known as overdispersion, so the mean and the 
variance are modeled separately. EdgeR works on a table of read counts where rows 
correspond to genes and columns to independent libraries containing the non-normalized 
count produced by HTSeq. This design matrix was created into an object (DGE list) in R. 
Adjustment for sequencing depth is always done automatically by EdgeR, since different 
libraries can have different sequencing depths and it can affect read counts.  
 
Another important issue is dealing with the total RNA output in a flow cell. Genes 
that have a very high expression level can consume most of the library size and cause the 
remaining genes to be under sampled; this can make them look down-regulated unless 
this effect is controlled for in the analysis. This is potentially a concern with skeletal 
muscle where a few genes such as actin and myosin will likely encompass a large 
proportion of the RNA-seq reads. The calcNormFactor function normalizes for RNA 
composition using a trimmed mean of M-values (TMM) between each pair of samples. 
This creates the effective library size, which is the dataset used for downstream analysis. 
EdgeR considers that GC content and gene length have little effect on differential 
expression analysis since they do not change from sample to sample (the same genes will 
have the same length and GC content regardless of the sample). Then dispersion was 
estimated and a linear model fitted (GLM) to ask the questions of interest (figure 8). 
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Pathway Analysis 
Pathway analysis can be performed from using both bottom-up and top-down 
approaches. Bottom up approaches focus on examining a preset list of genes (which have 
the largest difference between groups) to evaluate their biological function. Top-down 
approaches focus on a pathway or gene list that has been identified a priori, and typically 
test for association with all gene members in the pathway or list, with the association 
statistic summing over multiple genes to determine statistical significance. Both Bottom-
up (DAVID) and top-down (GSEA) approaches were used in analysis of this data.  
 
David 
Following identification of genes differentially expressed, biologic themes, 
disease-gene relationships and metabolic pathways within the gene lists were identified 
with tools available from the DAVID bioinformatics resource (NIAID, 
http://david.abcc.ncifcrf.gov/). DAVID consists of an integrated biological 
knowledgebase and analytic tools aiming at systematically extracting biological meaning 
from large gene lists. This is an exploratory procedure more than a pure statistical 
solution. The goal of the analysis is to map a large number of interesting genes in a list to 
the associated biological annotation, and then statistically highlight the most over-
represented (enriched) biological annotation out of thousands of linked terms and 
contents.  
 
First a gene list is provided for the analysis (differently expressed genes). In the 
gene name batch viewer, a gene history report is provided and information about each 
gene can be accessed. The genes from the gene list are then cluster into groups according 
to their biological function. An enrichment score is provided and represents how 
important is this gene group in the gene list (the higher the level the greater the 
importance). Next, the functional annotation chart tool identifies the most relevant (over-
expressed) biological terms with a given gene list. In this output, enriched functional 
annotations are divided in different categories which include term (e.g., transcription 
factor activity), number of genes in each category, percentage of genes involved in this 
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category from the total gene list, and a modified Fisher exact p-value. Fisher Exact is 
adopted to measure the gene-enrichment in annotation terms. It ranges from 0 to 1 (a p-
value of zero represents perfect enrichment). Other tools are also available to visualize 
the same data in different formats (pathway map viewer, tabular format and others).  
 
Gene Set Enrichment Analysis – GSEA 
 
 Traditional strategies for gene expression analysis have focused on identifying 
individual genes (single gene analysis) that exhibit differences between two states of 
interest. Although useful, they fail to detect biological processes, such as metabolic 
pathways and responses, that are distributed across an entire network of genes and subtle 
at the level of individual genes72. Cellular processes often affect sets of genes acting 
together. An increase of 20% in all genes encoding members of a metabolic pathway may 
dramatically alter the flux through the pathway and may be more important than a 20-fold 
increase in a single gene72.  
 
Gene Set Enrichment Analysis (GSEA) is a computational method that 
determines whether an a priori defined set of genes shows statistically significant, 
concordant differences between two biological states (cases and controls for example). 
Gene sets are defined based on prior biological knowledge about the physiology of the 
disease of interest. The prior defined set of genes is chosen by the user, based on what is 
known about the pathological process of interest. It is a tool to interpret gene expression 
profile results, extracting meaning from their expression level and gaining insights into 
biological mechanisms72. Instead of a single gene analysis, GSEA calculates expression 
data at the level of gene sets. The goal of the program is to determine whether members 
of a gene set tend to occur at the top or bottom of the expression dataset, in which case 
the gene set is correlated with the phenotype of interest. Given an a priori defined set of 
genes S (e.g., genes encoding products in a metabolic pathway, located in the same 
cytogenetic band, or sharing the same GO category), the goal of GSEA is to determine 
whether the members of S are randomly distributed throughout L or primarily found at 
the top or bottom. We expect that sets related to the phenotypic distinction will tend to 
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show the latter distribution. GSEA applies Kolmogorov-Smirnof test to find 
asymmetrical distributions for defined blocks of genes in datasets whole distribution. 
 
The program requires an expression dataset (created by the user). The first 
column contains information about genes (HUGO gene names in case of RNA-Seq data), 
the second column a description of the genes that is ignored by the program, followed by 
sample names (third column onwards). The rows are filled with expression value for each 
feature (gene) in each sample. Each column contains expression values for 1 sample. A 
phenotype label set (associates each sample to a phenotype) and gene sets which are 
exported from MSigDb or created by the user are also required. The expression data used 
in the present study was the read count number generated from HTSeq.  
 
First GSEA calculates a rank for each one of the genes present in the expression 
dataset that are also present in the gene set list from a specific predefined pathway (list of 
genes expressed in a specific condition and their expression values). The genes are 
ranked based on their correlation with the phenotype and a ranked list is created (list L). 
Then an enrichment score (ES) is calculated and reflects the degree to which a set S (gene 
list from a specific pathway) is overrepresented at the extremes (top or bottom) of the 
entire ranked list L. The score is calculated by walking down the list L, increasing a 
running-sum statistic when a gene is encountered that is in the gene set S and decreasing 
it when a gene is encountered that is not in S. The magnitude of the increase or decrease 
in the running-sum statistic depends on the correlation of the gene with the phenotype. 
The enrichment score (ES) is the maximum deviation from zero encountered in the 
random walk; it corresponds to a weighted Kolmogorov–Smirnov-like statistic.  
 
GSEA then estimates the significance level of the ES by using an empirical 
phenotype-based permutation test procedure that preserves the complex correlation 
structure of the gene expression data. 1000 phenotype label swapping permutations were 
performed to determine ES score significance. Estimated significance level to account for 
multiple hypothesis testing is also performed since a large number of gene sets are often 
evaluated. A normalized enrichment score (NES) is also performed to account for the size 
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of the set and allows for comparison of the results between different pathways. The 
proportion of false positives is calculated using false discovery rate (FDR) corresponding 
to each NES. The FDR is the estimated probability that a set with a given NES represents 
a false positive finding; it is computed by comparing the tails of the observed and null 
distributions for the NES. The leading edge subset of a gene set is the subset of members 
that contribute most to the ES.  
 
The Molecular Signature Database (MSigDB) is a catalog of 1,325 gene sets, 
which are annotated gene sets for use with GSEA software. Gene sets for pathway 
analysis from the MSigDB database were selected by the use of keywords. First, general 
key words known to be important based on what is known about PSSM1 were used. 
Also, gene names or symbols can be used as keywords.  The genes with the highest 
differential expression levels between cases and controls and genes which expression 
values were significantly different in mice with genetically modified muscle glycogen 
content due to disruption of the muscle GYS1 genes in comparison to mice line GSL30 
that hyper-accumulates glycogen in the muscle were also used as keywords.  
 
The analysis described above was first performed using a ranked gene list created 
by GSEA using the genes that are on the expression dataset and also on the gene set file, 
and correlating them with the phenotype. Following this analysis, a customized ranked 
gene list was created using the list of the top differential genes for each time point. Those 
genes were ranked by EdgeR according to their log-fold change and FDR. The pathway 
analysis was then repeated, using the customized gene list.  
 
GSEA calls all the pathways with FDR< 0.25 significant. Due to the low number 
of horses in this analysis instead of the typical significance FDR cut-off of < 0.25, FDRs 
< 0.35 were called suggestive of being significant.   
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Results 
 
CK activity	  
Baseline CK activity was mildly elevated in PSSM1 cases (mean 617 U/L ± 82) 
and was significantly greater than baseline CK activity in controls (mean 255 U/L ± 34, 
p=0.007). Four hour post-exercise CK activity in PSSM horses was highest at the start of 
training and declined significantly over the 3 week training period. CK activity was 
significantly higher in PSSM cases than in controls throughout the training protocol 
(Figure 9).  
 
RNA and sequencing quality controls 
Total RNA integrity following isolation using an Agilent Technologies 2100 
Bioanalyzer revealed a RNA Integrity Number (RIN) value greater than eight for all 
samples. An average Q score for base calling above the quality cutoff of 30 was observed 
for all lanes. The Q score is a PHRED score.  A Q score of 30 equates to a 1/1000 
probability that the base call is incorrect. All samples also met the sequencing criteria of 
40 million reads/sample.  
 
Mapping summary  
Approximately 90-95% of the total reads per library mapped to the equine 
reference genome, and approximately 8% of the reads per library did not align uniquely 
to the reference genome. In this chapter the reads were mapped to the equine GTF file to 
generate non-normalized counts and this information was used for downstream analysis.  
 
Differentially expressed gene analysis in PSSM1 cases and controls 
Figure 8 shows the questions of interest that were asked on the gene expression 
analysis based on the study design. The differences representing exercise effect and 
training effect for controls were described in Chapter 2. Here the differences in gene 
expression between cases and controls at all three time points (pre-trial t1; pre-exercise t2 
and post-exercise t3), and cases at different time points, were evaluated. Also, a 
comparison between the effect of training and exercise in cases and controls was 
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performed (double difference; Figure 8 F and G). Table 9 reports the number of genes 
that were differentially expressed with an FDR < 0.05 in each one of the comparisons. 
Those top genes were added to DAVID for functional annotation. Table 10 to table 16 
shows the top 100 genes differently expressed between groups at different time points.  
 
Pathway analysis 
 
DAVID 
 The top genes from the differential expression analysis were imported to DAVID 
to find clusters of biological function without a priori knowledge. The top 10 most 
significant clusters for each one of the comparisons are summarized on Table 17. 
Clusters involved in inflammation were overrepresented. Genes differentially expressed 
between cases at time point 1 and cases at time point 2 were also involved in hypoxia, 
response to oxygen and myofibril assembly. Genes differentially expressed between 
cases at time point 2 and cases at time point 3 were also identified as being important for 
mitochondrion and actin cytoskeleton. Those clusters (mitochondrion and actin 
cytoskeleton) were not between the top 10 clusters but also had FDRs lower than 0.05 
and are reported on table 17.  
 
 
GSEA 
 Different from DAVID the pathways analyzed on GSEA were chosen prior to the 
analysis based on the criteria described in the methods. The keywords used were: 
glycogen, glycolysis, mitochondria metabolism, mitochondria biogenesis, inflammation, 
muscle contraction and structure, and the following gene names: CYT-B and NADH (both 
of which were top ranked on the differentially expressed analysis performed by EdgeR) 
and UDPG2 and Hsd17B7 (expression varies with glycogen levels in mice muscle).  A 
significant number of pathways selected by the use of those keywords overlapped (e.g. 
CYT-B, NADH and mitochondria metabolism revealed similar pathways).  Table 18 
summarizes all the pathways used in the analysis and the ones that were significantly 
different between time points. Table 19 shows all the significant pathways and the genes 
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included in the gene set and the ones from the expression data that were the major 
contributors to the high and significant enrichment scores.  A total of 10 keywords were 
used and 14 pathways were found to be enriched.  
 
 When evaluating fatty acid oxidation, enrichment was found at t2 in controls 
when compared to cases (figure 10A). No enrichment was found when comparing cases 
and controls at time points 1 and 3. Three different pathways (when using the keyword 
CYT-B) were enriched between cases and controls at t2. Those pathways are: reactome 
TCA cycle and respiratory electron transport (FDR 0.23), KEEG oxidative 
phosphorylation (FDR 0.21) and reactome respiratory electron transport (FDR 0.20). The 
use of NADH as a keyword revealed 2 pathways that were enriched in controls at t2 in 
comparison to cases (mitochondrial respiratory chain – suggestive with FDR 0.26 and 
mitochondrial membrane - FDR 0.22).  
 
When evaluating glucose metabolism 2 pathways were enriched; both in cases 
when compared to controls at t1 using the key word glycolysis (KEEG glycolysis and 
gluconeogenesis FDR 0.009 and Reactome glycolysis FDR 0.09; figure 10 B).  The use 
of the keyword glycogen generated 2 pathways from which glycogen metabolism was 
enriched in cases in comparison to controls at time point 1 (FDR 0.22) and enriched in 
cases at time point 1 in comparison to cases at time point 2 (FDR 0.11). The other 
generated pathway (glycogen breakdown) was not enriched in any of the time points.  
 
Pathways using the word inflammation were not enriched in any of the 
comparisons performed.  Four pathways involved in cellular components and 
organization were enriched in cases in comparison to controls at t1 (negative regulation 
of cellular component organization and biogenesis FDR 0.17; regulation of cytoskeleton 
organization and biogenesis FDR 0.21; actin cytoskeleton organization and biogenesis 
FDR 0.24; cytoskeleton organization and biogenesis FDR 0.22). Pathways generated with 
the key word muscle contraction were not enriched in any of the time points.  
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The findings described above were generated using a rank list created by GSEA 
using the genes present in the gene set and expression matrix and their correlation with 
the phenotype. The same analysis was performed using a pre-ranked file containing the 
top genes differentially expressed at each time point generated by EdgeR. Both analyses 
were consistent and generated the same enrichment results.  
 
 
Discussion 
   
Overall, alterations in the expression of genes and pathways involved in oxidative 
metabolism, glycolysis, mitochondrial biogenesis and fatty acid metabolism are of great 
importance in PSSM1.  
 
The increase in CK activity in controls in comparison to cases demonstrated that 
subclinical rhabdomyolysis occurred at the beginning of the exercise trial. The CK 
activity in cases decreased significantly by the end of the exercise study, which is 
consistent with the improvement observed in PSSM1 horses with controlled regular 
exercise.  
 
Hundreds of genes were found to be differentially expressed in cases and controls 
at different time points. Those transcripts were clustered based on their biological 
function using DAVID software. Several clusters were identified and the ones involved 
in inflammation were overrepresented. Clusters involved in hypoxia, response to oxygen, 
myofibril assembly, mitochondrion and actin cytoskeleton were also identified.  
 
Several genes involved in mitochondrial oxidation and glucose metabolism were 
present in the list of top genes differentially expressed (in most cases those genes had a 
lower expression in cases in comparison to controls). While this method evaluates only 
the statistical significance of genes by itself, there are advantages to analyze sets of genes 
together according to their biological functions. GSEA considers all of the genes in an 
experiment. If the genes only change moderately it may be difficult to find significant 
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changes by looking at each gene separately. If, on the other hand, many genes belonging 
to the same gene set are changed, even small changes can become significant. Pathways 
involved in fatty acid oxidation, oxidative metabolism, mitochondrial biogenesis and 
glycolysis were found to be enriched by GSEA in several of the comparisons between 
cases and controls. Most of the available pathways are missing key elements (genes) that 
would allow us to understand the direction of those changes and how they affect the 
physiological process. For example, the fatty acid oxidation pathway was observed to be 
enriched in controls at time point 2 in comparison to cases. Enrichment in this case means 
that the program found a correlation between the gene counts from the expression dataset 
(experimental expression) that were also present in the gene set (pathway set), with the 
phenotype (in this case, time point2). It does not give an answer to which direction this 
correlation is going (if it is an up or down regulation in fat metabolism in controls in 
relation to cases at that time point). If key gene elements were not missing from this 
pathway, the direction of the change could be further evaluated by looking at the gene 
expression values of those genes in the dataset and their biological function.  
 
This study has a few other limitations. It has been shown that gene expression in 
muscle can increase hours after exercise. Several myogenic and metabolic genes, for 
example, have a peak in gene expression 4 to 8 hours post-exercise73. The samples in this 
study were collected immediately after exercise, so it is possible that some genes would 
have a higher/lower level of expression if the biopsies were performed in a few hours 
after exercise. Although this might be a limitation of the study, muscle biopsy 
immediately after exercise enables the identification of differentially expressed early 
response genes that are rapidly induced by exercise. Also, the library prep kit used was 
specific for polyA selection (mRNA) so regulatory elements, such as miRNA, that might 
be important for changes in gene expression might have been missed.  
 
 The read counts performed in this study used the horse GTF file (from Ensemble) 
to map reads to genes, so this process relies on proper annotation of the reference 
genome. This is less of a problem in model species, like mice and human, but can be a 
challenge in species where the reference is not as well annotated like the horse. To 
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overcome this issue de novo assembly of the raw reads can be performed. This method 
does not rely on a reference genome and novel transcripts and isoforms can be identified.  
The de novo transcripts and isoforms can also be included in the differential expression 
analysis.    
 
Also, hundreds of transcripts with significant expression levels were not 
annotated in the reference genome and had only ensemble IDs without associated gene 
names. Several of those IDs could not be converted using Biomart and DAVID software 
and had to be manually annotated by blasting their sequence to available databases. Also, 
to perform GSEA the equine transcript names have to be converted to HUGO gene 
names, which can be a challenge since a greater number of isoforms are present in the 
human database and the conversion is not always straightforward. A reference genome 
with better annotation and the use of a more consistent gene nomenclature between 
species would greatly improve this issue.  
 
In addition, changes in gene expression not always indicate alterations in protein 
from a specific gene. Posttranslational modification of amino acids and phosphorylation 
of proteins might also interfere with protein behavior and activity level.  
 
In conclusion, alterations in the expression of genes and pathways involved in 
oxidative metabolism, glycolysis, mitochondrial biogenesis and fatty acid metabolism are 
of great importance in PSSM1. The pathways generated by the analysis performed on this 
chapter with high enrichment score in different time points and conditions (case/control) 
were very consistent between analyses and are of great importance to determine which 
pathways should be manually curated for follow up analysis.  Due to incomplete 
annotation of the equine reference genome and the publicly available gene sets for 
pathway analysis it is difficult to say with complete certainty how those pathways are 
influencing the energy deficit observed in those horses at a lower level (from the gene set 
to the list of genes in the expression dataset and their specific biological function in a 
pathway). Manual annotation/creation of pathways based on what is known about PSSM1 
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and the use of this new more specific pathway on GSEA is the next step to better 
understand the pathophysiology of this disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
Baseline	  biopsy	   Trained	  biopsies	  
Figure 7. Sample collection protocol. Horses were acclimatized to the treadmill for 1 to 
2 weeks. Horses trained 5 days/week for 3 weeks during the training period. On day 21 
biopsies were taken before and after exercise  
 3 week training period 	  Acclimatization 
Prior to trial Day 1 Day 7 Day 14 Day 21 
Controls 
PSSM1	  Cases	  A. Case/control	  differences	  untrained	  B. Case/control	  differences	  trained	  	  C. Case/control	  differences	  after	  exercise	  D. Training	  affect	  within	  group	  E. Exercise	  effect	  within	  group	  F. Differences	  in	  training	  effect	  G. Differences	  in	  exercise	  effect	  
Figure 8. Comparisons performed by EdgeR between time points.  
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Figure	   9.	   Post exercise CK 
activity during the 3 week 
training period. Serum CK 
activity (y-axis) was measured 
four hours post-exercise daily in 
cases and twice weekly in 
controls.  	  	  
	   	  
Figure 10.Case control analyses for 2 different pathways. Cases are represented on the left side 
of each plot and controls are represented on the right side of each plot. The top portion of the 
plots show the running ES for the gene set as the analysis walks down the ranked list. The score at the 
peak of the plot (the score furthest from 0.0, green line) is the ES for the gene set. Gene sets with a 
distinct peak at the beginning (picture on the right) or end of the ranked list (picture on the left) are 
generally the most interesting. Black bars illustrate the position of the gene sets belonging to each 
pathway. The ranked list metric shown in gray illustrates the correlation between the signal to noise 
values of all individually ranked genes according to the class labels (experimental conditions). A. Up-
regulation of genes involved in fatty acid oxidation in controls. B. Up-regulation of genes involved in 
glycolysis in cases.  
Figure	  10A.	  	   Figure	  10B.	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Comparison Number of Genes Differentially Expressed 
Case t1 X Case t2 124 
Case t2 X Case t3 2781 
Case t1 X Control t1 201 
Case t2 X Control t2 303 
Case t3 X Control t3 803 
Case t1/Case t2 X Control t1/Control t2 236 
Case t2/Case t3 X Control t2/Control t3 251 
Comparison Ensembl Gene ID Gene Name logFC PValue FDR 
Case X Control t1 ENSECAG00000016536 MT-CYB -6.44352971 4.18833E-50 4.83082E-46 
Case X Control t1 ENSECAG00000000144 AKR1C1   7.147289214 1.55515E-44 8.96855E-41 
Case X Control t1 ENSECAG00000021785 MHCB3 5.385977863 1.29323E-39 4.97205E-36 
Case X Control t1 ENSECAG00000004995 TAL2 6.817512323 7.35227E-36 2.12003E-32 
Case X Control t1 ENSECAG00000017642 GBP5 -4.02369594 2.37748E-22 5.48436E-19 
Case X Control t1 ENSECAG00000019568  MYH13  3.891363384 2.50295E-21 4.81151E-18 
Case X Control t1 ENSECAG00000009368 MICA 
-
3.359264206 2.47516E-18 4.07835E-15 
Case X Control t1 ENSECAG00000000658 GPNMB 3.733808481 1.48044E-17 2.13442E-14 
Case X Control t1 ENSECAG00000018002 FOSB 7.692903635 7.41621E-17 9.50428E-14 
Case X Control t1 ENSECAG00000004135 AMPH 4.354576511 1.58206E-16 1.82475E-13 
Case X Control t1 ENSECAG00000010841 AKR1C1 6.29745467 6.05027E-16 6.34399E-13 
Case X Control t1 ENSECAG00000005658 MTND1 
-
3.249861369 1.16841E-14 1.12303E-11 
Case X Control t1 ENSECAG00000000291 PLCG2 3.028463326 2.1164E-14 1.87773E-11 
Case X Control t1 ENSECAG00000016867 CISH 
-
3.433100456 5.25637E-14 4.3305E-11 
Case X Control t1 ENSECAG00000007258 IGHG1 4.050317454 3.29885E-13 2.5366E-10 
Case X Control t1 ENSECAG00000021104 MYH6 
-
2.671436436 8.95666E-13 6.45663E-10 
Case X Control t1 ENSECAG00000016737  SLC34A1 
-
3.620931828 3.51552E-12 2.27634E-09 
Table 9. Comparisons performed by EdgeR between time points  
 
Table 10. Comparisons performed between cases and controls at time point 1 (t1). The list 
shows the top 100 genes differentially expressed with FDR<0.05 
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Case X Control t1 ENSECAG00000008335 PDK4 -2.84733351 3.55246E-12 2.27634E-09 
Case X Control t1 ENSECAG00000003845 HLA-A 2.612146261 8.80376E-12 5.34435E-09 
Case X Control t1 ENSECAG00000003774 IGHG1  3.325283298 1.71127E-11 9.86887E-09 
Case X Control t1 ENSECAG00000018476 TPX2 
-
2.621336512 1.92123E-11 1.05521E-08 
Case X Control t1 ENSECAG00000007171 FGL1 2.910501933 2.70146E-11 1.4163E-08 
Case X Control t1 ENSECAG00000014546 SLC7A4  2.446930383 6.58152E-11 3.30049E-08 
Case X Control t1 ENSECAG00000003783 UCHL3 
-
2.745914544 2.64835E-10 1.27275E-07 
Case X Control t1 ENSECAG00000008850 OSCP1 
-
2.499490042 3.59915E-10 1.6605E-07 
Case X Control t1 ENSECAG00000017191 SPP1 2.326231695 4.59036E-10 2.03636E-07 
Case X Control t1 ENSECAG00000003052 ZCCHC5 2.735353485 5.34485E-10 2.28324E-07 
Case X Control t1 ENSECAG00000027336 RN5S1@  
-
2.615693126 5.87002E-10 2.41803E-07 
Case X Control t1 ENSECAG00000009440 TYRP1 2.655802456 8.65097E-10 3.4407E-07 
Case X Control t1 ENSECAG00000025060 MYH3 2.337624402 1.13628E-09 4.30731E-07 
Case X Control t1 ENSECAG00000016634 RPS2 -2.72140274 1.15768E-09 4.30731E-07 
Case X Control t1 ENSECAG00000024746 PDGFD 
-
2.552282187 2.42468E-09 8.73947E-07 
Case X Control t1 ENSECAG00000015094 ATCAY 
-
3.197877066 2.72683E-09 9.53067E-07 
Case X Control t1 ENSECAG00000022647 CHMP4C 
-
2.286552447 9.85543E-09 3.34331E-06 
Case X Control t1 ENSECAG00000003944 GAPDH 
-
2.431083287 1.09558E-08 3.6104E-06 
Case X Control t1 ENSECAG00000024656 KRT10 
-
3.107798868 1.48666E-08 4.7631E-06 
Case X Control t1 ENSECAG00000013692 IGL  4.520148012 1.61978E-08 5.04934E-06 
Case X Control t1 ENSECAG00000000591 TRAF3IP2 
-
2.271550418 1.91845E-08 5.72137E-06 
Case X Control t1 ENSECAG00000000325 HLA-A  
-
2.062714602 1.93457E-08 5.72137E-06 
Case X Control t1 ENSECAG00000012751 CCKBR 2.858969202 3.29454E-08 9.4998E-06 
Case X Control t1 ENSECAG00000014515 CILP 2.093233726 3.8051E-08 1.06643E-05 
Case X Control t1 ENSECAG00000010475 IL33 
-
2.244286718 3.8833E-08 1.06643E-05 
Case X Control t1 ENSECAG00000027324 RNA28S1 
-
2.244126802 6.60847E-08 1.77261E-05 
Case X Control t1 ENSECAG00000018724 ETNPPL 2.031390644 8.49557E-08 2.227E-05 
Case X Control t1 ENSECAG00000013022 ACTC1 2.008164211 2.09216E-07 5.36245E-05 
Case X Control t1 ENSECAG00000006674 RRAD 1.859979143 3.96495E-07 9.83687E-05 
Case X Control t1 ENSECAG00000011854 CFB  2.180890095 4.00844E-07 9.83687E-05 
Case X Control t1 ENSECAG00000009549 TNFRSF14 2.091431588 4.41017E-07 0.000105973 
Case X Control t1 ENSECAG00000013384 STX3 2.232490446 4.75644E-07 0.000111961 
Case X Control t1 ENSECAG00000018973 ENTHD1 1.958830583 6.56193E-07 0.000151371 
Case X Control t1 ENSECAG00000014709 SDC1 2.08165221 7.12616E-07 0.000161163 
Case X Control t1 ENSECAG00000008356 ZNF577 
-
1.974548323 9.38878E-07 0.00020825 
Case X Control t1 ENSECAG00000021683 LGALS4 2.237321116 1.04161E-06 0.000226679 
Case X Control t1 ENSECAG00000010717 MTMR7 
-
2.326509569 1.27425E-06 0.000272171 
Case X Control t1 ENSECAG00000020599 HOXD10 -2.10608317 1.38602E-06 0.000290661 
Case X Control t1 ENSECAG00000016560 CRABP2 1.959406783 1.55869E-06 0.000321035 
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Case X Control t1 ENSECAG00000019928 EQMHCC1 1.780506453 1.64908E-06 0.000333693 
Case X Control t1 ENSECAG00000016531 KLHL6 1.972934904 1.95331E-06 0.000388439 
Case X Control t1 ENSECAG00000024940 RNF207 1.831255331 2.17595E-06 0.000420123 
Case X Control t1 ENSECAG00000013859 PIEZO2 2.057732939 2.18549E-06 0.000420123 
Case X Control t1 ENSECAG00000013363 DACT2 2.417109589 2.69752E-06 0.000510053 
Case X Control t1 ENSECAG00000022673 NSUN7 
-
2.260179178 2.81121E-06 0.000521 
Case X Control t1 ENSECAG00000016873 CPEB1 2.004579871 2.84576E-06 0.000521 
Case X Control t1 ENSECAG00000009625 IGHA1 2.915785796 3.41959E-06 0.000616275 
Case X Control t1 ENSECAG00000016486 ARRDC2 
-
1.744349081 3.66517E-06 0.00065037 
Case X Control t1 ENSECAG00000006669 ACSM3 
-
2.050104353 3.78966E-06 0.000657914 
Case X Control t1 ENSECAG00000005924 TSKU 1.77721529 3.82177E-06 0.000657914 
Case X Control t1 ENSECAG00000018254 UCHL1 1.725722072 4.02736E-06 0.000683111 
Case X Control t1 ENSECAG00000019795 ARID5B 
-
1.732537184 4.27155E-06 0.00071403 
Case X Control t1 ENSECAG00000001379 RBM17 
-
2.057950623 4.70524E-06 0.00077529 
Case X Control t1 ENSECAG00000000943 PTGES 1.817464981 6.19082E-06 0.001005703 
Case X Control t1 ENSECAG00000008177 FAM213B 1.683290456 6.37907E-06 0.001021892 
Case X Control t1 ENSECAG00000006203 RAP1A 
-
2.175919083 7.12503E-06 0.001111212 
Case X Control t1 ENSECAG00000015998 ABRA 
-
1.624812642 7.12933E-06 0.001111212 
Case X Control t1 ENSECAG00000026307 U1 
-
2.216865645 7.69394E-06 0.001169701 
Case X Control t1 ENSECAG00000023023 OSGIN1 2.220375433 7.70741E-06 0.001169701 
Case X Control t1 ENSECAG00000013728 MFSD2A -2.06339479 8.08346E-06 0.001210839 
Case X Control t1 ENSECAG00000022841 NMRK2 1.728508498 9.17542E-06 0.001356786 
Case X Control t1 ENSECAG00000025814 5S_rRNA 
-
2.227279299 9.88223E-06 0.001442805 
Case X Control t1 ENSECAG00000026964 RPTN 
-
1.659554249 1.08637E-05 0.001565992 
Case X Control t1 ENSECAG00000027377 5_8S_rRNA 
-
1.581700449 1.09975E-05 0.001565992 
Case X Control t1 ENSECAG00000000847 SLC16A9 
-
1.958679506 1.11819E-05 0.001572837 
Case X Control t1 ENSECAG00000005487 IGLC7 4.050972304 1.26291E-05 0.001754983 
Case X Control t1 ENSECAG00000014817 RND2 1.713844404 1.35886E-05 0.00186584 
Case X Control t1 ENSECAG00000022695 MAP1A 1.614876629 1.59054E-05 0.002158266 
Case X Control t1 ENSECAG00000019318 HLA-B 1.715804399 1.71506E-05 0.00230018 
Case X Control t1 ENSECAG00000000430 ACE2 2.129071935 1.79829E-05 0.002373281 
Case X Control t1 ENSECAG00000017093 TPC3 
-
2.431903261 1.81072E-05 0.002373281 
Case X Control t1 ENSECAG00000020210 RIC3 1.898956938 1.85068E-05 0.002398401 
Case X Control t1 ENSECAG00000020112 LZTS1 
-
1.994545074 1.99774E-05 0.002554497 
Case X Control t1 ENSECAG00000000548 IGHM 1.939893308 2.01543E-05 0.002554497 
Case X Control t1 ENSECAG00000024790 
ENSECAG0
0000024790 1.683436373 2.47102E-05 0.003097903 
Case X Control t1 ENSECAG00000014255 SAG 
-
1.882965907 2.91525E-05 0.003615537 
Case X Control t1 ENSECAG00000003702 CLEC4G 1.567178373 3.02035E-05 0.003706035 
Case X Control t1 ENSECAG00000017655 PNP 1.871015908 3.20445E-05 0.00389054 
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Case X Control t1 ENSECAG00000013935 MTUS2 1.876429009 3.65482E-05 0.004391115 
Case X Control t1 ENSECAG00000021702 PANX2 1.813050554 3.70445E-05 0.004404854 
Case X Control t1 ENSECAG00000015212 MT3 
-
1.568927675 3.79474E-05 0.004466181 
Case X Control t1 ENSECAG00000024596 CCP110 
-
1.735065924 4.13104E-05 0.004812866 
Case X Control t1 ENSECAG00000010104 KCNIP2 1.574258528 4.884E-05 0.005583402 
Comparison Ensembl Gene ID Gene Name logFC PValue FDR 
Case X Control t2 ENSECAG00000016536 MT-CYB -6.279302249 2.24967E-49 2.59477E-45 
Case X Control t2 ENSECAG00000000144 AKR1C1   7.498775828 7.78211E-49 4.48794E-45 
Case X Control t2 ENSECAG00000021785 MHCB3 5.466465229 5.14082E-40 1.97647E-36 
Case X Control t2 ENSECAG00000005186 HMGB1 -7.594922843 2.18073E-30 6.28813E-27 
Case X Control t2 ENSECAG00000017642 GBP5 -4.442999814 1.4022E-26 3.2346E-23 
Case X Control t2 ENSECAG00000004995 TAL2 5.546112346 1.42193E-24 2.73342E-21 
Case X Control t2 ENSECAG00000003944 GAPDH -3.778484464 7.04629E-24 1.16103E-20 
Case X Control t2 ENSECAG00000016634 RPS2 -3.928122718 2.89044E-23 4.16729E-20 
Case X Control t2 ENSECAG00000019568  MYH13  3.66954906 3.74115E-22 4.79449E-19 
Case X Control t2 ENSECAG00000005658 
ENSECAG000
00005658 -3.443461067 6.438E-20 7.42558E-17 
Case X Control t2 ENSECAG00000004135 AMPH 4.676364894 2.33181E-18 2.44501E-15 
Case X Control t2 ENSECAG00000009368 MICA -3.327319611 2.67413E-17 2.57029E-14 
Case X Control t2 ENSECAG00000017191 SPP1 2.822426359 1.80096E-16 1.59787E-13 
Case X Control t2 ENSECAG00000003783 UCHL3 -3.347979538 4.62559E-16 3.81083E-13 
Case X Control t2 ENSECAG00000007171 FGL1 3.650037825 6.2184E-16 4.78153E-13 
Case X Control t2 ENSECAG00000010841 AKR1C1 6.330285964 6.72737E-16 4.8496E-13 
Case X Control t2 ENSECAG00000014255 SAG -3.583531518 2.77334E-15 1.88163E-12 
Case X Control t2 ENSECAG00000001290 CABP1 -3.013107446 9.77689E-15 6.26481E-12 
Case X Control t2 ENSECAG00000018002 FOSB 7.39043152 1.47993E-14 8.98394E-12 
Case X Control t2 ENSECAG00000013022 ACTC1 3.094243431 5.51837E-14 3.18245E-11 
Case X Control t2 ENSECAG00000006487 METTL21EP  -3.923824444 8.07671E-14 4.43604E-11 
Case X Control t2 ENSECAG00000021104 MYH6 -2.771172537 1.49485E-13 7.83709E-11 
Case X Control t2 ENSECAG00000023023 OSGIN1 3.689085107 1.70096E-13 8.52992E-11 
Case X Control t2 ENSECAG00000013532 CCDC162P 4.416066954 2.92731E-13 1.40682E-10 
Case X Control t2 ENSECAG00000002376 CHRNG 3.168669863 1.46386E-12 6.75368E-10 
Case X Control t2 ENSECAG00000003845 HLA-A 2.70313616 7.84468E-12 3.48002E-09 
Case X Control t2 ENSECAG00000001379 RBM17 -2.823289603 1.14444E-11 4.88888E-09 
Case X Control t2 ENSECAG00000027324 RNA28S1 -2.552226197 1.44616E-11 5.95715E-09 
Case X Control t2 ENSECAG00000011553 FAM65B -2.704525614 2.52251E-11 1.00326E-08 
Table 11. Comparisons performed between cases and controls at time point 2 (t2). The list 
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Case X Control t2 ENSECAG00000005106 FIBIN 2.516312758 2.67293E-11 1.02765E-08 
Case X Control t2 ENSECAG00000024790 
ENSECAG000
00024790 2.661669162 3.37989E-11 1.25754E-08 
Case X Control t2 ENSECAG00000025060 MYH3 2.385463812 2.94947E-10 1.0631E-07 
Case X Control t2 ENSECAG00000014709 SDC1 2.784183062 5.10633E-10 1.74944E-07 
Case X Control t2 ENSECAG00000014546 SLC7A4  2.452785091 5.15702E-10 1.74944E-07 
Case X Control t2 ENSECAG00000018254 UCHL1 2.297375204 1.11675E-09 3.68017E-07 
Case X Control t2 ENSECAG00000006203 RAP1A -2.632569233 1.60103E-09 5.12952E-07 
Case X Control t2 ENSECAG00000000658 GPNMB 2.636052867 1.71319E-09 5.34052E-07 
Case X Control t2 ENSECAG00000013859 PIEZO2 2.620545237 2.0226E-09 6.13912E-07 
Case X Control t2 ENSECAG00000018973 ENTHD1 2.318907612 2.15024E-09 6.16078E-07 
Case X Control t2 ENSECAG00000022647 CHMP4C -2.355038577 2.17487E-09 6.16078E-07 
Case X Control t2 ENSECAG00000009440 TYRP1 2.621522814 2.18998E-09 6.16078E-07 
Case X Control t2 ENSECAG00000018724 ETNPPL 2.253282645 2.55345E-09 7.01226E-07 
Case X Control t2 ENSECAG00000011389 YBX1 -2.181044386 3.01446E-09 8.08577E-07 
Case X Control t2 ENSECAG00000016737  SLC34A1 -3.20096384 3.28038E-09 8.59908E-07 
Case X Control t2 ENSECAG00000024746 PDGFD -2.409219595 3.88485E-09 9.95731E-07 
Case X Control t2 ENSECAG00000008957 NCF4 -2.249502939 7.4862E-09 1.87708E-06 
Case X Control t2 ENSECAG00000023949 CCL2 2.765369967 1.0143E-08 2.48914E-06 
Case X Control t2 ENSECAG00000024656 KRT10 -3.167159425 1.46659E-08 3.52409E-06 
Case X Control t2 ENSECAG00000013836 PKLR 3.549210512 1.7143E-08 4.03526E-06 
Case X Control t2 ENSECAG00000010847 PGLYRP1 -3.410625363 1.85431E-08 4.27752E-06 
Case X Control t2 ENSECAG00000002023 SOD2 -2.181964564 1.90178E-08 4.30102E-06 
Case X Control t2 ENSECAG00000007883 TLR7 -2.822542068 2.43933E-08 5.41063E-06 
Case X Control t2 ENSECAG00000010475 IL33 -2.254000613 2.65612E-08 5.78032E-06 
Case X Control t2 ENSECAG00000010928 MMP25 -2.677258333 3.86051E-08 8.13758E-06 
Case X Control t2 ENSECAG00000014338 EGR1 2.251158964 3.88042E-08 8.13758E-06 
Case X Control t2 ENSECAG00000011811 
ENSECAG000
00011811 3.456228166 4.75458E-08 9.70438E-06 
Case X Control t2 ENSECAG00000021702 PANX2 2.459528637 4.79582E-08 9.70438E-06 
Case X Control t2 ENSECAG00000024873 C1orf110 -2.675344743 5.22803E-08 1.03966E-05 
Case X Control t2 ENSECAG00000013723 SLC7A8 -2.033176064 6.51522E-08 1.27367E-05 
Case X Control t2 ENSECAG00000006610 CHMP4B -2.117602302 8.64374E-08 1.63481E-05 
Case X Control t2 ENSECAG00000000325 HLA-A  -2.011674521 8.64867E-08 1.63481E-05 
Case X Control t2 ENSECAG00000010717 MTMR7 -2.560390598 8.78778E-08 1.63481E-05 
Case X Control t2 ENSECAG00000017093 TPC3 -2.912117032 9.11345E-08 1.66849E-05 
Case X Control t2 ENSECAG00000004837 CPN2 3.493356844 9.56025E-08 1.72294E-05 
Case X Control t2 ENSECAG00000000430 ACE2 2.749075107 1.05576E-07 1.87341E-05 
Case X Control t2 ENSECAG00000003052 ZCCHC5 2.158911512 1.7942E-07 3.10532E-05 
Case X Control t2 ENSECAG00000014658 SCD -2.02483265 1.80385E-07 3.10532E-05 
Case X Control t2 ENSECAG00000019083 SORL1 -2.325454996 2.51682E-07 4.26897E-05 
Case X Control t2 ENSECAG00000020485 PCOLCE2 2.085041003 2.59897E-07 4.3271E-05 
Case X Control t2 ENSECAG00000013179 PCDH20 -2.482501425 2.64957E-07 4.3271E-05 
Case X Control t2 ENSECAG00000023741 EGR3 2.356320618 2.66364E-07 4.3271E-05 
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Case X Control t2 ENSECAG00000016873 CPEB1 2.223759393 2.70948E-07 4.34044E-05 
Case X Control t2 ENSECAG00000018071 PGPEP1L 2.044717576 2.85817E-07 4.51591E-05 
Case X Control t2 ENSECAG00000013363 DACT2 2.751038848 3.05333E-07 4.75907E-05 
Case X Control t2 ENSECAG00000000816 AMPD3 2.083843571 3.147E-07 4.83966E-05 
Case X Control t2 ENSECAG00000018927 ANGPTL4 2.96149184 3.45228E-07 5.22737E-05 
Case X Control t2 ENSECAG00000021683 LGALS4 2.309194745 3.48975E-07 5.22737E-05 
Case X Control t2 ENSECAG00000013081 MMP9 -2.609361064 3.59156E-07 5.3109E-05 
Case X Control t2 ENSECAG00000011292 MSR1 2.983476089 4.9353E-07 7.17552E-05 
Case X Control t2 ENSECAG00000013129 TOP1MT -2.384472561 4.97695E-07 7.17552E-05 
Case X Control t2 ENSECAG00000013745 SNX10 -2.471013995 6.0592E-07 8.62801E-05 
Case X Control t2 ENSECAG00000024845 PI16 1.985061006 7.13816E-07 0.000100404 
Case X Control t2 ENSECAG00000024585 PDIA2 2.153246504 9.50219E-07 0.000130666 
Case X Control t2 ENSECAG00000020122 SELL -2.301853718 9.51616E-07 0.000130666 
Case X Control t2 ENSECAG00000014566 WISP2 1.866462476 1.25947E-06 0.000170411 
Case X Control t2 ENSECAG00000021044 C1QA 1.881313047 1.27062E-06 0.000170411 
Case X Control t2 ENSECAG00000018101 FBLN1 1.897361598 1.28794E-06 0.000170748 
Case X Control t2 ENSECAG00000008881 LYVE1 2.288043552 1.69352E-06 0.000221967 
Case X Control t2 ENSECAG00000022673 NSUN7 -2.313687972 1.87672E-06 0.000243215 
Case X Control t2 ENSECAG00000019557 LDLR -1.833637839 1.95388E-06 0.000250401 
Case X Control t2 ENSECAG00000024506 ARMC2 1.949170584 2.24416E-06 0.000284441 
Case X Control t2 ENSECAG00000017295 PLSCR1  -2.010299438 2.33458E-06 0.000292685 
Case X Control t2 ENSECAG00000002368 RPS15A -1.646028284 2.68006E-06 0.000332385 
Case X Control t2 ENSECAG00000003418 TMEM140 1.729741129 2.99131E-06 0.000364451 
Case X Control t2 ENSECAG00000024939 ZNF385A -1.855674162 3.0018E-06 0.000364451 
Case X Control t2 ENSECAG00000012662 SEMA3A -2.042304022 3.64226E-06 0.000437602 
Case X Control t2 ENSECAG00000006877 CCDC88A -1.696068494 3.93283E-06 0.000467642 
Case X Control t2 ENSECAG00000010617 VGLL3 -1.716564128 4.3272E-06 0.000509285 
Case X Control t2 ENSECAG00000020599 HOXD10 -1.974910747 5.6267E-06 0.000655538 
Case X Control t2 ENSECAG00000019928 EQMHCC1 1.759599834 7.49464E-06 0.000864432 
 
      
Comparison Ensembl Gene ID Gene Name logFC PValue FDR 
 
Case X Control t3 ENSECAG00000016536 MT-CYB -6.635778897 5.18186E-51 5.97675E-47 
 
Case X Control t3 ENSECAG00000000144 AKR1C1   7.581446302 3.88594E-49 2.24102E-45 
 
Case X Control t3 ENSECAG00000021785 MHCB3 5.62590826 3.6033E-41 1.38535E-37 
 
Case X Control t3 ENSECAG00000018002 FOSB 9.001347733 2.06766E-28 5.96211E-25 
 
Case X Control t3 ENSECAG00000017642 GBP5 -4.579445187 5.14037E-28 1.18578E-24 
 
Case X Control t3 ENSECAG00000004995 TAL2 5.867184918 1.39859E-27 2.68857E-24 
 
Case X Control t3 ENSECAG00000014338 EGR1 4.284435522 3.32853E-23 5.48447E-20 
 
Case X Control t3 ENSECAG00000019568  MYH13  3.840934084 3.27601E-21 4.72319E-18 
 
Table	   12. Comparisons performed between cases and controls at time point 3 (t3). The list 
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Case X Control t3 ENSECAG00000017191 SPP1 3.386270758 4.20501E-20 5.38895E-17 
 
Case X Control t3 ENSECAG00000003816 JUNB 3.679581243 5.51781E-19 5.78568E-16 
 
Case X Control t3 ENSECAG00000007171 FGL1 4.068153714 5.47622E-19 5.78568E-16 
 
Case X Control t3 ENSECAG00000003845 HLA-A 3.366774392 6.62635E-18 6.36903E-15 
 
Case X Control t3 ENSECAG00000014260 FOS 3.548851284 6.91942E-17 6.13912E-14 
 
Case X Control t3 ENSECAG00000002376 CHRNG 3.633129519 8.78185E-17 6.75265E-14 
 
Case X Control t3 ENSECAG00000010841 AKR1C1 6.47631027 8.50924E-17 6.75265E-14 
 
Case X Control t3 ENSECAG00000013532 CCDC162P 5.104513221 4.97956E-16 3.58964E-13 
 
Case X Control t3 ENSECAG00000004135 AMPH 4.229939468 3.14748E-15 2.13547E-12 
 
Case X Control t3 ENSECAG00000009958 DUSP1 3.051552372 5.86287E-15 3.7568E-12 
 
Case X Control t3 ENSECAG00000009012 IER2 2.99571758 1.04755E-13 6.35916E-11 
 
Case X Control t3 ENSECAG00000009368 MICA -2.86857496 1.23206E-13 7.10531E-11 
 
Case X Control t3 ENSECAG00000001471 GPR34 3.828829237 1.81416E-13 9.96406E-11 
 
Case X Control t3 ENSECAG00000005658 
ENSECAG0
0000005658 -3.063160068 3.61924E-13 1.89747E-10 
 
Case X Control t3 ENSECAG00000022125 TNNT2 2.879859339 4.5041E-13 2.25871E-10 
 
Case X Control t3 ENSECAG00000016737  SLC34A1 -3.910548985 5.52101E-13 2.65331E-10 
 
Case X Control t3 ENSECAG00000023023 OSGIN1 3.476517088 8.37482E-13 3.7152E-10 
 
Case X Control t3 ENSECAG00000024746 PDGFD -2.995524959 8.18832E-13 3.7152E-10 
 
Case X Control t3 ENSECAG00000009549 TNFRSF14 2.967933031 1.57554E-12 6.73047E-10 
 
Case X Control t3 ENSECAG00000014255 SAG -3.038288155 6.27267E-12 2.58389E-09 
 
Case X Control t3 ENSECAG00000021104 MYH6 -2.572751007 3.43649E-11 1.36678E-08 
 
Case X Control t3 ENSECAG00000006487 
METTL21E
P  -3.503777449 4.44989E-11 1.71083E-08 
 
Case X Control t3 ENSECAG00000010475 IL33 -2.742057167 5.28151E-11 1.96506E-08 
 
Case X Control t3 ENSECAG00000007258 IGHG1 3.648616776 6.92867E-11 2.49735E-08 
 
Case X Control t3 ENSECAG00000005106 FIBIN 2.443854996 8.67946E-11 3.0336E-08 
 
Case X Control t3 ENSECAG00000018973 ENTHD1 2.492035286 9.65526E-11 3.27541E-08 
 
Case X Control t3 ENSECAG00000024790 
ENSECAG0
0000024790 2.574779674 1.87641E-10 6.18357E-08 
 
Case X Control t3 ENSECAG00000023949 CCL2 2.873320551 2.3713E-10 7.59739E-08 
 
Case X Control t3 ENSECAG00000014546 SLC7A4  2.357022832 6.11204E-10 1.9053E-07 
 
Case X Control t3 ENSECAG00000027336 RN5S1@  -2.891549632 7.3992E-10 2.24585E-07 
 
Case X Control t3 ENSECAG00000004180 HSPA6 3.148146505 1.04582E-09 3.09294E-07 
 
Case X Control t3 ENSECAG00000010818 EGR2 3.186271221 1.0846E-09 3.12745E-07 
 
Case X Control t3 ENSECAG00000017436 TREM1 3.030376365 1.6899E-09 4.75398E-07 
 
Case X Control t3 ENSECAG00000018927 ANGPTL4 3.477820765 2.10855E-09 5.79049E-07 
 
Case X Control t3 ENSECAG00000000816 AMPD3 2.363568246 2.93935E-09 7.88429E-07 
 
Case X Control t3 ENSECAG00000014709 SDC1 2.641603183 3.22558E-09 8.45541E-07 
 
Case X Control t3 ENSECAG00000024585 PDIA2 2.631610623 3.31911E-09 8.50724E-07 
 
Case X Control t3 ENSECAG00000018254 UCHL1 2.225856638 3.6492E-09 9.14996E-07 
 
Case X Control t3 ENSECAG00000003192 FTL 2.207436704 4.18826E-09 1.02782E-06 
 
Case X Control t3 ENSECAG00000003783 UCHL3 -2.570787919 5.76725E-09 1.38582E-06 
 
Case X Control t3 ENSECAG00000013723 SLC7A8 -2.181099464 7.44586E-09 1.75266E-06 
 
Case X Control t3 ENSECAG00000017203 BTG2 2.25980575 8.24568E-09 1.90211E-06 
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Case X Control t3 ENSECAG00000001249 SOCS3 3.823063104 8.73047E-09 1.97445E-06 
 
Case X Control t3 ENSECAG00000009625 IGHA1 3.165246837 1.13354E-08 2.51428E-06 
 
Case X Control t3 ENSECAG00000003774 IGHG1  2.716488322 1.24802E-08 2.70675E-06 
 
Case X Control t3 ENSECAG00000010717 MTMR7 -2.771382509 1.28897E-08 2.70675E-06 
 
Case X Control t3 ENSECAG00000014566 WISP2 2.166916818 1.29072E-08 2.70675E-06 
 
Case X Control t3 ENSECAG00000000291 PLCG2 2.18157265 1.37321E-08 2.82099E-06 
 
Case X Control t3 ENSECAG00000005487 IGLC7 4.700151347 1.41857E-08 2.82099E-06 
 
Case X Control t3 ENSECAG00000017093 TPC3 -3.197628571 1.39512E-08 2.82099E-06 
 
Case X Control t3 ENSECAG00000023387 FRRS1 -2.091911067 1.46868E-08 2.87114E-06 
 
Case X Control t3 ENSECAG00000020971 RND1 2.745166689 2.33916E-08 4.49665E-06 
 
Case X Control t3 ENSECAG00000013179 PCDH20 -2.733958905 2.69842E-08 5.10223E-06 
 
Case X Control t3 ENSECAG00000015261 IL18 2.450718838 3.22823E-08 6.00555E-06 
 
Case X Control t3 ENSECAG00000022673 NSUN7 -2.706267053 3.89368E-08 7.12852E-06 
 
Case X Control t3 ENSECAG00000012122 DLK1  -2.379683331 4.04331E-08 7.2868E-06 
 
Case X Control t3 ENSECAG00000017807 NAV2 -2.103500163 4.13115E-08 7.33057E-06 
 
Case X Control t3 ENSECAG00000011560 GSTO1 2.068696309 4.74128E-08 8.28575E-06 
 
Case X Control t3 ENSECAG00000012662 SEMA3A -2.446785456 4.86256E-08 8.37085E-06 
 
Case X Control t3 ENSECAG00000014817 RND2 2.177342543 5.21172E-08 8.84E-06 
 
Case X Control t3 ENSECAG00000027377 5_8S_rRNA -2.305542088 5.65391E-08 9.45105E-06 
 
Case X Control t3 ENSECAG00000025060 MYH3 2.107864354 7.71801E-08 1.27171E-05 
 
Case X Control t3 ENSECAG00000019928 EQMHCC1 2.008779116 1.21112E-07 1.96748E-05 
 
Case X Control t3 ENSECAG00000024656 KRT10 -2.963530191 1.42263E-07 2.27897E-05 
 
Case X Control t3 ENSECAG00000022151 MATK 2.087146689 1.51962E-07 2.401E-05 
 
Case X Control t3 ENSECAG00000013129 TOP1MT -2.478771156 1.60062E-07 2.49481E-05 
 
Case X Control t3 ENSECAG00000011292 MSR1 3.052642042 1.6581E-07 2.54994E-05 
 
Case X Control t3 ENSECAG00000003944 GAPDH -2.24167016 1.79046E-07 2.71726E-05 
 
Case X Control t3 ENSECAG00000010617 VGLL3 -2.008365623 1.8969E-07 2.84141E-05 
 
Case X Control t3 ENSECAG00000008177 FAM213B 1.997585248 2.03508E-07 3.0093E-05 
 
Case X Control t3 ENSECAG00000013022 ACTC1 2.17580528 2.16101E-07 3.13427E-05 
 
Case X Control t3 ENSECAG00000016873 CPEB1 2.251923627 2.17394E-07 3.13427E-05 
 
Case X Control t3 ENSECAG00000011811 
ENSECAG0
0000011811 3.466505017 2.42284E-07 3.44599E-05 
 
Case X Control t3 ENSECAG00000018395 TYROBP 2.022794251 2.4499E-07 3.44599E-05 
 
Case X Control t3 ENSECAG00000014500 ART5 1.942982689 2.66377E-07 3.70168E-05 
 
Case X Control t3 ENSECAG00000001290 CABP1 -1.981930974 2.97134E-07 4.07205E-05 
 
Case X Control t3 ENSECAG00000011068 CHI3L1 2.360708432 3.04924E-07 4.07205E-05 
 
Case X Control t3 ENSECAG00000018071 PGPEP1L 2.077078008 3.04863E-07 4.07205E-05 
 
Case X Control t3 ENSECAG00000023650 ABAT -2.215541168 3.07151E-07 4.07205E-05 
 
Case X Control t3 ENSECAG00000010846 DPP8 -1.885136449 3.36683E-07 4.39906E-05 
 
Case X Control t3 ENSECAG00000024055 JUN 1.959029012 3.39446E-07 4.39906E-05 
 
Case X Control t3 ENSECAG00000013425 IGFBP-5 -1.864301348 3.77614E-07 4.83933E-05 
 
Case X Control t3 ENSECAG00000019318 HLA-B 2.0412217 4.07691E-07 5.11121E-05 
 
Case X Control t3 ENSECAG00000022647 CHMP4C -2.02518771 4.04176E-07 5.11121E-05 
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Case X Control t3 ENSECAG00000016942 NUDT14 2.051385558 4.18035E-07 5.18453E-05 
 
Case X Control t3 ENSECAG00000025814 5S_rRNA -2.714435664 4.4694E-07 5.48405E-05 
 
Case X Control t3 ENSECAG00000000074 METRNL 2.05544234 5.46588E-07 6.37614E-05 
 
Case X Control t3 ENSECAG00000000430 ACE2 2.568639899 5.45137E-07 6.37614E-05 
 
Case X Control t3 ENSECAG00000003052 ZCCHC5 2.079159785 5.43414E-07 6.37614E-05 
 
Case X Control t3 ENSECAG00000003418 TMEM140 1.849839114 5.47284E-07 6.37614E-05 
 
Case X Control t3 ENSECAG00000004837 CPN2 3.313827519 5.36784E-07 6.37614E-05 
 
Case X Control t3 ENSECAG00000010339 TLR4 1.914316263 5.93723E-07 6.848E-05 
 
Comparison Ensembl Gene ID Gene Name logFC PValue FDR 
Case t1 X Case t2 ENSECAG00000011484 EPS8L2 -4.78128379 1.23738E-52 1.4272E-48 
Case t1 X Case t2 ENSECAG00000007809 OR2T27 -3.143150421 5.35865E-30 3.09033E-26 
Case t1 X Case t2 ENSECAG00000016846 
ENSECAG0
0000016846 -2.598850406 2.99273E-22 1.15061E-18 
Case t1 X Case t2 ENSECAG00000020221 KNDC1 -3.2791048 6.42218E-22 1.85184E-18 
Case t1 X Case t2 ENSECAG00000026913 
ENSECAG0
0000026913 -2.10756729 1.96691E-18 4.53727E-15 
Case t1 X Case t2 ENSECAG00000024589 
ENSECAG0
0000024589 -2.311686808 3.89025E-17 7.47837E-14 
Case t1 X Case t2 ENSECAG00000013836 PKLR 2.298607192 4.91875E-16 8.1047E-13 
Case t1 X Case t2 ENSECAG00000019552 SLCO1C1 2.33545454 3.87642E-15 5.58883E-12 
Case t1 X Case t2 ENSECAG00000013781 KIAA1211 -1.697206356 3.77175E-14 4.83371E-11 
Case t1 X Case t2 ENSECAG00000006267 NR1D1 -1.346418978 7.26095E-11 7.61343E-08 
Case t1 X Case t2 ENSECAG00000019557 LDLR -1.388341109 6.80243E-11 7.61343E-08 
Case t1 X Case t2 ENSECAG00000014500 ART5 1.271377618 2.75373E-10 2.64679E-07 
Case t1 X Case t2 ENSECAG00000021096 NRXN2 -1.564598167 4.40512E-10 3.90836E-07 
Case t1 X Case t2 ENSECAG00000024790 
ENSECAG0
0000024790 1.322693497 2.19685E-09 1.80989E-06 
Case t1 X Case t2 ENSECAG00000020485 PCOLCE2 1.296580385 2.54646E-09 1.95806E-06 
Case t1 X Case t2 ENSECAG00000027324 RNA28S1 1.36718335 4.25282E-09 3.06575E-06 
Case t1 X Case t2 ENSECAG00000023949 CCL2 1.515983122 1.90284E-08 1.29102E-05 
Case t1 X Case t2 ENSECAG00000016634 RPS2 -1.170961299 9.40957E-08 6.02944E-05 
Case t1 X Case t2 ENSECAG00000008710 FCER1A 1.588999592 1.08387E-07 6.57966E-05 
Case t1 X Case t2 ENSECAG00000007161 CYP2F1 1.294710352 1.40488E-07 8.10194E-05 
Case t1 X Case t2 ENSECAG00000002962 ADIPOQ 1.238907368 1.63498E-07 8.97993E-05 
Case t1 X Case t2 ENSECAG00000014226 
ENSECAG0
0000014226 1.062158811 2.28842E-07 0.000119976 
Case t1 X Case t2 ENSECAG00000016225 TMEM144 1.665037785 2.63014E-07 0.000126209 
Case t1 X Case t2 ENSECAG00000025328 RNA45S5 1.056872193 2.67001E-07 0.000126209 
Case t1 X Case t2 ENSECAG00000027524 
ENSECAG0
0000027524 1.058301003 2.73558E-07 0.000126209 
Case t1 X Case t2 ENSECAG00000013022 ACTC1 1.097707766 3.73807E-07 0.000165827 
Case t1 X Case t2 ENSECAG00000021019 CPXM1 1.102435473 4.71363E-07 0.000201359 
Table 13. Comparisons performed between cases at time point 1 (t1) and cases at time 
point 2 (t2). The list shows the top 100 genes differentially expressed with FDR<0.05  
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Case t1 X Case t2 ENSECAG00000020878 MNDA 1.104024877 4.97943E-07 0.000205117 
Case t1 X Case t2 ENSECAG00000013687 SMG1 -1.110581229 1.55494E-06 0.000618435 
Case t1 X Case t2 ENSECAG00000027056 
ENSECAG0
0000027056 0.982814572 1.89724E-06 0.000729427 
Case t1 X Case t2 ENSECAG00000016560 CRABP2 1.00124932 2.22157E-06 0.000826569 
Case t1 X Case t2 ENSECAG00000019220 PROX1 -1.1209383 3.81444E-06 0.001374867 
Case t1 X Case t2 ENSECAG00000020059 FGF4 1.222608401 3.99579E-06 0.001396591 
Case t1 X Case t2 ENSECAG00000016782 MYO1F -0.960312958 4.84248E-06 0.001595806 
Case t1 X Case t2 ENSECAG00000017431 MYOZ2 0.916496424 4.74411E-06 0.001595806 
Case t1 X Case t2 ENSECAG00000027624 
ENSECAG0
0000027624 0.956400782 5.02439E-06 0.001609758 
Case t1 X Case t2 ENSECAG00000008916 ANKRD2 0.942918425 5.80386E-06 0.001805296 
Case t1 X Case t2 ENSECAG00000021324 NR6A1 -1.022308695 5.94774E-06 0.001805296 
Case t1 X Case t2 ENSECAG00000016582 SSPO -1.118591246 7.19798E-06 0.002128757 
Case t1 X Case t2 ENSECAG00000017807 NAV2 -0.916963886 8.5914E-06 0.002416907 
Case t1 X Case t2 ENSECAG00000024660 DPF3 -0.943473031 8.5434E-06 0.002416907 
Case t1 X Case t2 ENSECAG00000027699 
ENSECAG0
0000027699 0.869780299 1.27308E-05 0.003496134 
Case t1 X Case t2 ENSECAG00000026887 TSPAN8 0.871818503 1.39415E-05 0.003739571 
Case t1 X Case t2 ENSECAG00000013517 LCOR -0.902060461 1.5827E-05 0.004148821 
Case t1 X Case t2 ENSECAG00000009126 NOS1 -0.849016463 2.32812E-05 0.005967233 
Case t1 X Case t2 ENSECAG00000013728 MFSD2A 1.092417355 2.42829E-05 0.006088682 
Case t1 X Case t2 ENSECAG00000015909 MYBPHL 0.965982026 2.52362E-05 0.006193059 
Case t1 X Case t2 ENSECAG00000013913 PCK2 1.011936261 3.0714E-05 0.007115326 
Case t1 X Case t2 ENSECAG00000018927 ANGPTL4 1.315852475 3.00746E-05 0.007115326 
Case t1 X Case t2 ENSECAG00000018973 ENTHD1 0.882669224 3.0845E-05 0.007115326 
Case t1 X Case t2 ENSECAG00000011254 SMG1 -0.881040155 3.25071E-05 0.007332647 
Case t1 X Case t2 ENSECAG00000019769 PPARGC1B -0.845040345 3.30586E-05 0.007332647 
Case t1 X Case t2 ENSECAG00000008881 LYVE1 1.081690146 4.2435E-05 0.009063802 
Case t1 X Case t2 ENSECAG00000023163 
ENSECAG0
0000023163 -0.823719561 4.24087E-05 0.009063802 
Case t1 X Case t2 ENSECAG00000009390 SEPT1 0.935311453 4.85474E-05 0.009823606 
Case t1 X Case t2 ENSECAG00000023118 MCC -0.839393141 4.82161E-05 0.009823606 
Case t1 X Case t2 ENSECAG00000024143 MYO7A -0.976939527 4.7703E-05 0.009823606 
Case t1 X Case t2 ENSECAG00000001101 SESN1 0.791257883 5.67922E-05 0.01092791 
Case t1 X Case t2 ENSECAG00000010266 NFAT5 -0.831615204 5.68471E-05 0.01092791 
Case t1 X Case t2 ENSECAG00000019083 SORL1 -0.930650876 5.52259E-05 0.01092791 
Case t1 X Case t2 ENSECAG00000000171 NPAS2 -0.988864073 6.25025E-05 0.011818092 
Case t1 X Case t2 ENSECAG00000022544 KMT2C -0.803892872 6.43492E-05 0.011971036 
Case t1 X Case t2 ENSECAG00000019111 CD163 0.874990518 7.04406E-05 0.012499409 
Case t1 X Case t2 ENSECAG00000023280 FADS1 -0.910205273 6.8483E-05 0.012499409 
Case t1 X Case t2 ENSECAG00000024267 TFRC -0.788703171 6.993E-05 0.012499409 
Case t1 X Case t2 ENSECAG00000007663 GIMAP5 0.924855529 7.46506E-05 0.013045752 
Case t1 X Case t2 ENSECAG00000018324 SLC43A2 0.794473572 7.76775E-05 0.013372127 
Case t1 X Case t2 ENSECAG00000007047 ASPN 0.891294062 7.94172E-05 0.013470556 
Case t1 X Case t2 ENSECAG00000007582 GIMAP7 0.915221414 8.58579E-05 0.014146927 
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Case t1 X Case t2 ENSECAG00000023076 GPCPD1 0.777738691 8.55911E-05 0.014146927 
Case t1 X Case t2 ENSECAG00000006043 PHC3 -0.826927649 8.81954E-05 0.014327404 
Case t1 X Case t2 ENSECAG00000000040 IKZF2 -0.842827447 9.06308E-05 0.014518552 
Case t1 X Case t2 ENSECAG00000017294 SNTB1 -0.771538188 9.34903E-05 0.014771462 
Case t1 X Case t2 ENSECAG00000009759 TNRC6B -0.783049732 0.000100611 0.015681693 
Case t1 X Case t2 ENSECAG00000017238 MTC1 0.893145088 0.000104608 0.016087346 
Case t1 X Case t2 ENSECAG00000023387 FRRS1 -0.771461128 0.000108041 0.016396608 
Case t1 X Case t2 ENSECAG00000020410 FREM2 -0.840703902 0.000113946 0.017068175 
Case t1 X Case t2 ENSECAG00000015076 INO80D -0.841658102 0.00012068 0.017845165 
Case t1 X Case t2 ENSECAG00000008221 S100A4 0.777938675 0.000147727 0.021298474 
Case t1 X Case t2 ENSECAG00000016173 TK1 0.898468848 0.000147266 0.021298474 
Case t1 X Case t2 ENSECAG00000004773 TET2  -0.814472475 0.000154296 0.021971001 
Case t1 X Case t2 ENSECAG00000024549 KIAA2018 -0.761033967 0.000161431 0.022706626 
Case t1 X Case t2 ENSECAG00000017015 MYH11 -0.766792538 0.000165872 0.023050243 
Case t1 X Case t2 ENSECAG00000005666 ZBED6 -0.755511021 0.000173707 0.023851587 
Case t1 X Case t2 ENSECAG00000002206 SPRY3 -0.938833481 0.000191771 0.026022189 
Case t1 X Case t2 ENSECAG00000012155 GAN -0.814082401 0.000197192 0.026446642 
Case t1 X Case t2 ENSECAG00000023650 ABAT -0.872861552 0.000204686 0.027136222 
Case t1 X Case t2 ENSECAG00000009535 FCER1G 0.801428029 0.000213226 0.027947086 
Case t1 X Case t2 ENSECAG00000013723 SLC7A8 -0.744908856 0.000215895 0.027979051 
Case t1 X Case t2 ENSECAG00000021790 LNPEP -0.75209736 0.000222891 0.028564707 
Case t1 X Case t2 ENSECAG00000017042 
ENSECAG0
0000017042 0.854906711 0.000226468 0.028704213 
Case t1 X Case t2 ENSECAG00000020053 SLC4A4 -0.792815614 0.000230056 0.028831319 
Case t1 X Case t2 ENSECAG00000023632 RGS10 0.741984139 0.00023247 0.028831319 
Case t1 X Case t2 ENSECAG00000018191 GUCY1A2 -0.818695963 0.000244669 0.030021411 
Case t1 X Case t2 ENSECAG00000017946 KMT2D -0.73014834 0.000258841 0.031425966 
Case t1 X Case t2 ENSECAG00000000762 DDI2 -0.754614254 0.000272737 0.032230268 
Case t1 X Case t2 ENSECAG00000016683 SMYD1 -0.718670775 0.000273848 0.032230268 
Case t1 X Case t2 ENSECAG00000017427 OTOR 0.974489221 0.000270382 0.032230268 
Case t1 X Case t2 ENSECAG00000000237 DGKH -0.819461561 0.0002859 0.033308769 
Case t1 X Case t2 ENSECAG00000007668 
ENSECAG0
0000007668 0.925416797 0.000289727 0.033417098 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 14. Comparisons performed between cases at time point t2 (t2) and cases at time 
point 3 (t3). The list shows the top 100 genes differentially expressed with FDR<0.05 
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Comparison Ensembl Gene ID Gene Name logFC PValue FDR 
Case t2 X Case t3 ENSECAG00000014260 FOS 7.598763208 1.1264E-170 1.2992E-166 
Case t2 X Case t3 ENSECAG00000014338 EGR1 7.033589317 7.7632E-161 4.477E-157 
Case t2 X Case t3 ENSECAG00000018002 FOSB 8.638430603 2.0631E-146 7.932E-143 
Case t2 X Case t3 ENSECAG00000003816 JUNB 4.473073737 4.89699E-81 1.41205E-77 
Case t2 X Case t3 ENSECAG00000017203 BTG2 4.275525933 2.09277E-72 4.8276E-69 
Case t2 X Case t3 ENSECAG00000014232 NR4A2 4.130895224 5.90984E-57 1.13607E-53 
Case t2 X Case t3 ENSECAG00000010560 MGSA 4.774409938 1.12126E-56 1.84752E-53 
Case t2 X Case t3 ENSECAG00000011486 ATF3 3.418073922 1.55216E-51 2.23783E-48 
Case t2 X Case t3 ENSECAG00000010818 EGR2 3.999060604 4.51143E-50 5.78165E-47 
Case t2 X Case t3 ENSECAG00000009012 IER2 3.304921184 6.50951E-49 7.50807E-46 
Case t2 X Case t3 ENSECAG00000009958 DUSP1 3.09207054 4.50384E-46 4.72248E-43 
Case t2 X Case t3 ENSECAG00000004180 HSPA6 3.755188486 4.94437E-45 4.75237E-42 
Case t2 X Case t3 ENSECAG00000024993 CYR61 3.087759541 1.82075E-43 1.61542E-40 
Case t2 X Case t3 ENSECAG00000010613 KLF4 2.830283968 1.69338E-37 1.39511E-34 
Case t2 X Case t3 ENSECAG00000001249 SOCS3 3.838014794 1.60919E-34 1.23736E-31 
Case t2 X Case t3 ENSECAG00000024055 JUN 2.576022754 3.60964E-33 2.6021E-30 
Case t2 X Case t3 ENSECAG00000013836 PKLR -
5.039210367 
6.11038E-33 4.14571E-30 
Case t2 X Case t3 ENSECAG00000019552 SLCO1C1 -
5.987065861 
3.30454E-32 2.11748E-29 
Case t2 X Case t3 ENSECAG00000020971 RND1 3.001285982 6.22398E-32 3.77829E-29 
Case t2 X Case t3 ENSECAG00000016611 KLF2 2.367888106 9.14709E-28 5.27513E-25 
Case t2 X Case t3 ENSECAG00000007242 DUSP2 4.011343384 3.77467E-27 2.07319E-24 
Case t2 X Case t3 ENSECAG00000011488 MIP-2BETA 3.905463879 4.3806E-27 2.29663E-24 
Case t2 X Case t3 ENSECAG00000020059 FGF4 -4.04051323 2.29056E-25 1.14867E-22 
Case t2 X Case t3 ENSECAG00000005487 IGLC7 4.043096642 6.73026E-24 3.23445E-21 
Case t2 X Case t3 ENSECAG00000017436 TREM1 2.788982413 3.46108E-22 1.5968E-19 
Case t2 X Case t3 ENSECAG00000011496 NFKBIZ 2.123171438 5.58381E-22 2.47706E-19 
Case t2 X Case t3 ENSECAG00000011895 ILT11B 2.629998058 3.49189E-20 1.49168E-17 
Case t2 X Case t3 ENSECAG00000013457 CSF3R 2.168765643 1.38393E-18 5.70079E-16 
Case t2 X Case t3 ENSECAG00000013081 MMP9 2.386807876 2.43589E-18 9.68813E-16 
Case t2 X Case t3 ENSECAG00000004066 APOLD1 2.118307517 4.09667E-18 1.57503E-15 
Case t2 X Case t3 ENSECAG00000013781 KIAA1211 -
2.520995413 
6.05905E-18 2.25436E-15 
Case t2 X Case t3 ENSECAG00000013730 ID1 1.818135687 1.84767E-17 6.65969E-15 
Case t2 X Case t3 ENSECAG00000023949 CCL2 2.009780927 2.03138E-17 7.09998E-15 
Case t2 X Case t3 ENSECAG00000020122 SELL 2.095629557 1.59054E-16 5.39566E-14 
Case t2 X Case t3 ENSECAG00000001471 GPR34 2.451200089 2.2118E-16 7.28884E-14 
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Case t2 X Case t3 ENSECAG00000004312 IL1RN 2.20639216 6.33413E-16 2.02938E-13 
Case t2 X Case t3 ENSECAG00000025128 PIWIL2 -
2.795650277 
8.42879E-16 2.62751E-13 
Case t2 X Case t3 ENSECAG00000023741 EGR3 1.829703695 3.47678E-15 1.0553E-12 
Case t2 X Case t3 ENSECAG00000026998 LRRC10B -
2.702773129 
8.86041E-15 2.62041E-12 
Case t2 X Case t3 ENSECAG00000007258 IGHG1 2.507466372 1.56053E-14 4.49979E-12 
Case t2 X Case t3 ENSECAG00000003072 C8orf4 1.640009076 3.07419E-14 8.64822E-12 
Case t2 X Case t3 ENSECAG00000009625 IGHA1 2.271488141 5.32225E-14 1.46159E-11 
Case t2 X Case t3 ENSECAG00000003774 IGHG1  2.157271251 6.11847E-14 1.64117E-11 
Case t2 X Case t3 ENSECAG00000012179 RGS2 1.630506187 1.11621E-13 2.92599E-11 
Case t2 X Case t3 ENSECAG00000010277 PPP1R15A 1.503818816 1.71201E-13 4.38808E-11 
Case t2 X Case t3 ENSECAG00000008555 LTB 2.003356512 2.7128E-13 6.80205E-11 
Case t2 X Case t3 ENSECAG00000019922 ADAMDEC1 2.355693585 4.53342E-13 1.11252E-10 
Case t2 X Case t3 ENSECAG00000013692 IGL  2.639383224 5.58415E-13 1.34182E-10 
Case t2 X Case t3 ENSECAG00000022059 MYC 1.555354914 6.40528E-13 1.50772E-10 
Case t2 X Case t3 ENSECAG00000012527 ENSECAG00
000012527 
-
2.532313598 
1.00159E-12 2.31047E-10 
Case t2 X Case t3 ENSECAG00000026913 ENSECAG00
000026913 
-
2.617271225 
1.27844E-12 2.89127E-10 
Case t2 X Case t3 ENSECAG00000023399 GADD45G 1.493241798 1.93254E-12 4.28653E-10 
Case t2 X Case t3 ENSECAG00000010847 PGLYRP1 2.151552793 3.15514E-12 6.8663E-10 
Case t2 X Case t3 ENSECAG00000000436 FCN1 1.798933702 5.87134E-12 1.25407E-09 
Case t2 X Case t3 ENSECAG00000015010 CYP4F3 1.828240309 6.89398E-12 1.44573E-09 
Case t2 X Case t3 ENSECAG00000000400 AMICA1 1.667306579 7.61419E-12 1.56825E-09 
Case t2 X Case t3 ENSECAG00000016610 CTGF 1.434782053 1.38568E-11 2.80394E-09 
Case t2 X Case t3 ENSECAG00000016661 NR4A1 1.344950583 2.18034E-11 4.33586E-09 
Case t2 X Case t3 ENSECAG00000023992 S100P 1.597944532 3.43324E-11 6.71169E-09 
Case t2 X Case t3 ENSECAG00000018649 UCP2 1.503545561 4.06927E-11 7.82249E-09 
Case t2 X Case t3 ENSECAG00000006561 TRBC2 1.474580243 4.90167E-11 9.26817E-09 
Case t2 X Case t3 ENSECAG00000006674 RRAD 1.346281032 5.29021E-11 9.8415E-09 
Case t2 X Case t3 ENSECAG00000000548 IGHM 1.636314299 5.48074E-11 1.00341E-08 
Case t2 X Case t3 ENSECAG00000015657 TNNT1 1.4281332 1.20509E-10 2.17179E-08 
Case t2 X Case t3 ENSECAG00000004763 XIRP1 1.293548826 1.94338E-10 3.44845E-08 
Case t2 X Case t3 ENSECAG00000009742 S100A12 2.019360365 2.1197E-10 3.70434E-08 
Case t2 X Case t3 ENSECAG00000010089 DUSP6 1.288609136 3.23354E-10 5.56652E-08 
Case t2 X Case t3 ENSECAG00000007960 LIMD2 1.60180998 4.69878E-10 7.96997E-08 
Case t2 X Case t3 ENSECAG00000019932 LGALS9C 1.413355658 5.05261E-10 8.44592E-08 
Case t2 X Case t3 ENSECAG00000000419 TRAC 1.489322423 5.28441E-10 8.63161E-08 
Case t2 X Case t3 ENSECAG00000020452 TNNC1 1.369704764 5.31337E-10 8.63161E-08 
Case t2 X Case t3 ENSECAG00000010020 HBB 2.119562201 6.78278E-10 1.08656E-07 
Case t2 X Case t3 ENSECAG00000014875 PTPRCAP 1.4345552 7.53092E-10 1.18988E-07 
Case t2 X Case t3 ENSECAG00000016339 ADAMTS1 1.250351605 8.17222E-10 1.27376E-07 
Case t2 X Case t3 ENSECAG00000024788 CORO1A 1.349284846 1.16008E-09 1.78404E-07 
Case t2 X Case t3 ENSECAG00000007867 MYL2 1.316652752 1.4061E-09 2.13394E-07 
Case t2 X Case t3 ENSECAG00000017410 MYL3 1.309558654 2.60811E-09 3.90675E-07 
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Case t2 X Case t3 ENSECAG00000018395 TYROBP 1.309718806 5.23159E-09 7.73605E-07 
Case t2 X Case t3 ENSECAG00000020463 HSPB1 1.187957489 5.31064E-09 7.75354E-07 
Case t2 X Case t3 ENSECAG00000015834 DMD  -
1.201494777 
5.69262E-09 8.20733E-07 
Case t2 X Case t3 ENSECAG00000014552 ENSECAG00
000014552 
-
1.223198618 
6.2907E-09 8.95765E-07 
Case t2 X Case t3 ENSECAG00000017799 MYO1G 1.308878054 6.98058E-09 9.81879E-07 
Case t2 X Case t3 ENSECAG00000009192 SRGN 1.203957895 7.67809E-09 1.06698E-06 
Case t2 X Case t3 ENSECAG00000009474 ENSECAG00
000009474 
1.97331704 8.21324E-09 1.12776E-06 
Case t2 X Case t3 ENSECAG00000000763 CSRNP1 1.311913009 8.31742E-09 1.12862E-06 
Case t2 X Case t3 ENSECAG00000024888 CCL5 1.28672592 9.00109E-09 1.20719E-06 
Case t2 X Case t3 ENSECAG00000016776 TNNI1 1.257187544 9.85638E-09 1.30671E-06 
Case t2 X Case t3 ENSECAG00000009363 IRG1 1.854095132 1.0617E-08 1.39155E-06 
Case t2 X Case t3 ENSECAG00000011254 SMG1 -
1.260155461 
1.43074E-08 1.85417E-06 
Case t2 X Case t3 ENSECAG00000012148 NMES1 1.690723335 1.50469E-08 1.92834E-06 
Case t2 X Case t3 ENSECAG00000002668 RHOB 1.148074246 1.77873E-08 2.2545E-06 
Case t2 X Case t3 ENSECAG00000012572 ENSECAG00
000012572 
-
1.183876651 
1.93002E-08 2.41966E-06 
Case t2 X Case t3 ENSECAG00000020638 NEB -
1.122713663 
2.39429E-08 2.96943E-06 
Case t2 X Case t3 ENSECAG00000023322 ID3 1.158760487 2.48422E-08 3.04819E-06 
Case t2 X Case t3 ENSECAG00000019124 LILRA5 1.516827666 2.63168E-08 3.19514E-06 
Case t2 X Case t3 ENSECAG00000001159 FOXS1 1.260488919 2.75603E-08 3.31126E-06 
Case t2 X Case t3 ENSECAG00000001784 CD14 1.168974284 3.75389E-08 4.46364E-06 
Case t2 X Case t3 ENSECAG00000016508 HK3 1.29768793 3.88245E-08 4.56941E-06 
Case t2 X Case t3 ENSECAG00000018028 TLR2 1.357514574 4.04357E-08 4.71096E-06 
Case t2 X Case t3 ENSECAG00000010918 SELP 1.305331929 5.07243E-08 5.85055E-06 
      
Comparison Ensembl Gene ID Gene  logFC PValue FDR 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000008335 PDK4 -3.493037034 4.96122E-24 2.86114E-20 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000016867 CISH -3.792464215 3.41662E-24 2.86114E-20 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000013728 MFSD2A -3.934524569 3.58301E-23 1.37755E-19 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000018927 ANGPTL4 -4.347620478 1.58601E-19 4.57327E-16 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000000548 IGHM 3.422578748 2.39987E-19 5.53601E-16 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000014658 SCD 2.792882878 1.70865E-16 3.28459E-13 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000013532 CCDC162P -3.608370261 2.76014E-16 4.54792E-13 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000011811 
ENSECAG
000000118
11 -3.716882066 6.10348E-16 8.7997E-13 
Table 15. Comparisons between the effect of training in cases and controls (double 
difference). The list shows the top 100 genes differentially expressed with FDR<0.05 	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Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000003774 IGHG1  3.468734353 1.77083E-15 2.26942E-12 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000013692 IGL  4.316407242 3.42804E-15 3.9539E-12 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000022841 NMRK2 2.462906634 4.60312E-15 4.82658E-12 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000014500 ART5 -2.351614959 1.75959E-14 1.69125E-11 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000016486 ARRDC2 -2.412914117 3.37972E-14 2.99859E-11 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000015109 IGL 3.71109855 1.83393E-13 1.5109E-10 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000000816 AMPD3 -2.397086735 5.48344E-13 3.95287E-10 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000020122 SELL 2.628961698 5.15141E-13 3.95287E-10 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000011895 ILT11B 3.001168096 1.49389E-12 1.01356E-09 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000019557 LDLR 2.216682949 2.78922E-12 1.78727E-09 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000005186 HMGB1 5.341137575 4.38147E-12 2.65978E-09 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000001101 SESN1 -2.055316588 1.02591E-11 5.91645E-09 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000018324 SLC43A2 -2.081769899 1.72751E-11 9.48815E-09 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000005487 IGLC7 4.100649508 8.89203E-11 4.66185E-08 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000009075 MPZ -2.393397776 9.79764E-11 4.9133E-08 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000002376 CHRNG -2.603185935 1.24787E-10 5.99704E-08 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000012472 COPS4 4.326125448 3.38041E-10 1.55959E-07 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000014861 GRAMD2 2.329533153 1.0268E-09 4.55505E-07 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000018228 IGSF6 2.384168002 1.136E-09 4.85282E-07 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000013836 PKLR -2.776604306 1.74133E-09 7.17304E-07 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000024506 ARMC2 -2.066890128 2.01103E-09 7.99836E-07 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000004107 DDIT4 -1.828966441 3.16194E-09 1.21566E-06 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000019083 SORL1 2.066805753 3.60144E-09 1.33997E-06 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000013457 CSF3R 2.178250644 5.21136E-09 1.87837E-06 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000007258 IGHG1 2.880562427 5.46045E-09 1.90851E-06 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000011304 FKBP5 -1.816883506 5.84507E-09 1.98285E-06 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000011258 RFXAP -1.757145014 1.06718E-08 3.51682E-06 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000013291 PER1 -1.749458223 1.21701E-08 3.89915E-06 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000009363 IRG1 2.468727808 1.52993E-08 4.64375E-06 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000011493 ARMC12 -1.798445513 1.52274E-08 4.64375E-06 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000019922 
ADAMDE
C1 2.596207929 1.87829E-08 5.55492E-06 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000012751 CCKBR 2.231184237 2.04443E-08 5.75133E-06 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000026887 TSPAN8 -1.718399093 2.0049E-08 5.75133E-06 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000023399 GADD45G -1.815538962 2.1516E-08 5.9087E-06 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000020162 PRR5L -1.756210925 3.18836E-08 8.55223E-06 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000023728 DDIT4L -1.661272698 4.57829E-08 1.20014E-05 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000010918 SELP 1.95398925 6.12615E-08 1.53606E-05 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000012395 S100B -2.277994451 6.0288E-08 1.53606E-05 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000009625 IGHA1 2.540219168 9.40344E-08 2.30764E-05 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000009370 ORC1 -2.073471946 1.31071E-07 3.14952E-05 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000016002 FBXO32 -1.625352808 1.44828E-07 3.40908E-05 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000019552 SLCO1C1 -2.419179259 1.69818E-07 3.91736E-05 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000019795 ARID5B -1.632961495 1.73508E-07 3.92401E-05 
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Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000024873 C1orf110 2.111534393 1.78746E-07 3.96472E-05 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000008555 LTB 2.165138463 1.92318E-07 4.18527E-05 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000017758 SH3KBP1 1.543913257 3.65209E-07 7.80058E-05 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000000368 MT1A -1.859123905 4.02219E-07 8.32345E-05 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000023076 GPCPD1 -1.530815255 4.04121E-07 8.32345E-05 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000006487 
METTL21
EP  1.894091686 4.27251E-07 8.64546E-05 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000007960 LIMD2 1.903686488 5.49002E-07 0.000107716 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000020809 C3orf18 -1.877145944 5.50999E-07 0.000107716 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000013081 MMP9 2.094235107 6.26331E-07 0.000120402 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000013302 LRIT3 1.776649067 7.78873E-07 0.000142718 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000017956 TOR3A 1.518978148 7.78471E-07 0.000142718 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000024993 CYR61 -1.595454215 7.79542E-07 0.000142718 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000021110 
ENSECAG
000000211
10 2.188733271 8.61224E-07 0.000155209 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000015010 CYP4F3 2.003100551 8.95462E-07 0.000158896 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000004066 APOLD1 -1.872247484 9.77055E-07 0.000170733 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000016679 GALNT15 -1.605751767 9.91772E-07 0.000170733 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000002437 NFIL3 1.465191139 1.64683E-06 0.000279331 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000001290 CABP1 1.590830173 1.70518E-06 0.000285038 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000018476 TPX2 -1.482187953 1.89903E-06 0.000312905 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000000591 TRAF3IP2 -1.595454765 2.12189E-06 0.000344703 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000011731 
HORMAD
1 2.020373099 2.31513E-06 0.000370871 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000014255 SAG 1.700565611 2.34887E-06 0.000371121 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000001394 MPEG1 1.835494677 2.46493E-06 0.00038412 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000015730 NAPSA 2.01604271 2.49775E-06 0.00038412 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000021092 KLF15 -1.440983499 2.55012E-06 0.000387014 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000020485 PCOLCE2 -1.520597225 2.68647E-06 0.000402412 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000011075 RFX3 -1.451974041 2.95948E-06 0.000437624 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000023280 FADS1 1.581068934 3.48182E-06 0.000508345 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000019779 KCNS3 1.413131296 3.62593E-06 0.000522769 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000009180 TLR8 2.154214622 3.82728E-06 0.000544986 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000020059 FGF4 -1.948259987 4.10225E-06 0.000577016 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000000400 AMICA1 1.678231149 5.12722E-06 0.000705942 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000010020 HBB 2.756559142 5.14124E-06 0.000705942 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000013781 KIAA1211 -1.675443309 5.64101E-06 0.000764004 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000016899 FAM134B -1.377575494 5.69658E-06 0.000764004 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000006153 C5AR1 1.758422358 6.00536E-06 0.000796158 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000009488 SYK 1.784977723 6.13719E-06 0.000804391 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000013745 SNX10 1.819990056 6.82795E-06 0.000884872 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000018029 THSD1 -1.360199365 7.46282E-06 0.000956402 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000000291 PLCG2 1.386435511 1.09675E-05 0.001387472 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000015275 MT2A -1.374624615 1.11874E-05 0.001387472 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000017436 TREM1 2.081526634 1.11435E-05 0.001387472 
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Comparison Ensembl Gene ID 
Gene 
Name logFC PValue FDR 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000011895 ILT11B -3.700267044 1.33417E-18 1.53884E-14 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000005487 IGLC7 -4.749828551 3.05813E-17 1.61901E-13 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000020122 SELL -3.225458636 4.21106E-17 1.61901E-13 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000010847 PGLYRP1 -3.721698591 7.22114E-17 2.08222E-13 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000013457 CSF3R -3.074511081 1.09579E-15 2.52778E-12 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000013081 MMP9 -3.295642061 1.51545E-15 2.9132E-12 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000000400 AMICA1 -2.822624572 6.76733E-14 1.11506E-10 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000017436 TREM1 -3.101915574 2.75996E-13 3.97917E-10 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000019922 
ADAMDE
C1 -3.262182853 5.96629E-13 7.64614E-10 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000008555 LTB -2.82910483 2.06382E-12 2.38041E-09 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000003774 IGHG1  -2.859939377 2.80715E-12 2.49059E-09 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000005186 HMGB1 -5.228995048 2.42972E-12 2.49059E-09 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000019932 LGALS9C -2.507087061 2.59919E-12 2.49059E-09 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000009363 IRG1 -3.022610333 5.78044E-12 4.76225E-09 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000019083 SORL1 -2.548273671 8.02132E-12 6.16786E-09 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000018228 IGSF6 -2.688283335 1.35312E-11 9.7543E-09 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000012148 NMES1 -3.002444769 2.05163E-11 1.38379E-08 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000018649 UCP2 -2.386061991 2.15954E-11 1.38379E-08 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000015010 CYP4F3 -2.65826464 2.71763E-11 1.64974E-08 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000004180 HSPA6 -2.705035144 2.87983E-11 1.6608E-08 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000023992 S100P -2.485513848 4.64183E-11 2.54947E-08 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000009625 IGHA1 -2.789680209 5.4331E-11 2.84842E-08 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000004312 IL1RN -2.723709132 9.29302E-11 4.66025E-08 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000010185 IFIT2 -2.430795128 1.11373E-10 5.35238E-08 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000012472 COPS4 -4.495591031 1.19869E-10 5.44165E-08 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000021110 ENSECAG -2.893511188 1.22666E-10 5.44165E-08 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000013723 SLC7A8 1.33899928 1.16163E-05 0.001425347 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000015500 
ENSECAG
000000155
00 2.09757972 1.23667E-05 0.001501442 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000006674 RRAD 1.318039042 1.28768E-05 0.001547099 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000023457 GPR183 1.941546839 1.35794E-05 0.001614688 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000010108 ITPRIP -1.396310825 1.59721E-05 0.001865478 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000010185 IFIT2 1.541130915 1.6012E-05 0.001865478 
Case t1 - Case t2 X Control t1 - Control t2 ENSECAG00000005489 PTAFR 1.787160092 1.75293E-05 0.002021828 
Table 16. Comparisons between the effect of exercise in cases and controls (double difference). 
The list shows the top 100 genes differentially expressed with FDR<0.05 
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000000211
10 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000024788 CORO1A -2.214543452 1.63664E-10 6.99149E-08 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000009192 SRGN -2.068425374 3.68813E-10 1.51925E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000013692 IGL  -3.082838319 4.18814E-10 1.66572E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000000794 EMB -2.690474342 4.33807E-10 1.66784E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000023216 VNN2 -2.186570963 4.81243E-10 1.79054E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000010496 LILRB4 -3.046489353 5.08458E-10 1.83267E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000015500 
ENSECAG
000000155
00 -2.971479994 6.60956E-10 2.31014E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000007960 LIMD2 -2.372634321 7.03829E-10 2.38764E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000014338 EGR1 -2.033276557 8.91445E-10 2.93769E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000010918 SELP -2.253015046 1.13668E-09 3.6418E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000005081 CD3G -2.378491343 1.23152E-09 3.83903E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000019124 LILRA5 -2.479281806 1.31528E-09 3.94445E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000024888 CCL5 -2.084978314 1.33374E-09 3.94445E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000006561 TRBC2 -2.098882749 1.49699E-09 4.31658E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000013745 SNX10 -2.451216177 1.68906E-09 4.75161E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000016508 HK3 -2.230025104 1.81158E-09 4.97495E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000003816 JUNB -1.931563897 2.08682E-09 5.59753E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000016721 
KIAA0226
L -2.554547498 2.19435E-09 5.75218E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000018395 TYROBP -2.096004716 3.18461E-09 8.1625E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000019527 SELPLG -2.334331202 3.54539E-09 8.88968E-07 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000000419 TRAC -2.125409118 5.38461E-09 1.30268E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000010500 ITGA4 -2.310995741 5.42124E-09 1.30268E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000009742 S100A12 -2.680913805 5.88207E-09 1.38457E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000024457 SPI1_PU.1 -2.165422882 6.21429E-09 1.43351E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000011890 
ARHGAP3
0 -2.055683961 6.50724E-09 1.47166E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000011467 ALPL -2.010014322 6.64461E-09 1.47383E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000022135 VNN1 -2.291625358 7.1298E-09 1.55161E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000014635 CD3E -2.178724514 8.97611E-09 1.91723E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000017799 MYO1G -1.975760811 9.82747E-09 2.06091E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000011994 CYFIP2 -2.249022665 1.14506E-08 2.35842E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000011733 RNASE6 -2.029589202 1.31128E-08 2.65339E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000010020 HBB -2.703851364 1.37985E-08 2.744E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000007837 FGR -1.91333279 1.57644E-08 3.08181E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000015730 NAPSA -2.329142973 1.80821E-08 3.47599E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000018113 LYZ -1.964649709 1.85813E-08 3.51339E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000014260 FOS -1.875001557 1.93582E-08 3.60124E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000023457 GPR183 -2.334375263 2.17441E-08 3.9809E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000011917 DOCK8 -2.003423114 2.32637E-08 4.19256E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000010263 SASH3 -2.290350755 2.97502E-08 5.27905E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000000436 FCN1 -2.201588713 3.04748E-08 5.3257E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000009488 SYK -2.209233495 4.15293E-08 7.14925E-06 
	  	  
115	  	  
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000023430 TRPM2 -2.132410191 5.45452E-08 9.25183E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000013534 CD53 -2.013422633 5.76233E-08 9.63228E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000004162 EVI2B -2.068210539 5.93179E-08 9.77389E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000018339 IKZF1 -2.428211372 6.0624E-08 9.84841E-06 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000018028 TLR2 -2.08182229 6.3883E-08 1.02337E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000012029 TBC1D10C -2.268495829 6.8951E-08 1.08943E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000009282 GZMH  -2.293328115 7.99386E-08 1.24596E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000007258 IGHG1 -2.478861748 9.16454E-08 1.40938E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000017457 CYTIP -1.932888956 1.38184E-07 2.09713E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000012179 RGS2 -1.788376736 1.51821E-07 2.27416E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000010928 MMP25 -2.002613228 1.6158E-07 2.35907E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000021765 TSPO -1.837750868 1.61044E-07 2.35907E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000009012 IER2 -1.658100148 2.04572E-07 2.94942E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000012738 COTL1 -1.860346707 2.23731E-07 3.18582E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000015742 FGD3 -1.966875942 2.74939E-07 3.86725E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000009535 FCER1G -1.783326767 2.96287E-07 4.11732E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000000548 IGHM -1.852543348 4.01344E-07 5.51084E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000018996 PLEK -1.885025848 4.80676E-07 6.52249E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000016449 ILT11A -2.191857588 5.21993E-07 7.00078E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000001141 NAIP -2.240956853 5.64873E-07 7.40369E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000026984 GPSM3 -1.968535415 5.62072E-07 7.40369E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000009075 MPZ 1.842645541 6.13573E-07 7.95163E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000006153 C5AR1 -1.933402662 6.8455E-07 8.67649E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000014875 PTPRCAP -1.75461438 6.83141E-07 8.67649E-05 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000017644 CFP -1.808064321 9.92219E-07 0.000124394 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000009958 DUSP1 -1.500559818 1.03776E-06 0.000128705 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000010977 HMHA1 -1.899568828 1.06559E-06 0.000129603 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000016634 RPS2 -1.794909152 1.06748E-06 0.000129603 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000023256 LCK -1.825708901 1.27648E-06 0.000153364 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000016962 APOBR -1.880188828 1.32197E-06 0.000157192 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000017707 HCK -2.023327464 1.65424E-06 0.000192909 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000023596 RASSF2 -1.917177054 1.6558E-06 0.000192909 
Case t2 - Case t3 X Control t2 - Control t3 ENSECAG00000015034 PLAC8 -1.731486151 1.80965E-06 0.000208725 
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            Table 17. DAVID clusters based on biological function for all of the comparisons. The list shows the top 10 cluster are represented 
 
CASE X CONTROL t1 
      
Category Term Count PValue List Total Fold Enrichment FDR 
GOTERM_BP_FAT GO:0001775~cell activation 39 5.28E-16 371 4.954985584 9.77E-13 
GOTERM_BP_FAT GO:0045321~leukocyte activation 34 1.97E-14 371 5.12298679 3.47E-11 
GOTERM_BP_FAT GO:0006955~immune response 57 1.69E-13 371 3.012211415 2.99E-10 
SP_PIR_KEYWORDS signal 139 2.09E-12 463 1.776816747 2.96E-09 
GOTERM_BP_FAT 
GO:0002684~positive regulation of immune system 
process 31 2.54E-12 371 4.749462049 4.47E-09 
UP_SEQ_FEATURE signal peptide 139 2.86E-12 462 1.769368631 4.74E-09 
GOTERM_BP_FAT GO:0046649~lymphocyte activation 28 5.73E-12 371 5.130558453 1.01E-08 
GOTERM_BP_FAT GO:0050865~regulation of cell activation 25 7.09E-11 371 5.209087409 1.25E-07 
SP_PIR_KEYWORDS disulfide bond 124 1.04E-10 463 1.761795582 1.47E-07 
GOTERM_BP_FAT GO:0006952~defense response 48 1.47E-10 371 2.845940438 2.60E-07 
       
CASE X CONTROL t2 
      
Category Term Count PValue List Total Fold Enrichment FDR 
SP_PIR_KEYWORDS signal 93 4.16E-12 271 2.031058757 5.77E-09 
GOTERM_CC_FAT GO:0005576~extracellular region 73 5.26E-12 206 2.253504323 6.88E-09 
UP_SEQ_FEATURE signal peptide 93 5.99E-12 271 2.018176554 9.5E-09 
SP_PIR_KEYWORDS Secreted 61 1.24E-11 271 2.563439578 1.72E-08 
SP_PIR_KEYWORDS disulfide bond 83 1.74E-10 271 2.01476141 0.000000242 
SP_PIR_KEYWORDS extracellular matrix 21 2.19E-10 271 6.184792761 0.000000303 
GOTERM_CC_FAT GO:0044421~extracellular region part 44 4.89E-10 206 2.843891586 0.000000639 
UP_SEQ_FEATURE disulfide bond 79 1.5E-09 271 1.976476178 0.00000239 
GOTERM_CC_FAT GO:0005578~proteinaceous extracellular matrix 24 1.73E-09 206 4.653640777 0.00000226 
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GOTERM_CC_FAT GO:0031012~extracellular matrix 24 7.27E-09 206 4.316420431 0.00000951 
       
CASE X CONTROL t3 
      
Category Term Count PValue List Total Fold Enrichment FDR 
GOTERM_BP_FAT GO:0009991~response to extracellular stimulus 29 1.17972E-07 561 3.178674445 0.000212246 
GOTERM_BP_FAT GO:0010033~response to organic substance 61 1.65446E-07 561 2.040165051 0.000297658 
UP_SEQ_FEATURE sequence variant 512 3.40794E-07 716 1.139709527 0.000591765 
GOTERM_BP_FAT GO:0010035~response to inorganic substance 27 3.59908E-07 561 3.176001043 0.00064752 
GOTERM_CC_FAT GO:0009986~cell surface 36 4.58914E-07 511 2.587623996 0.000636047 
GOTERM_BP_FAT GO:0006955~immune response 57 9.88464E-07 561 1.992032861 0.00177836 
SP_PIR_KEYWORDS phosphoprotein 333 1.01098E-06 717 1.229988991 0.001463873 
SP_PIR_KEYWORDS polymorphism 491 1.34079E-06 717 1.140440266 0.001941425 
SP_PIR_KEYWORDS signal 170 1.76868E-06 717 1.403261453 0.002560984 
SP_PIR_KEYWORDS actin-binding 27 1.93454E-06 717 2.932512324 0.002801142 
       
CASE t1 X CASE t2 
      
Category Term Count PValue List Total Fold Enrichment FDR 
GOTERM_BP_FAT GO:0014866~skeletal myofibril assembly 3 0.000510136 81 83.50617284 0.815056651 
GOTERM_BP_FAT GO:0045471~response to ethanol 5 0.000550345 81 13.04783951 0.879033544 
GOTERM_BP_FAT GO:0001666~response to hypoxia 6 0.001173746 81 7.478164732 1.866000879 
GOTERM_BP_FAT GO:0070482~response to oxygen levels 6 0.001471828 81 7.106908327 2.334661762 
UP_SEQ_FEATURE domain:LDL-receptor class A 6 3 0.001474173 102 51.10427807 2.079536352 
UP_SEQ_FEATURE domain:LDL-receptor class A 7 3 0.001474173 102 51.10427807 2.079536352 
UP_SEQ_FEATURE domain:LDL-receptor class A 5 3 0.00176292 102 46.84558824 2.482117355 
GOTERM_BP_FAT 
GO:0002714~positive regulation of B cell mediated 
immunity 3 0.001834911 81 45.54882155 2.902683904 
GOTERM_BP_FAT 
GO:0002891~positive regulation of immunoglobulin 
mediated immune response 3 0.001834911 81 45.54882155 2.902683904 
UP_SEQ_FEATURE domain:LDL-receptor class A 4 3 0.00316146 102 35.13419118 4.410322607 
       
CASE t2 X CASE t3 
      
Category Term Count PValue List Total Fold Enrichment FDR 
	  	  
118	  	  
SP_PIR_KEYWORDS phosphoprotein 1294 6.63E-68 2390 1.433879058 1.00E-64 
GOTERM_BP_FAT GO:0006414~translational elongation 67 4.46E-33 1855 4.837746524 8.31E-30 
GOTERM_CC_FAT GO:0033279~ribosomal subunit 71 2.88E-29 1680 4.220247396 4.32E-26 
SP_PIR_KEYWORDS acetylation 513 3.47E-29 2390 1.566863036 5.25E-26 
SP_PIR_KEYWORDS ribosomal protein 86 4.56E-29 2390 3.681585507 6.89E-26 
SP_PIR_KEYWORDS ribosome 51 9.22E-29 2390 5.62265719 1.39E-25 
GOTERM_MF_FAT GO:0003735~structural constituent of ribosome 81 1.16E-26 1776 3.524583736 1.91E-23 
KEGG_PATHWAY hsa03010:Ribosome 57 2.05E-26 754 4.418503613 2.53E-23 
GOTERM_CC_FAT GO:0022626~cytosolic ribosome 52 1.30E-25 1680 4.88436214 1.95E-22 
SP_PIR_KEYWORDS cytoplasm 599 5.46E-25 2390 1.446825383 8.25E-22 
GOTERM_CC_FAT GO:0005739~mitochondrion 222 2.75E-12 1680 1.553863845 4.11E-09 
GOTERM_CC_FAT GO:0015629~actin cytoskeleton 76 7.29E-11 1680 2.149566295 1.09E-07 
       
Double difference  t1 X t2 
      
Category Term Count PValue List Total Fold Enrichment FDR 
SP_PIR_KEYWORDS transmembrane protein 26 2.90E-08 208 3.745132399 3.94E-05 
GOTERM_CC_FAT GO:0005887~integral to plasma membrane 35 1.04E-07 140 2.689814815 1.30E-04 
GOTERM_CC_FAT GO:0031226~intrinsic to plasma membrane 35 1.79E-07 140 2.630041152 2.23E-04 
SP_PIR_KEYWORDS disulfide bond 61 2.89E-07 208 1.929218076 3.94E-04 
SP_PIR_KEYWORDS signal 65 4.39E-07 208 1.849519231 5.97E-04 
UP_SEQ_FEATURE signal peptide 65 4.56E-07 207 1.846666667 6.96E-04 
GOTERM_BP_FAT GO:0007159~leukocyte adhesion 7 9.07E-07 166 20.37349398 0.001521206 
GOTERM_BP_FAT GO:0007229~integrin-mediated signaling pathway 9 2.05E-06 166 10.4777969 0.003443328 
KEGG_PATHWAY hsa04514:Cell adhesion molecules (CAMs) 12 2.15E-06 74 6.246928747 0.002304074 
UP_SEQ_FEATURE disulfide bond 57 2.47E-06 207 1.866974104 0.003766139 
       
Double difference t2 X t3 
      
Category Term Count PValue List Total Fold Enrichment FDR 
GOTERM_BP_FAT GO:0001775~cell activation 33 5.01E-21 178 8.738675958 8.34E-18 
GOTERM_BP_FAT GO:0045321~leukocyte activation 30 5.51E-20 178 9.421487603 9.17E-17 
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GOTERM_BP_FAT GO:0006955~immune response 46 6.78E-20 178 5.066666667 1.13E-16 
GOTERM_BP_FAT GO:0006952~defense response 39 6.08E-16 178 4.819512195 9.21E-13 
GOTERM_BP_FAT GO:0046649~lymphocyte activation 23 1.36E-14 178 8.783919598 2.25E-11 
GOTERM_BP_FAT GO:0042110~T cell activation 19 4.35E-14 178 11.46031746 7.22E-11 
GOTERM_BP_FAT 
GO:0002684~positive regulation of immune system 
process 23 5.53E-13 178 7.344537815 9.20E-10 
GOTERM_BP_FAT GO:0050867~positive regulation of cell activation 16 1.42E-11 178 10.95495495 2.36E-08 
GOTERM_BP_FAT GO:0050865~regulation of cell activation 18 1.27E-10 178 7.817142857 2.11E-07 
GOTERM_CC_FAT GO:0044459~plasma membrane part 62 2.11E-10 161 2.234344471 2.69E-07 
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COMPARISON CASE X CONTROL T2 
      
PATHWAY SIZE ES NES NOM p-val FDR q-val 
 
FATTY_ACID_METABOLIC_PROCESS 39 -0.5141444 -1.584686 0.011320755 0.07342478 ENRICHED CONTROLS 
       
       
COMPARISON CASE X CONTROL T2 
      
PATHWAYS SIZE ES NES NOM p-val FDR q-val 
 
REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPORT 101 -0.4952191 -1.4742914 0.14604463 0.23013428 ENRICHED CONTROLS 
KEGG_OXIDATIVE_PHOSPHORYLATION 90 -0.4816668 -1.4316875 0.19631901 0.21576932 ENRICHED CONTROLS 
REACTOME_RESPIRATORY_ELECTRON_TRANSPORT 54 -0.5169294 -1.3437802 0.22129436 0.20644842 ENRICHED CONTROLS 
       
       
COMPARISON CASE X CONTROL T2 
      
PATHWAYS SIZE ES NES NOM p-val FDR q-val 
 
MITOCHONDRIAL_RESPIRATORY_CHAIN 21 -0.52548486 -1.3155179 0.21713148 0.2634178 ENRICHED CONTROLS 
MITOCHONDRIAL_MEMBRANE 68 -0.42892662 -1.3052319 0.25 0.22932892 ENRICHED CONTROLS 
       
       
COMPARISON CASE X CONTROL T1 
      
PATHWAYS SIZE ES NES NOM p-val FDR q-val 
 
KEGG_GLYCOLYSIS_GLUCONEOGENESIS 35 0.64731264 2.0261514 0 0.009430527 ENRICHED CASES 
REACTOME_GLYCOLYSIS 21 0.58073455 1.8121207 0.031189084 0.094652504 ENRICHED CASES 
       
       
Table 18. Summary of pathways used by GSEA and their enrichment scores and FDRs   	  
	  	  
121	  	  
 
 
COMPARISON CASE T1 X CASE T2 
      
PATHWAYS SIZE ES NES NOM p-val FDR q-val 
 
MOOTHA_GLYCOGEN_METABOLISM 16 0.6143548 1.4592139 0.062248997 0.11375212 ENRICHED CASES T1 
       
       
COMPARISON CASE X CONTROL T1 
      
PATHWAYS SIZE ES NES NOM p-val FDR q-val 
 
MOOTHA_GLYCOGEN_METABOLISM 16 0.4889237 1.3183392 0.16302186 0.22617124 ENRICHED CASES 
       
       
COMPARISON CASE X CONTROL T1 
      
PATHWAYS SIZE ES NES NOM p-val FDR q-val 
 
REGULATION_OF_CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS 25 0.4370639 1.4382352 0.036363635 0.21895188 ENRICHED CASES 
NEGATIVE_REGULATION_OF_CELLULAR_COMPONENT_ORGANIZATIO
N_AND_BIOGENESIS 24 0.47610074 1.4318788 0.060796645 0.17171904 ENRICHED CASES 
CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS 156 0.38595834 1.361863 0.10309278 0.22401287 ENRICHED CASES 
ACTIN_CYTOSKELETON_ORGANIZATION_AND_BIOGENESIS 83 0.40572113 1.2894213 0.1764706 0.24646045 ENRICHED CASES 
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FATTY ACID METABOLIC PROCESS CASE X CONTROL t2 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
ALOX12 arachidonate 12-lipoxygenase -0.001875266 No 
ALOX15B arachidonate 15-lipoxygenase, type B -0.021472909 No 
CPT1B carnitine palmitoyltransferase 1B (muscle) -0.01708801 No 
PTGES prostaglandin E synthase -0.024569668 No 
CYP2J2 cytochrome P450, family 2, subfamily J, polypeptide 2 -0.03541219 No 
CYP4F3 cytochrome P450, family 4, subfamily F, polypeptide 3 -0.14990844 No 
SLC27A5 solute carrier family 27 (fatty acid transporter), member 5 -0.15139365 No 
BRCA1 breast cancer 1, early onset -0.15417928 No 
CPT1A carnitine palmitoyltransferase 1A (liver) -0.15676837 No 
MCAT malonyl CoA:ACP acyltransferase (mitochondrial) -0.1827632 No 
BDH2 3-hydroxybutyrate dehydrogenase, type 2 -0.19757262 No 
PPARA peroxisome proliferative activated receptor, alpha -0.1946696 No 
PPARD peroxisome proliferative activated receptor, delta -0.24661613 No 
ADIPOR1 adiponectin receptor 1 -0.2491975 No 
MIF macrophage migration inhibitory factor (glycosylation-
inhibiting factor) 
-0.24033439 No 
ACADVL acyl-Coenzyme A dehydrogenase, very long chain -0.3069712 No 
ECHS1 enoyl Coenzyme A hydratase, short chain, 1, mitochondrial -0.3094807 No 
ACOT9 acyl-CoA thioesterase 9 -0.29732838 No 
HACL1 2-hydroxyacyl-CoA lyase 1 -0.35747975 No 
GNPAT glyceronephosphate O-acyltransferase -0.33733857 No 
ACADM acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain -0.419112 No 
CROT carnitine O-octanoyltransferase -0.43554103 No 
TNFRSF1A tumor necrosis factor receptor superfamily, member 1A -0.48220152 Yes 
ADIPOR2 adiponectin receptor 2 -0.4722387 Yes 
LTA4H leukotriene A4 hydrolase -0.4513995 Yes 
PNPLA8 patatin-like phospholipase domain containing 8 -0.43264836 Yes 
ACOX3 acyl-Coenzyme A oxidase 3, pristanoyl -0.41427162 Yes 
DEGS1 degenerative spermatocyte homolog 1, lipid desaturase 
(Drosophila) 
-0.3820845 Yes 
HADHB hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl- -0.35460165 Yes 
Table 19. Summary of pathways used by GSEA and the genes from the expression data set that 
contributed to the enrichment. ES: enrichment score. Core enrichment YES: Genes that contributed 
for the pathway to be significant 	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REACTOME TCA CYCLE AND RESPIRATORY ELECTRON TRANSPORT  
CASE X CONTROL t2 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
UCP3 uncoupling protein 3 (mitochondrial, proton carrier) -0.077779755 No 
PDPR - -0.08084049 No 
ADHFE1 alcohol dehydrogenase, iron containing, 1 -0.100758 No 
PDK4 pyruvate dehydrogenase kinase, isozyme 4 -0.11849339 No 
PDK1 pyruvate dehydrogenase kinase, isozyme 1 -0.13074146 No 
UCP2 uncoupling protein 2 (mitochondrial, proton carrier) -0.19924106 No 
PDK2 pyruvate dehydrogenase kinase, isozyme 2 -0.2427115 No 
LDHB lactate dehydrogenase B -0.27059102 No 
ETFB electron-transfer-flavoprotein, beta polypeptide -0.2748912 No 
NDUFA8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 
19kDa 
-0.27950856 No 
ND1 mitochondrially encoded NADH dehydrogenase 1 -0.3084035 No 
IDH1 isocitrate dehydrogenase 1 (NADP+), soluble -0.3174611 No 
ATP6 mitochondrially encoded ATP synthase 6 -0.32303014 No 
SLC16A1 solute carrier family 16, member 1 (monocarboxylic acid 
transporter 1) 
-0.3297972 No 
NDUFA4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, -0.36693737 No 
Coenzyme A thiolase/enoyl-Coenzyme A hydratase 
(trifunctional protein), beta subunit 
PPARGC1A peroxisome proliferative activated receptor, gamma, 
coactivator 1, alpha 
-0.31814194 Yes 
ACOT4 acyl-CoA thioesterase 4 -0.30559286 Yes 
PTGES3 prostaglandin E synthase 3 (cytosolic) -0.26580158 Yes 
CD74 CD74 molecule, major histocompatibility complex, class II 
invariant chain 
-0.22571754 Yes 
ECH1 enoyl Coenzyme A hydratase 1, peroxisomal -0.19469436 Yes 
ALDH5A1 aldehyde dehydrogenase 5 family, member A1 (succinate-
semialdehyde dehydrogenase) 
-0.16179325 Yes 
FADS2 fatty acid desaturase 2 -0.11499819 Yes 
PTGS1 prostaglandin-endoperoxide synthase 1 (prostaglandin G/H 
synthase and cyclooxygenase) 
-0.069887646 Yes 
OXSM 3-oxoacyl-ACP synthase, mitochondrial -0.028105699 Yes 
FADS1 fatty acid desaturase 1 0.013948627 Yes 
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9kDa 
ATP5F1 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit B1 
-0.37451062 No 
ATP5D ATP synthase, H+ transporting, mitochondrial F1 complex, 
delta subunit 
-0.40883926 No 
IDH2 isocitrate dehydrogenase 2 (NADP+), mitochondrial -0.4318312 No 
SUCLG2 succinate-CoA ligase, GDP-forming, beta subunit -0.42755577 No 
NDUFB10 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 
22kDa 
-0.43041644 No 
NDUFB7 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 
18kDa 
-0.4390531 No 
COX5B cytochrome c oxidase subunit Vb -0.43678913 No 
IDH3B isocitrate dehydrogenase 3 (NAD+) beta -0.44030583 No 
L2HGDH L-2-hydroxyglutarate dehydrogenase -0.4794819 No 
UQCRC1 ubiquinol-cytochrome c reductase core protein I -0.47791737 No 
NDUFA12 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 -0.47513583 No 
NDUFB1 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 1, 
7kDa 
-0.47571597 No 
SUCLG1 succinate-CoA ligase, GDP-forming, alpha subunit -0.47174224 No 
NDUFA2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 
8kDa 
-0.46660233 No 
ND6 mitochondrially encoded NADH dehydrogenase 6 -0.48280084 No 
SDHA succinate dehydrogenase complex, subunit A, flavoprotein 
(Fp) 
-0.48646623 No 
COX4I1 cytochrome c oxidase subunit IV isoform 1 -0.4807532 No 
ETFDH electron-transferring-flavoprotein dehydrogenase -0.48745328 Yes 
COX5A cytochrome c oxidase subunit Va -0.47994524 Yes 
NDUFS5 NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15kDa 
(NADH-coenzyme Q reductase) 
-0.47252077 Yes 
ATP5A1 ATP synthase, H+ transporting, mitochondrial F1 complex, 
alpha subunit 1, cardiac muscle 
-0.4678567 Yes 
NDUFA7 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7, 
14.5kDa 
-0.4625415 Yes 
UQCRC2 ubiquinol-cytochrome c reductase core protein II -0.46068302 Yes 
ATP5C1 ATP synthase, H+ transporting, mitochondrial F1 complex, 
gamma polypeptide 1 
-0.4593392 Yes 
NDUFAB1 NADH dehydrogenase (ubiquinone) 1, alpha/beta 
subcomplex, 1, 8kDa 
-0.45755434 Yes 
BSG basigin (Ok blood group) -0.44950238 Yes 
ND5 mitochondrially encoded NADH dehydrogenase 5 -0.44753554 Yes 
SDHC succinate dehydrogenase complex, subunit C, integral 
membrane protein, 15kDa 
-0.43956238 Yes 
NDUFB2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, -0.43862152 Yes 
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8kDa 
PDK3 pyruvate dehydrogenase kinase, isozyme 3 -0.43044227 Yes 
NDUFB9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9, 
22kDa 
-0.435454 Yes 
NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 
9kDa 
-0.4412764 Yes 
COX3 mitochondrially encoded cytochrome c oxidase III -0.43556845 Yes 
COX6A1 cytochrome c oxidase subunit VIa polypeptide 1 -0.43302214 Yes 
CYC1 cytochrome c-1 -0.4257684 Yes 
SUCLA2 succinate-CoA ligase, ADP-forming, beta subunit -0.41726094 Yes 
D2HGDH D-2-hydroxyglutarate dehydrogenase -0.42121458 Yes 
ACO2 aconitase 2, mitochondrial -0.42224848 Yes 
NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 
16kDa 
-0.42209738 Yes 
COX2 mitochondrially encoded cytochrome c oxidase II -0.42619342 Yes 
NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa 
(NADH-coenzyme Q reductase) 
-0.4242266 Yes 
DLD dihydrolipoamide dehydrogenase -0.42364955 Yes 
NDUFA6 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 
14kDa 
-0.41777354 Yes 
PDHX pyruvate dehydrogenase complex, component X -0.41212803 Yes 
OGDH oxoglutarate (alpha-ketoglutarate) dehydrogenase 
(lipoamide) 
-0.40362877 Yes 
NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa 
(NADH-coenzyme Q reductase) 
-0.39775926 Yes 
NNT nicotinamide nucleotide transhydrogenase -0.39500913 Yes 
DLAT dihydrolipoamide S-acetyltransferase (E2 component of 
pyruvate dehydrogenase complex) 
-0.3890362 Yes 
NDUFS7 NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa 
(NADH-coenzyme Q reductase) 
-0.38227606 Yes 
IDH3G isocitrate dehydrogenase 3 (NAD+) gamma -0.38258222 Yes 
ATP5H ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit d 
-0.37176874 Yes 
PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1 -0.3689542 Yes 
NDUFA10 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 
42kDa 
-0.38033962 Yes 
MDH2 malate dehydrogenase 2, NAD (mitochondrial) -0.37475726 Yes 
IDH3A isocitrate dehydrogenase 3 (NAD+) alpha -0.39041668 Yes 
ATP5J ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit F6 
-0.38110152 Yes 
NDUFV3 NADH dehydrogenase (ubiquinone) flavoprotein 3, 10kDa -0.3685029 Yes 
ATP8 mitochondrially encoded ATP synthase 8 -0.35860977 Yes 
NDUFA1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, -0.3462651 Yes 
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7.5kDa 
COX6B1 cytochrome c oxidase subunit Vib polypeptide 1 (ubiquitous) -0.338455 Yes 
UQCRB ubiquinol-cytochrome c reductase binding protein -0.32693925 Yes 
PDHB pyruvate dehydrogenase (lipoamide) beta -0.31708035 Yes 
DLST dihydrolipoamide S-succinyltransferase (E2 component of 2-
oxo-glutarate complex) 
-0.30652368 Yes 
NDUFS3 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa 
(NADH-coenzyme Q reductase) 
-0.29791242 Yes 
NDUFS2 NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa 
(NADH-coenzyme Q reductase) 
-0.28541273 Yes 
UQCRH ubiquinol-cytochrome c reductase hinge protein -0.27418014 Yes 
UQCRFS1 ubiquinol-cytochrome c reductase, Rieske iron-sulfur 
polypeptide 1 
-0.26170817 Yes 
ATP5I ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit E 
-0.2478872 Yes 
CS citrate synthase -0.23318207 Yes 
NDUFB4 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 
15kDa 
-0.22114788 Yes 
NDUFS6 NADH dehydrogenase (ubiquinone) Fe-S protein 6, 13kDa 
(NADH-coenzyme Q reductase) 
-0.20644939 Yes 
NDUFV2 NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa -0.1948261 Yes 
NDUFC1 NADH dehydrogenase (ubiquinone) 1, subcomplex 
unknown, 1, 6kDa 
-0.18074577 Yes 
FH fumarate hydratase -0.16779904 Yes 
ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, 
beta polypeptide 
-0.15359361 Yes 
PDP2 - -0.14403482 Yes 
SDHB succinate dehydrogenase complex, subunit B, iron sulfur (Ip) -0.14627676 Yes 
NDUFV1 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa -0.1289687 Yes 
ATP5G1 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit C1 (subunit 9) 
-0.11278582 Yes 
CYCS cytochrome c, somatic -0.09721736 Yes 
COX7A2L cytochrome c oxidase subunit VIIa polypeptide 2 like -0.08111649 Yes 
NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 
12kDa 
-0.06670696 Yes 
NDUFS4 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kDa 
(NADH-coenzyme Q reductase) 
-0.048332803 Yes 
ETFA electron-transfer-flavoprotein, alpha polypeptide (glutaric 
aciduria II) 
-0.0320098 Yes 
LDHA lactate dehydrogenase A -0.016022952 Yes 
ATP5J2 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit F2 
0.004851622 Yes 
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KEEG OXIDATIVE PHOSPHORILATION CASE X CONTROL t2 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
PPA2 pyrophosphatase (inorganic) 2 -0.1383572 No 
ATP6V1D ATPase, H+ transporting, lysosomal 34kDa, V1 subunit D -0.15502721 No 
COX10 COX10 homolog, cytochrome c oxidase assembly protein, 
heme A: farnesyltransferase (yeast) 
-0.18437451 No 
ATP6V1A ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A -0.2146047 No 
COX15 COX15 homolog, cytochrome c oxidase assembly protein  -0.2532385 No 
NDUFA8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 
19kDa 
-0.28776148 No 
ATP6V1B2 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit 
B2 
-0.28587264 No 
ND1 mitochondrially encoded NADH dehydrogenase 1 -0.31285247 No 
ATP6 mitochondrially encoded ATP synthase 6 -0.33049637 No 
ATP6V0A1 ATPase, H+ transporting, lysosomal V0 subunit a1 -0.338963 No 
ATP6V1G1 ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1 -0.34955636 No 
TCIRG1 T-cell, immune regulator 1, ATPase, H+ transporting, 
lysosomal V0 subunit A3 
-0.36079842 No 
COX4I2 cytochrome c oxidase subunit IV isoform 2 (lung) -0.3595485 No 
ATP6V0B ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b -0.35486048 No 
NDUFA4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 
9kDa 
-0.3537128 No 
ATP5F1 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit B1 
-0.36062658 No 
ATP5D ATP synthase, H+ transporting, mitochondrial F1 complex, 
delta subunit 
-0.39418468 No 
PPA1 pyrophosphatase (inorganic) 1 -0.39780587 No 
ATP6V1C1 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 -0.40256605 No 
ATP6V0A2 ATPase, H+ transporting, lysosomal V0 subunit a2 -0.41142514 No 
NDUFB10 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 
22kDa 
-0.40730393 No 
NDUFB7 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 
18kDa 
-0.41508955 No 
COX5B cytochrome c oxidase subunit Vb -0.41197765 No 
ATP6V0E2 ATPase, H+ transporting V0 subunit e2 -0.4440703 No 
UQCRC1 ubiquinol-cytochrome c reductase core protein I -0.45747873 No 
NDUFB1 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 1, 
7kDa 
-0.46119997 No 
NDUFA2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 
8kDa 
-0.45813844 No 
ND6 mitochondrially encoded NADH dehydrogenase 6 -0.47325832 Yes 
ATP6V1E1 ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1 -0.47262648 Yes 
	  	  
	  	   128	  
SDHA succinate dehydrogenase complex, subunit A, flavoprotein 
(Fp) 
-0.46717972 Yes 
COX4I1 cytochrome c oxidase subunit IV isoform 1 -0.46037856 Yes 
COX5A cytochrome c oxidase subunit Va -0.46629417 Yes 
NDUFS5 NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15kDa 
(NADH-coenzyme Q reductase) 
-0.45775256 Yes 
ATP5A1 ATP synthase, H+ transporting, mitochondrial F1 complex, 
alpha subunit 1, cardiac muscle 
-0.45195973 Yes 
NDUFA7 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7, 
14.5kDa 
-0.4455115 Yes 
UQCRC2 ubiquinol-cytochrome c reductase core protein II -0.4425063 Yes 
ATP5C1 ATP synthase, H+ transporting, mitochondrial F1 complex, 
gamma polypeptide 1 
-0.4400004 Yes 
NDUFAB1 NADH dehydrogenase (ubiquinone) 1, alpha/beta 
subcomplex, 1, 8kDa 
-0.43704113 Yes 
ND5 mitochondrially encoded NADH dehydrogenase 5 -0.43406275 Yes 
SDHC succinate dehydrogenase complex, subunit C, integral 
membrane protein, 15kDa 
-0.42490643 Yes 
NDUFB2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 
8kDa 
-0.42275935 Yes 
NDUFB9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9, 
22kDa 
-0.42679137 Yes 
NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 
9kDa 
-0.43133307 Yes 
COX3 mitochondrially encoded cytochrome c oxidase III -0.42434645 Yes 
COX6A2 cytochrome c oxidase subunit VIa polypeptide 2 -0.4184304 Yes 
COX6A1 cytochrome c oxidase subunit VIa polypeptide 1 -0.4101815 Yes 
CYC1 cytochrome c-1 -0.40163118 Yes 
ATP6V0E1 ATPase, H+ transporting, lysosomal 9kDa, V0 subunit e1 -0.4023538 Yes 
NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 
16kDa 
-0.41394666 Yes 
ATP5G3 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit C3 (subunit 9) 
-0.40557447 Yes 
COX2 mitochondrially encoded cytochrome c oxidase II -0.40551218 Yes 
NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa 
(NADH-coenzyme Q reductase) 
-0.40210256 Yes 
NDUFA6 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 
14kDa 
-0.40443856 Yes 
NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa 
(NADH-coenzyme Q reductase) 
-0.40392387 Yes 
ATP6V0D1 ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1 -0.4020192 Yes 
NDUFS7 NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa 
(NADH-coenzyme Q reductase) 
-0.39615637 Yes 
ATP5G2 ATP synthase, H+ transporting, mitochondrial F0 complex, -0.39425188 Yes 
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subunit C2 (subunit 9) 
ATP5H ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit d 
-0.3824515 Yes 
ATP6V1H ATPase, H+ transporting, lysosomal 50/57kDa, V1 subunit 
H 
-0.3785939 Yes 
ATP6AP1 ATPase, H+ transporting, lysosomal accessory protein 1 -0.37433064 Yes 
NDUFA10 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 
42kDa 
-0.37419033 Yes 
COX7A1 cytochrome c oxidase subunit VIIa polypeptide 1 (muscle) -0.37512848 Yes 
ATP6V0C ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c -0.37813464 Yes 
ATP5J ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit F6 
-0.36921194 Yes 
NDUFV3 NADH dehydrogenase (ubiquinone) flavoprotein 3, 10kDa -0.35471496 Yes 
ATP8 mitochondrially encoded ATP synthase 8 -0.34290394 Yes 
NDUFA1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 
7.5kDa 
-0.32863364 Yes 
COX6B1 cytochrome c oxidase subunit Vib polypeptide 1 (ubiquitous) -0.31886044 Yes 
UQCRB ubiquinol-cytochrome c reductase binding protein -0.30537233 Yes 
NDUFA4L2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-
like 2 
-0.29027393 Yes 
COX11 COX11 homolog, cytochrome c oxidase assembly protein 
(yeast) 
-0.2863223 Yes 
NDUFS3 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa 
(NADH-coenzyme Q reductase) 
-0.27018216 Yes 
NDUFS2 NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa 
(NADH-coenzyme Q reductase) 
-0.25560707 Yes 
UQCRH ubiquinol-cytochrome c reductase hinge protein -0.24227697 Yes 
UQCRFS1 ubiquinol-cytochrome c reductase, Rieske iron-sulfur 
polypeptide 1 
-0.22769533 Yes 
ATP5I ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit E 
-0.21176222 Yes 
NDUFB4 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 
15kDa 
-0.19768006 Yes 
NDUFS6 NADH dehydrogenase (ubiquinone) Fe-S protein 6, 13kDa 
(NADH-coenzyme Q reductase) 
-0.18084544 Yes 
NDUFV2 NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa -0.1670558 Yes 
NDUFC1 NADH dehydrogenase (ubiquinone) 1, subcomplex 
unknown, 1, 6kDa 
-0.1508006 Yes 
COX7A2 cytochrome c oxidase subunit VIIa polypeptide 2 (liver) -0.13513853 Yes 
ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, 
beta polypeptide 
-0.11933161 Yes 
SDHB succinate dehydrogenase complex, subunit B, iron sulfur (Ip) -0.12545924 Yes 
NDUFV1 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa -0.105614856 Yes 
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ATP5G1 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit C1 (subunit 9) 
-0.086865924 Yes 
COX7A2L cytochrome c oxidase subunit VIIa polypeptide 2 like -0.07075241 Yes 
NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 
12kDa 
-0.053585187 Yes 
NDUFS4 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kDa 
(NADH-coenzyme Q reductase) 
-0.032419592 Yes 
LHPP - -0.012746587 Yes 
ATP5J2 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit F2 
0.004846758 Yes 
 
 
 
 
 
 
 
 
 
 
 
REACTOME RESPIRATORY ELECTRON TRANSPORT CASE X CONTROL t2 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
ETFB electron-transfer-flavoprotein, beta polypeptide -0.2840789 No 
NDUFA8 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 8, 
19kDa 
-0.28658172 No 
ND1 mitochondrially encoded NADH dehydrogenase 1 -0.31288022 No 
NDUFA4 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 
9kDa 
-0.37895304 No 
NDUFB10 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 
22kDa 
-0.4588479 No 
NDUFB7 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 7, 
18kDa 
-0.46307394 No 
COX5B cytochrome c oxidase subunit Vb -0.45640588 No 
UQCRC1 ubiquinol-cytochrome c reductase core protein I -0.5051085 Yes 
NDUFA12 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 12 -0.49720556 Yes 
NDUFB1 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 1, 
7kDa 
-0.49259153 Yes 
NDUFA2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, -0.48529938 Yes 
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8kDa 
ND6 mitochondrially encoded NADH dehydrogenase 6 -0.49591264 Yes 
SDHA succinate dehydrogenase complex, subunit A, flavoprotein 
(Fp) 
-0.49390626 Yes 
COX4I1 cytochrome c oxidase subunit IV isoform 1 -0.48253882 Yes 
ETFDH electron-transferring-flavoprotein dehydrogenase -0.48338273 Yes 
COX5A cytochrome c oxidase subunit Va -0.4700721 Yes 
NDUFS5 NADH dehydrogenase (ubiquinone) Fe-S protein 5, 15kDa 
(NADH-coenzyme Q reductase) 
-0.45684117 Yes 
NDUFA7 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 7, 
14.5kDa 
-0.44888905 Yes 
UQCRC2 ubiquinol-cytochrome c reductase core protein II -0.44107547 Yes 
NDUFAB1 NADH dehydrogenase (ubiquinone) 1, alpha/beta 
subcomplex, 1, 8kDa 
-0.4399557 Yes 
ND5 mitochondrially encoded NADH dehydrogenase 5 -0.4319962 Yes 
SDHC succinate dehydrogenase complex, subunit C, integral 
membrane protein, 15kDa 
-0.41787323 Yes 
NDUFB2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 
8kDa 
-0.4106692 Yes 
NDUFB9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9, 
22kDa 
-0.40949014 Yes 
NDUFA3 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 
9kDa 
-0.40866888 Yes 
COX3 mitochondrially encoded cytochrome c oxidase III -0.39631727 Yes 
COX6A1 cytochrome c oxidase subunit VIa polypeptide 1 -0.38703766 Yes 
CYC1 cytochrome c-1 -0.3730457 Yes 
NDUFB5 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 
16kDa 
-0.3901185 Yes 
COX2 mitochondrially encoded cytochrome c oxidase II -0.38681197 Yes 
NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa 
(NADH-coenzyme Q reductase) 
-0.37735277 Yes 
NDUFA6 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 
14kDa 
-0.37344348 Yes 
NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa 
(NADH-coenzyme Q reductase) 
-0.36653602 Yes 
NDUFS7 NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa 
(NADH-coenzyme Q reductase) 
-0.36453146 Yes 
NDUFA10 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 
10, 42kDa 
-0.38742667 Yes 
NDUFV3 NADH dehydrogenase (ubiquinone) flavoprotein 3, 10kDa -0.40431452 Yes 
NDUFA1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 
7.5kDa 
-0.3854751 Yes 
COX6B1 cytochrome c oxidase subunit Vib polypeptide 1 
(ubiquitous) 
-0.3674662 Yes 
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UQCRB ubiquinol-cytochrome c reductase binding protein -0.3457001 Yes 
NDUFS3 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa 
(NADH-coenzyme Q reductase) 
-0.33408844 Yes 
NDUFS2 NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa 
(NADH-coenzyme Q reductase) 
-0.31080255 Yes 
UQCRH ubiquinol-cytochrome c reductase hinge protein -0.2886703 Yes 
UQCRFS1 ubiquinol-cytochrome c reductase, Rieske iron-sulfur 
polypeptide 1 
-0.2652342 Yes 
NDUFB4 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 
15kDa 
-0.24315336 Yes 
NDUFS6 NADH dehydrogenase (ubiquinone) Fe-S protein 6, 13kDa 
(NADH-coenzyme Q reductase) 
-0.21735151 Yes 
NDUFV2 NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa -0.19447073 Yes 
NDUFC1 NADH dehydrogenase (ubiquinone) 1, subcomplex 
unknown, 1, 6kDa 
-0.16908643 Yes 
SDHB succinate dehydrogenase complex, subunit B, iron sulfur 
(Ip) 
-0.16829608 Yes 
NDUFV1 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa -0.13780451 Yes 
CYCS cytochrome c, somatic -0.11045275 Yes 
COX7A2L cytochrome c oxidase subunit VIIa polypeptide 2 like -0.08054676 Yes 
NDUFB3 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 
12kDa 
-0.051807072 Yes 
NDUFS4 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kDa 
(NADH-coenzyme Q reductase) 
-0.018924028 Yes 
ETFA electron-transfer-flavoprotein, alpha polypeptide (glutaric 
aciduria II) 
0.012561537 Yes 
 
 
MITOCHONDRIAL RESPIRATORY CHAIN  CASE X CONTROL t2 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
COX15 COX15 homolog, cytochrome c oxidase assembly protein 
(yeast) 
-0.2475849 No 
ND1 mitochondrially encoded NADH dehydrogenase 1 -0.30186266 No 
OXA1L oxidase (cytochrome c) assembly 1-like -0.32289225 No 
UQCRC1 ubiquinol-cytochrome c reductase core protein I -0.4941741 Yes 
NDUFA2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 
8kDa 
-0.47838348 Yes 
SDHA succinate dehydrogenase complex, subunit A, flavoprotein 
(Fp) 
-0.47811702 Yes 
SURF1 surfeit 1 -0.46947172 Yes 
NDUFAB1 NADH dehydrogenase (ubiquinone) 1, alpha/beta 
subcomplex, 1, 8kDa 
-0.44593906 Yes 
BCS1L BCS1-like (yeast) -0.48089308 Yes 
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NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa 
(NADH-coenzyme Q reductase) 
-0.46584612 Yes 
NDUFA6 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 
14kDa 
-0.4322777 Yes 
NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa 
(NADH-coenzyme Q reductase) 
-0.39497527 Yes 
NNT nicotinamide nucleotide transhydrogenase -0.35341427 Yes 
NDUFS7 NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa 
(NADH-coenzyme Q reductase) 
-0.31198752 Yes 
NDUFA1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 
7.5kDa 
-0.33827668 Yes 
UQCRB ubiquinol-cytochrome c reductase binding protein -0.2828647 Yes 
NDUFS3 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa 
(NADH-coenzyme Q reductase) 
-0.22991017 Yes 
NDUFS2 NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa 
(NADH-coenzyme Q reductase) 
-0.16503948 Yes 
UQCRH ubiquinol-cytochrome c reductase hinge protein -0.100903094 Yes 
NDUFV1 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa -0.06063692 Yes 
NDUFS4 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kDa 
(NADH-coenzyme Q reductase) 
0.016554177 Yes 
 
MITOCHONDRIAL MEMBRANE  CASE X CONTROL t2 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
VDAC3 voltage-dependent anion channel 3 0.023018867 No 
BNIP3 BCL2/adenovirus E1B 19kDa interacting protein 3 -0.007206425 No 
UCP3 uncoupling protein 3 (mitochondrial, proton carrier) -0.044556625 No 
MCL1 myeloid cell leukemia sequence 1 (BCL2-related) -0.07062096 No 
FIS1 fission 1 (mitochondrial outer membrane) homolog (S. 
cerevisiae) 
-0.14470601 No 
COX18 COX18 cytochrome c oxidase assembly homolog (S. 
cerevisiae) 
-0.18328793 No 
PHB2 prohibitin 2 -0.21242206 No 
COX15 COX15 homolog, cytochrome c oxidase assembly protein 
(yeast) 
-0.21088022 No 
PPOX protoporphyrinogen oxidase -0.26368093 No 
BCL2 B-cell CLL/lymphoma 2 -0.2684764 No 
ND1 mitochondrially encoded NADH dehydrogenase 1 -0.26528937 No 
TIMM13 translocase of inner mitochondrial membrane 13 homolog 
(yeast) 
-0.2802119 No 
OXA1L oxidase (cytochrome c) assembly 1-like -0.2924411 No 
RHOT2 ras homolog gene family, member T2 -0.31599358 No 
TIMM10 translocase of inner mitochondrial membrane 10 homolog 
(yeast) 
-0.3386818 No 
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ATP5D ATP synthase, H+ transporting, mitochondrial F1 complex, 
delta subunit 
-0.3562254 No 
HCCS holocytochrome c synthase (cytochrome c heme-lyase) -0.36811918 No 
PMPCA peptidase (mitochondrial processing) alpha -0.3885494 No 
TIMM50 translocase of inner mitochondrial membrane 50 homolog (S. 
cerevisiae) 
-0.3837079 No 
MFN2 mitofusin 2 -0.38769987 No 
TIMM8B translocase of inner mitochondrial membrane 8 homolog B 
(yeast) 
-0.39885062 No 
MSTO1 misato homolog 1 (Drosophila) -0.40797 No 
UQCRC1 ubiquinol-cytochrome c reductase core protein I -0.4052011 No 
ABCB7 ATP-binding cassette, sub-family B (MDR/TAP), member 7 -0.39853916 No 
NDUFA2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 
8kDa 
-0.39990288 No 
TIMM9 translocase of inner mitochondrial membrane 9 homolog 
(yeast) 
-0.41715932 Yes 
SDHA succinate dehydrogenase complex, subunit A, flavoprotein 
(Fp) 
-0.4108912 Yes 
MTX2 metaxin 2 -0.40036273 Yes 
ATP5A1 ATP synthase, H+ transporting, mitochondrial F1 complex, 
alpha subunit 1, cardiac muscle 
-0.40689746 Yes 
SLC25A11 solute carrier family 25 (mitochondrial carrier; oxoglutarate 
carrier), member 11 
-0.39935133 Yes 
SURF1 surfeit 1 -0.38947535 Yes 
TIMM17B translocase of inner mitochondrial membrane 17 homolog B 
(yeast) 
-0.37909773 Yes 
ATP5C1 ATP synthase, H+ transporting, mitochondrial F1 complex, 
gamma polypeptide 1 
-0.37184763 Yes 
NDUFAB1 NADH dehydrogenase (ubiquinone) 1, alpha/beta 
subcomplex, 1, 8kDa 
-0.36533776 Yes 
SLC25A3 solute carrier family 25 (mitochondrial carrier; phosphate 
carrier), member 3 
-0.3541259 Yes 
OPA1 optic atrophy 1 (autosomal dominant) -0.37710023 Yes 
SLC25A1 solute carrier family 25 (mitochondrial carrier; citrate 
transporter), member 1 
-0.36799163 Yes 
VDAC1 voltage-dependent anion channel 1 -0.36720273 Yes 
SLC25A15 solute carrier family 25 (mitochondrial carrier; ornithine 
transporter) member 15 
-0.36253235 Yes 
BCS1L BCS1-like (yeast) -0.35946345 Yes 
ATP5G3 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit C3 (subunit 9) 
-0.35621962 Yes 
NDUFS1 NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa 
(NADH-coenzyme Q reductase) 
-0.35970587 Yes 
VDAC2 voltage-dependent anion channel 2 -0.3515104 Yes 
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NDUFA6 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 6, 
14kDa 
-0.34142992 Yes 
OGDH oxoglutarate (alpha-ketoglutarate) dehydrogenase 
(lipoamide) 
-0.33172283 Yes 
NDUFS8 NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa 
(NADH-coenzyme Q reductase) 
-0.31973976 Yes 
NNT nicotinamide nucleotide transhydrogenase -0.3107831 Yes 
CASP7 caspase 7, apoptosis-related cysteine peptidase -0.29399756 Yes 
NDUFS7 NADH dehydrogenase (ubiquinone) Fe-S protein 7, 20kDa 
(NADH-coenzyme Q reductase) 
-0.28566563 Yes 
ATP5G2 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit C2 (subunit 9) 
-0.27889383 Yes 
RHOT1 ras homolog gene family, member T1 -0.28263167 Yes 
IMMT inner membrane protein, mitochondrial (mitofilin) -0.28474042 Yes 
TOMM22 translocase of outer mitochondrial membrane 22 homolog 
(yeast) 
-0.28202373 Yes 
ATP5J ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit F6 
-0.27192336 Yes 
NDUFA1 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 
7.5kDa 
-0.25604352 Yes 
MPV17 MpV17 mitochondrial inner membrane protein -0.23638073 Yes 
UQCRB ubiquinol-cytochrome c reductase binding protein -0.22114263 Yes 
NDUFS3 NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa 
(NADH-coenzyme Q reductase) 
-0.211956 Yes 
NDUFS2 NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa 
(NADH-coenzyme Q reductase) 
-0.19109695 Yes 
UQCRH ubiquinol-cytochrome c reductase hinge protein -0.17141747 Yes 
ATP5B ATP synthase, H+ transporting, mitochondrial F1 complex, 
beta polypeptide 
-0.16190857 Yes 
TIMM17A translocase of inner mitochondrial membrane 17 homolog A 
(yeast) 
-0.15715274 Yes 
NDUFV1 NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa -0.13332075 Yes 
ATP5G1 ATP synthase, H+ transporting, mitochondrial F0 complex, 
subunit C1 (subunit 9) 
-0.10680163 Yes 
PHB prohibitin -0.07910502 Yes 
NDUFS4 NADH dehydrogenase (ubiquinone) Fe-S protein 4, 18kDa 
(NADH-coenzyme Q reductase) 
-0.058720794 Yes 
RAB11FIP5 RAB11 family interacting protein 5 (class I) -0.034326315 Yes 
TOMM34 translocase of outer mitochondrial membrane 34 0.003430086 Yes 
 
KEEG GLYCOLYSIS GLUCONEOGENESIS  CASE X CONTROL t1 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
ACSS1 acyl-CoA synthetase short-chain family member 1 0.07301347 Yes 
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PGK1 phosphoglycerate kinase 1 0.14413437 Yes 
PGAM2 phosphoglycerate mutase 2 (muscle) 0.21352457 Yes 
PGM1 phosphoglucomutase 1 0.2759036 Yes 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 0.32415113 Yes 
LDHA lactate dehydrogenase A 0.3691173 Yes 
GPI glucose phosphate isomerase 0.4181434 Yes 
ENO3 enolase 3 (beta, muscle) 0.4571662 Yes 
BPGM 2,3-bisphosphoglycerate mutase 0.49810046 Yes 
TPI1 triosephosphate isomerase 1 0.5033853 Yes 
GALM galactose mutarotase (aldose 1-epimerase) 0.5333864 Yes 
PFKM phosphofructokinase, muscle 0.5564322 Yes 
PGAM4 phosphoglycerate mutase family member 4 0.5759253 Yes 
FBP2 fructose-1,6-bisphosphatase 2 0.5952478 Yes 
LDHB lactate dehydrogenase B 0.582899 Yes 
ENO1 enolase 1, (alpha) 0.602715 Yes 
ALDOA aldolase A, fructose-bisphosphate 0.62129945 Yes 
ALDOC aldolase C, fructose-bisphosphate 0.62718666 Yes 
ACSS2 acyl-CoA synthetase short-chain family member 2 0.64731264 Yes 
AKR1A1 aldo-keto reductase family 1, member A1 (aldehyde 
reductase) 
0.59136206 No 
PCK2 phosphoenolpyruvate carboxykinase 2 (mitochondrial) 0.60139984 No 
HK1 hexokinase 1 0.4881909 No 
DLAT dihydrolipoamide S-acetyltransferase (E2 component of 
pyruvate dehydrogenase complex) 
0.4593283 No 
ALDH3A2 aldehyde dehydrogenase 3 family, member A2 0.46381518 No 
PDHA1 pyruvate dehydrogenase (lipoamide) alpha 1 0.47123164 No 
PFKP phosphofructokinase, platelet 0.43549097 No 
PFKL phosphofructokinase, liver 0.41168368 No 
PGM2 phosphoglucomutase 2 0.4133238 No 
ALDH7A1 aldehyde dehydrogenase 7 family, member A1 0.40297154 No 
PDHB pyruvate dehydrogenase (lipoamide) beta 0.3331222 No 
PKLR pyruvate kinase, liver and RBC 0.32172167 No 
DLD dihydrolipoamide dehydrogenase 0.28562146 No 
HK3 hexokinase 3 (white cell) 0.23301776 No 
ALDH9A1 aldehyde dehydrogenase 9 family, member A1 0.23804194 No 
ALDH1A3 aldehyde dehydrogenase 1 family, member A3 0.1783741 No 
 
 
REACTOME GLYCOLYSIS  CASE X CONTROL t1 
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GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
PGK1 phosphoglycerate kinase 1 0.10073286 Yes 
PGAM2 phosphoglycerate mutase 2 (muscle) 0.2043479 Yes 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 0.27660838 Yes 
GPI glucose phosphate isomerase 0.34129986 Yes 
ENO3 enolase 3 (beta, muscle) 0.40402585 Yes 
PFKFB4 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 0.46630123 Yes 
TPI1 triosephosphate isomerase 1 0.4921814 Yes 
PFKM phosphofructokinase, muscle 0.52397835 Yes 
PFKFB1 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 0.50159955 Yes 
ENO1 enolase 1, (alpha) 0.5306825 Yes 
ALDOA aldolase A, fructose-bisphosphate 0.5624456 Yes 
ALDOC aldolase C, fructose-bisphosphate 0.58073455 Yes 
PFKFB2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 0.49269098 No 
PPP2CA protein phosphatase 2 (formerly 2A), catalytic subunit, alpha 
isoform 
0.42801282 No 
PPP2R1A protein phosphatase 2 (formerly 2A), regulatory subunit A 
(PR 65), alpha isoform 
0.41373107 No 
PPP2R5D protein phosphatase 2, regulatory subunit B (B56), delta 
isoform 
0.41594967 No 
PFKP phosphofructokinase, platelet 0.36459467 No 
PFKL phosphofructokinase, liver 0.34349662 No 
PKLR pyruvate kinase, liver and RBC 0.24259447 No 
PPP2R1B protein phosphatase 2 (formerly 2A), regulatory subunit A 
(PR 65), beta isoform 
0.0180843 No 
PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 0.010247904 No 
 
MOOTHA GLYCOGEN METABOLISM   CASE X CONTROL t1 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
GYS1 glycogen synthase 1 (muscle) 0.076006 Yes 
PPP1R3D protein phosphatase 1, regulatory subunit 3D 0.035474524 Yes 
PYGM phosphorylase, glycogen; muscle (McArdle syndrome, 
glycogen storage disease type V) 
0.11755047 Yes 
AGL amylo-1, 6-glucosidase, 4-alpha-glucanotransferase 
(glycogen debranching enzyme, glycogen storage disease 
type III) 
0.18208763 Yes 
GSK3B glycogen synthase kinase 3 beta 0.25337955 Yes 
SLC37A4 solute carrier family 37 (glycerol-6-phosphate transporter), 
member 4 
0.32485268 Yes 
PPP1CA protein phosphatase 1, catalytic subunit, alpha isoform 0.37860835 Yes 
PPP1R2 protein phosphatase 1, regulatory (inhibitor) subunit 2 0.42269337 Yes 
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PPP1R3A protein phosphatase 1, regulatory (inhibitor) subunit 3A 
(glycogen and sarcoplasmic reticulum binding subunit, 
skeletal muscle) 
0.4889237 Yes 
PPP1CC protein phosphatase 1, catalytic subunit, gamma isoform 0.36544198 No 
GBE1 glucan (1,4-alpha-), branching enzyme 1 (glycogen 
branching enzyme, Andersen disease, glycogen storage 
disease type IV) 
0.36072287 No 
GAA glucosidase, alpha; acid (Pompe disease, glycogen storage 
disease type II) 
0.3116328 No 
PPP1CB protein phosphatase 1, catalytic subunit, beta isoform 0.2176989 No 
GYG1 glycogenin 1 0.22291675 No 
PYGL phosphorylase, glycogen; liver (Hers disease, glycogen 
storage disease type VI) 
0.052709203 No 
PHKA2 phosphorylase kinase, alpha 2 (liver) 0.013395293 No 
 
 
 
MOOTHA GLYCOGEN METABOLISM CASE t1 X CASE t2 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
PPP1R3D protein phosphatase 1, regulatory subunit 3D 0.16643764 Yes 
GYS1 glycogen synthase 1 (muscle) 0.27559268 Yes 
PPP1CB protein phosphatase 1, catalytic subunit, beta isoform 0.31016192 Yes 
PPP1R3A protein phosphatase 1, regulatory (inhibitor) subunit 3A 
(glycogen and sarcoplasmic reticulum binding subunit, 
skeletal muscle) 
0.40646014 Yes 
AGL amylo-1, 6-glucosidase, 4-alpha-glucanotransferase 
(glycogen debranching enzyme, glycogen storage disease 
type III) 
0.47425106 Yes 
PYGM phosphorylase, glycogen; muscle (McArdle syndrome, 
glycogen storage disease type V) 
0.54834193 Yes 
PPP1R2 protein phosphatase 1, regulatory (inhibitor) subunit 2 0.6143548 Yes 
PPP1CA protein phosphatase 1, catalytic subunit, alpha isoform 0.54543614 No 
GAA glucosidase, alpha; acid (Pompe disease, glycogen storage 
disease type II) 
0.59190416 No 
PHKA2 phosphorylase kinase, alpha 2 (liver) 0.25628397 No 
PPP1CC protein phosphatase 1, catalytic subunit, gamma isoform 0.19566712 No 
GSK3B glycogen synthase kinase 3 beta 0.19816622 No 
SLC37A4 solute carrier family 37 (glycerol-6-phosphate transporter), 
member 4 
0.19769964 No 
GYG1 glycogenin 1 0.1696309 No 
PYGL phosphorylase, glycogen; liver (Hers disease, glycogen 
storage disease type VI) 
0.052225552 No 
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GBE1 glucan (1,4-alpha-), branching enzyme 1 (glycogen 
branching enzyme, Andersen disease, glycogen storage 
disease type IV) 
0.03790926 No 
 
 
REGULATION OF CYTOSKELETON ORGANIZATION AND BIOGENESIS  CASE X CONTROL t1 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
ARHGEF2 rho/rac guanine nucleotide exchange factor (GEF) 2 0.03316236 Yes 
NEXN nexilin (F actin binding protein) 0.09743831 Yes 
TSC1 tuberous sclerosis 1 0.1337783 Yes 
MID1IP1 MID1 interacting protein 1 (gastrulation specific G12 
homolog (zebrafish)) 
0.15742613 Yes 
LATS1 LATS, large tumor suppressor, homolog 1 (Drosophila) 0.21806374 Yes 
CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 0.26494676 Yes 
ARHGEF10L Rho guanine nucleotide exchange factor (GEF) 10-like 0.2945469 Yes 
APC adenomatosis polyposis coli 0.34008536 Yes 
LIMA1 LIM domain and actin binding 1 0.38118127 Yes 
KATNB1 katanin p80 (WD repeat containing) subunit B 1 0.3836476 Yes 
GSN gelsolin (amyloidosis, Finnish type) 0.40263125 Yes 
CLASP1 cytoplasmic linker associated protein 1 0.41141662 Yes 
MAPRE1 microtubule-associated protein, RP/EB family, member 1 0.4370639 Yes 
CAPG capping protein (actin filament), gelsolin-like 0.43520662 No 
CLASP2 cytoplasmic linker associated protein 2 0.41874808 No 
NF2 neurofibromin 2 (bilateral acoustic neuroma) 0.37957373 No 
ARF6 ADP-ribosylation factor 6 0.36749858 No 
RASA1 RAS p21 protein activator (GTPase activating protein) 1 0.36380446 No 
NEBL nebulette 0.37078935 No 
MAPT microtubule-associated protein tau 0.3084394 No 
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived 
factor 1) 
0.3155228 No 
CEP250 centrosomal protein 250kDa 0.29234973 No 
NCK1 NCK adaptor protein 1 0.17506157 No 
NCK2 NCK adaptor protein 2 0.07128077 No 
SORBS3 sorbin and SH3 domain containing 3 0.07044592 No 
 
 
NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION AND BIOGENESIS   
CASE X CONTROL t1 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
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ARHGEF2 rho/rac guanine nucleotide exchange factor (GEF) 2 0.034818135 Yes 
RTN4 reticulon 4 0.085308164 Yes 
PACSIN3 protein kinase C and casein kinase substrate in neurons 3 0.15222615 Yes 
TERF2IP telomeric repeat binding factor 2, interacting protein 0.19961797 Yes 
MID1IP1 MID1 interacting protein 1 (gastrulation specific G12 
homolog (zebrafish)) 
0.23437274 Yes 
RAC1 ras-related C3 botulinum toxin substrate 1 (rho family, 
small GTP binding protein Rac1) 
0.27261388 Yes 
APC adenomatosis polyposis coli 0.2997492 Yes 
LIMA1 LIM domain and actin binding 1 0.3417722 Yes 
KATNB1 katanin p80 (WD repeat containing) subunit B 1 0.34504876 Yes 
GSN gelsolin (amyloidosis, Finnish type) 0.3647888 Yes 
SET SET translocation (myeloid leukemia-associated) 0.40582877 Yes 
CLASP1 cytoplasmic linker associated protein 1 0.41731393 Yes 
MAPRE1 microtubule-associated protein, RP/EB family, member 1 0.44361857 Yes 
THY1 Thy-1 cell surface antigen 0.44530573 Yes 
CAPG capping protein (actin filament), gelsolin-like 0.47610074 Yes 
TERF2 telomeric repeat binding factor 2 0.45130882 No 
HMGB1 high-mobility group box 1 0.46613076 No 
PAIP2 poly(A) binding protein interacting protein 2 0.43860796 No 
ARF6 ADP-ribosylation factor 6 0.4339451 No 
YWHAH tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 
activation protein, eta polypeptide 
0.41088012 No 
ERCC1 excision repair cross-complementing rodent repair 
deficiency, complementation group 1 (includes overlapping 
antisense sequence) 
0.40767527 No 
CDC42 cell division cycle 42 (GTP binding protein, 25kDa) 0.34322494 No 
ERCC4 excision repair cross-complementing rodent repair 
deficiency, complementation group 4 
0.24674492 No 
EIF2AK3 eukaryotic translation initiation factor 2-alpha kinase 3 0.10881366 No 
 
ACTIN CYTOSKELETON ORGANIZATION AND BIOGENESIS   
CASE X CONTROL t1 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
PDPK1 3-phosphoinositide dependent protein kinase-1 0.033945695 Yes 
AMOT angiomotin 0.070539415 Yes 
ABL1 v-abl Abelson murine leukemia viral oncogene homolog 1 0.09357531 Yes 
NUAK2 NUAK family, SNF1-like kinase, 2 0.11775713 Yes 
LIMK1 LIM domain kinase 1 0.13267873 Yes 
DBN1 drebrin 1 0.14638913 Yes 
ARHGEF2 rho/rac guanine nucleotide exchange factor (GEF) 2 0.16538118 Yes 
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MRAS muscle RAS oncogene homolog 0.1667544 Yes 
SORBS1 sorbin and SH3 domain containing 1 0.18894957 Yes 
SHROOM1 shroom family member 1 0.2004331 Yes 
ARPC4 actin related protein 2/3 complex, subunit 4, 20kDa 0.21009779 Yes 
FGD1 FYVE, RhoGEF and PH domain containing 1 (faciogenital 
dysplasia) 
0.22905678 Yes 
TSC1 tuberous sclerosis 1 0.23837093 Yes 
SSH1 slingshot homolog 1 (Drosophila) 0.2554579 Yes 
MYH11 myosin, heavy chain 11, smooth muscle 0.2701921 Yes 
DYNLL1 dynein, light chain, LC8-type 1 0.28441378 Yes 
DSTN destrin (actin depolymerizing factor) 0.29534206 Yes 
FLNA filamin A, alpha (actin binding protein 280) 0.3055571 Yes 
KPTN kaptin (actin binding protein) 0.3233233 Yes 
LATS1 LATS, large tumor suppressor, homolog 1 (Drosophila) 0.32650152 Yes 
CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 0.3297135 Yes 
RAC1 ras-related C3 botulinum toxin substrate 1 (rho family, 
small GTP binding protein Rac1) 
0.33929306 Yes 
WASL Wiskott-Aldrich syndrome-like 0.3385046 Yes 
ARHGEF10L Rho guanine nucleotide exchange factor (GEF) 10-like 0.35050374 Yes 
RAC3 ras-related C3 botulinum toxin substrate 3 (rho family, 
small GTP binding protein Rac3) 
0.3553531 Yes 
DLG1 discs, large homolog 1 (Drosophila) 0.3696003 Yes 
MTSS1 metastasis suppressor 1 0.37901616 Yes 
LIMA1 LIM domain and actin binding 1 0.38922855 Yes 
CFL1 cofilin 1 (non-muscle) 0.39229783 Yes 
ARPC1A actin related protein 2/3 complex, subunit 1A, 41kDa 0.3871715 Yes 
DST dystonin 0.38670564 Yes 
FGD2 FYVE, RhoGEF and PH domain containing 2 0.38633513 Yes 
ROCK1 Rho-associated, coiled-coil containing protein kinase 1 0.39300364 Yes 
GSN gelsolin (amyloidosis, Finnish type) 0.39766422 Yes 
RICTOR - 0.40572113 Yes 
MYOZ1 myozenin 1 0.40213743 No 
NF1 neurofibromin 1 (neurofibromatosis, von Recklinghausen 
disease, Watson disease) 
0.37924445 No 
CRK v-crk sarcoma virus CT10 oncogene homolog (avian) 0.37131223 No 
CAPG capping protein (actin filament), gelsolin-like 0.37228256 No 
WASF3 WAS protein family, member 3 0.37646213 No 
MYH9 myosin, heavy chain 9, non-muscle 0.36927468 No 
TAOK2 TAO kinase 2 0.37040472 No 
ACTA1 actin, alpha 1, skeletal muscle 0.3579654 No 
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ARHGDIB Rho GDP dissociation inhibitor (GDI) beta 0.36089736 No 
SSH2 slingshot homolog 2 (Drosophila) 0.3512532 No 
ARHGEF17 Rho guanine nucleotide exchange factor (GEF) 17 0.34981555 No 
ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 0.33907065 No 
NF2 neurofibromin 2 (bilateral acoustic neuroma) 0.33328462 No 
WASF2 WAS protein family, member 2 0.33233544 No 
RND3 Rho family GTPase 3 0.33210284 No 
ARF6 ADP-ribosylation factor 6 0.3194002 No 
FGD5 FYVE, RhoGEF and PH domain containing 5 0.30799395 No 
BCAR1 breast cancer anti-estrogen resistance 1 0.312076 No 
RASA1 RAS p21 protein activator (GTPase activating protein) 1 0.3131686 No 
TTN titin 0.30946496 No 
NEBL nebulette 0.31350935 No 
LLGL1 lethal giant larvae homolog 1 (Drosophila) 0.30931765 No 
WIPF1 WAS/WASL interacting protein family, member 1 0.26001358 No 
CDC42BPG CDC42 binding protein kinase gamma (DMPK-like) 0.25807148 No 
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived 
factor 1) 
0.25365242 No 
CDC42 cell division cycle 42 (GTP binding protein, 25kDa) 0.23018591 No 
CDC42BPA CDC42 binding protein kinase alpha (DMPK-like) 0.1892067 No 
DOCK2 dedicator of cytokinesis 2 0.18374656 No 
FLNB filamin B, beta (actin binding protein 278) 0.17661224 No 
CDC42BPB CDC42 binding protein kinase beta (DMPK-like) 0.17109722 No 
PREX1 - 0.16672099 No 
ARPC5 actin related protein 2/3 complex, subunit 5, 16kDa 0.15549023 No 
RHOJ ras homolog gene family, member J 0.11759609 No 
NCK1 NCK adaptor protein 1 0.107007734 No 
FGD4 FYVE, RhoGEF and PH domain containing 4 0.09491257 No 
PACSIN2 protein kinase C and casein kinase substrate in neurons 2 0.09496649 No 
ARFIP2 ADP-ribosylation factor interacting protein 2 (arfaptin 2) 0.035752892 No 
FSCN1 fascin homolog 1, actin-bundling protein 
(Strongylocentrotus purpuratus) 
-0.002878757 No 
RHOF ras homolog gene family, member F (in filopodia) 0.005722532 No 
EVL Enah/Vasp-like 0.011573711 No 
NCK2 NCK adaptor protein 2 0.018718315 No 
TESK2 testis-specific kinase 2 0.004319156 No 
TNXB tenascin XB 0.009022218 No 
SORBS3 sorbin and SH3 domain containing 3 0.00532494 No 
ELMO1 engulfment and cell motility 1 0.01163458 No 
RND1 Rho family GTPase 1 0.025040116 No 
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PRKG1 protein kinase, cGMP-dependent, type I 0.017584505 No 
FGD6 FYVE, RhoGEF and PH domain containing 6 0.026243845 No 
 
 
CYTOSKELETON ORGANIZATION AND BIOGENESIS   
CASE X CONTROL t1 
GENE  GENE_TITLE RUNNING ES CORE ENRICHMENT 
TPPP - 0.03288339 Yes 
PDPK1 3-phosphoinositide dependent protein kinase-1 0.050044857 Yes 
AMOT angiomotin 0.070103094 Yes 
ABL1 v-abl Abelson murine leukemia viral oncogene homolog 1 0.07896637 Yes 
NUAK2 NUAK family, SNF1-like kinase, 2 0.0899258 Yes 
LIMK1 LIM domain kinase 1 0.09289135 Yes 
PAK1 p21/Cdc42/Rac1-activated kinase 1 (STE20 homolog, yeast) 0.10423227 Yes 
DBN1 drebrin 1 0.11140865 Yes 
TUBGCP2 tubulin, gamma complex associated protein 2 0.124831244 Yes 
ARHGEF2 rho/rac guanine nucleotide exchange factor (GEF) 2 0.13473904 Yes 
PCLO piccolo (presynaptic cytomatrix protein) 0.13753198 Yes 
NEXN nexilin (F actin binding protein) 0.1420253 Yes 
MRAS muscle RAS oncogene homolog 0.1535937 Yes 
SORBS1 sorbin and SH3 domain containing 1 0.16619688 Yes 
MYL6B myosin, light chain 6B, alkali, smooth muscle and non-
muscle 
0.17731306 Yes 
SHROOM1 shroom family member 1 0.18157506 Yes 
KIF5B kinesin family member 5B 0.19229221 Yes 
ARPC4 actin related protein 2/3 complex, subunit 4, 20kDa 0.19494826 Yes 
FGD1 FYVE, RhoGEF and PH domain containing 1 (faciogenital 
dysplasia) 
0.20519032 Yes 
TSC1 tuberous sclerosis 1 0.20608422 Yes 
SSH1 slingshot homolog 1 (Drosophila) 0.21490462 Yes 
YKT6 YKT6 v-SNARE homolog (S. cerevisiae) 0.2250897 Yes 
MYH11 myosin, heavy chain 11, smooth muscle 0.23283455 Yes 
MYL6 myosin, light chain 6, alkali, smooth muscle and non-muscle 0.24193592 Yes 
5-Sep septin 5 0.25157663 Yes 
DYNLL1 dynein, light chain, LC8-type 1 0.26125437 Yes 
DSTN destrin (actin depolymerizing factor) 0.26436415 Yes 
FLNA filamin A, alpha (actin binding protein 280) 0.2669862 Yes 
KPTN kaptin (actin binding protein) 0.27721795 Yes 
PAFAH1B1 platelet-activating factor acetylhydrolase, isoform Ib, alpha 
subunit 45kDa 
0.2815223 Yes 
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MID1IP1 MID1 interacting protein 1 (gastrulation specific G12 
homolog (zebrafish)) 
0.2853397 Yes 
LATS1 LATS, large tumor suppressor, homolog 1 (Drosophila) 0.29335856 Yes 
HOOK3 hook homolog 3 (Drosophila) 0.30259475 Yes 
CDC42EP2 CDC42 effector protein (Rho GTPase binding) 2 0.29950082 Yes 
APOE apolipoprotein E 0.30807284 Yes 
PLD2 phospholipase D2 0.31297514 Yes 
RAC1 ras-related C3 botulinum toxin substrate 1 (rho family, small 
GTP binding protein Rac1) 
0.32121584 Yes 
WASL Wiskott-Aldrich syndrome-like 0.3138553 Yes 
TMED10 transmembrane emp24-like trafficking protein 10 (yeast) 0.32225296 Yes 
ARHGEF10L Rho guanine nucleotide exchange factor (GEF) 10-like 0.32836238 Yes 
APC adenomatosis polyposis coli 0.32838488 Yes 
RAC3 ras-related C3 botulinum toxin substrate 3 (rho family, small 
GTP binding protein Rac3) 
0.33555984 Yes 
DLG1 discs, large homolog 1 (Drosophila) 0.34360656 Yes 
ANK3 ankyrin 3, node of Ranvier (ankyrin G) 0.3497158 Yes 
MTSS1 metastasis suppressor 1 0.355401 Yes 
LIMA1 LIM domain and actin binding 1 0.3595685 Yes 
DMD dystrophin (muscular dystrophy, Duchenne and Becker 
types) 
0.36146313 Yes 
RHOT1 ras homolog gene family, member T1 0.36857027 Yes 
CFL1 cofilin 1 (non-muscle) 0.37309808 Yes 
ARPC1A actin related protein 2/3 complex, subunit 1A, 41kDa 0.3623623 Yes 
DST dystonin 0.35654652 Yes 
KATNB1 katanin p80 (WD repeat containing) subunit B 1 0.3626624 Yes 
KIF1B kinesin family member 1B 0.3697526 Yes 
TUBGCP6 tubulin, gamma complex associated protein 6 0.37366083 Yes 
FGD2 FYVE, RhoGEF and PH domain containing 2 0.3727357 Yes 
ROCK1 Rho-associated, coiled-coil containing protein kinase 1 0.3743642 Yes 
GSN gelsolin (amyloidosis, Finnish type) 0.3740774 Yes 
ABI2 abl interactor 2 0.37834227 Yes 
RICTOR - 0.38400975 Yes 
MARK4 MAP/microtubule affinity-regulating kinase 4 0.38024947 Yes 
MYOZ1 myozenin 1 0.3822342 Yes 
CLASP1 cytoplasmic linker associated protein 1 0.37660682 Yes 
SNAP29 synaptosomal-associated protein, 29kDa 0.37588665 Yes 
MAPRE1 microtubule-associated protein, RP/EB family, member 1 0.37703222 Yes 
NF1 neurofibromin 1 (neurofibromatosis, von Recklinghausen 
disease, Watson disease) 
0.37311253 Yes 
TUBGCP5 tubulin, gamma complex associated protein 5 0.37027234 Yes 
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SOD1 superoxide dismutase 1, soluble (amyotrophic lateral 
sclerosis 1 (adult)) 
0.37296537 Yes 
RCC1 regulator of chromosome condensation 1 0.37804592 Yes 
CRK v-crk sarcoma virus CT10 oncogene homolog (avian) 0.3778033 Yes 
THY1 Thy-1 cell surface antigen 0.37771603 Yes 
SMC3 structural maintenance of chromosomes 3 0.38079202 Yes 
CAPG capping protein (actin filament), gelsolin-like 0.38554215 Yes 
WASF3 WAS protein family, member 3 0.38595834 Yes 
MYH9 myosin, heavy chain 9, non-muscle 0.37516308 No 
TAOK2 TAO kinase 2 0.37283552 No 
SMC1A structural maintenance of chromosomes 1A 0.3624592 No 
CLASP2 cytoplasmic linker associated protein 2 0.36462402 No 
ACTA1 actin, alpha 1, skeletal muscle 0.36610198 No 
ARHGDIB Rho GDP dissociation inhibitor (GDI) beta 0.3659102 No 
ARHGAP4 Rho GTPase activating protein 4 0.369791 No 
KIF13B kinesin family member 13B 0.36446396 No 
LASP1 LIM and SH3 protein 1 0.36284262 No 
SSH2 slingshot homolog 2 (Drosophila) 0.36581233 No 
ARHGEF17 Rho guanine nucleotide exchange factor (GEF) 17 0.3615478 No 
SPTBN4 spectrin, beta, non-erythrocytic 4 0.36246285 No 
PEX1 peroxisome biogenesis factor 1 0.36341113 No 
ATP2C1 ATPase, Ca++ transporting, type 2C, member 1 0.35575497 No 
DES desmin 0.34908554 No 
NF2 neurofibromin 2 (bilateral acoustic neuroma) 0.35090283 No 
WASF2 WAS protein family, member 2 0.34756207 No 
RND3 Rho family GTPase 3 0.34501284 No 
SNAP23 synaptosomal-associated protein, 23kDa 0.34425005 No 
NUBP1 nucleotide binding protein 1 (MinD homolog, E. coli) 0.34702995 No 
STMN1 stathmin 1/oncoprotein 18 0.33778834 No 
ARF6 ADP-ribosylation factor 6 0.33933508 No 
KPNA2 karyopherin alpha 2 (RAG cohort 1, importin alpha 1) 0.33023727 No 
FGD5 FYVE, RhoGEF and PH domain containing 5 0.3286789 No 
BCAR1 breast cancer anti-estrogen resistance 1 0.33092526 No 
RASA1 RAS p21 protein activator (GTPase activating protein) 1 0.3301985 No 
RAN RAN, member RAS oncogene family 0.3321233 No 
TTN titin 0.3272826 No 
NEBL nebulette 0.3296204 No 
ARHGAP10 Rho GTPase activating protein 10 0.32907704 No 
LLGL1 lethal giant larvae homolog 1 (Drosophila) 0.32614556 No 
UXT ubiquitously-expressed transcript 0.30591947 No 
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WIPF1 WAS/WASL interacting protein family, member 1 0.2774688 No 
TNNT2 troponin T type 2 (cardiac) 0.27880004 No 
CDC42BPG CDC42 binding protein kinase gamma (DMPK-like) 0.27599272 No 
MAPT microtubule-associated protein tau 0.27104625 No 
CXCL12 chemokine (C-X-C motif) ligand 12 (stromal cell-derived 
factor 1) 
0.27194208 No 
MAP1S microtubule-associated protein 1S 0.25153556 No 
CDC42 cell division cycle 42 (GTP binding protein, 25kDa) 0.24864152 No 
CEP250 centrosomal protein 250kDa 0.2464166 No 
KIFAP3 kinesin-associated protein 3 0.2463104 No 
KLHL20 kelch-like 20 (Drosophila) 0.23248412 No 
MAP3K11 mitogen-activated protein kinase kinase kinase 11 0.23203112 No 
NUSAP1 nucleolar and spindle associated protein 1 0.22319677 No 
DYNC1I1 dynein, cytoplasmic 1, intermediate chain 1 0.2207803 No 
MYO9B myosin IXB 0.21821648 No 
CKAP5 cytoskeleton associated protein 5 0.21597366 No 
MYH10 myosin, heavy chain 10, non-muscle 0.21150638 No 
CDC42BPA CDC42 binding protein kinase alpha (DMPK-like) 0.21136378 No 
DOCK2 dedicator of cytokinesis 2 0.2058683 No 
FLNB filamin B, beta (actin binding protein 278) 0.19857502 No 
CDC42BPB CDC42 binding protein kinase beta (DMPK-like) 0.19282143 No 
PREX1 - 0.18814115 No 
ARPC5 actin related protein 2/3 complex, subunit 5, 16kDa 0.17640477 No 
CENPJ centromere protein J 0.16994065 No 
CNTROB centrobin, centrosomal BRCA2 interacting protein 0.16744404 No 
MYO1E myosin IE 0.16675504 No 
RHOJ ras homolog gene family, member J 0.1398397 No 
NCK1 NCK adaptor protein 1 0.1279464 No 
KIF3B kinesin family member 3B 0.12822892 No 
FGD4 FYVE, RhoGEF and PH domain containing 4 0.116065934 No 
PACSIN2 protein kinase C and casein kinase substrate in neurons 2 0.11458786 No 
RHOT2 ras homolog gene family, member T2 0.10045373 No 
MYO6 myosin VI 0.10237117 No 
MARK1 MAP/microtubule affinity-regulating kinase 1 0.08314791 No 
LRPPRC leucine-rich PPR-motif containing 0.08071049 No 
OPA1 optic atrophy 1 (autosomal dominant) 0.07919062 No 
ARFIP2 ADP-ribosylation factor interacting protein 2 (arfaptin 2) 0.06683145 No 
LRMP lymphoid-restricted membrane protein 0.059105266 No 
FSCN1 fascin homolog 1, actin-bundling protein (Strongylocentrotus 
purpuratus) 
0.028137863 No 
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RHOF ras homolog gene family, member F (in filopodia) 0.03299651 No 
EVL Enah/Vasp-like 0.035020374 No 
NCK2 NCK adaptor protein 2 0.03828239 No 
MYH6 myosin, heavy chain 6, cardiac muscle, alpha 
(cardiomyopathy, hypertrophic 1) 
0.030611664 No 
STX5 syntaxin 5 0.03410283 No 
TESK2 testis-specific kinase 2 0.031171339 No 
TNXB tenascin XB 0.03098458 No 
SORBS3 sorbin and SH3 domain containing 3 0.021640798 No 
ELMO1 engulfment and cell motility 1 0.022043116 No 
RND1 Rho family GTPase 1 0.029565593 No 
PRKG1 protein kinase, cGMP-dependent, type I 0.014540377 No 
FGD6 FYVE, RhoGEF and PH domain containing 6 0.014791662 No 
MAP7 microtubule-associated protein 7 0.025527434 No 
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Evaluation of a potential PSSM 2 locus on equine chromosome 18 
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Summary 	  
 Polysaccharide Storage Myopathy (PSSM) is a form of glycogen storage disease 
in horses, characterized by abnormal polysaccharide inclusions in skeletal muscle. One 
form of PSSM, termed PSSM1 is caused by a dominant mutation in the GYS1 gene. A 
second form of PSSM, termed PSSM2, has also been described. The mutation 
responsible for PSSM2 is unknown. Histopathology and ultrastructural studies have 
demonstrated phenotypic differences between the GYS1 (PSSM1) and non-GYS1 
(PSSM2) forms of PSSM.  
Preliminary GWAS data revealed significant markers associated with PSSM2 on 
equine chromosome 18. The region contains 2 protein coding genes (ACVR2A and 
ORC4L) and a novel protein coding mRNA containing several repetitive elements 
(composed 100% of LINE sequences). Sanger sequence of ORC4L and most of ACVR2A 
revealed no mutations associated with PSSM2. However, due to poor assembly and 
annotation of the reference genome, the sequence of the 5’ UTR/ promoter region and the 
first exon of ACVR2a could not be evaluated.   
Next generation sequencing of amplicons generated by long PCR, next generation 
sequencing and de novo assembly of BAC clones, and next generation whole genome 
sequencing were performed in PSSM2 cases and controls to further interrogate this 
region on chromosome 18. The sequenced reads were mapped to the equine reference 
genome and the de novo reference created from the BAC clones. Variants were then 
called and annotated for location, biological function and abundance in cases versus 
controls. The use of BAC clones was efficient in creating a new reference encompassing 
the gaps present in the reference genome and the use of long PCR enabled good sequence 
comparison of the PSSM2 and controls. A total of 12,903,963 variants were called by 
GATK in cases and controls, in the entire genome. Mapping of the amplicons generated a 
total of 24,495 variants. In both cases the majority of the variants were intergenic. No 
variants significantly associated with PSSM2 were identified within this region on equine 
chromosome 18. The absence of variants that explain PSSM2 on chromosome 18 and the 
lack of other significant hits in the GWAS in other regions of the genome may be due to 
false positive association, low power of the GWAS analysis, partial penetrance of risk 
alleles on ECA18. 
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Introduction 
 
 Polysaccharide Storage Myopathy (PSSM) is a muscle glycogen storage disease 
in horses characterized by accumulation of excess and abnormal skeletal muscle 
glycogen and clinical myopathy2. A dominant mutation in the GYS1 gene has been 
described as a causative mutation in one form of PSSM (PSSM1). However, a significant 
portion of PSSM horses cannot be attributed to the GYS1 mutation and evidence points to 
a second heritable form of PSSM25, referred to as type 2 PSSM. Histopathology and 
ultrastructural studies have demonstrated phenotypic differences between the GYS1 
(PSSM1) and non-GYS1 (PSSM2) forms of PSSM12,25.  
Preliminary GWAS data performed in a cohort of 104 PSSM2 Quarter Horses 
(QH) cases and 124 QH controls, genotyped with the Illumina Equine SNP50 Beadchip, 
demonstrated six SNPs on equine chromosome 18 (ECA18) (p=9.44 x 10-7 to 2.84 x 10-
6) and a single SNP on ECA3 (2.99 x 10-6) that were associated with PSSM2 using a 
dominant logistic regression model (Fritz et al, unpublished data, figure 11). The SNP on 
ECA3 was no longer associated with PSSM2 when correction for population structure 
was performed. Association of PSSM2 with the SNPs on chromosome 18 persisted after 
correction for multiple testing using 10,000 label-swapping permutations. These six 
ECA18 SNPs span an interval of ~350 kb (349,806 base pairs; chr18:30,479,171-
30,828,977).  
The 350 kb interval contains two protein coding genes, both expressed in equine 
skeletal muscle, activin A receptor, type IIA (ACVR2A) and origin recognition complex, 
subunit 4 like (ORC4L), as well as a novel transcript (ENSECAG00000024833) (figure 
11). PCR was attempted to amplify 5’ and 3’ untranslated regions (UTR), coding 
(exonic) regions and exon/intron boundaries (splice sites) from each gene to enable 
Sanger sequencing and detection of simple mutations (nonsynonymous substitutions, 
missense mutations and small insertions or deletions). Complete sequencing of these 
regions in ORCL4 did not identify simple mutations associated with PSSM2 (unpublished 
data). Sequencing of most ACVR2A exons and intron/exon boundaries has also not 
identified simple mutations within these sequences (unpublished data). Due to poor 
annotation and assembly of the reference equine genome (EqCab 2.0 [Twilight])55, the 
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amplification and sequencing of the 5’ UTR/ promoter region and the first exon of 
ACVR2a was unsuccessful. Attempts to design primers and “walk” through the region 
with Sanger sequencing of genomic DNA in PSSM2 cases and controls and BAC clones 
(bacterial artificial chromosome clones)56 were also unsuccessful and suggest that large 
structural variants may be present in this region (unpublished data) (figure 11). The novel 
gene (ENSECAG00000024833) is approximately 68 kb in length, is 268kb from 
ACVR2A and is composed of several repetitive elements (LINE sequences).  
The objective of this chapter was to use high throughput next-generation 
sequencing strategies to thoroughly interrogate the genomic regions on ECA18 associated 
with PSSM2 and overcome the issues with poor genome annotation and assembly in 
order to identify a potential genetic mutation that might be responsible for PSSM2. This 
approach allowed us: 1) to overcome limitations in SNP-based fine structure mapping 
and Sanger sequencing of candidate genes imposed by haplotype structure and 
incomplete genome annotation in the horse; and 2) to identify structural variants that may 
be difficult to detect with traditional Sanger sequencing technologies (i.e. large insertions, 
deletions, and/or inversions).  
 
 
Material and Methods 
 
  
To overcome poor annotation and possible structural variation associated with 
ACVR2A, first, 2 BAC clones that contain approximately 230 kb of equine sequence 
encompassing ACVR2A were sequenced to create a new assembly of the equine genome 
in this region. Second, long range PCR was used to amplify the entire 350 kb region 
associated with PSSM2 in 11 cases and 11 controls allowing for alignment and 
identification of all sequence differences (both simple and complex structural differences) 
between cases and controls across the entire region (figure 11). 
PSSM2 cases were selected based on the presence of aggregates of amylase 
sensitive polyssacharide in the muscle biopsy, history of clinical signs of rhabdomyolysis 
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and the absence of the GYS1 mutation. Controls were selected based on no prior history 
of rhabdomyolysis, normal muscle biopsy and absence of the GYS1 mutation.  
 
BAC clones next generation sequencing  
Two BAC clones (CH241-325M2 - BAC-A1 and CH241-57G18 - BAC-A2) 
encompassing the promoter region of ACVR2A gene were ordered from a BAC equine 
library originated from BRAVO, a male Thoroughbred closely related to Twilight (the 
mare that provided DNA for assembling of the current equine reference genome). The 
BAC clones were chosen based on their genomic location (chr18: 30,288,821 – 
30,511,282 and chr18: 30,292,625 – 30,522,271), to cover the region around ACVR2A 
where the long-range PCR primers were unable to amplify (figure 11; figure 12). Those 
are regions where gaps are present in the reference genome. The BAC clones were 
sequenced using Illumina Mi-Seq sequencer, 150 bp paired-end run, 60x coverage.  
 
Target next generation sequencing – equine chromosome 18 
Long range PCR was used to amplify the entire 350 kb region associated with 
PSSM2, based on the GWAS, in 11 cases and 11 controls. 61 overlapping long-PCR 
primer pairs were designed and optimized to produce amplicons across a 537 kb (chr18: 
30,251,565 – 30,789,048) region encompassing the 350 kb region around ACVR2A 
(table). The long range PCR was unable to amplify two small areas on ACVR2A, where 
gaps are present in the reference genome (figure11: dotted lines between primer pairs 
and table 20: primer pairs 23 and 27) and a third area around ENSECAG00000024833 
(figure11 and table 20: primer pair 52). The amplicons were sequenced at the University 
of Minnesota’s Biomedical Genomics Center (BMGC) using the MiSeq technology. Each 
sample was prepared with an indexed barcode for a (150bp) paired–end run on the 
Illumina Mi-Seq sequencer (i.e. ~5 million reads). For the 537kb of amplified sequence, 
this resulted in > 60-fold sequence coverage per individual.  
 
De novo assembly of BAC clones and target next generation sequencing reads 
De novo assembly of the reads was performed on CLC bio79, using de Brujin 
graphs. The software automatically finds the ideal k-mer size, after evaluating the amount 
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of input data. Prior to de novo assembly, Illumina adaptors were trimmed from the raw 
reads and reads with low quality were discarded. Next, the fastq reads were mapped to 
the BAC clone vector sequence (pTARBAC2.1)	  extracted	   from	  NCBI. Only unmapped 
reads (which would represent equine DNA) were used to create de novo contigs. The 
procedure above was first performed on each BAC clone individually (BAC-A1and BAC-
A2) and then using both BAC clones reads together (BAC-A1A2). The fasta de novo 
contigs were further assembled using the software Sequencher80, allowing different 
overlapping and mismatch parameters. The best de novo contigs, based on length and 
blast identity to the region of interest on equine chromosome 18 were chosen for 
downstream analysis.  
The same protocol was used for de novo assembly of targeted next generation 
sequencing reads of PSSM2 cases and controls, with the exception of mapping reads to 
the BAC clone sequence. Each one of the 11 PSSM2 cases and 11 controls (61 amplicons 
per horse) were assembled individually and the generated de novo contigs were further 
evaluated on Sequencher software to identify possible sequence differences (large 
structural variants) between cases and controls that be the causative mutation for PSSM2. 
 
To identify possible variants surrounding the novel protein coding ‘mRNA’ 
(ENSECAG00000024833) and to overcome the same problems experienced when 
amplifying ACVR2, next generation whole genome sequence was performed in 3 PSSM2 
horses and 3 controls.   
 
Whole genome next generation sequencing  
3 PSSM2 Quart Horse cases and 3 control Quarter Horses were selected for whole 
genome next generation sequencing (NGS). The cases were selected based on clinical 
signs of PSSM, severity of muscle biopsy findings and were also previously genotyped 
on the equine SNP50 array. Controls were randomly selected from the list of horses 
previously genotyped on the SNP50 array. Reads were sequenced using Illumina HiSeq, 
100 bp paired-end, 12x coverage per horse (~160 million reads/horse). Each sample was 
sequenced in more than one lane.   
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Sequence Mapping and Variant Calling  
Target next generation sequencing data on chromosome 18 and whole genome 
next generation sequencing were mapped and variants were called according to the 
protocol below.  
Prior to mapping, the raw reads were checked for quality using FastQC, the ends 
were trimmed when the quality base score was below 20 and paired reads were 
synchronized. The Illumina fastq files were then aligned the equine reference genome 
(EqCab2) using BWA aligner, originating BAM files. Following mapping, variants were 
called by the Genome Analysis toolkit (GATK)81,82. Raw BAM files generated by 
BWA83,84 are not of sufficient quality to identify real biological variants so quality 
filtering and correction for systematic biases was performed prior to variant calling. 
Reads that were ambiguously mapped (mapped equally well to multiple locations) and 
were of low quality were removed. Reads were then sorted in coordinate order with the 
reference genome, mates were synchronized and PCR duplicates were removed using 
Picard-Tools85. The GATK realigned target creator tool81,86 was used to systematically 
check BAM files for the presence of indels and realign reads around them to avoid 
incorrect mapping and false positive SNPs, followed by base quality recalibration. Next, 
the GATK unified genotyper tool was used for variant discovery (SNPs and indels). 
Variants were then recalibrated by GATK’s variant quality score recalibrator tool using 
only internal evidence (the data itself) and a final VCF file containing SNPs and indels 
was created. Each sample was mapped individually.  
Cases and Controls were mapped individually using BWA and were then merged 
prior to GATK analysis, to call variants simultaneously.  Sample identity was preserved 
during the process.  
 Variants from whole genome sequence were called initially with a confidence 
score threshold of Q20. The samples were individually sequenced at 12x coverage, but 
since depth of coverage is not uniformly around the entire genome, variants were also 
called using a quality score threshold of Q4, following guidelines by the Broad Institute 
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for shallow data (less than 10X coverage per sample). Variants from the target next 
generation sequencing were called with a confidence score threshold of Q20, since a 
coverage of more than 60X was expected per sample. 
 
Miseq and whole genome NGS mapping to BAC clones 
The reads originated from the target next generation sequencing on chromosome 
18 and the whole genome next generation sequencing experiment were also mapped to 
the de novo assembly reference generated from the BAC clones using BWA.  	  
Variant annotation and prioritization 
After variants were identified from sequence data (target sequence on ECA18, 
and whole genome data), they were annotated by snpEff87 software for variant location 
and their potential effect. SnPSift88 case control was used to calculate variant abundance 
differences between cases and controls. Variant abundancy between groups was 
calculated for each one of the variants discovered by GATK. The program counts how 
many cases and controls have each one of those variants and calculates p-values for the 
differences in abundance using Fisher exact test. The p-values are calculated using 
different models: dominant, recessive, allelic and co-dominant, all of which are reported 
in the output. Variants were prioritized if 1) they were relatively abundant in cases 
compared to controls; 2) they occurred within a gene with known biologic function 
relevant to PSSM2 pathogenesis; and/or 3) the variant had a predicted functional effect. 
Variants detected on target reads and whole genome reads after mapping to the de novo 
reference created from BAC clones were evaluated for location and abundance between 
cases and controls.  
 
Results 
   
Target next generation sequencing  
A total of 16,291,228 reads from the 61 amplicons were present in cases and 
controls; 99.98% of the reads mapped to EqCab2 and 15,110,584 (92.75% of total reads) 
mapped to equine chromosome 18. A total of 24,495 variants (SNPs and indels) were 
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called by GATK (3,176 on chromosome 18), with the vast majority being intergenic 
(table 21) single nucleotide polymorphisms (SNP) denoted as ‘modifier’ by GATK 
(usually non-coding variants or variants affecting non-coding genes, where predictions 
are difficult or there is no evidence of functional impact) (table 22). No variants with 
major effect or significant differences in abundance between the 11 cases and 11controls 
were observed in the region of interest on chromosome 18.  
 
Whole genome next generation sequencing  
A total of 168,074,580 reads were aligned to the reference genome (168,052,258 
in pairs) and 12,903,963 variants (SNPs and indels) were identified across the entire 
genome (table 23). When evaluating only chromosome 18 (position: 30,200,171 - 
31,027,348), 626 variants were called using a quality score of Q4 and 614 using a quality 
score of Q20. The vast majority of the variants were intergenic, single nucleotide 
polymorphisms and had a modifier effect (table 24). No variants with major effect or 
significant differences in abundance between cases and controls were observed in the 
region of interest on chromosome 18.  
    
De novo assembly of BAC clones 
De novo assembly of BAC clone CH241-325M2 (BAC-A1) 
 The input data for de novo assembly of BAC-A1 consisted of 505,153 fastq reads 
from next generation sequencing, from which 494,410 were matched when creating 
contigs, resulting in 616 contigs with N50 of 1,688 (minimum contig length: 210; 
maximum contig length: 157,687).   
 
De novo assembly of BAC clone CH241-57G18 (BAC-A2) 
 The input data for de novo assembly of BAC-A2 consisted of 488,414 fastq reads 
from next generation sequencing, from which 480,080 were matched when creating 
contigs, resulting in 271 contigs with N50 of 75,820 (minimum contig length: 223; 
maximum contig length: 153,846).   
 
De novo assembly of both BAC clones together (BAC-A1A2) 
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The input data for de novo assembly of BAC-A1A2 consisted of 993,567 fastq 
reads, from which 977,934 were matched when creating contigs, resulting in 1,295 
contigs with N50 of 495 (minimum contig length: 204; maximum contig length: 
157,687).    
 
Further BAC clone assembly on Sequencher 
The de novo contigs from CLCbio were further evaluated on Sequencher software 
in order to allow more flexibility with the overlapping parameters and the goal of creating 
even longer contigs. The longest contigs and the ones that blast to the equine reference 
chromosome 18 with higher identity were the ones selected from CLCbio for further 
evaluation on Sequencher. This process was done individually for contigs from BAC-A1, 
BAC-A2 and BAC-A1A2. The 3 longest contigs from BAC-A1 (sizes 157,689; 10,090 and 
65,689) were further assembled on Sequencher, creating a final single contig of size 
233,376 bp (contig1) (figure 12). Those 3 contigs overlapped by 26 and 16 base pairs, 
with only 2 mismatches (figure 12) and had 100% identity when blasted to equine 
chromosome 18 (chr18: 30,288,742 – 30,522,282). From BAC-A2, 2 contigs were further 
assembled together on sequencher (sizes 153,846 and 75,820) with a total size of 
229,659. Those 2 contigs overlapped by just 7bp, with 1bp mismatch and had lower 
identity to equine chromosome 18.  Contigs created from both BACs together (BAC-
A1A2), had marked number of mismatches, less overlapping and slightly lower identity 
when assembled on Sequencher. Based on the amount of overlapping, best blast results to 
equine reference chromosome 18 and low number of mismatches, contig1 was chosen as 
the de novo reference from the BAC clones for further mapping.  
The de novo assembled sequence from contig1 contained approximately 233kb 
through the promoter and 5’ UTR of ACVR2A gene and encompasses 4 gap regions 
present on chromosome 18 in the reference genome. The gaps have a total size of 1087 
bp (figure 12).  
 
In addition to being mapped to the equine reference genome (above, EqCab2), both 
whole genome sequencing and targeted next generation sequencing products were 1) de 
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novo assembled to look for variants that were different between PSSM2 cases and 
controls; and  2) mapped to BAC contig 1.  
 
De novo assembly of target next generation sequencing reads 
A total of 22 individual de novo assemblies were created (11 cases and 11 
controls were assembled individually). Each individual sample had an average 816,544 
read counts that were used to create the de novo contigs. After de novo assembly, the 
contigs had an average N50 of 6,430 (range: 2,378-18,844), the mean number of created 
contigs was 734 (range: 370-1,212) and their average minimum and maximum size was 
161bp (range: 105-202) and 71,926bp (range: 27,169-134,684), respectively. All contigs 
were further evaluated on Sequencher software in attempt to identify possible structural 
variant differences between cases and controls. The expected size of each one of the 
contigs was 570kb (224kb and 208kb if accounting for amplification failure of 2 of the 61 
primer pairs around ACVR2A; figure 11) and the longest individual de novo contig 
created by CLC was 130 kb, indicating that they did not contain the entire expected 
sequence. Cases and controls did not show any sequence differences (including structural 
variants) that could explain PSSM2, but this comparison was compromised by the fact 
that individual contigs, regardless of cases/control status were missing different sections 
of sequences in comparison to the reference.  
 
 
Target and whole genome NGS mapping to contig1  
 
Whole genome NGS mapping to contig1 
The total number of input reads from the sequences of 3 PSSM2 and 3 control 
horses was 1,113,307,670, from where 2,906,220 mapped to contig1, resulting in the 
discovery of 438 variants.  
 
Target mapping to contig1  
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The total number of input reads from the targeted long PCR products (11 PSSM2 
cases and 11 controls) was 388,924.  142,604 of these reads mapped to contig1, resulting 
in the discovery of 1,169 variants.  
 
Seventy-five of the variants called by whole genome sequence mapping to 
contig1 were also called by target sequence (ie long PCR product) mapping to contig1. 
None of the variants called on the target and whole genome sequence data after mapping 
to contig1 had a significant difference in abundance between cases and controls, and 
could explain PSSM2.  Overall, when comparing the number of variants that were called 
in the different experiments across the 233kb region in the reference genome (region that 
corresponds to contig1) and contig1 itself; the target sequencing mapping to contig1 
produced the larger number of variants (1,168 variants), followed by target sequencing 
mapping to the reference genome (1,133 variants), whole genome sequencing mapping to 
the reference genome (677 variants) and whole genome sequencing mapping to contig1 
(437 variants).  
 
 
Discussion 
  
The GATK unified genotyper did not identify any SNPs, or indels on equine 
chromosome 18 that clearly segregated with PSSM2. However, the unified genotyper is 
not ideal to call large indels. The largest indel called by the software in the present data 
was a 46bp deletion. To look for possible large structural variant differences between 
cases and controls, de novo assembly of the produced amplicons for each one of the cases 
and controls, individually, was performed. No large indels that could explain PSSM2 
were observed between cases and controls, but the larger de novo contig (130kb) created 
by the de novo assembly software was smaller than its expected size of 570kb (based on 
the amplicons generated from long range PCR products; 224kb and 208kb if accounting 
for amplification failure of 2 of the primer pairs). This suggests that parts of sequences 
were missing, compromising any case-control comparisons for large structural variants. 
This issue can be explained by a poor performance of the de novo assembler software 
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and/or the difficulty with sequencing of the original amplicons (61 primer pairs). In both 
instances the presence of repetitive elements in the region was likely a limiting factor. 
The presence of gaps in the reference genome also made it difficult to successfully 
sequence a few of the long range PCR products. Also, no significant variant differences 
in cases and controls were observed when the amplicons were mapped to the equine 
reference genome, but problems with the original PCR products caused a few regions to 
have decreased coverage, again potentially compromising variant discovery. The 3 
PSSM2 cases and 3 controls with whole genome sequence data provided the opportunity 
to detect variants that could have been missed by the target sequencing experiment, since 
the whole genome sequence data was not dependent on generation of specific PCR 
products to amplify this region of ECA18. Although large structural variants might not be 
called due to limitations of the variant caller software, evaluation of depth of coverage in 
the region of interest did not show evidence of the presence of large indels. 
 
The de novo assembly generated from the BAC clones was successful in covering 
gaps in the reference genome and is a valuable approach to overcome issues with poor 
assembly of the equine reference genome. This process is facilitated by the presence of 
an equine BAC library. Mapping of the amplicons and whole genome sequence reads to 
the de novo contig created from the BAC clones also ruled out the possibility that 
important variants were not called in the region due to poor assembly or annotation of the 
reference genome.   
 
No variants on chromosome 18 associated with PSSM2 were identified in the 22 
horses analyzed. There are several possible technical explanations for this. One possible 
explanation is that incomplete penetrance or low-to-moderate relative risk for putative 
functional allele(s) on ECA18 made it difficult to differentiate risk alleles from other 
variants in the region. With only 22 horses, the allele count differences between cases and 
controls for low penetrance or low-to-moderate genotypic relative risk would not be easy 
to differentiate from random variants. Genotyping a much larger number of cases and 
controls for any putative functional variants would be needed to determine if low-to-
moderate risk alleles for PSSM2 were present on ECA18. Failure to identify functional 
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alleles might also indicate that the initial association on ECA 18 was a false positive, and 
that the true region(s) of the genome harboring PSSM2 risk alleles were not identified 
due to low power of the GWAS analysis. The GWAS performed on the preliminary data 
had only 50,000 markers. While this technology was successful in finding several disease 
related markers in other studies, it was not powerful enough for PSSM2. Quarters Horses 
are known to have lower linkage disequilibrium (LD) in comparison with other breeds, 
due to a quick expansion of the breed. GWAS analysis relies on LD between the markers 
and the causative allele. A denser SNP genotyping array would be advantageous since it 
would increase the power to find a causative mutation. To overcome this issue in a cost-
effective way, imputation can be performed and the density of the markers present on the 
initial GWAS can be increased without the need to further genotype the test population, 
as long as a reference population that was genotyped on a denser array is available.  
 
 It is also possible that other forms of excessive glycogen storage diseases, caused 
by more than 2 mutations are present, and the horses called PSSM2 actually represent 
more than one disease. Also, PSSM2 might not be caused by a single gene with major 
effect, but several genes with minor effect. In both cases the power of the GWAS would 
be significantly affected and an increased number of cases and controls would be 
necessary to find significant markers. If more than 2 forms of excessive glycogen storage 
disease are present in horses, a better understanding of the pathophysiology of those 
diseases would be necessary to better phenotype the horses prior to the analysis. Studying 
gene expression profile in PSSM1, PSSM2 horses and controls would help answering 
these questions.     
 
 In conclusion, no mutations that can explain PSSM2 were identified on equine 
reference chromosome 18. Further analysis, including the use of imputation, would be 
necessary in attempt to improve power of the initial GWAS analysis and identify variants 
responsible for the disease. The study of metabolic changes on equine muscle of PSSM2 
horses prior and during exercise, and gene expression analysis would improve our 
understanding of the physiology of the disease and the differences between PSSM1 and 
PSSM2 at the molecular level. 
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Primer	  Name	   Location	   Forward	   Reverse	  	   Size	   Gene	  Location	  
    	    
LR	  Set	  1	  F	   30251565	  30251586	   GAAACCTCTACTTCCCCAGTCC	   	   	   	  
LR	  Set	  1	  R	   30260086	  30260105	   	   CGTTGTCACTTTCCCTCTGG	   8540	  bp	   	  
    	    
LR	  Set	  2	  F	   30259372	  30259395	   CTCTGCACCAATCAAGTACAGATG	   	   	   	  
LR	  Set	  2	  R	   30267774	  30267797	   	   CCACGCCATATGGTATAATGTCAG	   8425	  	  bp	   	  
    	    
LR	  Set	  3	  F	   30267128	  30267148	   ATCTTGCAGCTCAGGCTTACC	   	   	   	  
LR	  Set	  3	  R	   30276952	  30276974	   	   GTGCCAGGACAGAGATGAAATAC	   9846	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  4	  F	   30275904	  30275926	   GCTCGGTGCCTTTCACATAATAG	   	   	   	  
LR	  Set	  4	  R	   30285764	  30285784	   	   AATGAAAGCCTGGGTTGAGAG	   9880	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  5F	   30284825	  30284847	   GCACATTTGGGGAGAAACTACAC	   	   	   	  
LR	  Set	  5R	   30294550	  30294570	   	   ATGGCATCCCATTCTGTCAAG	   9745	  bp	   	  
    	    
LR	  Set	  6F	   30293783	  30293806	   CATGTTACTTCTCACCCTCAGATG	   	   	   	  
LR	  Set	  6R	   30302644	  30302667	   	   TCACCTATCCCTACTCTCTCAAGG	   8884	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  7F	   30302246	  30302266	   GGAACCCAGAAAATGAAGCTC	   	   	   	  
LR	  Set	  7R	   30311917	  30311937	   	   TACTTTGTTGGCCCCAATACC	   9691	  bp	   	  
    	    
LR	  Set	  8F	   30311215	  30311238	   CACTCATGTAACCTCTGGGAGATG	   	   	   	  
LR	  Set	  8R	   30320080	  30320103	   	   GAGAAAGGTAGTTGGAGAGTGGA
C	  
8888	  bp	   	  
    	    
LR	  Set	  9F	   30319729	  30319752	   ATCACCCACAGGACTAACTGTTTC	   	   	   	  
LR	  Set	  9R	   30328934	  30328957	   	   TTCTGCCCTACCCTCAACTATTTC	   9228	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  10F	   30328238	  30328258	   CCCAACCTCTGGAATTACTGG	   	   	   	  
LR	  Set	  10R	   30338048	  30338068	  	   	   GGATGGGGCAGAGGTATAATG	   9830	  bp	   	  
    	    
LR	  Set	  11F	   30337195	  30337217	   AATTGGGCACAATATTCAGGATG	   	   	    
LR	  Set	  11R	   30346536	  30346559	   	   TGTAAAACTCAGAGGTTGCAAGTG	   9364	  bp	    
    	    
LR	  Set	  12F	   30345907	  30345930	   AGACAGACTTCACAGATTCAGTCC	   	   	   	  
LR	  Set	  12R	   30355225	  30355248	   	   GTTTTCCCCCTATTCACTATCACC	   9341	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  13F	   30354415	  30354435	   TCTTCCAGGAGACATGCAGAC	   	   	   	  
LR	  Set	  13R	   30364137	  30364158	   	   AACCACTGTGGCCAAGTTAATC	   9743	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  14F	   30363227-­‐30363247	   TGTCATGATGCCTGTCACCTC	   	   	   	  
LR	  Set	  14R	   30372783-­‐30372804	   	   CTACTCTGAGGGTTTTGGCAAG	   9577	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  15F	   30371974	  30371994	   AGGAGAGAAGGGTTGGGAAAC	   	   	   	  
LR	  Set	  15R	   30381539-­‐30381560	   	   AGGGTAAAAAGTGTCCCTTTGC	   9586	  bp	   	  
    	    
LR	  Set	  16F	   30379741	  30379764	   GTCCTTGTTAATATTGGCCATCAG	    	    
LR	  Set	  16R	   30386275	  30386298	   	   CAGGTTCCATAATCCTCTGAGTTC	   6557	  bp	    
    	    
LR	  Set	  17F	   30389665	  30389685	   ACAAAGGCGGTTTATCTGCTC	   	   	   	  
LR	  Set	  17R	   30399071	  30399092	   	   TGAATTGACCTCATCCGTAATG	   9427	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  18F	   30397929	  30397949	   CACAGATGCTGAACAGAGCAG	   	   	   	  
LR	  Set	  18R	   30407802	  30407822	   	   TACCTACATGCCACACCCTTG	   9893	  bp	   	  
	  
	  
	  
	  
	  
	  
	  
	  
Table 20. Primer sequence of all 61 primer pairs. F: forward; R: reverse; bp: base pair. Primers 23R, 
27F and 27R did not work (due to gaps and repetitive elements in the reference genome). This 
corresponds to the region where the ordered BAC clones originated from. Primer pair 52F and 52R, 
located before the novel gene ENSECAG00000024833 also failed 
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LR	  Set	  19F	   30406820	  30406840	   TGGAGCCTAACCATCAAACAG	   	   	   	  
LR	  Set	  19R	   30416481	  30416501	   	   TCTGGATCTCTGGTCATTTGC	   9681	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  20F	   30415390	  30415410	   TCCGTGTTCTTCAGACACCAG	   	   	   	  
LR	  Set	  20R	   30425352	  30425372	   	   ATGGATGCTGTGGAGGAGAAG	   9982	  bp	   	  
    	    
LR	  Set	  21F	   30428928	  30428950	   GGAAAGCCTGATAATGAAAGGTC	    	    
LR	  Set	  21R	   30433728	  30433751	   	   ACATCTTGTGTCTTTTTCCTCCTC	   4823	  bp	    
    	    
LR	  Set	  22F	   30433156	  30433176	   AGAGCTCTGCAGAACACCATC	   	   	   	  
LR	  Set	  22R	   30442872	  30442892	   	   ATCCCAAGGGTAACGTTTGAC	   9696	  bp	   	  
    	    
LR	  Set	  23Fa	   30442537	  30442560	   GGACTGGTTTAGATAGCGAATCTC	    	   ACVR2A	  Upstream	  
LR	  Set	  23	  Ra	      	   ACVR2A	  Promoter	  
    	    
LR	  Set	  23Fb	   30446941	  30446963	   TTGATTTTACACCAGGAGGTTTG	    	   ACVR2A	  Exon	  1	  
LR	  Set	  23Rb	   30451338	  30451361	   	   TTGCATACTTCTTGTGGGAGTGAC	   4420	  bp	   ACVR2A	  Intron	  1	  
    	    
LR	  Set	  24F	   30450742	  30450767	   AAGGTATCAAGTTTAATTATATTTG
C	  
	   	   ACVR2A	  Intron	  1	  
LR	  Set	  24R	   30459957	  30459983	   	   TGTGAATCCTTCCTATTGTTCTCTAC
T	  
9241	  bp	   ACVR2A	  Intron	  1	  
	   	   	   	   	   	  
LR	  Set	  25F	   30459635	  30459655	   GGGCTGGTTTGGTAGAAAGAG	   	   	   ACVR2A	  Intron	  1	  
LR	  Set	  25R	   30469199	  30469219	   	   CTCGGCTCCTTTAATCCCTTC	   9584	  bp	   ACVR2A	  Intron	  1	  
    	    
LR	  Set	  26F	   30468981	  30469003	   TACACAAACCTAGCAGGGATAGC	    	   ACVR2A	  Intron	  1	  
LR	  Set	  26	  R	   30476349	  30476371	   	   TTTACCTCAGACCCTACCTCTCC	   7390	  bp	   ACVR2A	  Intron	  1	  
    	    
LR	  Set	  27F	   	   	    	   ACVR2A	  Intron	  1	  
LR	  Set	  27R	   	   	   	   	   ACVR2A	  Intron	  1	  
    	    
LR	  Set	  28F	   30485921	  30485944	   TCTGTCTCTCCTTAATAGCCTTGC	   	   	   ACVR2A	  Intron	  1	  
LR	  Set	  28R	   30495682	  30495707	   	   CGGTTCTTACCTATAGTTCTCACCA
C	  
9786	  bp	   ACVR2A	  Intron	  2	  
	   	   	   	   	   	  
LR	  Set	  29F	   30494729	  30494749	   TGTCTGCCAGATACCCAACTC	   	   	   ACVR2A	  Intron	  1	  
LR	  Set	  29R	   30504519	  30504543	   	   CCACCTTAACTCTAACCACAACAAG	   9814	  bp	   ACVR2A	  Intron	  4	  
    	    
LR	  Set	  30FB	   30504124	  30504146	   GAATTGCTGAATTGACTTCGTTG	    	   ACVR2A	  Intron	  4	  
LR	  Set	  30RB	   30514092	  30514119	   	   GCAGATAGGTACATCAAATACAAA
GCAC	  
9995	  bp	   ACVR2A	  Intron	  4	  
    	    
LR	  Set	  31F	   30512483	  30512503	   TGACTGCTGACACGTTCTTTG	   	   	   ACVR2A	  Intron	  4	  
LR	  Set	  31R	   30522107	  30522127	   	   AGCTGGGGAATCACAATCTAC	   9644	  bp	   ACVR2A	  Intron	  8	  
	   	   	   	   	   	  
LR	  Set	  32F	   30521198	  30521220	   TCTTCTATCCTGTTGACCTCCAG	   	   	   ACVR2A	  Intron	  8	  
LR	  Set	  32R	   30530869	  30530889	   	   CAACAATTGTGAGGCACAGTC	   9691	  bp	   End	  ACVR2A	  	  
	   	   	   	   	   	  
LR	  Set	  33F	   30530020	  30530039	   TTGGTTTTGCTTCCACTTCG	   	   	   ORC4L	  
LR	  Set	  33R	   30539843	  30539864	   	   ACCTCTCCAGTAACCGGGAAAC	   9844	  bp	   ORC4L	  
	   	   	   	   	   	  
LR	  Set	  34F	   30538816	  30538837	   CACCCAGAAACAACTCTCACTG	   	   	   ORC4L	  
LR	  Set	  34R	   30548554	  30548573	   	   CGCAAAGCTTCTAATGTTGC	   9757	  bp	   ORC4L	  
	   	   	   	   	   	  
LR	  Set	  35F	   30547509	  30547530	   CCAGATATCCAATCATCCTCAC	   	   	   ORC4L	  
LR	  Set	  35R	   30557408	  30557428	   	   CAGCCTGTTTTGCTAGACCAC	   9919	  bp	   ORC4L	  
    	    
LR	  Set	  36F	   30556788	  30556811	   CCACTCAAGAACTTCATGTCTCAG	    	   ORC4L	  
LR	  Set	  36R	   30564407	  30564429	   	   AGTGAATCGTTTGCTTTGCTTAG	   7641	  bp	   ORC4L	  
    	    
LR	  Set	  37F	   30565110	  30565134	   CCCTGTTAGACTCATTGAGAGAGA
G	  
	   	   ORC4L	  
LR	  Set	  37R	   30575021	  30575044	   	   ACTGTTTTCCGCAGCTACTATACC	   9934	  bp	   ORC4L	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LR	  Set	  38F	   30574244	  30574265	   GCTTCATGACATTTGACTTTGC	   	   	   ORC4L	  
LR	  Set	  38R	   30584166	  30584185	   	   CGCAGCTGGATAAAAAGGAC	   9941	  bp	   ORC4L	  
    	    
LR	  Set	  39F	   30583833	  30583856	   GACCTCCATGACAGGATAAATTGG	   	   	   ORC4L	  
LR	  Set	  39R	   30592329	  30592352	   	   CTAGCTGGCTGAAAAACAGCTTAC	   8519	  bp	   ORC4L	  
	   	   	   	   	   	  
LR	  Set	  40F	   30591872	  30591891	   TTCATGGACGGAACTGAAAA	   	   	   ORC4L	  
LR	  Set	  40R	   30601649	  30601668	   	   CTTGGATCGTGCTTTTGATG	   9796	  bp	   ORC4L	  
	   	   	   	   	   	  
	   	   	   	   	   	  
LR	  Set	  41F	   30600765	  30600784	   TGTTCACAGATGGCACGATT	   	   	   ORC4L	  
LR	  Set	  41R	   30610372	  30610391	   	   GCCTCGGATTTAGAGCCTTT	   9626	  bp	   ORC4L	  
	   	   	   	   	   	  
LR	  Set	  42F	   30609561	  30609580	   GGAATGCTGACAGAGGTGGT	   	   	   ORC4L	  
LR	  Set	  42R	   30619125	  30619144	   	   GCCAAGAAATCCTTCAGCAC	   9583	  bp	   ORC4L	  
	   	   	   	   	   	  
LR	  Set	  43F	   30618196	  30618215	  	   AGGTGAGAACCAGGCTTGAC	   	   	   	  
LR	  Set	  43R	   30627848	  30627867	   	   TCCCCTTGAGTCAGGATTTG	   9671	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  44F	   30626728	  30626749	   TGAACTTTCGAAAAGCACTAGG	   	   	   	  
LR	  Set	  44R	   30636543	  30636564	   	   TTTGGGAACAACTAACTTCAGC	   9836	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  45F	   30635736	  30635755	   CACCATAGTGCTCCGGACTG	   	   	   	  
LR	  Set	  45R	   30645328	  30645347	  	   	   TCTTGTGGGCTGTCTTAGGG	   9611	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  46F	   30643793	  30643813	   TGGATTTTGTATCCCCTTTCC	   	   	    
LR	  Set	  46R	   30654237	  30654257	   	   TGCCATCACAGGGTTAATCAC	   10464	  
bp	  
	  
	   	   	   	   	   	  
LR	  Set	  47F	   30653511	  30653532	   GGGGCTAGAATCTCTAGTGCTG	   	   	   	  
LR	  Set	  47R	   30662944	  30662963	   	   GATGGCAAGGAATCTGCAAC	   9452	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  48F	   30662137	  30662158	   TGGTGGTCTTATCCTTGAGATG	   	   	   	  
LR	  Set	  48R	   30671683	  30671702	   	   TTGGGAGGATTCTTGGTCAG	   9560	  bp	   	  
    	    
LR	  Set	  49F	   30670678	  30670701	   AAGTCTACCCTGCTCATGCTATCC	   	   	   	  
LR	  Set	  49R	   30680598	  30680621	   	   CTATCACCTCTCTGCGCTACTTAC	   9550	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  50F	   30679787	  30679807	   GCTGGAAATGTATCAAAATGC	   	   	   	  
LR	  Set	  50R	   30689373	  30689392	   	   ATGCCAATGCACTTCTTTGA	   9605	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  51F	   30688570	  30688593	   ATTCTCCTTATGGCACCTAATCTG	   	   	   	  
LR	  Set	  51R	   30694509	  30694531	   	   TGGTTACTTCTCAGCAGGTTTTG	   5961	  	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  52F	   	   	   	   	   	  
LR	  Set	  52R	   	   	   	   	   	  
	   	   	   	   	   	  
LR	  Set	  53F	   30706564	  30706588	   CCTTTGACTTTGGTATTCCATTAGG	   	   	   	  
LR	  Set	  53R	   30715505	  30715528	   	   TCTTTCCCATCTAGGTCTGTTTTC	   8964	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  54F	   30715056	  30715080	   AAGTAATTACCCACAAGAGAAGCT
G	  
	   	   	  
LR	  Set	  54R	   30724139	  30724163	   	   CTTTCTTTGAGTAAGGAATGTGTGG	   9107	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  55F	   30723804	  30723827	   CCTCCATATGTGATAACCAGAGTG	   	   	   	  
LR	  Set	  55R	   30732857	  30732880	   	   GGGATATGCTGAGACTCTAGAAGG	   9076	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  56F	   30732064	  30732087	   CAGAACCTCCATCTGTTTTCTATG	   	   	   	  
LR	  Set	  56R	   30741773	  30741796	   	   TCTGAAGAAATGACGACTGAAAGC	   9732	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  57F	   30741123	  30741146	  	   TATTTCTTGGGCAAAACTCCTAGC	   	   	   	  
LR	  Set	  57R	   30750366	  30750389	  	   	   CTGCAGTAGTTTTTATGGTGGATG	   9266	  bp	   	  
	   	   	   	   	   	  
LR	  Set	  58F	   30749675	  30749698	   TATCCTTGGTCCCTAACATAGTGC	   	   	   	  
LR	  Set	  58R	   30758913	  30758936	   	   AAAGGCTAGGATTCAGGTTTCTTC	   9261	  bp	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LR	  Set	  59F	   30757957	  30757980	   CTGCAAAATGGGAACCTAAAACAC	   	   	   	  
LR	  Set	  59R	   30768916	  30768942	   	   GTTCTCATAGACCACCTTAATTACA
TC	  
10985	  
bp	  
	  
	   	   	   	   	   	  
LR	  Set	  60F	   	  30778657	  30778679	   CTTTCGTCTTTCCAATACCTGTG	   	   	   	  
LR	  Set	  60R	   30785283	  30785305	   	   ACAATTGTTGAGACAGGAAGGTC	   6648	  bp	   	  
	   	   	   	   	   	  
	   	   	   	   	   	  
LR	  Set	  61F	   30778522	  30778545	   TGATCTTGGTTCTAACAACAGTGC	   	   	   	  
LR	  Set	  61R	   30789025	  30789048	   	   AGACAGAGCCAAGCAGAACAGTAG	   10526	  	  
bp	  
	  
	   	   	   	   	   	  
Figure 11. Ensembl. Equine chromosome 18: the vertical red arrows represent the 6 
significant SNPs on the GWAS analysis; horizontal colorful arrows represent the approximate 
genomic position of the 61 PCR products in relation to the genome; green boxes represent the 
genomic location of the BAC clones in relation to the genome; horizontal dotted lines 
represent regions that could not be sequenced with the long range PCR; black horizontal 
arrows represent the length of the PCR products, BAC clones and GWAS hits.    
 	  	  
	  
	  	  
	  	   166	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 21. Target next generation sequencing – distribution of variants called by GATK. The vast majority of 
the variants were intergenic  
Number of effects by type and region 
Type Region 
Type (alphabetical order) Count Percent 
CODON_CHANGE_PLUS_CODON_DELETION 6 0.021% 
DOWNSTREAM 1,338 4.585% 
EXON 42 0.144% 
FRAME_SHIFT 31 0.106% 
INTERGENIC 14,177 48.578% 
INTRON 8,945 30.65% 
NONE 2,730 9.354% 
NON_SYNONYMOUS_CODING 312 1.069% 
SPLICE_SITE_ACCEPTOR 7 0.024% 
SPLICE_SITE_DONOR 12 0.041% 
START_GAINED 1 0.003% 
START_LOST 1 0.003% 
STOP_GAINED 9 0.031% 
SYNONYMOUS_CODING 153 0.524% 
UPSTREAM 1,377 4.718% 
UTR_3_PRIME 38 0.13% 
UTR_5_PRIME 5 0.017% 
 
Type (alphabetical order) Count Percent 
DOWNSTREAM 1,338 4.585% 
EXON 554 1.898% 
INTERGENIC 14,177 48.578% 
INTRON 8,945 30.65% 
NONE 2,730 9.354% 
SPLICE_SITE_ACCEPTOR 7 0.024% 
SPLICE_SITE_DONOR 12 0.041% 
UPSTREAM 1,377 4.718% 
UTR_3_PRIME 38 0.13% 
UTR_5_PRIME 6 0.021% 
 
	  
Number of changes by type 
 
Type Total 
SNP 22,595 
INS 769 
DEL 1,131 
Total 24,495 	  
Number of effects by functional class 
 
Type Total 
MISSENSE 313 (65.89%) 
NONSENSE 9 (1.89%) 
SILENT 153 (32.21%) 
  	  
Number of effects by impact 
 
Type Total 
HIGH 60 
LOW 154 
MODERATE 318 
MOFIFIER 28,652 	  Table 22. Target next generation sequencing – distribution of variants called by GATK by type, 
effect by functional class and effects by impact.  
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Number of effects by type and region 
Type Region 
Type (alphabetical order) Count Percent 
CODON_CHANGE_PLUS_CODON_DELETION 90 0.001% 
CODON_CHANGE_PLUS_CODON_INSERTION 63 0% 
CODON_DELETION 124 0.001% 
CODON_INSERTION 106 0.001% 
DOWNSTREAM 705,109 4.616% 
EXON 16,707 0.109% 
EXON_DELETED 2 0% 
FRAME_SHIFT 6,655 0.044% 
INTERGENIC 8,762,874 57.372% 
INTRON 3,982,642 26.075% 
NONE 914,400 5.987% 
NON_SYNONYMOUS_CODING 46,474 0.304% 
NON_SYNONYMOUS_START 13 0% 
SPLICE_SITE_ACCEPTOR 1,747 0.011% 
SPLICE_SITE_DONOR 1,941 0.013% 
START_GAINED 612 0.004% 
START_LOST 56 0% 
STOP_GAINED 533 0.003% 
STOP_LOST 33 0% 
SYNONYMOUS_CODING 50,406 0.33% 
SYNONYMOUS_START 1 0% 
SYNONYMOUS_STOP 26 0% 
UPSTREAM 769,798 5.04% 
UTR_3_PRIME 7,810 0.051% 
UTR_5_PRIME 5,576 0.037% 
 
Type (alphabetical order) Count Percent 
DOWNSTREAM 705,109 4.616% 
EXON 121,289 0.794% 
INTERGENIC 8,762,874 57.372% 
INTRON 3,982,642 26.075% 
NONE 914,400 5.987% 
SPLICE_SITE_ACCEPTOR 1,747 0.011% 
SPLICE_SITE_DONOR 1,941 0.013% 
UPSTREAM 769,798 5.04% 
UTR_3_PRIME 7,810 0.051% 
UTR_5_PRIME 6,188 0.041% 
 
	  
Table 23. Whole genome next generation sequencing – distribution of variants called by GATK in the 
entire genome. The vast majority of the variants were intergenic  
Number of changes by type 
 
Type Total 
SNP 11,622,781 
INS 602,815 
DEL 678,316 
Total 12,903,963 	  
Number of effects by functional class 
 
Type Total 
MISSENSE 46,574 (47.75%) 
NONSENSE 522 (0.53%) 
SILENT 50,434 (51.71%) 
  	  
Number of effects by impact 
 
Type Total 
HIGH 10,967 
LOW 51,058 
MODERATE 46,857 
MOFIFIER 15,164,916 	  
Table 24. Whole genome next generation sequencing – distribution of variants called by GATK by 
type in the entire genome, effect by functional class and effects by impact 
	  	  
	  	   168	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12. Flow chart of the de novo assembly of BAC clones. The gene structure of the 
reference ACVR2A and the gaps (gray boxes) present in the reference genome are 
represented, followed by the BAC clones that were ordered (red boxes) and their location in 
relation to ACVR2A. The 3 longest contigs used to generate contig1 from BAC-A1 on 
CLCbio are represented by the black arrows. Those 3 contigs were further assembled on 
Sequencher, creating the new reference for the region (contig1 – green arrow),that 
encompasses all the gaps present in the reference genome in the region.  
	  
De	  novo	  assembly	  	  size	  (contig1)	  :	  233,376	  bp 
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Chapter 5 
 
Enhancing the PSSM2 GWAS by Genotype Imputation 
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Summary 
  
 Polysaccharide Storage Myopathy (PSSM) is a glycogen storage disease in horses 
characterized by abnormal polysaccharide inclusions in skeletal muscle. There are two 
forms of PSSM in horses recognized so far, type 1 and type 2. A mutation in the GYS1 
gene results in type 1 PSSM, but the mutation responsible for type 2 PSSM (PSSM2) is 
unknown.  Although preliminary genome wide association  (GWA) data revealed 
significant markers associated with PSSM2 on equine chromosome 18 no variants 
associated with PSSM2 were identified after extensive investigation of this region using a 
combination of target and whole genome sequencing in PSSM2 cases and controls 
(Chapter 4). Failure to identify putative functional variants on ECA18 may be due to the 
limitations of the approach used to investigate the region, or due to incomplete 
penetrance of risk the allele(s) on ECA18; making it hard to differentiate from other 
variants in the region with only 22 horses. Failure to identify functional alleles might also 
indicate that the initial association on ECA 18 was a false positive, and that the true 
region(s) of the genome harboring PSSM2 risk alleles were not identified due to low 
power of the GWA analysis.  
 
In this study, imputation was performed to increase the number of SNP markers in 
the initial GWA from 54,000 to close to 1.8 million markers (970,131 after pruning for 
minor allele frequency and marker missingness).  Association using the imputed dataset, 
while accounting for population stratification, revealed new regions associated with 
PSSM2 on chromosomes 27 and 11. Subsequent Bayesian analysis of both single marker 
and haplotype associations using hapQTL supported the association only on chromosome 
11. The region of ECA11 encompasses several annotated genes. Next generation 
sequencing data from cases and controls revealed non-synonymous mutations in the 
phosphoribosylformylglycinamidine synthase gene (PFAS) in 2 out of 3 cases and none 
of the controls. The PFAS gene encodes an enzyme that catalyzes the forth step of inosine 
monophosphate biosynthesis, which is part of the purine de novo nucleotide cycle, an 
important step for energy metabolism. Sequencing the PFAS gene in a larger population 
of cases and controls will be necessary to confirm an association with PSSM2.  This 
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study therefore has identified a new region and positional candidate gene in which to 
focus our efforts to define the genetic basis for PSSM2. 
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Introduction 
   
The power of many GWA studies in non-human species is limited by the density 
of the SNP markers on the commercially available genotyping arrays.  The goal of 
genotype imputation is to predict the genotypes of SNPs that are not directly genotyped 
in the study sample. In imputation, a reference panel of haplotypes at a denser set of 
SNPs is used to impute the genotypes in a study sample of individuals that have been 
genotyped for only a subset of these SNPs.  This is possible by using patterns of 
haplotypic variation seen in the reference panel89. The use of genotype imputation to 
increase marker density can be carried out across the whole genome to improve the 
power of GWA studies58. 
 
 According to McCoy et al59 the size of the imputed population did not impact 
imputation success when assessing genotype imputation accuracy from the 54,000 
(SNP50) to 65,000 (SNP60) equine genotyping array. However, imputation accuracy did 
increase with larger reference population sizes and when imputed and reference 
populations were breed-matched. Linkage disequilibrium (LD) also influenced genotype 
accuracy, as breeds with longer LD (Thoroughbred) had higher imputation success than 
did breeds with shorter LD (Quarter Horses)59.  Previous studies have also reported 
increased imputation accuracy with increased numbers of samples in the reference 
population, increased number of markers in the test set, and the presence of closely-
related animals in the reference panel90.  
 
The previous chapter reported results of a preliminary GWA data performed on 
PSSM2 cases and controls, genotyped with low density (54,000 marker57) equine SNP 
array, that revealed significant markers associated with PSSM2 on equine chromosome 
18 using a dominant logistic regression (p=9.44	  x	  10-­‐7	  to	  2.84	  x	  10-­‐6). Sanger and next 
generation sequencing approaches and de novo assembly of BAC clones were performed 
to further interrogate the region on chromosome 18 in cases and controls, but no variants 
associated with PSSM2 were identified. Failure to identify putative functional variants on 
ECA18 may be due to the limitations of the approach used to investigate the region, or 
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due to incomplete penetrance of risk the allele(s) on ECA18; making it hard to 
differentiate from other variants in the region with only 22 horses. Failure to identify 
functional alleles might also indicate that the initial association on ECA 18 was a false 
positive, and that the true region(s) of the genome harboring PSSM2 risk alleles were not 
identified due to low power of the GWA analysis.  
 
A new high density equine SNP array containing 670,000 markers is now 
available. The 54,000 markers from the equine SNP5057 are also present in the new 670k 
equine SNP array.  Haplotype information from 1.8 million markers (from which the 
670K SNPs were selected from) is also available, making it possible to impute from 50k 
to 670K or even up to 1.8 million markers. Population based imputation methods rely on 
linkage disequilibrium relationship between SNPs, and essentially consist of two steps 
(inference of haplotypes and imputing untyped genotypes in the test set using information 
from the best fit haplotypes derived from the reference panel)91.  Imputing less-dense 
genotype arrays is a cost-effective and powerful way to include more genetic markers 
into association studies without the need to re-genotype the samples58. Imputation from 
50K to 800K has been previously reported with very high accuracy in dairy cattle90.  
 
The purpose of the present study is to impute from 54,000 to 1.8 million markers, 
perform association analyses of the imputed data, and look for possible causative 
mutations in any regions of GWA significance in the next generation sequencing data 
from 3 PSSM2 cases and 3 controls.  
 
Material and Methods 
 
Imputation from low to high-density markers 
 
Description of the datasets 
Two datasets genotyped on 2 different SNP chips were used for the imputation, 
the reference and the test population datasets. The reference population consisted of 63 
Quarter Horses (QH) that were genotyped on the high-density 1.8 million Affymetrix 
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SNP array. The test population, to be imputed, consisted of 104 PSSM2 QH cases and 
124 QH controls, previously genotyped on the lower density Illumina Equine SNP50 
Beadchip (54,000 markers). Twenty-two of the horses genotyped on the 50K SNPchip 
were also genotyped on the 1.8 million array and are therefore present in the test and 
reference population, at different genotyping density. Also, nearly all of the 54,000 
thousand markers from the SNP50 are present in the high-density array.  
 
Data pre-processing and imputation 
The ped and map files from the 50K chip test population were converted to 
variant calling format (VCF). The reference population VCF file was split by 
chromosome using vcftools software92. Each chromosome was then individually phased 
by BEAGLE4 software93. Prior to imputation the reference and test population VCF files 
were re-organized so they had the same chromosome and marker order. The test 
population was then imputed using data from the phased reference population by 
BEAGLE4 software94. Each chromosome was imputed individually.  
BEAGLE is a population-based imputation technique that relies on LD 
relationships between markers. First there is inference of haplotypes followed by 
imputation of un-genotyped markers in the test population using information from the 
best-fit haplotype derived from the reference panel. The output file provides the 
probability of all three possible genotypes (homozygous wild-type, heterozygous and 
homozygous mutant) at each imputed marker. Further analysis was conducted using the 
most likely genotype and all 3 genotype probabilities (posterior probabilities)95.     
 
Imputation accuracy 
To determine imputation accuracy and identify poorly imputed markers, the 22 
horses that were genotyped on both arrays were extracted from both the imputed VCF file 
and the reference VCF file to generate 2 datasets; one with the imputed data from the 22 
horses and one with their known genotype. Next the imputed variants were checked for 
accuracy, by comparing which genotype BEAGLE predicted at the specific location and 
the real genotype. SNPs that did not perform well (did not have the corrected genotype in 
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more than 90% of the horses) were removed from the VCF file used for downstream 
analysis (association test).    
 
 
Genome wide association analysis (GWA) 
 
 The calculated genome inflation factor for this population of cases and controls 
was 1.12. Inflation factors greater than 1 are indicative of population structure. Also, 
multidimensional scaling plots to visualize the relationship between cases and controls in 
6 different dimensions showed controls clustering separated from cases on PC3 (principal 
component 3) and PC4 and PC1 and PC3; another evidence for the presence of 
population stratification (figure 13; figure 14). For this reason an association analysis that 
takes into consideration population structure was performed.   
   
Imputed file with all genotype probabilities and accounting for population structure 
The Genome-wide Efficient Mixed Model Association algorithm software 
(GEMMA) was used for association analysis. It fits a univariate linear mixed model 
(LMM) for marker association tests with a single phenotype to account for population 
stratification96. First the imputed VCF file (containing only the markers remaining after 
filtering for accuracy) was converted to a genotype probability format file using 
vcf2probs from BEAGLE utilities. The file was then converted to bimbam format as 
require by GEMMA software97.  By default, prior to running the association, the file was 
filtered for minor allele frequency (alleles with maf > 1% were kept in the analysis) and 
marker missingness (SNPs with a 95% genotyping rate were kept in the analysis). A 
relatedness matrix file in addition to both genotype and phenotype files, was created and 
contained the estimated relatedness between individuals. An association was then 
performed taking into consideration all 3 possible genotypes at each imputed marker and 
their probabilities and the calculated relatedness between individuals.  
 
Haplotype analysis 
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A haplotype association test was performed with haplotype quantitative loci 
(hapQTL) software98. This program has advantages in comparison with other methods. 
First, it works directly with diploid data and no phasing is required, removing the issue of 
phasing uncertainty on downstream analysis. Secondly, most programs arbitrarily use 
predetermined window lengths to define haplotypes and then test each haplotype for 
association. HapQTL defines haplotypes by learning from the data using linkage 
disequilibrium (LD) information, which is a more appropriate way since the size of LD 
blocks varies along the genome. Each SNP is a core marker for its local haplotypes and 
its associated test statistics are computed99.  
The method first infers ancestral haplotypes and their loadings at each marker for 
each individual. The loadings are then used to quantify local haplotype sharing (LHS) 
between individuals at each marker. A statistical model links the local haplotype sharing 
and phenotypes to test for association. LHS reflects genetic similarity between 
individuals. By testing whether the genetic similarity is associated with the phenotypes, 
the program can identify associations between local haplotypes and phenotypes100.  
A window of 2 megabases (Mb) around the most significant markers found on the 
association analysis performed on GEMMA101 was included in the haplotype analysis. 
The imputed ped and map files from cases and controls were converted to bimbam format 
using PLINK (--recode-bimbam)102. The analysis on hapQTL was performed as single 
marker and haplotype significance. Markers with minor allele frequency lower than 10% 
were removed from prior to the analysis. The program generates Bayes factors (the 
change of odds ratio in light of data) for the haplotype and single marker association 
analysis.  
 
Variant discovery from whole genome next generation sequencing  
A VCF file containing variant data from 3 PSSM2 cases and 3 controls from 
whole genome next generation sequencing (NGS) was available from the work 
performed around chromosome 18. This file was originally used to investigate possible 
variants relevant to PSSM2 according to the original GWAS data. Briefly, the cases were 
selected based on severity of muscle biopsy findings and were also previously genotyped 
on the equine SNP50 array. Controls were randomly selected from the list of horses 
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previously genotyped on the SNP50 array. Reads were sequenced using Illumina HiSeq, 
100 bp paired-end, 12x coverage per horse (~160 million reads/horse). Each sample was 
sequenced in more than one lane. The reads were mapped to the equine reference genome 
(EqCab2) using BWA103 aligner and variants were called by the Genome Analysis toolkit 
(GATK)81 using the Unified genotyper tool for variant discovery (SNPs and indels). 
Cases and controls were mapped individually and then merged prior to GATK analysis, 
to call variants simultaneously. Variants were then annotated by snpEff software for 
variant location and their potential effect. SnPSift case control was used to calculate 
variant abundance differences between cases and controls. Variants were prioritized if 1) 
they were relatively abundant in cases compared to controls; 2) they occurred within a 
gene with known biologic function relevant to PSSM2 pathogenesis; and/or 3) the variant 
had a predicted functional effect.  
 
Results 
 
Imputation results and accuracy  
The reference VCF file had approximately 1,846,962 markers. The total number 
of markers in the target population (PSSM2 cases and controls) after imputation was 
approximately 1,662,356. Markers that were not correctly imputed in at least 90% of the 
22 horses present on target and reference population were removed from the final 
imputed file prior to downstream analysis.  After removing markers for imputation 
accuracy, 1,295,518 were kept for downstream analysis; 84% of the markers analyzed 
had their genotype correctly imputed by BEAGLE  
 
Association test, all genotype probabilities and accounting for population 
structure  
The total number of markers initially included in the association test performed on 
GEMMA was ~ 1,295,518. From those, 970,131 were included in the association 
analysis, after filtering for MAF and missingness. The most significant markers were 
found on chromosome 11 (bp: 51,156,324; p-value: 7.37E-06) and chromosome 27 (bp: 
33,027,045; p-value: 7.19E -06) (table 25; figure 15).  
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Haplotype Analysis  
 
Chromosome 11:  
A total of 499 markers were included on the haplotype association analysis for 
chromosome 11 (bp: 50,585,723 - 52,591,016); total region ~2 Mbp.  A higher bayes 
factor for the haplotype analysis (bf2) was observed between markers 51,255,930 – 
51,421,471, suggesting an association between this region and PSSM2 (figure 16). The 
region encompasses 5 annotated equine genes: RPL26, KRBA2, RNF222, NDEL1 and 
MYH10. Also, several other equine genes are present nearby.  
 
Chromosome 27:  
A total of 469 markers were included on the haplotype association analysis for 
chromosome 27 (bp: 32,790,007 – 35,930,826); total region ~2 Mbp. No significant 
haplotype associations were found between this region on chromosome 27 and PSSM2 
(figure 17).  
 
Variant discovery from whole genome next generation sequencing  
Variants on chromosome 11 from base pair position 51,104,988 to 52,026,206 
were annotated and their prevalence evaluated in cases and controls. A total of 4,663 
variants, mostly intronic, were present in this region.  A total of 18 annotated equine 
genes are present in the region (CTC1, PFAS, RANGRF, SLC25A35, ARHGEF15, ODF4, 
RPL26, KRBA2, RNF222, INDEL1, MYH10, CCDC42, MFSD6L, PIK3R5, PIK3R6, 
NTN1 and STX8. figure 16). Based on biological function, predicted functional effect and 
relative abundance between cases and controls, 4 variants in the 
phosphoribosylformylglycinamidine synthase gene (PFAS) were identified as possible 
mutations associated with the phenotype (table 26).   Three of the mutations were non-
synonymous and present in 2 out of 3 cases and none of the controls and 1 mutation was 
non-synonymous and present in 2 of the 3 cases and one of the 3 controls. All are 
missense mutations; a C to T substitution that changes the amino acid from threonine to 
methionine at position 37 (T37M); a G to A substitution that changes the amino acid 
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from valine to isoleucine at position 307 (V307I); a C to T substitution that changes the 
amino acid from threonine to isoleucine at position 593 (T593I); a A to G substitution 
that changes the amino acid from aspargine to serine at position 647 (N647S).  
Non-synonymous mutations were also found on genes CTC1, RANGRF, 
ARHGEF15, MFSD6L and NTN1, but their abundance was not different between cases 
and controls.  
   
Discussion 
  
Results presented in Chapter 4 found no detected variants on chromosome 18 in 
the region of the suggested GWA hit from the 54,000 SNP genome scan that were 
associated with PSSM2. Failure to identify putative functional variants on ECA18 may 
be due to the limitations of the approach used to investigate the region or due to 
incomplete penetrance of the risk allele(s) on ECA18. Genotyping an increased number 
of cases and controls for all possible variants on ECA18 would be necessary to find 
potential risk alleles with incomplete penetrance at this locus. Another potential 
explanation is that the initial association on ECA18 was a false positive association and 
failure to identify functional alleles would support this assertion.  
It is also possible that the true region(s) of the genome harboring PSSM2 risk 
alleles were not identified due to low power of the GWA analysis. While this 54K SNP 
chip technology has been successful in finding several genomic regions responsible for 
important phenotypes104, it may not be powerful enough for the study of PSSM2. 
Quarters Horses are known to have lower LD in comparison with other breeds, due to 
admixture at breed foundation and the rapid population expansion of the breed. GWA 
analysis relies on LD between the markers and the causative allele. A denser set of SNP 
markers would be advantageous since it would decrease the distance between the putative 
causal mutation and the nearest SNP marker, thus likely increasing the LD between the 
SNP markers and the causal mutation, therefore increasing the power to find a causative 
mutation. To overcome this issue in a cost-effective way, imputation can be performed 
and the density of the markers present on the initial GWA can be increased without the 
need to further genotype the test population, as long as a reference population that was 
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genotyped on a denser array is available. Here we took advantage of a dense set of ~1.8 
million markers genotyped in >500 horses (including 63 Quarter Horses) to impute from 
~54k to a higher density to perform a second GWA for PSSM2.  
Imputed genotypes are predictions, and not actual observations. Subsequent 
analyses, such as testing for phenotypic association should incorporate the uncertainty of 
these predictions, to avoid spurious results. A general approach for this is the use of 
posterior probabilities for the imputed genotypes, which are probabilities of the three 
possible genotypes obtained from imputation. Those without uncertainty due to 
imputation will be 1.0. Genotype probabilities can either be incorporated directly into the 
statistical analysis (in lieu of the actual genotype) or can be used to assign a best guess 
genotype. Typically the former is a more powerful approach. One potential pitfall of 
genotype imputation is unknown genotypic accuracy, which adds an additional level of 
uncertainty to the statistical analysis. However, since there were 22 horses that were 
genotyped on both arrays (54k low and 1.8M high-density), the accuracy of the 
imputation could be evaluated in these horses. This allowed for removal of markers that 
did not perform well, leaving high quality imputed markers for downstream analysis. 
 
 By performing genotype imputation the marker density increased dramatically 
from 54,000 to ~ 900,000 (after pruning for MAF and marker missingness) and new 
GWA hits were identified. The previous hit on chromosome 18 disappeared, likely 
confirming that the association on ECA18 was a false positive in the previous analysis.  
 The association analysis performed with the imputed data revealed a significant 
hit, also suggested by the haplotype analysis, on chromosome 11. The PFAS gene 
encodes an enzyme that catalyzes the forth step of IMP (inosine monophosphate) 
biosynthesis, which is part of the purine de novo nucleotide cycle (synthesis of purine 
nucleotides requires a total of 10 enzymatic steps). Purines are fundamental biological 
molecules, serving as components of DNA and RNA, and are essential for processes like 
intracellular and extracellular signaling, energy metabolism and as coenzymes. Skeletal 
muscle is a major site of de novo purine production in mammalians. During intense 
exercise a breakdown of the adenine nucleotide happens in the working muscle through 
the deamination of AMP to IMP and NH3 (ammonia).  It is possible that a mutation in 
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the PFAS gene could lead to a deficiency in the de novo purine nucleotide cycle, 
decreasing purine synthesis in the muscle which could lead to impaired muscle 
metabolism.  
 
Sequencing the PFAS gene in a larger population of cases and controls is 
necessary to confirm a possible association between this mutation and PSSM2 horses. In 
conclusion, the imputed GWA followed by association analysis on GEMMA has several 
advantages in relation to previous GWA analysis. It dramatically increases the number of 
markers, it considers all 3 genotype probabilities instead of the best guess genotype, and 
it accounts for population stratification. For those reasons, chromosome 11 is now the top 
priority location in the genome to look for PSSM2 and further evaluation of variants in 
the region, in a larger number of horses is essential.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  
CHR	   ID	   BP	   p_val	  
27	   AX-­‐103844004	   33027045	   7.19E-­‐06	  
11	   AX-­‐104426812	   51156324	   7.37E-­‐06	  
27	   AX-­‐104019388	   32984360	   1.05E-­‐05	  
11	   AX-­‐104121058	   51105100	   1.08E-­‐05	  
11	   AX-­‐104026085	   52025433	   1.13E-­‐05	  
27	   AX-­‐104877095	   35714262	   1.30E-­‐05	  
11	   AX-­‐103715095	   52016078	   1.37E-­‐05	  
11	   AX-­‐103082061	   51135152	   1.48E-­‐05	  
11	   AX-­‐103785085	   52013360	   1.55E-­‐05	  
11	   AX-­‐103817490	   52014372	   1.75E-­‐05	  
11	   AX-­‐103653838	   52044500	   1.79E-­‐05	  
11	   AX-­‐103724276	   51323761	   2.00E-­‐05	  
11	   AX-­‐104120636	   51752529	   2.44E-­‐05	  
11	   AX-­‐103088090	   51176877	   2.65E-­‐05	  
11	   AX-­‐104467824	   51166724	   2.66E-­‐05	  
11	   AX-­‐103037719	   51386640	   2.88E-­‐05	  
11	   AX-­‐104112223	   51103136	   2.91E-­‐05	  	  
Table 25.  List of most significant markers on chromosome 11, from GEMMA. CHR: 
chromosome; ID: marker name; BP: base pair position; p_val: p-value for marker association with 
phenotype 
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Figure 15. Manhatan plot from imputation and linear mixed model analysis on GEMMA.  
	  
Figure 14. Principal component analysis. Cases 
(red) and controls (blue). PC3 versus PC4. 
Figure 13. Principal component analysis. Cases 
(red) and controls (blue). PC1 versus PC3. 
	  
PC3 PC1 
PC4 PC3 
	  	  
	  	   183	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Haplotype analysis on chromosome 11. The log10 Bayes factor (y axis) are plotted at 
each marker (x axis). The peak area represents the region with the highest haplotype significance. 
The top figure shows the genes annotated on ensemble in the area with the highest haplotype 
significance 
Figure 17. Haplotype analysis on chromosome 27. The log10 Bayes factor(y axis) are plotted at 
each marker (x axis) 
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Chr Position Mutation Gene CT 
hom 
CT 
het 
CT 
wt 
CA 
hom 
CA 
het 
CA 
wt 
p-val  
11 51131050 NON_SYNONYMOUS
_CODING 
PFAS 0 0 3 0 2 1 GENO 
6.802e-
02 
11 51133614 NON_SYNONYMOUS
_CODING 
PFAS 0 0 3 0 2 1 GENO 
4.163e-
02 
11 51139603 NON_SYNONYMOUS
_CODING 
PFAS 1 0 2 0 2 1 DOM 
3.000e-
01 
11 51140158 NON_SYNONYMOUS
_CODING 
PFAS 0 0 3 0 2 1 GENO 
6.802e-
02 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 26. Significant markers on chromosome 11 and their base pair position and associated 
gene name. CT hom: control homozygous; CT het: control heterozygous; CT wt: control wild-type; 
CA hom: case homozygous; CA het: case heterozygous; CA wt: case wild-type; p-val: p-value for 
variant prevalence between cases and controls.  
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Chapter 6 
 
Final Considerations and Future Directions 
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Type 1 Polysaccharide Storage Myopathy 
 
 The gene expression profile and enrichment analysis in PSSM1 cases generated 
hypotheses to the metabolic pathways that are abnormal in those horses, which includes 
mitochondria biogenesis, oxidative phosphorylation, fatty acid metabolism, glycogen and 
glucose metabolism (Chapter 3). The study of enrichment analysis is of great value to 
understand changes in important pathways associated with diseases or conditions. While 
the results of the enrichment analysis observed in this study were very consistent between 
experiments, a better understanding of the specific alterations that are occurring in gene 
regulation in these pathways is necessary. Manual annotation of the pathways based on 
the disease of interest might be a good solution. Better pathway analysis results would 
probably be generated if poor annotation were not present on both ends (equine genome 
and the publicly available pathways). In the case of the equine reference genome, 
hundreds of transcripts could not be identified despite the effort of blasting them to other 
species. Some of the available pathways are missing key elements in the physiology of 
the processes that they describe. To overcome this issue, manually annotating pathways 
based on what is known about PSSM1 and the genes that are present on the gene 
expression profile as significant might be of great value. This process could be done by 
consulting available publications (text mining programs), protein and gene interaction 
databases.  
 
For a complete description of the equine muscle transcriptome de novo assembly 
of the raw RNA reads can help identify new transcripts and isoforms, since this approach 
does not depend in the reference genome. Oases105 is a de novo transcriptome assembler 
designed to produce transcripts from for short reads. Oases uploads a preliminary 
assembly produced by Velvet and clusters the contigs into small groups, called loci. 
Oases then processes the transcripts and constructs transcript isoforms. For good 
accuracy of de novo transcripts, high quality data from sequencing are necessary. One 
important step prior to performing the de novo assembly is to trim reads with low 
sequencing quality score. Oases runs the de novo assembly in several different k-mer 
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sizes. At the end (using the merge function) Oases merges transcripts from different k-
mer sizes, in an attempt to create longer reads. Once de novo transcripts are identified 
they can be annotated by blasting to available databases. The new transcripts and 
isoforms can also be added to the differentially expression analysis to better understand 
the changes in gene expression in cases and controls. First a new equine transcriptome 
containing the new transcripts/isoforms is generated and the raw reads are mapped to this 
reference for expression quantification with the caveat that reads will very frequently not 
map uniquely to the de novo reference transcriptome. For this reason the use of programs 
that deal with the mapping uncertainty is necessary to accurately identify changes in gene 
expression. Corset106 is a program that performs a gene level analysis of de novo 
assembled transcripts. It clusters the contigs into "genes" not just based on similarity. It 
takes in consideration the difference in abundance of raw reads that are present in cases 
and controls. Corset takes the issue of multi-mapping and uses it as an advantage and 
produces an output (gene counts) that can be used by Edge R (differentially expressed 
analysis).  
 
Also the transcriptome profile in this study was measured only at the gene level. 
When a better equine reference genome becomes available, expression profiles of the 
genes at the isoform (alternative splicing) levels can be performed. This is the ideal way 
to measure differences in expression between groups since the same gene can have 
isoforms that are upregulated and isoforms that are down regulated, causing the final 
expression for that specific gene to be erroneously unchanged. Creating libraries with 
longer (100 to 150 bp) and paired end reads would be ideal to detect splice variants.   
 
The need for a better assembled/annotated equine reference genome has become 
even more apparent with the studies performed in this thesis. To better annotate the 
reference genome that is already available, AUGUSTUS107 could be used. AUGUSTUS 
is a program for gene discovery that incorporates multiple hints into gene prediction 
models (sources of extrinsic and intrinsic hints). Intrinsic hints include the genomic 
sequence data and external hints include ESTs (downloaded from available databases) 
and data generated from RNA-Seq (BAM files). The program was developed into a 
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pipeline where high-throughput RNA-Seq data was incorporated. This information is 
used to improve annotation and identification of novel genes.   
 
 It is also possible that PSSM2 is not the result of mutation(s) in a protein-
encoding gene and is instead a result of alterations in regulatory elements that control 
gene expression.  To be able to look at the gene expression from all different angles, 
creating a new library that does not restrict the RNA collection to polyA (mRNA) would 
be ideal to identify possible regulatory elements that might drive changes in gene 
expression, like small (e.g. miRNA) and long-non coding RNAs (e.g. lincRNAS).  
 
 In addition, the study of proteomics and metabolomics, in addition to gene 
expression, would give the very last and most important piece of information to define 
the metabolic changes in PSSM1 horses, by looking at potential differences in profile 
between groups. Proteomics determines the protein content within a wide size range and 
metabolomics allows a non-target survey of small size metabolites in a biological sample 
(small-molecules called chemical fingerprints). For example, fatty acids, sugars and 
protein metabolites can be analyzed and their abundancy can be compared between 
groups, as well as proteins involved in oxidative metabolism (e.g. NADH ubiquinone), 
glycolysis, glycogen metabolism (e.g. glycogen phosphorylase) and anaerobic 
metabolism. In conclusion, the end products of cellular processes can be identified 
revealing a snap-shot of the physiology of the cell studied, which would be of great 
importance when comparing cases to controls. 
 
Type 2 Polysaccharide Storage Myopathy 
  
The genetic basis of type 2 PSSM is an area of ongoing research. A previous 
GWAS using the equine SNP50 array showed a significant marker associated with 
PSSM2 on equine chromosome 18. Whole genome and target (around chromosome 18) 
next generation sequencing of cases and controls and BAC clones to fill gaps in the 
reference genome did not identify mutations in the region that could explain PSSM2 
(Chapter 4). To overcome this issue imputation from 50K to 1.8 million markers was 
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performed and an association study of the new markers revealed a region on chromosome 
11 significantly associated with PSSM2 (Chapter 5). This region remained significant 
after haplotype analysis. 
 
 Four non-synonymous mutations of potential interest were identified in the 
phosphoribosylformylglycinamidine synthase gene (PFAS). Three of the mutations were 
non-synonymous and present in 2 out of 3 cases and none of the controls, and 1 mutation 
was non-synonymous and present in 2 of the 3 cases and one of the 3 controls. The PFAS 
gene encodes an enzyme that catalyzes the forth step of IMP (inosine monophosphate) 
biosynthesis, which is part of the purine de novo nucleotide cycle. Purines are 
fundamental biological molecules, serving as components of DNA and RNA, and are 
essential for processes like intracellular and extracellular signaling, energy metabolism 
and as coenzymes. The equine PFAS gene has 1 annotated transcript with 4,017 base 
pairs and 28 exons. To further evaluate these PFAS mutations as a possible cause of 
PSSM2, primers to amplify and sequence the region encompassing this gene in all 
PSSM2 cases (104 horses) and controls (124 horses) will be designed. However, as 
described more below, if PSSM2 is caused by a gene with incomplete penetrance or low-
to-moderate relative risk, or if more than one form of PSSM2 exists in the study 
population, a perfect correlation between the mutation and the phenotype will not be 
expected.  
 
If none of the four mutations in the PFAS gene have significant allele differences 
between cases and controls a new approach to investigate the region on chromosome 11 
will be necessary. A Sequenom assay could be designed to further investigate 
chromosome 11, including the non-synonymous mutations that were found on genes 
CTC1, RANGRF, ARHGEF15, MFSD6L and NTN1. Their abundance was not 
significantly different between cases and controls on the analysis performed on chapter 5, 
but sequence data from only 3 horses were present on each group to detect and estimate 
allele frequency. A Sequenom assay containing all cases (104 horses) and controls (124 
horses) would be far more informative. The SNP list can be submitted to GeneSeek to 
prepare multiplex SNP genotyping assays for the Sequenom platform. The data generated 
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by Sequenom can then be pruned for genotyping rate and quality and an association 
analysis can then be performed.  
 
Also, since imputation to the high-density 1.8 million SNP markers is being done 
in other breeds in our laboratory, a better understanding of which filter parameters should 
be used to keep just high quality imputed markers in the downstream analysis will be 
developed. By better filtering imputed markers for accuracy, a chance of finding false 
positive or false negative markers in the association analysis would decrease. If those 
approaches still do not answer what causes PSSM2 by finding a highly significant locus 
with alleles that are highly associated with the disease, increasing the number of cases 
and controls on the dataset and directly genotyping them on the 670K array might be 
necessary. This approach would increase the power of the study by increasing the number 
of cases and controls, and would also increase the marker density without having the 
genotype uncertainty that is due to the imputation process. Also increasing the number of 
horses in the study would be needed to find alleles with low-to-moderate risk. The 
approach described in this paragraph would be of value if the markers on chromosome 11 
are false positives and true loci associated with PSSM2 were not detected by the current 
analysis.   
 
It is also possible that PSSM2 is a polygenic disease or that other forms of 
excessive glycogen storage diseases exist and the horses called PSSM2 actually represent 
more than one disease. In both cases the power of the GWAS would be significantly 
affected. To overcome the issue of a polygenic disease, more cases and controls are 
necessary to increase the power of the GWAS. To overcome the issue of genetic and 
phenotypic heterogeneity, a different methodology is necessary to better phenotype the 
horses prior to association studies. Studying gene expression profile in PSSM2 horses 
and controls and integrating those findings with proteomics and metabolomics analysis 
might help cluster PSSM2 horses in different phenotype groups.  
  
Even if all the horses in a PSSM2 GWAS dataset have the same genetic basis for 
their glycogen storage disease, evaluation of the gene expression in the muscle of horses 
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with PSSM2 and comparing those changes with controls and PSSM1 horses before and 
after exercise might provide important information. Considering the use of gene 
expression profiling along with proteomics and metabolomics to explain what the 
ultimate changes are in the muscle of PSSM2 horses would be of great value. The 
metabolome represents the collection of all metabolites in a biological tissue and are the 
end products of cellular processes. Gene expression data and proteomic analyses reveal 
the set of gene products being produced in the cell and metabolic profiling can give an 
instantaneous picture of the physiology of the sampled tissue. The integration of 
transcriptomic, proteomic and metabolomic information would provide a better 
understanding of the muscle pathophysiology of PSSM2 horses and, when combined with 
clinical and other diagnostic data, might enable a better phenotype with which to perform 
a GWAS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	  
	  	   192	  
Reference List 	  	   1.	  	   Firshman	  AM,	  Valberg	  SJ,	  Bender	  JB,	  Finno	  CJ.	  Epidemiologic	  characteristics	  and	  management	  of	  polysaccharide	  storage	  myopathy	  in	  Quarter	  Horses.	  Am	  J	  Vet	  Res	  2003;	  64(10):	  1319-­‐27.	  	   2.	  	   Valberg	  SJ,	  Cardinet	  GH,	  III,	  Carlson	  GP,	  DiMauro	  S.	  Polysaccharide	  storage	  myopathy	  associated	  with	  recurrent	  exertional	  rhabdomyolysis	  in	  horses.	  Neuromuscul	  Disord	  1992;	  2(5-­‐6):	  351-­‐9.	  	   3.	  	   Carlstrom	  B.	  Uber	  die	  atiologie	  und	  pathogenese	  der	  kreuzlahme	  des	  pferdes	  (Hemaglobinaemia	  paralytica).	  Scandinav	  Archiv	  1932;	  62:	  1-­‐62.	  	   4.	  	   Firshman	  AM,	  Baird	  JD,	  Valberg	  SJ.	  Prevalences	  and	  clinical	  signs	  of	  polysaccharide	  storage	  myopathy	  and	  shivers	  in	  Belgian	  draft	  horses.	  J	  Am	  Vet	  Med	  Assoc	  2005;	  227(12):	  1958-­‐64.	  	   5.	  	   Valentine	  BA,	  Habecker	  PL,	  Patterson	  JS,	  Njaa	  BL,	  Shapiro	  J,	  Holshuh	  HJ	  et	  al.	  Incidence	  of	  polysaccharide	  storage	  myopathy	  in	  draft	  horse-­‐related	  breeds:	  a	  necropsy	  study	  of	  37	  horses	  and	  a	  mule.	  J	  Vet	  Diagn	  Invest	  2001;	  13(1):	  63-­‐8.	  	   6.	  	   Valentine	  BA,	  Cooper	  BJ.	  Incidence	  of	  polysaccharide	  storage	  myopathy:	  necropsy	  study	  of	  225	  horses.	  Vet	  Pathol	  2005;	  42(6):	  823-­‐7.	  	   7.	  	   McGowan	  CM,	  McGowan	  TW,	  Patterson-­‐Kane	  JC.	  Prevalence	  of	  equine	  polysaccharide	  storage	  myopathy	  and	  other	  myopathies	  in	  two	  equine	  populations	  in	  the	  United	  Kingdom.	  Vet	  J	  2009;	  180(3):	  330-­‐6.	  	   8.	  	   McCue	  ME,	  Ribeiro	  WP,	  Valberg	  SJ.	  Prevalence	  of	  polysaccharide	  storage	  myopathy	  in	  horses	  with	  neuromuscular	  disorders.	  Equine	  Vet	  J	  Suppl	  2006;(36):	  340-­‐4.	  	   9.	  	   McCue	  ME,	  Valberg	  SJ,	  Lucio	  M,	  Mickelson	  JR.	  Glycogen	  synthase	  1	  (GYS1)	  mutation	  in	  diverse	  breeds	  with	  polysaccharide	  storage	  myopathy.	  J	  Vet	  Intern	  Med	  2008;	  22(5):	  1228-­‐33.	  	   10.	  	   Byrne	  E,	  Jones	  S,	  Valberg	  SJ,	  Zimmel	  DN,	  Cohen	  N.	  Rhabdomylosis	  in	  two	  foals	  with	  polysaccharide	  storage	  myopathy	  and	  concurrent	  pneumonia.	  Compendium	  on	  Continuing	  Education	  for	  the	  Practicing	  Veterinarian	  2000;	  22:	  503-­‐7.	  	   11.	  	   Bloom	  BA,	  Valentine	  BA,	  Gleed	  RD,	  Cable	  CS.	  Postanaesthetic	  recumbency	  in	  a	  Belgian	  filly	  with	  polysaccharide	  storage	  myopathy.	  Vet	  Rec	  1999;	  144(3):	  73-­‐5.	  
	  	  
	  	   193	  
	   12.	  	   McCue	  M,	  Armien	  A,	  Lucio	  M,	  Mickelson	  J,	  Valberg	  S.	  Comparative	  skeletal	  muscle	  histopathologic	  and	  ultrastructural	  features	  in	  two	  forms	  of	  Polysaccharide	  Storage	  Myopathy	  in	  horses.	  Vet	  Pathol	  2009.	  	   13.	  	   Firshman	  AM,	  Valberg	  SJ,	  Bender	  JB,	  Annandale	  EJ,	  Hayden	  DW.	  Comparison	  of	  histopathologic	  criteria	  and	  skeletal	  muscle	  fixation	  techniques	  for	  the	  diagnosis	  of	  polysaccharide	  storage	  myopathy	  in	  horses.	  Vet	  Pathol	  2006;	  43(3):	  257-­‐69.	  	   14.	  	   De	  La	  Corte	  FD,	  Valberg	  SJ,	  MacLeay	  JM,	  Mickelson	  JR.	  Developmental	  onset	  of	  polysaccharide	  storage	  myopathy	  in	  4	  Quarter	  Horse	  foals.	  J	  Vet	  Intern	  Med	  2002;	  16(5):	  581-­‐7.	  	   15.	  	   Naylor	  RJ,	  Livesey	  L,	  Schumacher	  J,	  Henke	  N,	  Massey	  C,	  Brock	  KV	  et	  al.	  Allele	  copy	  number	  and	  underlying	  pathology	  are	  associated	  with	  subclinical	  severity	  in	  equine	  type	  1	  polysaccharide	  storage	  myopathy	  (PSSM1).	  PLoS	  One	  2012;	  7(7):	  e42317.	  	   16.	  	   Valentine	  BA,	  Credille	  KM,	  Lavoie	  JP,	  Fatone	  S,	  Guard	  C,	  Cummings	  JF,	  Cooper	  BJ.	  Severe	  polysaccharide	  storage	  myopathy	  in	  Belgian	  and	  Percheron	  draught	  horses.	  Equine	  Vet	  J	  1997;	  29(3):	  220-­‐5.	  	   17.	  	   Annandale	  EJ,	  Valberg	  SJ,	  Mickelson	  JR,	  Seaquist	  ER.	  Insulin	  sensitivity	  and	  skeletal	  muscle	  glucose	  transport	  in	  horses	  with	  equine	  polysaccharide	  storage	  myopathy.	  Neuromuscul	  Disord	  2004;	  14(10):	  666-­‐74.	  	   18.	  	   Firshman	  AM,	  Baird	  J.D.,	  Valberg	  SJ.	  Prevalence	  of	  polysaccharide	  storage	  myopathy	  and	  "shivers"	  in	  Belgian	  draft	  horses.	  J.Vet.Intern.Med.	  in	  press.	  2006.	  	  Ref	  Type:	  Abstract	  	   19.	  	   McCue	  ME,	  Ribeiro	  WP,	  Valberg	  SJ.	  The	  prevalence	  of	  polysaccharide	  storage	  myopathy	  in	  Quarter	  Horses.	  J	  Vet	  Intern	  Med	  2006;	  20(3):	  710.	  	   20.	  	   McCue	  ME,	  Valberg	  SJ.	  Estimated	  prevalence	  of	  polysaccharide	  storage	  myopathy	  among	  overtly	  healthy	  Quarter	  Horses	  in	  the	  United	  States.	  J	  Am	  Vet	  Med	  Assoc	  2007;	  231(5):	  746-­‐50.	  	   21.	  	   Valberg	  SJ,	  MacLeay	  JM,	  Billstrom	  JA,	  Hower-­‐Moritz	  MA,	  Mickelson	  JR.	  Skeletal	  muscle	  metabolic	  response	  to	  exercise	  in	  horses	  with	  'tying-­‐up'	  due	  to	  polysaccharide	  storage	  myopathy.	  Equine	  Vet	  J	  1999;	  31(1):	  43-­‐7.	  	   22.	  	   Valberg	  SJ,	  Townsend	  D,	  Mickelson	  JR.	  Skeletal	  muscle	  glycolytic	  capacity	  and	  phosphofructokinase	  regulation	  in	  horses	  with	  polysaccharide	  storage	  myopathy.	  Am	  J	  Vet	  Res	  1998;	  59(6):	  782-­‐5.	  
	  	  
	  	   194	  
	   23.	  	   Annandale	  EJ,	  Valberg	  SJ,	  Essen	  Gustavsson	  B.	  The	  effects	  of	  submaximal	  excercise	  of	  adenine	  nucleotide	  concentrations	  in	  skeletal	  muscle	  fibers	  of	  horses	  with	  polysaccharide	  storage	  myopathy.	  Am	  J	  Vet	  Res	  2005;	  66(5):	  839-­‐45.	  	   24.	  	   Dranchak	  P,	  Leiper	  F,	  Valberg	  S,	  Piercy	  R,	  Carling	  D,	  McCue	  M,	  Mickelson	  J.	  Biochemical	  and	  genetic	  evaluation	  of	  the	  role	  of	  AMPK	  in	  equine	  polysaccharide	  storage	  myopathy.	  Am	  J	  Vet	  Res	  2007.	  	   25.	  	   McCue	  ME,	  Valberg	  SJ,	  Miller	  MB,	  Wade	  C,	  DiMauro	  S,	  Akman	  HO,	  Mickelson	  JR.	  Glycogen	  synthase	  (GYS1)	  mutation	  causes	  a	  novel	  skeletal	  muscle	  glycogenosis.	  Genomics	  2008;	  91(5):	  458-­‐66.	  	   26.	  	   Valberg	  SJ,	  MacLeay	  JM,	  Billstrom	  JA,	  Hower-­‐Moritz	  MA,	  Mickelson	  JR.	  Skeletal	  muscle	  metabolic	  response	  to	  exercise	  in	  horses	  with	  'tying-­‐up'	  due	  to	  polysaccharide	  storage	  myopathy.	  Equine	  Vet	  J	  1999;	  31(1):	  43-­‐7.	  	   27.	  	   J.G	  Salway.	  Metabolism	  at	  a	  Glance.	  Third	  Edition.	  2004.	  	  Blackwell	  Publishing.	  	  Ref	  Type:	  Serial	  (Book,Monograph)	  	   28.	  	   Rutherford	  M,	  Kaese	  H,	  Hendrickson	  J,	  Wagner	  ML,	  McCue	  ME,	  Binns	  M	  et	  al.	  Equine	  recurrent	  Uveitis	  association	  with	  the	  major	  histocompatibility	  complex.	  Plant	  and	  Animal	  Genome	  XVI.	  Plant	  and	  Animal	  Genome	  	  XVI,	  586.	  2008.	  	  Ref	  Type:	  Conference	  Proceeding	  	   29.	  	   Ribeiro	  WP,	  Valberg	  SJ,	  Pagan	  JD,	  Gustavsson	  BE.	  The	  effect	  of	  varying	  dietary	  starch	  and	  fat	  content	  on	  serum	  creatine	  kinase	  activity	  and	  substrate	  availability	  in	  equine	  polysaccharide	  storage	  myopathy.	  J	  Vet	  Intern	  Med	  2004;	  18(6):	  887-­‐94.	  	   30.	  	   Borgia	  LA,	  Valberg	  SJ,	  McCue	  ME,	  Pagan	  JD,	  ROE	  CR.	  Effect	  of	  dietary	  fats	  with	  odd	  or	  even	  numbers	  of	  carbon	  atoms	  on	  metabolic	  response	  and	  muscle	  damage	  with	  exercise	  in	  Quarter	  HorseΓÇôtype	  horses	  with	  type	  1	  polysaccharide	  storage	  myopathy.	  American	  Journal	  of	  Veterinary	  Research	  2010;	  71(3):	  326-­‐36.	  	   31.	  	   Baird	  JD,	  Valberg	  SJ,	  Anderson	  SM,	  McCue	  ME,	  Mickelson	  JR.	  Presence	  of	  the	  glycogen	  synthase	  1	  (GYS1)	  mutation	  causing	  type	  1	  polysaccharide	  storage	  myopathy	  in	  continental	  European	  draught	  horse	  breeds.	  Vet	  Rec	  2010;	  167(20):	  781-­‐4.	  	   32.	  	   McCue	  ME,	  Valberg	  SJ,	  Jackson	  M,	  Borgia	  L,	  Lucio	  M,	  Mickelson	  JR.	  Polysaccharide	  storage	  myopathy	  phenotype	  in	  quarter	  horse-­‐related	  breeds	  is	  modified	  by	  the	  presence	  of	  an	  RYR1	  mutation.	  Neuromuscul	  Disord	  2009;	  19(1):	  37-­‐43.	  
	  	  
	  	   195	  
	   33.	  	   Stanley	  RL,	  McCue	  ME,	  Valberg	  SJ,	  Mickelson	  JR,	  Mayhew	  IG,	  McGowan	  CM	  et	  
al.	  A	  glycogen	  synthase	  1	  mutation	  associated	  with	  equine	  polysaccharide	  storage	  myopatyh	  and	  exertional	  rhabdomyolysis	  occurs	  in	  a	  variety	  of	  UK	  breeds.	  Equine	  Vet.J	  .	  2009.	  	  Ref	  Type:	  In	  Press	  	   34.	  	   Herszberg	  B,	  McCue	  ME,	  Larcher	  T,	  Mata	  X,	  Vaiman	  A,	  Chaffaux	  S	  et	  al.	  A	  GYS1	  gene	  mutation	  is	  highly	  associated	  with	  polysaccharide	  storage	  myopathy	  in	  Cob	  Normand	  draught	  horses.	  Anim	  Genet	  2009;	  40(1):	  94-­‐6.	  	   35.	  	   McCue	  M,	  Andersen	  S,	  Valberg	  S,	  Piercy	  R,	  Barakzai	  S,	  Binn	  M	  et	  al.	  Estimated 
prevalence of the Type 1 Polysaccharide Storage Myopathy mutation in selected 
North American and European breeds.	  Animal	  Genetics	  2010.	  	   36.	  	   Baird	  JD,	  Valberg	  SJ,	  Anderson	  SM,	  McCue	  ME,	  Mickelson	  JR.	  Presence	  of	  the	  glycogen	  synthase	  1	  (GYS1)	  mutation	  causing	  type	  1	  polysaccharide	  storage	  myopathy	  in	  continental	  European	  draught	  horse	  breeds.	  Vet	  Rec	  2010;	  167(20):	  781-­‐4.	  	   37.	  	   JOHLIG	  L,	  Valberg	  SJ,	  Mickelson	  JR,	  KLUKOWSKA	  J,	  REUSSER	  HR,	  Straub	  R,	  Gerber	  V.	  Epidemiological	  and	  genetic	  study	  of	  exertional	  rhabdomyolysis	  in	  a	  Warmblood	  horse	  family	  in	  Switzerland.	  Equine	  Veterinary	  Journal	  2011;	  43(2):	  240-­‐5.	  	   38.	  	   McCoy	  AM,	  Schaefer	  R,	  Petersen	  JL,	  Morrell	  PL,	  Slamka	  MA,	  Mickelson	  JR	  et	  al.	  Evidence	  of	  positive	  selection	  for	  a	  glycogen	  synthase	  (GYS1)	  mutation	  in	  domestic	  horse	  populations.	  J	  Hered	  2014;	  105(2):	  163-­‐72.	  	   39.	  	   McCoy	  AM,	  Schaefer	  R,	  Petersen	  JL,	  Morrell	  PL,	  Slamka	  MA,	  Mickelson	  JR	  et	  al.	  Evidence	  of	  positive	  selection	  for	  a	  glycogen	  synthase	  (GYS1)	  mutation	  in	  domestic	  horse	  populations.	  J	  Hered	  2014;	  105(2):	  163-­‐72.	  	   40.	  	   STEPHANIE	  J.VALBERG.	  Muscle	  anatomy,	  physiology,	  and	  adaptations	  to	  exercise	  and	  training.	  The	  Athletic	  Horse	  (Second	  Edition).	  Principles	  and	  Practice	  of	  Equine	  Sports	  Medicine.	  ELSEVIER.	  2014;	  174-­‐201.	  	   41.	  	   Eaton	  MD.	  Energetics	  and	  Performance.	  In:	  Hodgson	  DR,	  Rose	  RJ,	  eds,	  The	  Athletic	  Horse.	  Philadelphia:	  W.B.	  Saunders	  Company.	  1994;	  49-­‐61.	  	   42.	  	   Freyssenet	  D.	  Energy	  sensing	  and	  regulation	  of	  gene	  expression	  in	  skeletal	  muscle.	  J	  Appl	  Physiol	  2007;	  102(2):	  529-­‐40.	  	   43.	  	   Haller	  RG,	  Vissing	  J.	  Functional	  Evaluation	  of	  Metabolic	  Myopathies.	  In:	  Engel	  AG,	  Franzini-­‐Armstrong	  C,	  eds,	  Myology.	  New	  York:	  McGraw-­‐Hill.	  2004;	  665-­‐90.	  
	  	  
	  	   196	  
	   44.	  	   Brojer	  JT,	  Essen	  Gustavsson	  B,	  Valberg	  SJ.	  Skeletal	  muscle	  pro-­‐	  an	  macroglycogen	  in	  horses	  with	  polysaccharide	  storage	  myopathy	  performing	  light	  excercise.	  Am	  J	  Vet	  Res	  2006.	  	   45.	  	   Mortazavi	  A,	  Williams	  BA,	  McCue	  K,	  Schaeffer	  L,	  Wold	  B.	  Mapping	  and	  quantifying	  mammalian	  transcriptomes	  by	  RNA-­‐Seq.	  Nat	  Methods	  2008;	  5(7):	  621-­‐8.	  	   46.	  	   Wang	  Z,	  Gerstein	  M,	  Snyder	  M.	  RNA-­‐Seq:	  a	  revolutionary	  tool	  for	  transcriptomics.	  Nat	  Rev	  Genet	  2009;	  10(1):	  57-­‐63.	  	   47.	  	   Martin	  JA,	  Wang	  Z.	  Next-­‐generation	  transcriptome	  assembly.	  Nat	  Rev	  Genet	  2011;	  12(10):	  671-­‐82.	  	   48.	  	   Marguerat	  S,	  Bahler	  J.	  RNA-­‐seq:	  from	  technology	  to	  biology.	  Cell	  Mol	  Life	  Sci	  2010;	  67(4):	  569-­‐79.	  	   49.	  	   Khatri	  P,	  Sirota	  M,	  Butte	  AJ.	  Ten	  years	  of	  pathway	  analysis:	  current	  approaches	  and	  outstanding	  challenges.	  PLoS	  Comput	  Biol	  2012;	  8(2):	  e1002375.	  	   50.	  	   Valentine	  BA,	  Flint	  TH,	  Fischer	  KA.	  Ubiquitin	  expression	  in	  muscle	  from	  horses	  with	  polysaccharide	  storage	  myopathy.	  Vet	  Pathol	  2006;	  43(3):	  270-­‐5.	  	   51.	  	   Abecasis	  GR,	  Ghosh	  D,	  Nichols	  TE.	  Linkage	  disequilibrium:	  ancient	  history	  drives	  the	  new	  genetics.	  Hum	  Hered	  2005;	  59(2):	  118-­‐24.	  	   52.	  	   Hirschhorn	  JN,	  Daly	  MJ.	  Genome-­‐Wide	  Association	  Studies	  for	  Common	  Diseases	  and	  Complex	  Traits.	  Nat	  Rev	  Genet	  2005;	  6(2):	  95-­‐108.	  	   53.	  	   Clarke	  GM,	  Anderson	  CA,	  Pettersson	  FH,	  Cardon	  LR,	  Morris	  AP,	  Zondervan	  KT.	  Basic	  statistical	  analysis	  in	  genetic	  case-­‐control	  studies.	  Nat	  Protoc	  2011;	  6(2):	  121-­‐33.	  	   54.	  	   Balding	  DJ.	  A	  tutorial	  on	  statistical	  methods	  for	  population	  association	  studies.	  Nat	  Rev	  Genet	  2006;	  7(10):	  781-­‐91.	  	   55.	  	   Wade	  CM,	  Giulotto	  E,	  Sigurdsson	  S,	  Zoli	  M,	  Gnerre	  S,	  Imsland	  F	  et	  al.	  Genome	  sequence,	  comparative	  analysis,	  and	  population	  genetics	  of	  the	  domestic	  horse.	  Science	  2009;	  326(5954):	  865-­‐7.	  	   56.	  	   Leeb	  T,	  Vogl	  C,	  Zhu	  B,	  de	  Jong	  PJ,	  Binns	  MM,	  Chowdhary	  BP	  et	  al.	  A	  human-­‐horse	  comparative	  map	  based	  on	  equine	  BAC	  end	  sequences.	  Genomics	  2006;	  87(6):	  772-­‐6.	  	   57.	  	   McCue	  ME,	  Bannasch	  DL,	  Petersen	  JL,	  Gurr	  J,	  Bailey	  E,	  Binns	  MM	  et	  al.	  A	  high	  density	  SNP	  array	  for	  the	  domestic	  horse	  and	  extant	  Perissodactyla:	  utility	  
	  	  
	  	   197	  
for	  association	  mapping,	  genetic	  diversity,	  and	  phylogeny	  studies.	  PLoS	  Genet	  2012;	  8(1):	  e1002451.	  	   58.	  	   Marchini	  J,	  Howie	  B.	  Genotype	  imputation	  for	  genome-­‐wide	  association	  studies.	  Nat	  Rev	  Genet	  2010;	  11(7):	  499-­‐511.	  	   59.	  	   McCoy	  AM,	  McCue	  ME.	  Validation	  of	  imputation	  between	  equine	  genotyping	  arrays.	  Anim	  Genet	  2014;	  45(1):	  153.	  	   60.	  	   Egan	  B,	  Zierath	  JR.	  Exercise	  metabolism	  and	  the	  molecular	  regulation	  of	  skeletal	  muscle	  adaptation.	  Cell	  Metab	  2013;	  17(2):	  162-­‐84.	  	   61.	  	   Park	  KD,	  Park	  J,	  Ko	  J,	  Kim	  BC,	  Kim	  HS,	  Ahn	  K	  et	  al.	  Whole	  transcriptome	  analyses	  of	  six	  thoroughbred	  horses	  before	  and	  after	  exercise	  using	  RNA-­‐Seq.	  BMC	  Genomics	  2012;	  13:	  473.	  	   62.	  	   McGivney	  BA,	  McGettigan	  PA,	  Browne	  JA,	  Evans	  AC,	  Fonseca	  RG,	  Loftus	  BJ	  et	  al.	  Characterization	  of	  the	  equine	  skeletal	  muscle	  transcriptome	  identifies	  novel	  functional	  responses	  to	  exercise	  training.	  BMC	  Genomics	  2010;	  11:	  398.	  	   63.	  	   Marioni	  JC,	  Mason	  CE,	  Mane	  SM,	  Stephens	  M,	  Gilad	  Y.	  RNA-­‐seq:	  an	  assessment	  of	  technical	  reproducibility	  and	  comparison	  with	  gene	  expression	  arrays.	  Genome	  Res	  2008;	  18(9):	  1509-­‐17.	  	   64.	  	   Page	  GP,	  Edwards	  JW,	  Barnes	  S,	  Weindruch	  R,	  Allison	  DB.	  A	  design	  and	  statistical	  perspective	  on	  microarray	  gene	  expression	  studies	  in	  nutrition:	  the	  need	  for	  playful	  creativity	  and	  scientific	  hard-­‐mindedness.	  Nutrition	  2003;	  19(11-­‐12):	  997-­‐1000.	  	   65.	  	   Tempelman	  RJ.	  Assessing	  statistical	  precision,	  power,	  and	  robustness	  of	  alternative	  experimental	  designs	  for	  two	  color	  microarray	  platforms	  based	  on	  mixed	  effects	  models.	  Veterinary	  Immunology	  and	  Immunopathology	  2005;	  105(3-­‐4):	  175-­‐86.	  	   66.	  	   Illumina	  Tru_seq.	  Illumina	  website	  .	  2015.	  	  Ref	  Type:	  Electronic	  Citation	  	   67.	  	   Trapnell	  C,	  Pachter	  L,	  Salzberg	  SL.	  TopHat:	  discovering	  splice	  junctions	  with	  RNA-­‐Seq.	  Bioinformatics	  2009;	  25(9):	  1105-­‐11.	  	   68.	  	   Trapnell	  C,	  Roberts	  A,	  Goff	  L,	  Pertea	  G,	  Kim	  D,	  Kelley	  DR	  et	  al.	  Differential	  gene	  and	  transcript	  expression	  analysis	  of	  RNA-­‐seq	  experiments	  with	  TopHat	  and	  Cufflinks.	  Nat	  Protoc	  2012;	  7(3):	  562-­‐78.	  
	  	  
	  	   198	  
	   69.	  	   Trapnell	  C,	  Roberts	  A,	  Goff	  L,	  Pertea	  G,	  Kim	  D,	  Kelley	  DR	  et	  al.	  Differential	  gene	  and	  transcript	  expression	  analysis	  of	  RNA-­‐seq	  experiments	  with	  TopHat	  and	  Cufflinks.	  Nat	  Protoc	  2012;	  7(3):	  562-­‐78.	  	   70.	  	   Trapnell	  C,	  Roberts	  A,	  Goff	  L,	  Pertea	  G,	  Kim	  D,	  Kelley	  DR	  et	  al.	  Differential	  gene	  and	  transcript	  expression	  analysis	  of	  RNA-­‐seq	  experiments	  with	  TopHat	  and	  Cufflinks.	  Nat	  Protoc	  2012;	  7(3):	  562-­‐78.	  	   71.	  	   Anders	  S,	  McCarthy	  DJ,	  Chen	  Y,	  Okoniewski	  M,	  Smyth	  GK,	  Huber	  W,	  Robinson	  MD.	  Count-­‐based	  differential	  expression	  analysis	  of	  RNA	  sequencing	  data	  using	  R	  and	  Bioconductor.	  Nat	  Protoc	  2013;	  8(9):	  1765-­‐86.	  	   72.	  	   Subramanian	  A,	  Tamayo	  P,	  Mootha	  VK,	  Mukherjee	  S,	  Ebert	  BL,	  Gillette	  MA	  et	  al.	  Gene	  set	  enrichment	  analysis:	  A	  knowledge-­‐based	  approach	  for	  interpreting	  genome-­‐wide	  expression	  profiles.	  Proceedings	  of	  the	  National	  Academy	  of	  Sciences	  of	  the	  United	  States	  of	  America	  2005;	  102(43):	  15545-­‐50.	  	   73.	  	   Yang	  Y,	  Creer	  A,	  Jemiolo	  B,	  Trappe	  S.	  Time	  course	  of	  myogenic	  and	  metabolic	  gene	  expression	  in	  response	  to	  acute	  exercise	  in	  human	  skeletal	  muscle.	  J	  Appl	  Physiol	  2005;	  98(5):	  1745-­‐52.	  	   74.	  	   Parker	  GE,	  Pederson	  BA,	  Obayashi	  M,	  Schroeder	  JM,	  Harris	  RA,	  Roach	  PJ.	  Gene	  expression	  profiling	  of	  mice	  with	  genetically	  modified	  muscle	  glycogen	  content.	  Biochem	  J	  2006;	  395(1):	  137-­‐45.	  	   75.	  	   Barrey	  E,	  Mucher	  E,	  Jeansoule	  N,	  Larcher	  T,	  Guigand	  L,	  Herszberg	  B	  et	  al.	  Gene	  expression	  profiling	  in	  equine	  polysaccharide	  storage	  myopathy	  revealed	  inflammation,	  glycogenesis	  inhibition,	  hypoxia	  and	  mitochondrial	  dysfunctions.	  BMC	  Vet	  Res	  2009;	  5:	  29.	  	   76.	  	   Marguerat	  S,	  Bahler	  J.	  RNA-­‐seq:	  from	  technology	  to	  biology.	  Cell	  Mol	  Life	  Sci	  2010;	  67(4):	  569-­‐79.	  	   77.	  	   Trapnell	  C,	  Roberts	  A,	  Goff	  L,	  Pertea	  G,	  Kim	  D,	  Kelley	  DR	  et	  al.	  Differential	  gene	  and	  transcript	  expression	  analysis	  of	  RNA-­‐seq	  experiments	  with	  TopHat	  and	  Cufflinks.	  Nat	  Protoc	  2012;	  7(3):	  562-­‐78.	  	   78.	  	   Anders	  S,	  McCarthy	  DJ,	  Chen	  Y,	  Okoniewski	  M,	  Smyth	  GK,	  Huber	  W,	  Robinson	  MD.	  Count-­‐based	  differential	  expression	  analysis	  of	  RNA	  sequencing	  data	  using	  R	  and	  Bioconductor.	  Nat	  Protoc	  2013;	  8(9):	  1765-­‐86.	  	   79.	  	   CLC	  Genomics	  Workbench	  7.0.3	  (http://www.clcbio.com).	  CLC	  Genomics	  Workbench	  7.0.3	  (http://www.clcbio.com)	  .	  2015.	  	  Ref	  Type:	  Electronic	  Citation	  
	  	  
	  	   199	  
	   80.	  	   Sequencher®	  version	  5.3	  sequence	  analysis	  software,	  Gene	  Codes	  Corporation,	  Ann	  Arbor,	  MI	  USA.	  http://www.genecodes.com	  .	  2015.	  	  Ref	  Type:	  Electronic	  Citation	  	   81.	  	   DePristo	  MA,	  Banks	  E,	  Poplin	  R,	  Garimella	  KV,	  Maguire	  JR,	  Hartl	  C	  et	  al.	  A	  framework	  for	  variation	  discovery	  and	  genotyping	  using	  next-­‐generation	  DNA	  sequencing	  data.	  Nat	  Genet	  2011;	  43(5):	  491-­‐8.	  	   82.	  	   McKenna	  A,	  Hanna	  M,	  Banks	  E,	  Sivachenko	  A,	  Cibulskis	  K,	  Kernytsky	  A	  et	  al.	  The	  Genome	  Analysis	  Toolkit:	  a	  MapReduce	  framework	  for	  analyzing	  next-­‐generation	  DNA	  sequencing	  data.	  Genome	  Res	  2010;	  20(9):	  1297-­‐303.	  	   83.	  	   Li	  H,	  Durbin	  R.	  Fast	  and	  accurate	  long-­‐read	  alignment	  with	  Burrows-­‐Wheeler	  transform.	  Bioinformatics	  2010;	  26(5):	  589-­‐95.	  	   84.	  	   Li	  H,	  Durbin	  R.	  Fast	  and	  accurate	  short	  read	  alignment	  with	  Burrows-­‐Wheeler	  transform.	  Bioinformatics	  2009;	  25(14):	  1754-­‐60.	  	   85.	  	   http://broadinstitute.github.io/picard.	  Broad	  Institute	  .	  2015.	  	  Ref	  Type:	  Electronic	  Citation	  	   86.	  	   McKenna	  A,	  Hanna	  M,	  Banks	  E,	  Sivachenko	  A,	  Cibulskis	  K,	  Kernytsky	  A	  et	  al.	  The	  Genome	  Analysis	  Toolkit:	  a	  MapReduce	  framework	  for	  analyzing	  next-­‐generation	  DNA	  sequencing	  data.	  Genome	  Res	  2010;	  20(9):	  1297-­‐303.	  	   87.	  	   Cingolani	  P,	  Platts	  A,	  Wang	  lL,	  Coon	  M,	  Nguyen	  T,	  Wang	  L	  et	  al.	  A	  program	  for	  annotating	  and	  predicting	  the	  effects	  of	  single	  nucleotide	  polymorphisms,	  SnpEff:	  SNPs	  in	  the	  genome	  of	  Drosophila	  melanogaster	  strain	  w1118;	  iso-­‐2;	  iso-­‐3.	  Fly	  (Austin	  )	  2012;	  6(2):	  80-­‐92.	  	   88.	  	   Cingolani	  P,	  Platts	  A,	  Wang	  lL,	  Coon	  M,	  Nguyen	  T,	  Wang	  L	  et	  al.	  A	  program	  for	  annotating	  and	  predicting	  the	  effects	  of	  single	  nucleotide	  polymorphisms,	  SnpEff:	  SNPs	  in	  the	  genome	  of	  Drosophila	  melanogaster	  strain	  w1118;	  iso-­‐2;	  iso-­‐3.	  Fly	  (Austin	  )	  2012;	  6(2):	  80-­‐92.	  	   89.	  	   Browning	  BL,	  Browning	  SR.	  A	  unified	  approach	  to	  genotype	  imputation	  and	  haplotype-­‐phase	  inference	  for	  large	  data	  sets	  of	  trios	  and	  unrelated	  individuals.	  Am	  J	  Hum	  Genet	  2009;	  84(2):	  210-­‐23.	  	   90.	  	   Khatkar	  MS,	  Moser	  G,	  Hayes	  BJ,	  Raadsma	  HW.	  Strategies	  and	  utility	  of	  imputed	  SNP	  genotypes	  for	  genomic	  analysis	  in	  dairy	  cattle.	  BMC	  Genomics	  2012;	  13:	  538.	  	   91.	  	   Browning	  BL,	  Browning	  SR.	  Efficient	  multilocus	  association	  testing	  for	  whole	  genome	  association	  studies	  using	  localized	  haplotype	  clustering.	  Genet	  Epidemiol	  2007;	  31(5):	  365-­‐75.	  
	  	  
	  	   200	  
	   92.	  	   Danecek	  P,	  Auton	  A,	  Abecasis	  G,	  Albers	  CA,	  Banks	  E,	  DePristo	  MA	  et	  al.	  The	  variant	  call	  format	  and	  VCFtools.	  Bioinformatics	  2011;	  27(15):	  2156-­‐8.	  	   93.	  	   Browning	  BL,	  Browning	  SR.	  Efficient	  multilocus	  association	  testing	  for	  whole	  genome	  association	  studies	  using	  localized	  haplotype	  clustering.	  Genet	  Epidemiol	  2007;	  31(5):	  365-­‐75.	  	   94.	  	   Browning	  BL,	  Browning	  SR.	  Efficient	  multilocus	  association	  testing	  for	  whole	  genome	  association	  studies	  using	  localized	  haplotype	  clustering.	  Genet	  Epidemiol	  2007;	  31(5):	  365-­‐75.	  	   95.	  	   Browning	  BL,	  Browning	  SR.	  Efficient	  multilocus	  association	  testing	  for	  whole	  genome	  association	  studies	  using	  localized	  haplotype	  clustering.	  Genet	  Epidemiol	  2007;	  31(5):	  365-­‐75.	  	   96.	  	   Zhou	  X,	  Stephens	  M.	  Genome-­‐wide	  efficient	  mixed-­‐model	  analysis	  for	  association	  studies.	  Nat	  Genet	  2012;	  44(7):	  821-­‐4.	  	   97.	  	   Zhou	  X,	  Stephens	  M.	  Genome-­‐wide	  efficient	  mixed-­‐model	  analysis	  for	  association	  studies.	  Nat	  Genet	  2012;	  44(7):	  821-­‐4.	  	   98.	  	   Xu	  H,	  Guan	  Y.	  Detecting	  local	  haplotype	  sharing	  and	  haplotype	  association.	  Genetics	  2014;	  197(3):	  823-­‐38.	  	   99.	  	   Xu	  H,	  Guan	  Y.	  Detecting	  local	  haplotype	  sharing	  and	  haplotype	  association.	  Genetics	  2014;	  197(3):	  823-­‐38.	  	   100.	  	   Xu	  H,	  Guan	  Y.	  Detecting	  local	  haplotype	  sharing	  and	  haplotype	  association.	  Genetics	  2014;	  197(3):	  823-­‐38.	  	   101.	  	   Zhou	  X,	  Stephens	  M.	  Genome-­‐wide	  efficient	  mixed-­‐model	  analysis	  for	  association	  studies.	  Nat	  Genet	  2012;	  44(7):	  821-­‐4.	  	   102.	  	   Purcell	  S,	  Neale	  B,	  Todd-­‐Brown	  K,	  Thomas	  L,	  Ferreira	  MA,	  Bender	  D	  et	  al.	  PLINK:	  a	  tool	  set	  for	  whole-­‐genome	  association	  and	  population-­‐based	  linkage	  analyses.	  Am	  J	  Hum	  Genet	  2007;	  81(3):	  559-­‐75.	  	   103.	  	   LI	  H,	  Durbin	  R.	  Fast	  and	  accurate	  short	  read	  alignment	  with	  Burrows-­‐Wheeler	  transform.	  Bioinformatics	  2009;	  25(14):	  1754-­‐60.	  	   104.	  	   Petersen	  JL,	  Mickelson	  JR,	  Rendahl	  AK,	  Valberg	  SJ,	  Andersson	  LS,	  Axelsson	  J	  et	  al.	  Genome-­‐wide	  analysis	  reveals	  selection	  for	  important	  traits	  in	  domestic	  horse	  breeds.	  PLoS	  Genet	  2013;	  9(1):	  e1003211.	  	   105.	  	   Schulz	  MH,	  Zerbino	  DR,	  Vingron	  M,	  Birney	  E.	  Oases:	  robust	  de	  novo	  RNA-­‐seq	  assembly	  across	  the	  dynamic	  range	  of	  expression	  levels.	  Bioinformatics	  2012;	  28(8):	  1086-­‐92.	  
	  	  
	  	   201	  
	   106.	  	   Davidson	  NM,	  Oshlack	  A.	  Corset:	  enabling	  differential	  gene	  expression	  analysis	  for	  de	  novo	  assembled	  transcriptomes.	  Genome	  Biol	  2014;	  15(7):	  410.	  	   107.	  	   Li	  L,	  Chen	  E,	  Yang	  C,	  Zhu	  J,	  Jayaraman	  P,	  De	  PJ	  et	  al.	  Improved	  rat	  genome	  gene	  prediction	  by	  integration	  of	  ESTs	  with	  RNA-­‐Seq	  information.	  Bioinformatics	  2015;	  31(1):	  25-­‐32.	  	  108.	  	   Borgia	  L,	  Valberg	  S,	  McCue	  M,	  Watts	  K,	  Pagan	  J.	  Glycaemic	  and	  insulinaemic	  responses	  to	  feeding	  hay	  with	  different	  non-­‐structural	  carbohydrate	  content	  in	  control	  and	  polysaccharide	  storage	  myopathy-­‐affected	  horses.	  J	  Anim	  Physiol	  Anim	  Nutr	  (Berl)	  2011;	  95(6):	  798-­‐807.	  	  	  
} 
